Post-genomic structural analysis of single amino acid polymorphisms by McMillan, L.E.M.
UNIVERSITY COLLEGE LONDON
UCL Research Department of Structural and Molecular Biology
Post-genomic structural analysis of single
amino acid polymorphisms
Lisa Ellen Mary McMillan
A dissertation submitted to University College London
for the degree of Doctor of PhilosophyDeclaration
I, Lisa McMillan, conﬁrm that the work presented in this thesis is my own. Where information
has been derived from other sources, I conﬁrm that this has been indicated in the thesis.
Lisa McMillan
November 9, 2009
2Abstract
Inherited genetic variation is critical in deﬁning disease susceptibility. PDs, or pathogenic devi-
ations, are mutations reported to be disease-causing, while SNPs, or single nucleotide polymor-
phisms, are understood to have a negligible effect on phenotype. With recent developments in
biotechnology—most relevant being increased reliability and speed of sequencing—a wealth
of information regarding SNPs and PDs has been acquired. Quite apart from the analytical
challenge of analysing this information with a view to identifying novel therapies and targets
for disease, the challenge of simply storing, mapping and processing these data is signiﬁcant in
itself.
This thesis describes the development of a large-scale, automated pipeline that provides hy-
potheses as to what the structural effects of these genomic variations might be. This includes
the development of nine new analyses. Eight of these new methods are structural, identify-
ing mutations that disrupt various aspects of protein structure, including the interface, binding
sites, folding mechanics and stability. The ﬁnal new analysis is a novel method of identifying
highly conserved residues from sequence. Here, the distribution of conservation scores from
a multiple sequence alignment (MSA) is analysed to generate an MSA-speciﬁc threshold for
high conservation. In order to construct MSAs for the sequence analysis, a novel method for
identifying functionally equivalent proteins has been developed.
Further, PDs and SNPs are characterised with respect to these structural analyses, and with
respect to basic sequence and structural features. The ﬁndings support trends elsewhere in
the literature: PDs are more often found in the core of proteins and at highly conserved sites;
they most often affect the stability of protein structures; and they more often are between very
different amino acids. In addition to the implications for disease therapies, these ﬁndings are
informative in the more general context of protein structure.
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An introduction to mutations
The human body is a complex machine. Occasionally, individuals inherit very slight modiﬁca-
tions that have a signiﬁcant impact on their health. Other inherited modiﬁcations have little or
no effect on health. This chapter will explore the biology of inherited disease-associated mu-
tations, deﬁne the investigative scope to be pursued and introduce the scientiﬁc questions that
will be asked throughout this thesis.
1.1 Deoxyribonucleic acid: the blueprint for life
Deoxyribonucleic acid (DNA) is the blueprint for many living organisms. It encodes proteins
and other functional molecules that are necessary for the organism throughout its lifespan
and is the vehicle through which offspring inherit information from their parents. It is a dou-
ble stranded helical structure, comprising a sugar-phosphate backbone and a sequence of nu-
cleotides or ‘bases’: adenine (A), cytosine (C), guanine (G) and thymine (T). Complementary
base pairing between purine (A/G) and pyrimidine (C/T) bases (speciﬁcally between A/T and
C/G) bases hold the two helical strands together (Figure 1.1) (Berg et al., 2002, Sections 1.1.1-2).
It is the complete sequence of these four nucleotides—the genome—that deﬁnes the organism.
In Homo Sapiens, the genome is approximately 3.2 billion base pairs long (International Hu-
man Genome Sequencing Consortium, 2004). Approximately 1.5-2% of the genome encodes
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Figure 1.1: Deoxyribonucleic acid: DNA
The nucleotides are shown here, attached to the sugar-phosphate backbone. Figure obtained from Creative Commons.
proteins (Lander et al., 2001), biomolecules that do much of the ‘operational’ work in the organ-
ism. These ‘coding’ regions of the genome are organised into ‘genes’, distinct protein encod-
ing units that deﬁne individual proteins. The remaining 98% of the genome is ‘non-coding’.
Previously erroneously referred to as ‘junk’ DNA, some of these non-coding regions are now
known to be well conserved (Bejerano et al., 2004; Prabhakar et al., 2006). Further, the recent EN-
CODE project suggests that the genome is exhaustively transcribed (The ENCODE Project Con-
sortium, 2007). It is now commonly accepted that the non-coding regions of the genome per-
form other essential tasks in the cell, for example, the regulation of protein expression (Sandelin
et al., 2004; Couzin, 2002; Bi´ emont and Vieira, 2006).
1.2 Variation in the genome
The genome of individual organisms within a species varies; it is variation between organisms
that allows species to evolve via differental responses to external stimuli. The various different
forms of a gene that exist in a population are described as ‘alleles’.
There are various kinds of genomic variation and various mechanisms by which genomic vari-
ation can arise. This thesis will investigate one kind of small-scale genomic variation: the point
mutation, where a single nucleotide is exchanged for another. Speciﬁcally, it will look at pointCHAPTER 1. AN INTRODUCTION TO MUTATIONS 30
mutations in coding regions of DNA that lead to a single amino acid mutation at the protein
level (see Section 1.4).
Point mutations can be ‘germline’ or ‘somatic’. Germline mutations are transmitted to offspring
via germ cells (in humans, the egg and sperm). Somatic mutations however are acquired by the
organism during its lifespan and are not transmitted to offspring. Somatic mutations, therefore,
are a failure of the DNA repair mechanisms to identify errors in DNA replication (for speciﬁc
examples in cancer, see (Berg et al., 2002, Section 27.6.5)).
In sexual reproduction, offspring inherit half of their DNA from their mother and half from
their father. The inherited genomic information is combined to create the offspring genome,
and as such, children may inherit mutations from their parents. Rare alleles can come to persist
in the population if they offer some advantage to the individuals that carry them (Friedman
and Trager, 1981) or if they are completely neutral in their effect (Tomizawa, 2000). Some
pathogenic alleles may persist if their effects do not come into play until after the reproductive
lifespan of the parent (e.g., propensity towards cancer or heart disease).
Throughout this thesis, the word ‘native’ will be used to describe the genotype containing the
most common allele, while the word ‘mutant’ will describe the genotype containing mutations.
1.3 The vast phenotypic spectrum of mutations
The term ‘genotype’ describes the speciﬁc genomic information that deﬁnes an individual or-
ganism, i.e., the sequence of nucleotides in the organism’s genome. The term ‘phenotype’ refers
to the observable manifestation of the genotype. For example, human eye colour has been
shown to be associated with genomic variation near the OCA2 gene (Duffy et al., 2007); in this
example, thegenotypeisthespeciﬁcgenomicvariationneartheOCA2locusandthephenotype
is the resulting eye colour.
Genomic abberations will not have a consistent effect on phenotype: some will have negligible
or no effect on phenotype, some will introduce variation in phenotype without compromising
health, some will result in increased susceptibility to disease, some will be directly causitive of
disease and some will be fatal. It is important to appreciate that, in disease research, the mostCHAPTER 1. AN INTRODUCTION TO MUTATIONS 31
severe, fatal mutations will never be observed in a patient: any cell encoding a fatal mutation
will die without being replicated.
In this thesis, point mutations that have been shown to be causitive of disease are described
as Pathogenic Deviations or PDs and point mutations that have not been shown to be associ-
ated with disease are described as Single Nucleotide Polymorphisms or SNPs. The term SNP
(The International Hapmap Consortium, 2005) is often used to refer to any point mutation, but
strictly SNPs are deﬁned as alleleic variants where the least common allele occurs in 1% of
a normal population. So, while they may be associated with a complex disease, they cannot
be involved in high penetrance Mendelianly inherited disease states. The most conservative
estimates suggest that SNPs occur once every 1000 base pairs (Collins et al., 1998; Taillon-Miller
et al., 1998) although others suggest that SNPs may occur as often as once every 100-300 bases
(Wang et al., 2006).
1.4 Genomic mutations manifest at the protein level
Figure 1.2 gives a broad overview of protein synthesis (Berg et al., 2002, Chapter 5). The dou-
ble stranded DNA helix is unwound to expose a single strand of DNA. Complementary base
pairing forms messenger ribonucleic acid (or mRNA) in a process called transcription (note that
thymine is replaced by uracil at the mRNA level). The mRNA is then translated into a series of
amino acids, using the genetic code. The protein is the resulting sequence of amino acids.
The four letter alphabet of nucleotides encodes an alphabet of twenty amino acids (Berg et al.,
2002, Section 3.1). The amino acids vary in atom composition, size, charge, polarity, afﬁnity for
water (hydrophobicity) and so on. They are the building blocks of protein sequences. Further
complexity at the protein level is afforded by post-translational modiﬁcations: chemical alter-
ations of residues occurring after the protein sequence has been translated (Berg et al., 2002,
Section 10.4).
Given the redundancy in the genetic code and the structure of the genome, point mutations are
differentiallymanifestattheproteinlevel. Theﬁrstdifferentiationtobemadeisbetweencoding
and non-coding mutations. Coding point mutations occur in coding areas of the genome. Non-
coding point mutations occur between the coding areas of the genome (i.e., in the ‘junk’ DNA,CHAPTER 1. AN INTRODUCTION TO MUTATIONS 32
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Figure 1.2: A broad overview of protein synthesis
A section of DNA is shown at the top of this ﬁgure with the coding regions (i.e., genes) in blue and the non-coding
regions marked in grey. Proteins are synthesised from genes and proceeds as follows: (1): The double stranded helix
is broken to expose a DNA ‘template’; (2): The DNA is transcribed (using complementary base pairing) into RNA
(ribonucleic acid), speciﬁcally (3): mRNA ‘messenger RNA’ (note that thymine has become uracil); (4): the mRNA
is then translated according to the genetic code, where each three letter combination of RNA bases corresponds to an
amino acid; (5): the protein is formed by forming peptide bonds between the encoded amino acids (shown as grey
circles). Four mutations are marked in purple, green, red and orange in the DNA. The respective base changes, at the
DNA and mRNA levels are given in the corresponding colour. Coding mutations are marked with a triangle in the
corresponding colour above the appropriate nucleotide at the single-stranded DNA level. The native protein sequence
(i.e., the protein that would be synthesized without the mutations) is given below the mutant protein sequence in a light
blue box. The purple T>A mutation is same-sense/synonymous/silent, inducing no change in the protein sequence
(both GUU and GUA encode valine). The green G>T mutation is a nonsense mutation, introducing a premature stop
codon (indicated with the thick vertical line). The red A>G mutation is a missense/non-synonymous mutation, that
replaces the native cysteine residue (encoded by UGU) with an arginine (encoded by CGU). The orange T>C mutation
is non-coding as it occurs outside of a gene.CHAPTER 1. AN INTRODUCTION TO MUTATIONS 33
see Section 1.1); see the T>C mutation shown in orange in Figure 1.2 for an example.
Coding mutations can be further classiﬁed as synonymous, non-synonymous or nonsense.
Synonymous mutations (also described as same-sense or silent mutations) do not alter the pro-
tein sequence (e.g., the purple T>A mutation in Figure 1.2). Non-synonymous mutations (also
described as mis-sense mutations, nsSNPs (non synonymous SNPs) or SAAPs (single amino
acid polymorphisms)) induce a change in the amino acid sequence; see the red A>G mutation
in Figure 1.2 for an example. Finally, non-sense mutations replace the native amino acid with
a stop codon, resulting in an incomplete protein sequence.
Many cellular proteins are globular: once the protein sequence has been synthesised, the string
of amino acids fold together to adopt a three dimensional globe-like structure (as opposed to a
ﬁbrous structure) with a substantial buried ‘core’ (for example, myoglobin (Berg et al., 2002,
Section 3.4)). It is the folded structure that is functional.
There are four levels of protein structure. The ﬁrst (or primary) level describes the one di-
mensional string of amino acids that comprises the sequence (Berg et al., 2002, Section 3.2).
Hydrogen bonds are formed between the backbone atoms of the amino acids to form helical
() and sheet () ‘secondary structures’ in the secondary level (Berg et al., 2002, Section 3.3).
In the third (or tertiary) level, further bonds are formed between the residues to fold the entire
protein chain into a single globular unit (Berg et al., 2002, Section 3.4). In the fourth (quaternary)
and ﬁnal layer, multiple globular units (or ‘chains’) may be combined to create the functional
protein (Berg et al., 2002, Section 3.5).
Figures 1.3 and 1.4 show the four levels for Equus caballus alcohol dehydrogenase (chain A)
[UniProtKB:P00327/ADH1E HORSE], an enzyme that breaks down otherwise potentially toxic
alcohols to ketones and aldehydes1. Figure 1.3(a) shows the primary structure, the sequence of
amino acids (obtained from UniProtKB/Swiss-Prot and shown in FASTA format). Figure 1.3(b)
shows the same sequence annotated with the  (shown as purple helices) and  (shown as
purple arrows) secondary structures. The tertiary structure of ADH1E HORSE is shown in
Figure 1.4(a), with the same  and  structures highlighted in pink and gold respectively (turns
are shown in blue). The structure of ADH1E HORSE is complete when two identical structures
as shown in Figure 1.4(a) are combined to form a homodimer (i.e., a structure containing two
copies of the same chain). The completed quaternary structure is shown in Figure 1.4(b), where
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the two chains are coloured different shades of blue.
Each chain in the homodimer is bound to the ligand NAD, or nicotinamide-adenine-
dinucleotide, which is embedded within the structure (see Figure 1.4(b)). This demonstrates
the close structure/function relationship of proteins: if the structure were altered near the
ligand binding site, NAD may not be able to bind to the protein. The speciﬁc biochemical
action of alcohol dehydrogenase is to convert the bound NAD ligand into NADH by
converting alcohol to ketones and aldehydes2. Therefore, should the structure be mutated so as
to inhibit binding to NAD, the creation of NADH may be inhibited or completely eradicated.
Given the process described in Figure 1.2 and the alcohol dehydrogenase example described
above, it is clear that mutations at the genome level could induce a change in the protein se-
quence, thus altering the protein structure, and potentially affecting protein function.
1.5 An introduction to protein structure
Although protein structures vary immensely, they adhere closely to the same basic principles.
This section will introduce these underlying concepts of protein structure. At a very general
level, protein structure must (1) be stable; (2) fold correctly and (3) function properly. This
section will conclude with a brief description of the two major methods by which the struc-
tures of proteins are determined experimentally: X-ray crystallography and nuclear magnetic
resonance (NMR).
1.5.1 Hydrogen bonding
Hydrogen bonds form between (i) an electronegative atom and (ii) a hydrogen atom bonded
to an electronegative atom (Baker and Hubbard, 1984). In the context of amino acids, the elec-
tronegative atom is either oxygen or nitrogen. In this interaction, the hydrogen atom is de-
scribed as the donor atom and the electronegative atom is described as the acceptor atom. The
sidechains of Arginine, asparagine, glutamine, histidine, lysine, serine, threonine, tryptophan
and tyrosine can act as hydrogen bond donors and the sidechains of asparagine, aspartic acid,
2http://www.rcsb.org/pdb/static.do?p=education_discussion/molecule_of_the_month/
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(a) Primary structure: the sequence of amino acids
(b) Secondary structure:  and  structures are formed by hydrogen bonds
Figure 1.3: The primary and secondary structure of alcohol dehydrogenase
Figure 1.3(a) shows the UniProtKB/Swiss-Prot FASTA representation of ADH1E HORSE, with the header line em-
boldened. Figure 1.3(b) shows a representation of secondary structure elements in the protein, as described in the PDB
structure 6adh (diagram obtained from PDBSUM at the EBI). The  and  structures are shown as purple helices and
arrows respectively (for the purposes of this discussion, other annotations can be ignored).CHAPTER 1. AN INTRODUCTION TO MUTATIONS 36
(a) Tertiary structure: globular chains are formed
(b) Quaternary structure: multiple chainsare combined to create the biologically relevant
multimer
Figure 1.4: The tertiary and quaternary structure of alcohol dehydrogenase
Figure 1.4(a) shows the structure of 6adh, chain A.  secondary structure elements are shown as pink helices,  sec-
ondary structure elements are shown as gold arrows (an alternative secondary structure element, the turn, is shown
in blue). Figure 1.4(b) shows the complete quaternary structure for ADH1E HORSE. Here, two chains as described in
Figure (shown in different shades of blue) 1.4(a) form a single structure, the biologically relevant multimer (speciﬁcally,
a homodimer). A ligand (nicotinamide-adenine-dinucleotide or NAD) can be seen embedded in each chain.CHAPTER 1. AN INTRODUCTION TO MUTATIONS 37
glutamic acid, glutamine, uncharged histidine, serine, threonine and tyrosine can act as hydro-
gen bond acceptors; the sidechains of the nine remaining residues (alanine, cysteine, phenyl-
alanine, glycine, isoleucine, leucine, methionine, proline and valine) do not participate in hy-
drogen bonding. The backbones of all residues are able to both accept and donate a hydrogen
bond, save for proline, which may only accept a hydrogen bond, given its cyclic sidechain (Cuff
et al., 2006).
Most hydrogen bonds (68%) are formed between backbone atoms (Stickle et al., 1992); sec-
ondary structure elements (described in Section 1.4) are maintained largely by a scaffold of
backbone-backbone hydrogen bonding (see Figure 1.5). The remaining 32% of hydrogen bonds
are formed between backbone-sidechain and sidechain-sidechain atoms. Hydrogen bonds are
fundamental to the proper formation and stability of protein structure. It has been shown that
most buried, hydrogen bonding capable sidechains do form hydrogen bonds (McDonald and
Thornton, 1994).
1.5.2 Other important bonds
In addition to hydrogen bonds, protein structure is maintained by several other inter-residue
bonds. Saltbridges, ionicbondsthatareformedbetweenthepositivelyandnegativelycharged
sidechains, also contribute to protein stability when found in the buried core of the structure
(Torshin and Harrison, 2001). Other Van der Waals (non-electostatic, non-covalent) interac-
tions, which arise from induced dipole-induced dipole interactions, also contribute to protein
stability (Berg et al., 2002, p. 10).
Several covalent bonds can form between residues. The most well known of these is the disul-
phide bond, a bond that can form between two sulphur atoms of cysteine residues of certain
geometries (Hazes and Dijkstra, 1988); see Figure 1.6 for an example. Other covalent crosslinks
that are formed between amino acids include 4-amino-3-isothiazolidinone-L-serine3, a bond
that forms between cysteine and serine residues (for example in protein-tyrosine phosphatase
1B (van Montfort et al., 2003, see Figures 1(c) and 1(d) in manuscript)); N6-glycyl-L-lysine4 a
bond that forms between lysine and glycine residues (particularly important for interactions
with small proteins like ubiquitin (Cripps et al., 2006)), and N6-(L-isoglutamyl)-L-lysine5, a
3http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:00349
4http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:00134
5http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:00133CHAPTER 1. AN INTRODUCTION TO MUTATIONS 38
(a) Residues 1-20, secondary structure (b) Residues 1-20, hydrogen bonding
(c) Residues 40-60, secondary structure (d) Residues 40-60, hydrogen bonding
Figure 1.5: Backbone hydrogen bonding generates  and  secondary structures
A  helix (residues 1-20, Figures 1.5(a)-1.5(b)) and  sheet (residues 40-60, Figure 1.5(c)-1.5(d)) from the structure of
lysozyme (PDB ID 7lyz). Hydrogen bonds are indicated by thinner connections. Residues are coloured by structure
(with gold indicating  structures and pink indicating  structures).CHAPTER 1. AN INTRODUCTION TO MUTATIONS 39
Figure 1.6: Disulphide bonding
Disulphide bonds in lysozyme (PDB ID 7lyz) are highlighted in orange. Four disulphide bonds are formed between
eight cysteine residues (6-127, 30-115, 76-94 and 64-80).
bond that forms between lysine and glutamic acid residues (for example, between histone pro-
teins H4 and H2B (Shimizu et al., 1996, see Figure 1 in manuscript)).
1.5.3 Ligand binding
Proteins act on, or complex with, each other and a vast array of other biomolecules or ‘ligands’.
The ligands interact with the protein by way of a binding site, or pocket. Weak intra-molecular
forces (including ionic bonds, hydrogen bonds and Van der Waals interactions) secure the lig-
and to the protein (Berg et al., 2002, Section 1.3.2). Proteins can also incorporate metal ions in
their structure. The sidechains of histidine and aspartic and glutamic acids, and the sulfhydryl
sidechain of cysteine bind to metal ions in ‘metalloproteins’ (Branden and Tooze, 1999, p. 11).
See Figure 1.7 for examples of ligand and metal ion binding.CHAPTER 1. AN INTRODUCTION TO MUTATIONS 40
Figure 1.7: Ligand binding
Thestructureofalcoholdehydrogenase(PDBID6adh). Theligandnicotinamide-adenine-dinucleotide(NAD)isshown
in blue; a zinc co-factor is shown in dark red, and residues within 4 ˚ A of the zinc co-factor (four cysteines at 97, 100,
103 and 111) are highlighted in orange (the rest of the protein is coloured grey, with secondary structure elements indi-
cated). Note that the NAD is embedded in a binding pocket and that the zinc co-factor is supported by the sidechains
of the four cysteine residues.CHAPTER 1. AN INTRODUCTION TO MUTATIONS 41
1.5.4 Hydrophobicity and folding
The composition of a residue’s sidechain deﬁnes whether the residue is hydrophobic (repelled
from water) or hydrophilic (attracted to water). Biochemically, hydrophilic residues are those
that can form hydrogen bonds with water and are polar, while hydrophobic residues are non-
polar and are unable to form hydrogen bonds with water (Berg et al., 2002, Section 1.3.4). Many
hydrophobicity ‘scales’ assess the hydrophobic properties of amino acids. They can be con-
structed using (i) experimental data that assess directly the behaviour of the residue in water
(Yunger and Cramer, 1981) and/or (ii) structural data that identify residues commonly found
in the protein core (Chothia, 1976). Others combine existing scales (Kyte and Doolittle, 1982).
See Cornette et al. (1987) for a review of 38 hydrophobicity scales.
The driving force in protein folding is largely to bury hydrophobic residues in the protein core
so as to limit their contact with water (compare Figures 1.8(a) and 1.8(b)) (Branden and Tooze,
1999, p. 14). Where hydrophobic sidechains do occur in the hydrophilic core, their hydrogen
bonding potential is always satisﬁed (McDonald and Thornton, 1994).
1.5.5 Protein structure determination
There are two common methods of protein structure determination. Most widely used is X-ray
crystallography (Berg et al., 2002, Section 4.5.2). Here, the protein of interest must be ‘grown’ as
a crystal; that is, the same protein structure must be arranged in a repeating, symmetric array.
The crystal is bombarded with a stream of X-rays; on colliding with electrons in the crystal,
some of the X-rays are diffracted. The pattern and intensity of diffraction is recorded by an
X-ray detector placed behind the protein crystal. The pattern of diffraction and the intensity
of the diffracted X-rays can be mathematically transformed to yield an electron density map,
to which model structures can be ﬁtted (see Figure 1.9). A process of iterative reﬁnement is
applied to ﬁnd the structure that corresponds most closely to the diffraction pattern. Although
the structural representation is largely static (large scale motions are inhibited owing to the
fact that the structure is in a crystal and where regions do undergo large movements, these
are invisible as they are not described by the diffraction pattern) the B-factor, a measure of the
electron density spread of each atom, can provide some idea of local mobility. An estimate of
conﬁdence, called the R-factor, can be made from the data, by comparing the eventual modelCHAPTER 1. AN INTRODUCTION TO MUTATIONS 42
(a) Lysozyme (7lyz)
(b) Lysozyme (7lyz), sliced in half along the Z-axis
Figure 1.8: Hydrophobic residues are buried in the protein core
Hydrophobicity in lysozyme (PDB ID 7lyz). Blue indicates hydrophilic residues, red indicates hydrophobic residues.
Figure1.8(a)showsthewholeprotein; Figure1.8(b)showsthesameprotein, slicedinhalfalongtheZ-axis, toexposethe
patterns of hydrophobicity in the core of the structure. Hydrophilic residues cluster on the surface, while hydrophobic
residues predominantly form the core.CHAPTER 1. AN INTRODUCTION TO MUTATIONS 43
Figure 1.9: The process of X-ray crystallography
Crystalline forms of proteins and bombarded with a stream of X-rays. The resulting diffraction pattern can be inter-
preted as an electron density map, placing the electrons in 3D space. From this electron density map, a model can be
constructed. A process of iterative reﬁnement results in the best model for the diffraction pattern. Image obtained from
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with the diffraction pattern. The resolution of an X-ray structure indicates the angle at which
the X-rays were diffracted by the crystal (the larger the angle of diffraction, the higher the
quality of diffraction pattern and the higher resolution represented by a smaller number).
Nuclear magnetic resonance (NMR) spectroscopy is an alternative technology that exploits the
‘magnetic moments’ or ‘spin’ of certain atomic nuclei within a molecule (here, a protein of in-
terest) to derive information about their chemical environment (Branden and Tooze, 1999, pp.
387-391). The spin of such atomic nuclei (e.g., 1H) can be aligned by placing the atoms in a
strong magnetic ﬁeld. Irradiating the nuclei by applying a radio frequency pulse raises them
to an alternative excited state, disrupting the state of equilibrium. As the equilibrium state is
restored, the nuclei emit radio frequency radiation; the frequency of this radiation will depend
on the nucleus itself and its surrounding, chemical environment. The transition between these
alternative states is described as ‘resonance’. By varying the radio frequency pulses to which
the nuclei are exposed, recording the resulting resonance ‘spectra’ (or ‘chemical shifts’) and
plotting these spectra against each other, it is possible to elucidate many molecular properties
of the sample being analysed, including through-space information (in a nuclear Overhauser
effect Spectroscopy or NOESY experiment) and through-bind information (in a correlation
spectroscopy or COSY experiment). With these interactions identiﬁed, and with the identiﬁ-
cation of residue speciﬁc combinations of spectra, it is possible to derive distance constraints
between amino acids. These can then be used to derive possible structures of the molecule.
NMR structures are, therefore, an ensemble of possible structures, rather than one deﬁnitive
structure. Furthermore, NMR structures are solved in solution and therefore contain more in-
formation about ﬂexibility (Berg et al., 2002, Section 4.5.1).
Structures described by X-ray crystallography and NMR are complementary, and each method
has its strengths and weaknesses. For example, NMR is limited to small proteins, while crys-
tallography can determine the structure of large proteins, should it be possible to crystallise
them; crystallography requires that the protein structure be solid state, while NMR can more
successfully model the ﬂexibility of protein structures as the structure is determined in solution;
similarly, while NMR can capture dynamic processes such as protein folding, crystallography
allows the more precise characterisation of protein surfaces.
At the time of writing (November 2008), 85.50% (46570/54466) of the protein structures de-
scribed by the PDB are resolved using X-ray crystallography; 13.94% (7591/54466) are resolved
by NMR, and 0.56% (305/54466) are resolved by other means (e.g., electron microscopy). BothCHAPTER 1. AN INTRODUCTION TO MUTATIONS 45
kinds of structure are analysed by SAAPdb.
The structural information (including the secondary structure annotations in Figure 1.3(b))
shown in Figures 1.3-1.4 is derived from an X-ray crystal structure of the protein, described
by Protein Data Bank record 6adh (the Protein Data Bank, or PDB (Berman et al., 2000), will be
described in greater detail in Section 2.1.4).
1.6 Mutating protein structure can affect phenotype
As summarised in Section 1.5, protein folding is a complicated, hierarchical process that relies
on the proper formation of scaffolding bonds (particularly hydrogen bonds) between residues
in the protein sequence. Should a point mutation arise that alters the protein sequence, the
resulting protein structure may change, potentially affecting folding or function. In this thesis,
such a mutation is predominantly descrived as a SAAP, or single amino acid polymorphism
(see Section 1.4). A resulting functional change can either be (i) a gain of function, where the
protein acquires a novel (toxic) function; (ii) a loss of function, where the protein can no longer
perform its native function or (iii) both a gain and loss of function. Whether functionality is lost
or gained, the functional change caused by the SAAP may compromise native function and the
SAAP can be described as ‘deleterious’.
The most commonly cited structurally disruptive disease example is that of sickle-cell
anaemia6. Here, a single mutation A>T replaces a glutamic acid (glu, codon GAG) with a
valine (val, codon GTG) at position six in the protein sequence. This SAAP is highlighted in
the haemoglobin structure in Figure 1.10. This mutation is distant from the ligand binding site
and distant from the other chains in the protein. How then does it cause a disease phenotype?
Glutamic acid is a polar residue and as such is often found on the surface of proteins, where
it is solvated. Valine, however, is hydrophobic and is less often found on the surface of pro-
teins. Introducing the hydrophobic residue on the surface of the protein causes the protein to
aggregate; forming harmful ﬁbrils (see Figure 1.11); deforming the erythrocytes and resulting
in the disease phenotype (Finch et al., 1973). However, it is found that the sickle-cell phenotype
also gives some protection against malaria potentially offering a selective advantage, explain-
6http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=603903CHAPTER 1. AN INTRODUCTION TO MUTATIONS 46
Figure 1.10: Sickle-cell anaemia: the glu6val mutation
The glu6bval mutation known to cause sickle-cell anaemia is highlighted in red in chain B of the haemoglobin structure
(PDB ID 1bz0). Chain A, B, C and D are coloured dark blue, orange, light blue and green respectively. Haem ligands
are coloured using the CPK colour scheme.CHAPTER 1. AN INTRODUCTION TO MUTATIONS 47
ing why the deleterious phenotype has persisted in areas where malaria is common (Branden
and Tooze, 1999, pp. 43-45).
However, it is also possible that a SAAP will not compromise function. Although the twenty
amino acids are all different, many share similar characteristics (for example, isoleucine, leucine
and valine are all small hydrophobic residues) and therefore may be able to replace each other
without affecting protein structure and therefore function. As such, SAAPs may also be de-
scribed as ‘neutral’.
1.7 Quantifying the effect on protein structure
The work in this thesis rests upon the hypothesis that it will be possible to identify any struc-
tural effect of a deleterious SAAP. That is, where a pathogenic variation in the genome induces
a change at the protein level, the deleterious phenotype will be attributable to some disruption
of the protein structure and therefore the protein function.
To identify or quantify the structural effect of a particular mutation, the introduced residue
must be considered in the context of the protein structure. It will then be possible to assess
whether the mutation violates any of the underlying principles of protein structure, as de-
scribed in Section 1.5. Throughout this thesis, the act of identifying the structural effect of a
mutation is described as ‘explaining’ the mutation. Note that there there is no deleterious effect
to be explained in the case of SNPs, but the word ‘explained’ is used to keep the terminology
consistent.
The hypothesis is that disease-associated SAAPs will have a different impact on protein struc-
ture from neutral SAAPs. Should it be possible to quantify the structural effect(s) of disease-
associated SAAPs and neutral SAAPs, this hypothesis can be tested by comparing the kinds of
structural effects associated with disease-associated and neutral SAAPs.CHAPTER 1. AN INTRODUCTION TO MUTATIONS 48
Figure 1.11: Deleterious ﬁbrils in sickle-cell anaemia
A single mutation from glu to val at position 6 in the haemoglobin protein results in aggregation, ﬁbril accumulation,
malformed erythrocytes and, therefore, the disease phenotype. The image shows the mutated structure (PDB ID, 2hbs)
with the mutant residue highlighted in green in each protein chain. Image taken from the PDB and available from
Wikimedia Commons.CHAPTER 1. AN INTRODUCTION TO MUTATIONS 49
1.8 Learning from mutation data
Andrew Martin’s group has previously concentrated on explaining mutations in individual
proteins, including G6PD (Kwok et al., 2002) and p53 (Martin et al., 2002). In addition, sophis-
ticated analyses have been developed to assess the more complex aspects of protein structure
(Cuff and Martin, 2004; Cuff et al., 2006).
One objective of the work described in this thesis is to build on this previous work, maintain-
ing and further developing the existing structural analysis pipeline to process SAAPs automat-
ically.
Should it be possible to hypothesize what the structural effect of an amino acid substitution
might be, it may also be possible to predict whether previously unseen non-synonymous mu-
tations will have a signiﬁcant effect on protein structure or not, and therefore whether the muta-
tionwillbedeleteriousornot. Predictivemethodscanonlyworkifthereisadifferencebetween
PDs and SNPs. As such, it is important to characterise and compare both sets of data. Trends
identiﬁed here could inform which machine learning approaches would be most successful and
which data should be used to make predictions. The second objective of the work described
in this thesis is to characterise both sets of SAAPs and identify signiﬁcant differences between
them.
Characterising PDs also contributes to the design of novel therapies: should the deleterious
effect of the mutant protein structure be attributed to a speciﬁc structural abnormality, it may
be possible to design a compound that nulliﬁes the deleterious effect, thereby recovering native
function. For example, should the mutation destabilise the protein structure, a compound that
can either (i) stabilise the mutant form or (ii) chaperone the native structure may be a viable
therapy. To return to the sickle-cell anaemia example, drugs stabilising the oxygenated form of
haemoglobin were designed in light of the knowledge of the effect of the mutation (Beddell et
al., 1984). More recently, two such targets have been reported for cancers caused by destabilisa-
tion of P53 (Boeckler et al., 2008; Friedler et al., 2002).CHAPTER 1. AN INTRODUCTION TO MUTATIONS 50
Table 1.1: Existing characterisations of PDs and SNPs
: PDs were associated with this feature; : SNPs were associated with this feature. ‘-’: no relationship was found.
?: the paper includes some prediction work. y: the paper considered only deleterious data. A blank cell denotes that
the feature was not considered. Datasets: A = LacI repressor (Suckow et al., 1996); B = T4 lysozyme (Rennell et al.,
1991); C = HIV protease (Loeb et al., 1989); D = dbSNP (Smigielski et al., 2000); J = uses natural residue variation across
species to represent ‘neutral’ SAAPs; M = HMGD (Stenson et al., 2003); N = HGVBase (Fredman et al., 2002); O = OMIM
(McKusick, 1998; Amberger et al., 2009); S = UniProtKB/Swiss-Prot VARIANT (The UniProt Consortium, 2009); X =
other LSMDB (various references). Structural data used: Y = where PDB structures were unavailable, models were
used; Yi = structural features were inferred from sequence. AA: amino acid.
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Bao & Cui (2005) ? S Y Y     
Cai et al. (2004) ? AB Y Y  
Chasman & Adams (2001) ? AB Y Y    
Clifford et al. (2004) ? DX Y Y 
Dobson et al. (2006) ? S Y Y  
Ferrer-Costa et al. (2002) S Y Y      
Ferrer-Costa et al. (2004) ? AS Y Yi 
Khan & Vihinen (2007) y MX n Y  - 
Krishnan & Westhead (2003) ? AB Y Yi    
Needham et al. (2006) ? AB Y Y  -  
Ng & Henikoff et al. (2001) ? ABC Y n 
Saunders & Baker et al. (2002) ? AC Y Y -    
Stitziel et al. (2003) DO Y Y  -  
Steward et al. (2003) O Y Y   
Sunyaev et al. (2001) ?a DNS Y Y      
Torkamani & Schork (2007) X Y Y   
Verzilli et al. (2005) ? AB Y Y     
Vitkup et al. (2003) S Y Y    
Wang & Moult (2001) b DM n Y 
Yue et al. (2005) ? JM n Y   
a http://genetics.bwh.harvard.edu/pph/
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1.9 Characterising pathogenicity: existing work
Table 1.9 summaries 18 characterisations of pathogenic deviations (PDs) and single nucleotide
polymorphisms (SNPs) that exist in the literature.
Work has predominantly focussed on characterising PDs: compare the number of PD-feature
annotations () with the number of SNP-feature annotations () in Table 1.9. If the objective
is to understand the molecular basis of disease and use that knowledge to design appropri-
ate disease therapies, this is the most important perspective from which to consider the data.
However, with a view to predicting whether a novel mutation will be deleterious or not, or with
a view to extrapolating ﬁndings to protein structure in general, it is important to characterise
both pathogenic and neutral polymorphisms. It may be the case that the most informative char-
acterisation of disease-causing mutations is a characterisation that describes which features are
absent rather than present. Indeed, using decision trees to build predictors for pathogenicity, Kr-
ishnan and Westhead (2003) found that rules predicting ‘no effect’ (i.e., neutral) were of higher
conﬁdence than those predicting ‘effect’ (i.e., deleterious).
Most commonly, PDs are found (i) in the protein core (i.e., buried); (ii) at sites of high conserva-
tion and (iii) to introduce extreme changes in amino acid properties (including hydrophobicity
(Ferrer-Costa et al., 2002; Sunyaev et al., 2001; Saunders and Baker, 2002; Cai et al., 2004) and
volume (Ferrer-Costa et al., 2002; Khan and Vihinen, 2007)). Other features associated with PDs
are most commonly measurements of the structural environment of the mutation, including
overpacking or C density (Saunders and Baker, 2002; Yue et al., 2005), B-factor (Chasman and
Adams, 2001; Verzilli et al., 2005; Needham et al., 2006) and UniProtKB/Swiss-Prot features
(Saunders and Baker, 2002).
Only one result challenges the reasonably consistent characterisation that emerges from the
other investigations: Stitziel et al. (2003) did not ﬁnd PDs buried in the interior of the protein.
However, this is owing to a slightly different deﬁnition of ‘buried’. Stitziel et al. use a geometric
analysis of protein structure to categorize residues as belonging to one of three classes: (1) on
the surface (2) in a surface crevice or internal void or (3) completely buried in the interior of
the protein (i.e., remote from any void). They found that very few PDs nor SNPs belonged
to category (3). However, they did ﬁnd that PDs are more than twice as likely to be found in
an internal void or crevice. This is consistent with the characterisation that emerges from theCHAPTER 1. AN INTRODUCTION TO MUTATIONS 52
other studies and draws attention to a subtlety of protein structure that has otherwise not been
considered: maintainance of the protein core may be dependent on essential, stabilising voids.
In making predictions, structural information is largely found to be more valuable than se-
quence information (Bao and Cui, 2005; Needham et al., 2006), although where structural in-
formation is unavailable or it is difﬁcult to measure the structural feature (for example, ﬂexibil-
ity), sequence information can complement structural data when discriminating between PDs
and SNPs (Saunders and Baker, 2002). Further, signiﬁcant differences have been found when
considering combinations of features (e.g., native/mutant amino acid and secondary structure
(Khan and Vihinen, 2007); B-factor and conservation (Verzilli et al., 2005); accessibility and con-
servation (Stitziel et al., 2003)).
Further, some associations may be more complex even within the same ‘feature’. For example,
Chasman and Adams (2001) identiﬁed conservation based features associated with both PDs
and SNPs: PDs were found to be at sites of high conservation, whereas SNPs were found at
sites where the introduced residues were identiﬁed as the native residue in another species
(Chasman and Adams, 2001), explaining the  annotation in the corresponding cell in Table
1.9. Torkamani and Schork (2007) identiﬁed native and mutant amino acids associated with
both kinds of SAAPs.
Two-thirds (12/18) of the methods include some attempt at pathogenicity prediction; as
yet, no particular learning method has emerged as superior. Results vary with respect to
overclassiﬁcation—erroneously classifying neutral examples as deleterious (Bao and Cui,
2005)—and underclassiﬁcation—erroneously classifying deleterious examples as neutral
(Cai et al., 2004; Krishnan and Westhead, 2003)—however, prediction accuracy is reasonably
consistent at approximately 70-85%. Prediction peformance has peaked at MCC=0.50, where
support vector machines were used to predict the pathogenicity of polymorphisms annotated
in UniProtKB/Swiss-Prot (denoted with S in Table 1.9) using a 94-dimensional vector of
sequence attributes (Tian et al., 2007) (see Section 2.3.5 for a description of binary classiﬁcation
performance statistics, including MCC).
The characterisations in Table 1.9 portray PDs as mutations that primarily disrupt the stability
of proteins by altering the protein core. Further, it appears that extreme changes in the amino
acid property at the site of mutation are associated with pathogenicity. This motivates the
inclusion of both sequence and structural features in an analysis pipeline.CHAPTER 1. AN INTRODUCTION TO MUTATIONS 53
This thesis aims to contribute to this body of work, ﬁrst by collating data in a resource called
SAAPdb (Single Amino Acid Polymorphism database), then by either consolidating or chal-
lenging the existing characterisation of deleterious and neutral mutations. The analysis will be
motivated by identifying features that will beneﬁt future machine learning methods, and by an
understanding of the basic underlying principles of protein structure.
Thedatageneratedbythemethodsdescribedinthisthesishavebeenmadepublicallyavailable.
Indoingso, SAAPdbhasbecomeoneofseveralonlineresourcesthatattempttoidentifyand/or
quantify the effect of mutations on protein structure. These resources vary with respect to their
SNP/PD data; the level at which these data are considered (e.g., genomic, proteomic, biological
pathways and so on); the motivation for the analysis repertoire (e.g., structural or functional
explanations); website functionality and the frequency with which the data are updated. These
will be reviewed in the remainder of this section.
SNPeffect7 (Reumers et al., 2006) is primarily concerned with explaining neutral SNPs (taken
only from dbSNP) functionally—for example, change of subcellular localisation and protein
turnover—whereas the primary aim of SAAPdb is to ascribe a structural effect to SAAPs, both
PDs and SNPs. StSNP8 (Uzun et al., 2007) is another resource that adopts a functional per-
spective, in favour of SAAPdb’s structural perspective, when annotating neutral and disease-
associated SAAPs. SAAPs are mapped to protein structures via BLASTs against the PDB, and
further mapped to metabolic pathways via KEGG (Kanehisa et al., 2008).
LS-SNP9 (Karchin et al., 2005) annotates nsSNPs with information calculated from homologous
protein structures (including charge shift; solvent accessibility and hydrophobicity changes;
prolines introduced into a helix) taking a very similar rule-based approach as that of Ramensky
et al. (2002). However, as the authors note themselves, they have adopted a far less conserva-
tive approach to mapping from protein sequence to structure in an effort to characterise more
SAAPs structurally: structures are used from homologous proteins with an average of 28.5%
sequence identity. As an exploratory tool, where speciﬁc mutations are being considered, such
a relaxed mapping may be appropriate. However, with a view to learning about protein struc-
ture and its relationship to function, and making predictions regarding the pathogenicity of a
novel mutation—one of the main reasons for collating the SAAPdb dataset—this would result
in an unacceptably noisy dataset.
7http://snpeffect.vib.be/
8http://glinka.bio.neu.edu/StSNP/
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Although it aims to help elucidate the relationship between SAAPs and their effect on protein
structure, MutDB10 (Dantzer et al., 2005) contains minimal structural information, in that it pro-
vides a mapping to a PDB structure but no further analysis thereof. The SAAPs are annotated
withrespecttophenotypeandwithrespecttoSIFTscoreandprediction, buttheresourcewould
more appropriately be described as sequence-based SAAP data collation effort with enhanced
visualisation functionality, rather than a resource of structurally annotated SAAPs. Similarly,
the SNP function portal (Wang et al., 2006) characterises SNP alleles primarily with respect
to genomic and transcriptomic features (including occurence in a known transcription factor
binding site or microRNA transcript), with limited treatment at the level of protein structure.
SNP@DOMAIN11 (Han et al., 2006) provides visualisation of dbSNP polymorphisms mapped
to protein domains (via Pfam annotations in the Ensembl database), but provides limited in-
vestigation into the effect of these mutations by presenting SIFT scores (Ng and Henikoff, 2001)
and annotating SNPs that are described by OMIM.
Two resources exist with which it is most appropriate to compare SAAPdb: SNPs3D and
topoSNP. These resources consider both PDs and SNPs with respect to structure, providing the
results of structural analyses online.
The resource topoSNP12 (Stitziel et al., 2004) extends the work of Stitziel et al. (2003). Here,
neutral and disease-associated SAAPs are mapped to protein structure and assessed as to their
geometric location in the protein structure. Speciﬁcally, SAAPs are categorised as (a) occuring
in a surface pocket or interior void; (b) occurring on a convex region or (c) completely buried
in the protein structure. This seems a rather coarse-grained approach to structure analysis. For
example, surface pockets and interior voids exist in very different environments—one predom-
inantly hydrophilic and potentially near binding/interaction sites, the other predominantly
hydrophobic and distant from binding/interaction sites—it seems unlikely that the same muta-
tion will have similar effects in both environments. In addition, at the time of writing (Septem-
ber 2008), the topoSNP server was non-functional and it was therefore not possible to compare
the CHIME13 plug-in visualisation functionality with that of SAAPdb.
The resource SNP3D14 (Yue et al., 2006) focuses on the relationship between genes and dis-
ease, for both disease-associated SAAPs and neutral SAAPs, and is the nearest competitor
10http://mutdb.org/
11http://snpnavigator.net/
12http://gila.bioengr.uic.edu/snp/toposnp/
13http://www.mdlchime.com/
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to SAAPdb. It describes hypothesised gene/disease interactions and gene/gene interactions
(identiﬁed via text mining) in addition to hypothesized nsSNP/function interactions. The
repertoire of hypothesized functional effects of nsSNPs includes backbone strain; introduced
buried charge residue; introduced buried polar residue; electrostatic repulsion; disulphide
bond breaking; cavity creation; overpacking; loss of hydrophobic effect; loss of salt bridge;
loss of hydrogen bonds; loss of polar-polar interaction; loss of polar-charge interaction; loss
of charge-charge interaction and sequence conservation; all of these methods had been devel-
oped within the Moult group at the University of Maryland (Wang and Moult, 2001; Yue et
al., 2005; Yue and Moult, 2006). Admittedly, there is much overlap here with the repertoire of
SAAPdb (see Chapter 5). However, of the analyses the resources share, the SAAPdb approach
is more sophisticated. For example, the overpacking analysis in SNPs3D simply identiﬁes mu-
tations to a residue with a longer sidechain, whereas the analogous ‘clash’ analysis in SAAPdb
explicitly models the mutation into the structure in silico, thereby making more sensitive and
conservative hypotheses. In addition, SAAPdb currently contains dbSNP build 129, while the
data in SNPs3D has not been updated since January 2004 (build 124) (September 2008). This
amounts to an additional 4 654 231 SNPs (including 1 519 114 validated SNPs) that are consid-
ered in SAAPdb. Furthermore, unlike SNPs3D, SAAPdb allows the straightforward simultane-
ous viewing of multiple PDs and/or SNPs within a mutant or native protein structure.
In summary, there are several online resources that exist to catalogue PDs and/or SNPs. How-
ever, none exists that (1) is motivated primarily by an understanding of protein structure; (2)
takes a careful, conservative and sophisticated approach to providing explanations; (3) aims to
maintain and update the resource on a regular basis; and (4) provides a simple but powerful,
interactive graphical interface for viewing and comparing PDs and SNPs within the protein
structure. SAAPdb aims to provide the mutations research community with such a resource.
1.10 A summary of aims
This thesis will investigate the differential sequence and structural properties and effects of
neutral and deleterious point mutations. At a general level, the work described aims to (A)
expand the pre-existing suite of analyses which aim to ‘explain’ the structural effect of a SAAP
and (B) compare and contrast the neutral and deleterious mutations with a view to developing
predictive methods that will classify a novel point mutation as neutral or deleterious. In orderCHAPTER 1. AN INTRODUCTION TO MUTATIONS 56
to achieve this, the current SAAPdb pipeline has been extended, requiring the development
of several new structural analyses; a method for identifying functionally equivalent proteins,
and a method for identifying highly conserved residues. Very preliminary predictive work has
shown that the work described in this thesis should contribute signiﬁcantly to the problem of
identifying deleterious mutations (see Appendix [A]).Chapter 2
An introduction to bioinformatics
methods
This thesis describes a database of single amino acid polymorphisms (SAAPs) that have been
mapped to structure and subsequently analysed to provide hypotheses as to their effect(s), if
any, on protein structure. The resource, named SAAPdb, employs several well established
data resources, data handling methods and data analysis methods. In this chapter, these are
introduced to provide the context for later chapters.
2.1 Resources
SAAPdb requires data from several sources. SNPs are obtained from dbSNP (Sherry et al.,
1999; Smigielski et al., 2000) and HGVBase (Fredman et al., 2002); genomic information
is taken from EMBL (Kulikova et al., 2007) and Genbank (Benson et al., 2008); PDs are
extracted from OMIM (Amberger et al., 2009) and several smaller locus-speciﬁc mutation
databases (LSMDBs); protein data are taken from UniProtKB (The UniProt Consortium,
2009) (predominantly UniProtKB/Swiss-Prot), and protein structures are taken from the PDB
(Berman et al., 2000). Further, the PDBSWS resource (Martin, 2005) is used to map sequence
data onto structural data. These resources and their contents are described in this section.
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2.1.1 dbSNP and HGVBase
2.1.1.1 dbSNP
dbSNP is a central repository maintained by the NCBI that collates data about small-scale ge-
nomic variation, the vast majority of records (>95%) describing single nucleotide polymor-
phisms (SNPs) (Sherry et al., 1999; Smigielski et al., 2000). dbSNP accepts submissions of both
disease-associated and ‘neutral’ SNPs and makes no assumptions about allele frequency. Map-
pings to protein sequence are provided.
The version of dbSNP currently described by SAAPdb is dbSNP build 1291, which was made
available in April 2008 and describes 14 708 752 records for Homo Sapiens. The dbSNP data
analysed in Chapter 7 is dbSNP build 126 2, which was made available in May 2006. This build
includes 11 961 761 records for Homo Sapiens and 6 491 554 records for Mus Musculus.
2.1.1.2 HGVBase
The HGVBase (Human Genome Variation database) resource exclusively describes small-scale
human genetic variation, the vast majority of which (>95%) are SNPs (Fredman et al., 2002).
Although much of the information in HGVBase is complementary to that in dbSNP, the focus
here is to collate data relevant to phenotype, and stringent quality criteria are applied (Fredman
et al., 2002). Unfortunately, however, HGVBase has not been consistently maintained, with only
sporadicupdatessince2003(notethatanewresource, HGVBaseG2P(Thorissonetal., 2009), has
recently become available but was not used in this thesis).
2.1.2 OMIM and LSMDBs
The PD data in SAAPdb are derived from multiple sources.
1http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?view+summary=view+
summaryi&build_id=129
2http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?view+summary=view+
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Figure 2.1: (O)MIM growth since 1965
The size of the (O)MIM versions are marked with diamonds; image taken from Amberger et al. (2009).
The ﬁrst and largest of these resources is Online Mendelian Inheritance in Man, or OMIM3
(Amberger et al., 2009). OMIM is a central description of inherited, disease-associated genetic
mutations that is updated on a daily basis and is the online version of the original book re-
source, MIM (McKusick, 1998). As of October 2008, OMIM contains 19 023 mutations of which
6 514 (34.24%) are characterised phenotypically. OMIM is based on peer-reviewed literature:
journal contents are scanned to identify articles of relevance, with particular emphasis on dis-
ease phenotypes, genes with novel biology and genes currently absent in OMIM.
With genomic sequencing becoming cheaper and more reliable, the number of PDs being iden-
tiﬁed is increasing exponentially. Figure 2.1 shows the increase in MIM (1965-1998) and OMIM
(2008) content: in the last ten years, the number of disease mutations has increased more than
two-foldfromapproximately8000in1998(McKusick, 1998)toalmost20000in2008(Amberger
et al., 2009).
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OMIM provides a wealth of disease-associated information on which substantial bioinformatic
analysis can be done. However, data are also available in locus-speciﬁc mutation databases or
LSMDBs, which are maintained separately by research groups with an interest in a particular
disease. Such resources potentially hold much more data, both with respect to quantity and
quality (George et al., 2008): such special interest resources may include detailed phenotypic
information such as enzymatic function or prognosis. Bioinformatic analysis using these data
could reveal more subtle effects on protein structure: rather than training classiﬁers on the
coarse-grained binary classiﬁcation problem of disease-causing or neutral, methods could learn
to predict disease severity. As such, the PD dataset is augmented by seven other mutation
datasets.
ADAbase ADAbase4 is a mutations registry for inherited adenosine deaminase (ADA) deﬁ-
ciency mutations (OMIM:608958) (Piiril¨ a et al., 2006), which account for approximately
half of severe combined immunodeﬁciency disorders (SCID).
ZAP70base A second SCID disease is represented in SAAPdb: the ZAP70base5 resource de-
scribes a small number of mutations to the ZAP70 protein (Piiril¨ a et al., 2006) which cause
a ZAP70 deﬁciency (OMIM:176947).
HAMSTeRS The Haemophilia A Mutation Structure, Test and Resource Site (or HAMSTeRS6
resource) describes mutations to Factor VIII, the protein absent or defective in
haemophilia A (OMIM:306700). These mutations are collated from peer-reviewed
literature and electronic submissions.
G6PD The G6PDdb7 resource was developed in a collaboration with the Martin group (Kwok
et al., 2002) and describes mutations to human glucose 6-phosphate dehydrogenase (or
G6PD, OMIM:305900), which cause G6PD deﬁciency (Beutler et al., 1968). This X-linked
disease is characterised by abnormal breakdown of red blood cells (haemolysis), in re-
sponse to infection, chemicals or particular foods; most famously, haemolysis is often
induced by fava (broad) beans, explaining why G6PD deﬁciency is also known as ‘fav-
ism’.
IARC TP53 The IARC TP53 mutation database8 catalogues mutations to the gene TP53 and
its protein product P53 (Olivier et al., 2002; Petitjean et al., 2007). Mutations to P53 occur
4http://bioinf.uta.fi/ADAbase/
5http://bioinf.uta.fi/ZAP70base/index2.html
6http://europium.csc.mrc.ac.uk/WebPages/Main/main.htm
7http://www.bioinf.org.uk/g6pd/
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in approximately half of all human cancers (Greenblatt et al., 1994; Sidransky and Holl-
stein, 1996; Lane and Fischer, 2004). IARC collate both germline (inherited) and somatic
(acquired) mutations in P53 (OMIM:191170).
OTC OTC deﬁciency, a rare metabolic disorder, is caused by mutations to OTC (ornithine car-
bamoyltransferase, OMIM:300461). It is a disorder of the urea cycle which causes hyper-
ammonemia, an excess of ammonia in the blood (Gilbert-Dussardier et al., 1996). Tuch-
man et al. (2002) describe the dataset that is used in SAAPdb.
SOD1db Amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND) is a progres-
sive, often fatal, neurological disease characterised by the degeneration of motor neu-
rons (OMIM:147450). ALSOD9 at the Institute of Psychiatry, King’s College London de-
scribes ALS-associated mutations deposited by registered users. In SAAPdb, only ALS-
associated mutations to superoxide dismutase or SOD1 (a dataset that is referred to as
SOD1db) are analysed.
At the time of writing (November 2008), over 700 LSMDBs are recorded on the Human
Genome Variation Society’s website (http://www.hgvs.org/dblist/glsdb.html).
Although SAAPdb only includes a small fraction of these data, the system has been designed
and implemented so that integrating more locus-speciﬁc data is straightforward.
2.1.3 UniProtKB and UniProtKB/Swiss-Prot
UniProtKB10 is the world’s most comprehensive resource of protein information
(The UniProt Consortium, 2009). It is comprised of several smaller databases, including
UniProtKB/Swiss-Prot and UniProtKB/trEMBL. These datasets differ in their level of curation
and annotation. UniProtKB/Swiss-Prot is a manually annotated dataset, which aims to
reduce redundancy, improve annotation and provide comprehensive cross-references to
other resources. UniProtKB/trEMBL however is an automatic translation of the genome as
described by EMBL. It therefore contains a great deal of redundancy and little annotation
(where annotation does exist, it is transferred by homology and has not been experimentally
veriﬁed).
SAAPdb almost exclusively uses UniProtKB/Swiss-Prot; UniProtKB in its entirety is only
9http://alsod.iop.kcl.ac.uk/Als/index.aspx
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1: ID TACY_LISMO Reviewed; 529 AA.
2: AC P13128; Q48747; Q57096; Q57206;
...
3: DE Listeriolysin O precursor (Thiol-activated cytolysin) (LLO).
...
4: DR EMBL; X15127; CAA33223.1; -; Genomic_DNA.
5: DR PIR; A43505; A43505.
...
6: FT SIGNAL 1 25
7: FT CHAIN 26 529 Listeriolysin O.
8: FT /FTId=PRO_0000034102.
9: FT SITE 484 484 Binding to cholesterol (By similarity).
10: FT VARIANT 35 35 S -> L (in strain: F4233 / Serotype 1/2b,
11: FT F5782 / Serotype 4b, F6789 / Serotype 1/
12: FT 2b and 12067).
13: FT VARIANT 438 438 V -> I (in strain: F4233 / Serotype 1/2b,
14: FT F5782 / Serotype 4b, F6789 / Serotype 1/
15: FT 2b and 12067).
16: FT VARIANT 523 523 K -> S (in strain: F4233 / Serotype 1/2b,
17: FT F5782 / Serotype 4b, F6789 / Serotype 1/
18: FT 2b and 12067).
...
19: //
Figure 2.2: An example of a UniProtKB/Swiss-Prot record
The above record is for [UniProtKB:TACY LISMO/P13128], in UniProtKB/Swiss-Prot version 13.5/55.5;it has been
edited only to include those data that are relevant for SAAPdb and FOSTA, i.e., ID (the identiﬁer), AC (the accession
number), DE (the description ﬁeld),DR (database cross-reference line) and FT (annotated features);records are termi-
nated with a nn; line numbers are given on the left for references in the text and ‘...’ are used to indicate skipped
lines.
used to construct mappings between accession codes (ACs, see Section 2.1.3.1 below) and
to map protein records to gene records (see Section 6.2.2). All functional annotation is
provided by UniProtKB/Swiss-Prot by means of the uniprot sprot.dat ﬂatﬁle, released
with every new version of UniProtKB. The format of this ﬁle has recently changed (see
http://www.uniprot.org/docs/xml_news.htm). However the UniProtKB/Swiss-Prot
data used in SAAPdb at present is UniProtKB/Swiss-Prot version 55.5, dating from June 2008.
This section describes UniProtKB/Swiss-Prot version 55.5 (the SAAPdb parsers have recently
been updated to deal with the changed format).
Each UniProtKB/Swiss-Prot protein is described in a separate record using start-of-line, two-
character keys to classify the ﬁelds. An example is shown in Figure 2.2. Records are separated
by a line containing only the string ‘nn’ (line #19 in Figure 2.2). The data that are relevant to this
work are described in the remainer of this section (a full description of the UniProtKB/Swiss-
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2.1.3.1 The UniProtKB/Swiss-Prot identiﬁer and accession number
Each UniProtKB record is described with both an identiﬁer ID and an accession number (AC).
The ACs are a string of 6 alphanumeric characters (currently beginning with A, P, Q or O). Once
an AC has been assigned to a protein sequence, either in UniProtKB/Swiss-Prot or UniPro-
tKB/trEMBL, it is guaranteed always to refer to that particular protein (although the sequence
records may be amended). Should records be merged or deleted, the original AC will be re-
tained as a ‘secondary’ AC to the new ‘primary’ AC. In the example, the ID is TACY LISMO
and the primary AC is P13128 (lines #1-2 in Figure 2.2). There are three secondary ACs: Q48747,
Q57096 and Q57206 (the primary AC is simply the ﬁrst AC provided, see line #2 in Figure 2.2).
The IDs are of the format PROTEIN SPECIES, where PROTEIN is a string indicating what the
protein is or does, and SPECIES is a string describing the species from which the sequence
has been derived. The steadily expanding (and occassionally revised) vocabulary of species
is described and made available at http://www.uniprot.org/taxonomy/. IDs are not
guaranteed to remain the same. For example, in UniProtKB/Swiss-Prot version 4.0/46.0, hu-
man protein C had the identiﬁer PRTC HUMAN; in the successive version, the ID changed to
PROC HUMAN. It has, however, always been identiﬁable with the AC P00470.
When working with UniProtKB/Swiss-Prot data, it is important to ensure data integrity by
always using primary accession numbers.
2.1.3.2 The description ﬁeld
The description or DE ﬁeld contains a description of the protein. Proteins may be described
using any number of synonyms. In the example, there are three:“Listeriolysin O precursor”,
“Thiol-activated cytolysin” and “LLO” (line #3 in Figure 2.2). Also included in this line is an
indication of whether the protein is a “(Fragment)” or not, and any relevant EC number(s).
2.1.3.3 The database cross-references
UniProtKB/Swiss-Prot provides cross-references between databases. These data are used later
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equivalent proteins (FOSTA) against a similar existing method (Inparanoid) (see Section 3.3.7).
In the example, TACY LISMO is cross referenced to EMBL records X15127 and CAA33223.1,
and PIR records A43505 and A43505 (lines #4-5 in Figure 2.2).
2.1.3.4 Annotated features
UniProtKB/Swiss-Prot provides annotations of sequence, structural and functional features
that are found in the protein (see lines #4-5 in Figure 2.2). These may be transferred by ho-
mology, or there may be experimental evidence for the feature in the speciﬁc protein; however
this information is not guaranteed to be included. The use of UniProtKB/Swiss-Prot FT infor-
mation is described fully in Section 5.11.
2.1.4 PDB
The PDB is the largest publicly available repository for 3D data describing biological macro-
molecules (Berman et al., 2000). Structures are primarily solved using X-ray crystallography
(see Section 1.5.5). PDB ﬁles are plain text, most importantly describing the 3D coordinates of
each atom. Residues are described simply by annotating each constituent atom with the same
residue ID. In addition to the atomic coordinates, PDB ﬁles contain information regarding the
method by which the structure was solved; references to the literature; cross-references to other
resources (e.g., UniProtKB); speciﬁcation of ligands, and so on.
Unfortunately, the format is not well structured and standards are not enforced consistently.
Consequently, parsing is difﬁcult. In Section 2.2.3 an alternative format, developed by Andrew
Martin while at Inpharmatica, for the PDB that is more amenable to automated parsing is de-
scribed.
2.1.5 PDBSWS
SAAPdb uses the PDB-to-UniProtKB mapping PDBSWS (Martin, 2005) to map sequence
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UniProtKB IDs and ACs, and accurate mapping between primary and secondary accession
numbers (see Section 2.1.3). These data are parsed from the UniProtKB release (from both
UniProtKB/Swiss-Prot and UniProtKB/trEMBL). As of October 2008, 96.34% of PDB protein
chains are successfully mapped to a UniProtKB sequence.
The PDBSWS database is populated as follows:
1. Extract UniProtKB cross-references from PDB ﬁles
2. Extract PDB cross-references from UniProtKB ﬁles
3. Brute-force scan the remaining PDB chains against UniProtKB
4. Align PDB sequence with UniProtKB sequence to generate the PDBSWS mapping
In Step 1, UniProtKB accession (AC) and identiﬁer (ID) references are parsed from the DBREF
ﬁeld from all PDB ﬁles. If no UniProtKB cross-reference exists in the DBREF ﬁeld, the REMARK
999 ﬁeld is parsed in an attempt to ﬁnd UniProtKB AC or ID references. Invalid UniProtKB
references (e.g., references to obsolete IDs) are ﬂagged to be analysed later in the brute-force
scan (Step 3). References to UniProtKB IDs are replaced with their corresponding AC and all
AC references are updated to the current primary AC.
Next, PDB references are extracted from UniProtKB (Step 2). The UniProtKB sequence
is aligned with each PDB chain in turn to identify which chain (or chains) are relevant.
UniProtKB now includes chain information, but this protocol was designed at a time when it
did not.
Steps 1 and 2 may yield multiple matches as a protein sequence can map to multiple PDB
structures, and to several chains within a single PDB structure. All identiﬁed mappings are
stored in the PDBSWS relational database implemented in PostgreSQL.
The ﬁnal PDB/AC mapping step is a brute-force scan, which attempts to match all remaining
PDBs to UniProtKB ACs. A PDB sequence is reconstructed from the ATOM records. This
sequence is then searched for in UniProtKB (UniProtKB/Swiss-Prot and UniProtKB/trEMBL)
using fasta33 (Pearson and Lipman, 1988). The best match is identiﬁed and the mapping is
recorded if (i) the residue overlap is 30 and the identity is at least 90% (ii) the residue overlap
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Once all possible PDB-UniProtKB record-to-record mappings are identiﬁed, the two
sequences are aligned, using ssearch33 (Pearson and Lipman, 1988), to generate the
PDB-UniProtKB residue-to-residue mappings. These data are freely available via a webserver or
in ﬂatﬁle format at www.bioinf.org.uk/pdbsws.
2.1.6 EMBL and Genbank
EMBL (Kulikova et al., 2007) and Genbank (Benson et al., 2008) are two publicly available nu-
cleotide sequence databases, EMBL being curated by the EBI and Genbank being curated by
the NCBI. Data are derived from submissions from individual researchers, large-scale genome
sequencing projects and patent records. Each record describes a particular section of DNA and
includes annotations of coding regions, database cross-references, literature citations, biologi-
cally relevant features and so on. EMBL and Genbank exchange data on a regular basis, so the
sequence content should be identical.
2.2 Data handling
It is essential that appropriate and robust data handling is employed in large-scale, automated
systems such as SAAPdb to ensure data integrity. The vast quantities of information involved
require that data are retrieved and processed quickly and reliably. Here, several of the funda-
mental data handling methods are introduced: relational databases (Section 2.2.1), XML and
the associated XML translation speciﬁcation XSLT (Section 2.2.2) and an alternative representa-
tion of the PDB, XMAS, which is based on a combination of ideas from XML and ASN.1 formats
(Section 2.2.3).
2.2.1 Relational databases
Relationaldatabasesareameansofstoringinformation. Dataarestructuredastablesconsisting
of columns or ‘ﬁelds’ and contain data in unordered rows or ‘tuples’. The ‘relational’ aspect
of these data structures is in the use of ‘foreign keys’ and common attributes, which refer to
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ﬁelds and much data redundancy, to be ‘normalised’ into smaller data structures describing
individual concepts.
To illustrate the key concepts in a relational database, a small example dataset will be used
throughout this section. The example being used is a list of newspaper deliveries, where cus-
tomers can have any number of different papers delivered to an address. The ﬁrst step in good
database design is to decompose the problem into its constituent ‘entities’, ‘relationships’ and
‘attributes’. Entites describe distinct objects in the dataset. Combining entities using relation-
ships allows more abstract entities to exist. Further, both entities and relationships can have
attributes which describe a corresponding object. Good database design often begins with an
‘entity-relationship’ (ER) diagram that clearly deﬁnes what the entities and relationships are in
the data to be stored.
Figure 2.3(a) describes the entities, relationships and attributes in the newspaper delivery ex-
ample. There are two entities: a customer and a newspaper. These entities are joined by the
relationship ‘is delivered a’ which captures the more abstract or ‘associative’ delivery entity.
Both entities and relationships can have attributes: a customer has a name and an address, a
newspaper has a name and frequency (i.e., daily/weekly) and a delivery is deﬁned by the num-
ber of papers that are to be delivered. In addition, each entity is given an ‘ID’ which will allow
each example of an entity (i.e., each customer or newspaper) to be identiﬁed uniquely.
Often, itisusefultodecomposeanattributeintotwoormorefurtherattributes. Theseattributes
are ‘multi-valued’ attributes. In the example, a customer’s name has been split into ‘ﬁrstname’
and ‘surname’ and the address is split into the ‘address’ text and the ‘postcode’. This allows for
direct access to the sub-attribute.
Relationships between entities should also be deﬁned with respect to cardinality, which de-
scribes how entities are related to each other. The cardinality may be many-to-many, one-to-
many or one-to-one. In the example, the relationship between the customer entity and the
newspaper entity is many-to-many, as a customer may have more than one newspaper deliv-
ered and similarly a newspaper may be delivered to more than one customer; this is shown in
Figure 2.3(a) as grey text attached to the relationship connectors.
With the ER diagram completed, the application of several rules will derive a suitable database
design. In the newspaper example, the relevant rules are that (i) each entity should be repre-CHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 68
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(a) An example entity relationship (ER) diagram
Entities are in square-edged rectangles while attributes are in round-edged boxes. Lines join entities and relationships
to their attributes. Grey monospace text indicates the cardinality of a relationship.
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(b) An example relational database
The data to be represented is a list of newspaper deliveries, shown in the top half of Figure 2.3(b).These data can be
decomposed into smaller entities (Customer, Newspaper, Delivery) and stored in separate tables as shown in the
bottom half of Figure 2.3(b). Primary keys are annotated with an asterisk (*), foreign keys are annotated with a caret (ˆ).
Primary keys in the Customer, Address and Newspaper tables are highlighted in blue, red and green respectively. The
same colours are used in the Delivery table to indicate where these primary keys are used as foreign keys.
Figure 2.3: Using a toy dataset of newspaper deliveries to illustrate database designCHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 69
sented by a table (ii) each many-to-many relationship should be represented by a table and (iii)
any multiple attribute for which there are dependencies between the sub-attributes (e.g., the
address text and the postcode in the customer’s address) should be factored out into a different
table. The resulting database and its relationship to the original data are shown in Figure 2.3(b).
Two fundamental concepts in relational databases are primary and foreign keys. Primary keys
are IDs that allow each example in a table to be identiﬁed uniquely. Most often they are arbi-
trary numbers applied to data as they are entered into the database. Foreign keys are references
to external ﬁelds, that is, ﬁelds in other tables. In Figure 2.3(b) all primary keys are marked with
an asterisk (*) and all foreign keys are annotated with a caret (ˆ); further, all foreign keys and
the data to which to they refer are highlighted with the same background colour to ease iden-
tiﬁcation of inter-table referencing. Using foreign keys in a well designed database improves
data integrity and facilitates administration as changes need only be made in one table.
Additional ‘constraints’ may be placed on ﬁelds in a table to improve data integrity and per-
formance further. These can deﬁne whether a ﬁeld must be unique, whether a ﬁeld must be
present and not ‘null’, or what range of values the ﬁeld may take.
One ﬁnal mechanism of relational databases that vastly improves performance is indexing.
Indexing generates a secondary table that permits rapid look-up of the original data. Any ﬁeld,
or combination of ﬁelds, that are used frequently in constraining a search (i.e., often used as
elements of a ‘WHERE’ clause, see below) should be indexed. In both FOSTA (Chapter 3) and
SAAPdb (Chapter 6), indexes are used extensively for practicable use of the large datasets.
Once the database has been successfully designed, structured query language (SQL) can be
used to build, populate and query the database. The PostgreSQL database management system
is used throughout this thesis. Foreign keys are used to retrieve related data by ‘joining’ tables
together using a common term or terms. An example query is shown in Figure 2.4, which
requests the total number of each paper that is delivered daily. This query employs the basic
SELECT/FROM/WHEREgrammar, butalsousesGROUP BYandORDER BYtoaggregateandsort
the data respectively, and SUM(), one of many built-in, standard SQL functions. PostgreSQL
also allows the user to deﬁne new functions.CHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 70
mcmillan=> SELECT n.name, SUM(d.number)
FROM newspaper n, delivery d
WHERE d.paper = n.id
AND n.frequency = ’daily’
GROUP BY n.name
ORDER BY n.name;
name | sum
-------------------+-----
The Guardian | 5
The Local Gazette | 2
The Sun | 1
(3 rows)
Figure 2.4: An example PostgreSQL query
Two tables (newspaper aliased to n and delivery aliased to d) are joined on d.paper and n.id; the data are
constrained to those newspapers/n with a daily frequency (n.frequency = ’daily’); the aggregate function SUM
is calculated for each n.name as deﬁned by the GROUP BY n.name clause; results are sorted by n.name as deﬁned by
the ORDER BY n.name clause; all PostgreSQL commands and functions are given in capitals.
2.2.2 XML and XSLT
XML (eXtensible Markup Language) is a standard for document markup. By deﬁning a re-
stricted grammar of elements and attributes, the user can deﬁne a specialised framework for
representation and storage of their data. A DTD (document type deﬁnition) deﬁnes such a
framework.
By representing data in the same XML format, the same parser can be used to extract relevant
data for processing, database population and so on. Figure 2.5 shows an excerpt from an XML
ﬁle, which is taken from an RSS (version 2.0) feed of a website. The enclosing element is an ‘rss’,
within which a ‘channel’ is described. Within a channel, there is one instance of the elements
‘title’, ‘link’, ‘description’ and ‘language’, followed by multiple ‘item’s that enclose further sub
elements (‘title’, ‘link’, ‘description’ and ‘guid’), demonstrating the hierarchical nature of the
XML structure. The corresponding DTD that completely speciﬁes RSS 2.0 is shown in Figure
2.6.
Extensible stylesheet language translation (XSLT) is a method for translating XML into another
format. Commonly it is used to translate XML into HTML for display on a website. An exampleCHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 71
<rss>
<channel>
<title>
Craigends of the 20th Century
</title>
<link>
http://example.com/features/
</link>
<description>
Updates on new featues at craigends.net.
</description>
<language>
en-us
</language>
<item>
<title>
Johnstone Advertiser: 15th January 1960
</title>
<link>
http://craigends.net/feature/26/
</link>
<description>
The story of a German POW who painted the murals at Craigends Stables.
</description>
<guid>
http://craigends.net/feature/26/
</guid>
</item>
<item>
<title>
Driving Mrs Cuninghame
</title>
<link>
http://craigends.net/feature/27/
</link>
<description>
The work and duties of a Craigends chauffeur.
</description>
<guid>
http://craigends.net/feature/27/
</guid>
</item>
</channel>
</rss>
Figure 2.5: An example of XML, here taken from an RSS feed from a website
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<!ELEMENT rss (channel)>
<!ATTLIST rss version CDATA #FIXED "2.0">
<!ELEMENT channel ((item+)|
(title,link,description,(language|copyright|
managingEditor|webMaster|pubDate|lastBuildDate|
category|generator|docs|cloud|ttl|image|
textInput|skipHours|skipDays)*))>
<!ELEMENT item ((title|description)+,link?,
(author|category|comments|enclosure|guid|pubDate|source)*)>
<!ELEMENT author (#PCDATA)>
<!ELEMENT category (#PCDATA)>
<!ATTLIST category domain CDATA #IMPLIED>
<!ELEMENT cloud (#PCDATA)>
<!ATTLIST cloud domain CDATA #IMPLIED
port CDATA #IMPLIED
path CDATA #IMPLIED
registerProcedure CDATA #IMPLIED
protocol CDATA #IMPLIED>
<!ELEMENT comments (#PCDATA)>
<!ELEMENT copyright (#PCDATA)>
<!ELEMENT description (#PCDATA)>
<!ELEMENT docs (#PCDATA)>
<!ELEMENT enclosure (#PCDATA)>
<!ATTLIST enclosure url CDATA #REQUIRED
length CDATA #REQUIRED
type CDATA #REQUIRED>
<!ELEMENT generator (#PCDATA)>
<!ELEMENT guid (#PCDATA)>
<!ATTLIST guid isPermaLink (true|false) "true">
<!ELEMENT height (#PCDATA)>
<!ELEMENT image (url,title,link,(width|height|description)*)>
<!ELEMENT language (#PCDATA)>
<!ELEMENT lastBuildDate (#PCDATA)>
<!ELEMENT link (#PCDATA)>
<!ELEMENT managingEditor (#PCDATA)>
<!ELEMENT name (#PCDATA)>
<!ELEMENT pubDate (#PCDATA)>
<!ELEMENT skipDays (#PCDATA)>
<!ELEMENT skipHours (#PCDATA)>
<!ELEMENT source (#PCDATA)>
<!ATTLIST source url CDATA #REQUIRED>
<!ELEMENT textInput (title,description,name,link)>
<!ELEMENT title (#PCDATA)>
<!ELEMENT ttl (#PCDATA)>
<!ELEMENT url (#PCDATA)>
<!ELEMENT webMaster (#PCDATA)>
<!ELEMENT width (#PCDATA)>
Figure 2.6: An example of DTD for RSS 2.0
This DTD speciﬁes the format of RSS 2.0: which elements with which attributes can exist; what the hierarchical rela-
tionships between the elements are; what data type the attributes are (PCDATA/CDATA) and whether data is required
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<?xml version="1.0" encoding="ISO-8859-1"?>
<xsl:stylesheet version="1.0" xmlns:xsl="http://www.w3.org/1999/XSL/Transform">
<xsl:output method=’html’ version=’1.0’ encoding=’UTF-8’ indent=’yes’/>
<xsl:template match="/">
<html>
<head>
<style type="text/css">
body { width: 800px; margin: auto; }
table { border-collapse: collapse; border-bottom: 2px solid black;
border-top: 2px solid black; }
td, th { text-align: left; padding: 10px; }
td { vertical-align: top; border-bottom: 1px dotted black; }
th { background: #CFE9FF; border-bottom: 2px solid black; }
td.title { font-weight: bold; }
</style>
</head>
<body>
<h2>Craigends Updates</h2>
<table>
<tr>
<th>Title</th>
<th>Description</th>
</tr>
<xsl:for-each select="channel/item">
<tr>
<td class="title"><xsl:value-of select="title"/></td>
<td><xsl:value-of select="description"/></td>
</tr>
</xsl:for-each>
</table>
</body>
</html>
</xsl:template>
</xsl:stylesheet>
Figure 2.7: An example of XSLT
ThisXSLTconvertstheXMLshowninFigure2.5intoHTML,asshowninFigure2.8; thexsl:for-eachloopidentiﬁes
each item in the channel tag and displays them in tabular format.
Figure 2.8: The browser’s view of XML (Figure 2.5) translated to HTML using XSLT (Figure
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XSLT speciﬁcation is shown in Figure 2.7. This XSLT converts the XML shown in Figure 2.5 into
HTML (see Figure 2.8). Chapter 6 (speciﬁcially Section 6.2.6.4) describes how XSLT is used to
translate XML into SQL statements when populating SAAPdb.
2.2.3 An alternative format for the PDB: XMAS
There are numerous ﬂaws in the PDB data format, not least a lack of adherence to a standard
format (see Section 2.1.4). In addition, there is a wealth of information implicit in the PDB
ﬁles (for example, protein ligand bonds and accessibility) that is not explicitly stated and must
be calculated for each individual PDB structure. In the context of large automated structural
analysis systems such as SAAPdb, a standardised format containing all relevant PDB data,
that is easily parsed is essential. Ideally programs for adding information on hydrogen bonds,
accessibility and so on, may be run in any order, extending the data stored with the structure
in a self-describing way.
The XMAS format of PDB structures was developed by Dr Andrew Martin while at Inpharmat-
ica and represents PDB data using a hybrid XML/ASN.1 format (the XMAS name is derived
from the ﬁrst two letters of XML and ASN.1). XMAS ﬁles are used extensively in SAAPdb.
Conversion from PDB to XMAS format is as follows:
1. Convert raw PDB data to XMAS format
2. Calculate and add atom and residue solvent accessibility statistics
3. Calculate and add secondary structure assignments for each residue
4. Identify and add hydrogen bonds in the structure
Solvent accessibility (step 2) is calculated using the method of Lee and Richards (1971) and sec-
ondary structure assignments (step 3) are calculated using the method of Kabsch and Sander
(1983) as modiﬁed by Smith and Thornton (unpublished). Protein-protein, protein-ligand and
ligand-ligand hydrogen bonds are identiﬁed using the simple Baker and Hubbard (1984) cri-
teria for deﬁning a hydrogen bond (step 4). In addition, non-bonds (non-consecutive residue
atom pairs 2.7-3.35 ˚ A apart that are not covalently bonded or hydrogen bonded, for example,CHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 75
electrostatic interactions and Van der Waals contacts) and pseudo-Hbonds (atom pairs satisfy-
ing the constraints described in Baker and Hubbard (1984) for hydrogen bonding, where one
or both atoms do not strictly form hydrogen bonds, for example, metal ions) are identiﬁed and
annotated.
Locally, XMAS ﬁles are automatically generated for all new or updated structures from the
PDB. XMAS formatted structures are easily generated for mutant structures where necessary
using proprietary software.
All the desirable requirements for ﬁle formats would be achieved by using XML, allbeit with
considerably larger ﬁles sizes than XMAS ﬁles. In fact, PDB data are available in XML format11
(Westbrook et al., 2005). However, no functionality exists for generating the additional data in
XML and methods for handling the XMAS format were already implemented as part of the
SAAPdb system; there are no plans to update these as yet.
2.3 Methods and tools
Several established bioinformatics methods and tools are referred to throughout this thesis.
These are primarily methods of sequence alignment (MUSCLE, Needleman & Wunsch and
amino acid substitution matrices) or sequence similarity searching (BLAST). These are de-
scribed in this section.
2.3.1 BLAST
BLAST (Basic Local Alignment Search Tool) is a method by which similar sequences to a pro-
tein12 of interest, or query sequence, may be retrieved from a database (Altschul et al., 1990).
BLAST identiﬁes similar proteins by identifying smaller regions of high sequence similarity.
The use of an index of these smaller protein ‘words’ makes the search of large protein sequence
databases feasible.
BLAST decomposes the query sequence into its constituent set of words (for proteins, BLAST
11http://pdbml.pdb.org/
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uses a default word length of three). These words (plus similar, neighbouring words) are
searched for in a similarly decomposed, indexed database. Matches (including non-exact
matches scoring above a threshold) to these words that are found in the decomposed database
are expanded at both ends in an attempt to build ungapped alignments between the query
sequence and the corresponding sequence in the database. Any expanded alignment that
exceeds a pre-deﬁned threshold is returned as a match or ‘hit’. Each hit is scored on how
similar it is to the query sequence.
Using statistical theory, the scores are compared with the distribution of scores generated from
the entire database. BLAST provides an E-value (expectation value) for each hit. The P-value
describes the probability that the score for an alignment is no better than random. The E-value
describes how many equal-or-better scores are expected to be found by chance in this database
when queried with this sequence. For example, should a hit have an E-value of 0.02, there is
a one in ﬁfty chance that an alignment of the same or better quality would occur by chance
alone. This is dependent on the size and content of the database. Thus the E-value is the P-
value multiplied by the database size. However, in practice, the E-value is calculated from
integrating the tail of an extreme value distribution ﬁtted to the data.
2.3.2 MUSCLE
MUSCLE (Edgar, 2004a; Edgar, 2004b) (multiple sequence comparison by log-expectation) is
a method for generating multiple sequence alignments (MSAs) of proteins. The iterative ap-
proach is considered to be more accurate and is signiﬁcantly faster than the current de facto
standard multiple sequence alignment program, ClustalW (Thompson et al., 1994a). The algo-
rithm has three stages: (i) generating a draft alignment with which to start optimisation; (ii)
improving this initial alignment; and ﬁnally (iii) reﬁning the alignment.
Each stage employs the same general mechanism of generating a progressive alignment:
1. Construct a distance matrix (D) of the sequences to be aligned
2. Use D to construct a hypothesized phylogenetic tree, P
3. Build the progressive alignment by performing a pairwise alignment at each node of the
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(a) Describing a set of ten sequences using a
distance/dissimilarity matrix
(b) The phylogenetic tree generated from
the matrix in Figure 2.9(a)
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(c) Using the phylogenetic tree in Figure 2.9(b) to construct the progressive alignment
Figure 2.9: The underlying concept of MUSCLE: the progressive alignment
The similarity of ten sequences is shown as a distance matrix in Figure 2.9(a). These dissimilarity scores can be used
to generate a phylogenetic tree in Figure 2.9(b), which here is constructed using the kitsch method of the PHYLIP
(http://evolution.genetics.washington.edu/phylip.html) package. An alignment is made as each inter-
nal node of the tree is met when traversing from the leaf to the root node. Where two MSAs are required to be aligned,
proﬁle-proﬁle alignment methods are used. A representative progressive alignment for the ten sequence example is
shown in Figure 2.9(c), where progress is made from top-left to bottom-right and proﬁle-proﬁle alignment is indicated
with a blue border while a red border represents pairwise alignment steps.CHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 78
It is described as a progressive alignment because the process of merging pairwise or proﬁle-
proﬁle alignments progresses from the leaf nodes to the root node of the tree. The process is
shown in Figure 2.9. Here, an example set of ten sequences is represented by a distance matrix
as shown in Figure 2.9(a) where the dissimilarity of two sequences is scored between 0 and 1.
This matrix can be used to construct a phylogenetic tree. The corresponding rooted tree for the
dissimilarity scores of Figure 2.9(a) is shown in Figure 2.9(b) (this tree was constructed using
theFitch-Margoliash(1967)-basedkitschmethodfromthePHYLIP13 packageofphylogenetic
software).
A phylogenetic tree represents the hypothesized evolutionary relationship between the partic-
ular elements (sequences or species) being considered: at each branching of the tree, a differen-
tiating evolutionary mechanism is hypothesized to have occured. As such, a phylogenetic tree
can be used to deﬁne the MSA: where leaf nodes are individual sequences, a joining internal
node represents their pairwise alignment.
Leaf nodes are aligned ﬁrst. These pairwise alignments are then aligned using proﬁle-proﬁle
sequence alignment methods, until the entire MSA has been constructed. In Figure 2.9(c) the
alignment construction progresses from top-left to bottom-right. Simple pairwise alignments
are bordered with red, while proﬁle-proﬁle methods are bordered with blue.
The method of constructing a progressive alignment is employed at each stage of the MUSCLE
algorithm. These three stages are described brieﬂy below; for full details, see Edgar (2004a).
The drafting stage To begin optimisation, an initial draft alignment is constructed using k-mer
(speciﬁcally 6-mer) counting. k-mer counting generates a similarity score for each pair of
sequencesbasedontheprevalenceofsubsequences, orwords, oflengthk. Aphylogenetic
tree P is constructed using the unweighted pair group method with arithmetic mean
(UPGMA) (Sneath and Sokal, 1973).
The improvement stage The goal of this stage is to deﬁne and ﬁx the phylogenetic tree to al-
low for further reﬁnement of the MSA. A Kimura (1983) distance matrix using fractional
identities is calculated from the mutual alignment of each pair of sequences in the context
of the existing multiple alignment. UPGMA is used to generate a new phylogenetic tree,
P0, which is compared to P. Where the branching order of internal nodes has changed,
new mutual alignments are made, and a new progressive alignment is constructed. This
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step can be iterated and completes when the set of changed internal nodes is empty. The
phylogenetic relationship between the sequences is now ﬁxed and the MSA can be re-
ﬁned.
The reﬁnement stage The ﬁxed tree is then subject to bi-partitioning (Hirosawa et al., 1995) to
generate pairs of proﬁles which are then realigned. Improved MSAs are identiﬁed by
comparing the existing MSA to the new, realigned MSA using the sum-of-pairs metric
(the average pairwise alignment score of every pair of sequences in the alignment).
Figure 2.10 shows a MUSCLE alignment of P53 proteins at each stage of iteration (no improve-
ment is made after the ﬁfth iteration). Figure 2.10 demonstrate that the ﬁrst draft alignment
does successfully align the highly conserved section of sequence internal to the protein, but per-
forms poorly on the more sparsely populated start and end regions; alignment in these regions
appears to improve with each iteration. Most clearly, the optimisation procedure eliminates
many unecessary gaps present in the draft alignment (ﬁrst iteration, Figure 2.10(a)).
2.3.3 Needleman & Wunsch
The Needleman and Wunsch (1970) algorithm is a method for globally aligning two sequences.
It employs dynamic programming to identify the optimal global alignment between two se-
quences. Dynamic programming is an algorithm by which the optimal procedure of decisions
can be deduced by scoring all possible decisions at each step.
The method for aligning two sequences X and Y proceeds as follows (as described in Taylor
and Orengo (1989)):
1. Initialise matrix by plotting X against Y
2. Populate matrix with alignment scores for each X/Y residue pair
3. Propagate scores through the matrix from bottom-right to top-left
4. Trace back the ﬁnal alignment
In Step 1, X and Y are plotted against each other to derive an m by n matrix where every possi-
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(a) Iteration (1) (b) Iteration (2) (c) Iteration (3) (d) Iteration (4) (e) Iteration (5)
Figure 2.10: Aligning P53 proteins using MUSCLE
MUSCLE converges on an alignment after ﬁve iterations of the algorithm. The alignment from each iteration is shown
continuing down the page in each column above, from Figure 2.10(a)-2.10(e). Residues are coloured as shown in
Appendix [B.i], gaps are represented with white space. Signiﬁcant alignment change can be seen towards the more
sparsely populated ends of the alignment. The optimisation procedure eliminates many unecessary gaps in the ﬁrst
iteration (compare the length of the alignment in Figure 2.10(a) to that of the alignment in Figure 2.10(e)).CHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 81
ﬁrst sequence deﬁnes the rows and the second sequence deﬁnes the columns. Each cell is ini-
tialised with a score describing how well the two corresponding amino acids match each other.
Various scoring systems exist. Most simply, identical residues score 1 and all non identical
residues score 0; more representative scoring schemes, such as the amino acid scoring matrices
described in Section 2.3.4, can be used to represent the frequency with which pairs of residues
replace each other (from this, it is possible to summize that they have similar physicochemical
properties).
Step 2 propagates scores from the bottom right hand corner of the matrix to generate scores that
will be used in the ﬁnal step to deﬁne the alignment. Matrix population proceeds from bottom-
to-top row-wise and right-to-left column-wise, simultaneously. That is, row n and column n
are completed before row n   1 and column n   1.
When considering each possible X/Y residue-pair alignment, three operations are possible:
1. the two residues are aligned
2. a gap is inserted in the ﬁrst sequence
3. a gap is inserted in the second sequence
To represent this choice in the matrix, the score for the current cell in the matrix can be inherited
from the diagonal (when the residues are aligned, operation 1) or from the off-diagonal (when
gaps are inserted, operations 2-3). Each operation is scored and the highest score for each cell
is entered in the matrix. The score for cell (i,j) can be formalised as follows:
Di;j = s(i;j) + max
8
> > > > <
> > > > :
Di+m;j+1  
Di+1;j+m  
Di+1;j+1
(2.1)
where D is the dynamic programming matrix; Di+1;j+i is the score of a diagonal move from
cell i+1;j+1; Di+m;j+1 deﬁnes a score from the jth
1 row and Di+1;j+m deﬁnes a score from the
i + 1th column. Inheriting from the jth
1 row or i + 1th column requires that a gap be inserted in
the appropriate sequence. Gaps are penalised using the penalty term , which is calculated as
follows:CHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 82
 = gi + nge (2.2)
where gi is the gap initialisation penalty, ge is the gap extension penalty and n is the length
of the gap being inserted. Appropriate values for gi and ge are critical in obtaining reasonable
alignments. Throughout this thesis, gi = 10 and ge = 2.
Once the scores have been propagated through the matrix, the highest scoring path is traced
back from top-left to bottom right through the matrix to generate the optimal alignment of the
two sequences.
2.3.4 Amino acid substitution matrices
Amino acid (AA) substitution matrices describe how similar a pair of residues are to each other.
Matrices vary in the assumed mutation rate and scoring range. In general however, the ap-
proach is the same. Representative proteins are aligned and mutation rates (i.e., how often
residue X is aligned with residue Y) for each pair of amino acids are recorded. These are the
observed mutation rates between pairs of amino acids. The expected mutation rate is calculated
using the frequency of the amino acids. A ﬁnal log-odds value (Sij) is calculated as follows:
Sij = log

obsij
expij

(2.3)
where obsij is the observed mutation rate between residue i and j and expij is the expected
mutation rate between residue i and j.
In this thesis, three matrices are used (i) to score conservation (see Chapter 4) and (ii) to charac-
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2.3.4.1 PAM30
PAM matrices (Dayhoff et al., 1978) use the PAM (Point Accepted Mutation) as a unit of se-
quence divergence: if two protein sequences are 1 PAM apart, they share 99% of their amino
acids. Various PAMX matrices are available, where X describes the PAM distance between the
protein sequences that are aligned to derive the observed and expected mutation rates. All
PAM matrices are constructed by successive multiplications of the basic PAM1 matrix with it-
self; for example, the PAM30 = PAM130 (the PAM30 matrix is used in Chapter 7 and given in
Appendix [C.i]).
The PAM1 matrix gives an estimate of the probability of residue b replacing residue a over a
period of time t. These conditional probabilites are calculated from the phylogenetic analysis of
evolutionarily related sequences, all with 85% or better sequence identity to each other. Using
these observed probabilities, deﬁning the unit of time as 1PAM and scaling the matrix such that
rows and columns equal to one, the PAM1 matrix is derived (Durbin et al., 1998).
2.3.4.2 BLOSUM62
BLOSUM matrices (Henikoff and Henikoff, 1992) were an attempt to update the older PAM ma-
trices by exploiting the much increased wealth of protein sequence data and facilitate identiﬁca-
tion of very distantly related proteins. BLOSUM matrices use the BLOCKS resource (Henikoff
et al., 1999; Henikoff et al., 2000) (since integrated into InterPro (Mulder et al., 2007)) to generate
multiple alignments and calculate observed and expected scores from which log-odds values
are derived. Where PAM matrices use the basic unit of 1 PAM to construct matrices, BLOSUM
matrices are based on alignments of proteins of varying levels of sequence identity. For exam-
ple, the commonly used BLOSUM62 matrix (see Appendix [C.iii]) is derived from alignments
of sequences that are 62% identical.
2.3.4.3 PET91
In 1991, the PAM250 matrix was updated by Jones et al. (1992) to create the PET91 (Pairwise
Exchange Table 1991) matrix. The method used to derive the PET91 matrix is virtually identical
to that of the PAM250 matrix, save for the construction of the raw PAM matrix: Dayhoff etCHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 84
al. took the approach of inferring the common ancestral sequences and comparing this with
the observed present-day sequences, whereas Jones et al. use the pairwise distances between
present-day sequences to construct the PAM matrix.
Throughout this thesis, where the PET91 matrix is used, it has been normalised such that all
values on the diagonal (i.e., the residue identity scores) are maximal and equal, as follows:
M(a;b) =
m(a;b)   min(m)
max(m)   min(m)
(2.4)
where m is the PET91 matrix; M is the normalised matrix, and a;b are amino acids. See Ap-
pendix [C.ii] for this normalised matrix.
2.3.5 Performance evaluation
Binary classiﬁcation performance methods evaluate performance where the task is to assign
each example toone of two classes, forexample, present/absent, disease-causing/neutral orac-
tive/inactive. These three examples can all be generalised to positive/negative and the present
discussion will continue using these generalised class names.
It is possible to assess the predictions made by the method being evaluated by comparing them
with known answers, or with a gold standard dataset, which provides the best approximation
to the correct answers that is available. In such a comparison, a binary classiﬁcation method
can make two kinds of errors: a type I error occurs when a result known to be negative is
classiﬁed as positive and a type II error occurs when a results known to be positive is incorrectly
classiﬁed as negative. A type I error is also known as a false positive (FP) and a type II error
is also known as a false negative (FN); similarly, genuinely positive or negative results that are
correctly classiﬁed are known as true positives (TPs) and true negatives (TNs) respectively. A
successful prediction algorithm will minimise the number of incorrect results (i.e., FPs/FNs)
and maximise the number of correct results (i.e., TPs/TNs). In this section and throughout this
thesis, the four terms TP, TN, FP and FN will be used to describe the results of classiﬁcation
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These four counts may be combined in many ways to assess how well the prediction method
has performed. In this thesis, four measurements have been used to evaluate performance:
sensitivity, speciﬁcity, positive predictive value (PPV) and Matthew’s Correlation Coefﬁcient
(MCC). Their formulae for these statistics are shown below in Equations 2.5-2.8:
sensitivity =
TP
TP + FN
(2.5)
specificity =
TN
FP + TN
(2.6)
PPV =
TP
TP + FP
(2.7)
MCC =
TP:TN   FP:FN
p
(TP + FP):(TP + FN):(TN + FP):(TN + FN)
(2.8)
The sensitivity is the fraction of results that are known to be positive that are correctly classi-
ﬁed as positive by the prediction method; i.e., the number of positive examples that the method
classiﬁes correctly (Equation 2.5). A complementary measure is speciﬁcity, which describes
the fraction of known negative examples that are correctly classiﬁed as negative by the al-
gorithm (Equation 2.6). It is desirable to maximise both speciﬁcity and sensitivity such that
sensitivity   specificity = 0. These measurements can be combined in a receiver-operator
characteristic or ROC plot which plots sensitivity (also called the True Positive Rate or TPR)
against 1-speciﬁcity (also called the False Positive Rate or FPR); see Figure 2.11 for an exam-
ple. If sensitivity=1-speciﬁcity (i.e., TPR=FPR), results are essentially random (indicated by a
dashed blue line in Figure 2.11). As sensitivity increases and 1-speciﬁcity decreases (i.e., speci-
ﬁcityincreases), theresultsgravitatetothetop-leftoftheROCplotandresultsimprove; aperfect
result (indicated by a green circle in Figure 2.11) occurs when FPR = 0 and TPR = 1. It is possible
to evaluate varying thresholds in a predictive model by plotting sensitivity against 1-speciﬁcity
(FPR against TPR) and assessing which threshold maximises the sensitivity to 1-speciﬁcity ra-
tio; i.e., which threshold is found furthest from the sensitivity=1-speciﬁcity line.CHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 86
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Figure 2.11: An example receiver-operator characteristic (ROC) plot
The true positive rate (TPR) is plotted against the false positive rate (FPR). Where TPR=FPR, results are no better than
random (indicated with a dashed blue line); an example result is indicated with a grey circle. As the TPR increases and
the FPR decreases, performance improves and results gravitate towards the top left hand corner of the plot, away from
the line of no discrimination. Perfect prediction performance is achieved where TPR = 1 and FPR = 0; this is indicated
with a green circle. Where the results drop below the line of no discrimination, towards the bottom right hand corner
of the plot (as indicated by the red circle), the method more often predicts the incorrect result (i.e., predicts positive
where the correct result is negative, and vice versa). The orange circle indicates a more average performance result.CHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 87
An alternative measure is positive predictive value or PPV. This describes the fraction of those
results that are predicted as being positive that are correct (Equation 2.7). This measure is partic-
ularly useful when the aim is to make conservative positive predictions at the expense of more
false negatives.
Finally, the most comprehensive measurement of performance in a binary classiﬁcation system
is Matthews Correlation Coefﬁcient or MCC (Equation 2.8). Where the previous measure-
ments have considered a single ‘dimension’ of the performance, the MCC score incorporates all
measures (TP, TN, FP and FN) into one value. The MCC can range from -1 to 1, where 1 indi-
cates perfect performance, 0 indicates random performance and -1 indicates that performance
is precisely the opposite of what is expected.
In addition to providing a comprehensive summary of evaluation performance, the MCC score
is robust to class size inequality. This is not the case for the three other performance measures
described above. For example, in computational biology it is often the case that the TN exam-
ples vastly outnumber the TP examples, and as such, high levels of speciﬁcity can be achieved
simply by assigning everything to the negative class.
In reality, the appropriate performance statistics (the equations for which are summarised be-
low) will depend on the aims of the method, on aspects of the data being examined and on an
understanding of the gold standard dataset against which the method is being benchmarked.
In Chapters 3 and 4, FOSTA and ImPACT are evaluated variously using sensitivity, speciﬁcity,
ROC plots, PPV and MCC. The choice of the performance metrics is justiﬁed in each chapter.
2.3.6 Statistics and data representation
Chapter 7 analyses the data in SAAPdb and their hypothesised structural effects (see Chapters
5 and 6). In that chapter, several statistics are used to compare pathogenic deviations (PDs)
and single nucleotide polymorphisms (SNPs) with respect to several sequence and structural
features. Inthissection, thestatisticsusedaresummarised. Logratios, asameansforgraphically
comparing datasets rather than statistically comparing datasets, are also described.CHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 88
2.3.6.1 Log ratios
Log ratios compare the observed prevalence of a feature with the expected prevalence of a
feature, as shown in Equation 2.9. Throughout this theses, unless otherwise stated, log ratios
are calculated using log2. A value of 0 indicates that the observed and expected values are the
same. A value of 1 would indicate that the observed value is double (21) what is expected, a
value of 2 would indicate that the observed value is four times (22) what is expected, and so on.
Similarly, a value of -1 would indicate that the observed value is half (2 1) of what is expected.
logratio = log2

observed
expected

(2.9)
Log ratios are not a statistical test from which a p-value can be derived, but a way of represent-
ing the difference between an observed value and an expected value.
2.3.6.2 Kolmogorov-Smirnov
The Kolmogorov-Smirnov or KS test (Conover, 1971) is a non-parametric method for compar-
ing distributions. In the one-sample test, an observed sample distribution is compared with a
reference distribution (e.g., a normal distribution), while in the two-sample test, two observed
sample distributions are compared (in Chapter 7, only the two-sample test has been used).
The null hypothesis of the KS test is that the distributions being compared are drawn from
the same distribution. Therefore, should p <  ( is variously set at 0.05 or 0.01), the null
hypothesis is rejected and it is concluded that the distributions were not drawn from the same
distribution. The test statistic is the maximal vertical distance (D) between the two cumulative
distribution functions (CDFs), that is:
D = maxjF(x)   G(x)j (2.10)
where F and G are the test CDF and reference CDF respectively in the one-sample test, or the
two test CDFs in the two-sample test. The CDF of the distribution function f is calculated asCHAPTER 2. AN INTRODUCTION TO BIOINFORMATICS METHODS 89
follows:
F(x) =
Z x
 1
f(t)dt (2.11)
where x is the point at which the total is to be calculated. In this thesis, the CDFs are calculated
from data, rather than from probability distributions; in this case, the empirical cumulative dis-
tribution of data x at point i is calculated as:
Ci(x) =
1
N
ji;iD X
j=1
xj (2.12)
where i;j are bins of data; D is the number of bins; xj is the number of data points in x that
belong in bin j; and N is the number of datapoints in x.
Where distributions are being compared in the presence of ties (i.e., there are many repeated
values in the dataset), a bootstrapping method (n=1000) is carried out using the ks.boot() 14
method in R. This more accurately estimates the p-value when comparing discontinuous dis-
tributions (Abadie, 2002).
2.3.6.3 2 test
Where data are nominal counts, the 2 test (Mood et al., 1974) will indicate whether there is
a difference between two datasets. Note that where 2 results are reported with percentages
in this thesis, raw counts have been used to conduct the 2 test. The 2 statistic is calculated
as shown in Equation 2.13. Expected values may not always be available; they can however
be estimated using the observed data (Figure 2.12 shows an example). Where possible, known
expected values have been used throughout this thesis, rather than estimated values; i.e., ex-
pected values are calculated from known data rather than being estimated from the observed
data.
14http://sekhon.berkeley.edu/matching/ks.boot.html
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Figure 2.12: Calculating 2 expected values
Males and females have been classiﬁed as P and Q. Observed counts are in black, expected counts are in grey. Expected
values can be calculated as follows: e = (XY )=N where X is the row total, Y is the column total and N is the number
of examples in the dataset.
2 =
k X
i=1
(observed   expected)2
expected
(2.13)
Throughout this thesis, the 2 test is Yates corrected where a 2 test is carried out on a 2x2
contingency table. This prevents low p-values being derived where there is only one degree
of freedom by subtracting 0.5 from each observed value in the contingency table, as shown in
Equation 2.14.
2
Y ates =
k X
i=1
(jobserved   expectedj   0:5)2
expected
(2.14)
2.3.6.4 Fisher exact test
The 2 test becomes unreliable where the contingency table is sparsely populated (i.e., where
any cell has a value of  10) and where counts are distributed unevenly throughout the con-
tingency table. However, the statistical theory upon which the Fisher exact test is based allows
robust comparison of datasets of disparate sizes and is able to consider contingency tables with
empty cells (Fisher, 1935). The probability of obtaining the set of values a;b;c;d as shown in
the contingency table in Figure 2.13 can be calculated using the hypergeometric distribution as
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P Q
Male a b a+b
Female c d c+d
a+c b+d n
p =
(a + b)!(c + d)!(a + c)!(b + d)!
n!a!b!c!d!
(2.15)
Figure 2.13: Fisher exact test
Naming the values in the contingency table as a;b;c;d as shown, the probability of that particular combination of val-
ues can be calculated using the hypergeometric distribution as shown in Equation 2.15 where ! is the factorial operator.Chapter 3
FOSTA: Functional Orthologues
from Swiss-Prot Text Analysis
As introduced in Section 1.9, SAAPdb is a database of mutation data, which aims to identify the
structural effect, if any, of single amino acid polymorphisms (SAAPs). It is an on-going project:
the suite of structural analyses is expected to evolve to include a broader and more sophisti-
cated range of structural analyses (the current structural analyses will be described in detail
in Chapter 5). As such, while the pipeline is being developed, it may not always be possible
to explain a mutation with respect to its structural annotation. However, it may be possible
to infer functional relevance from sequence data. Residues that have been maintained across
evolution, and therefore have been subject to selection pressure, are likely to be important to
the native structure and/or function of the protein. The ﬁrst step in identifying such residues
is to construct an alignment of functionally equivalent proteins or FEPs. Proteins that have
diverged in function (either by gaining or losing functionality) will show differences at key
functional residues. To incorporate such an analysis in SAAPdb, a reliable, automatic method
for extracting groups of FEPs is required.
This chapter describes a novel method for identifying FEPs by analysing functional annotations
in UniProtKB/Swiss-Prot. This method and its evaluation have been published in McMillan
and Martin (2008).
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3.1 Introduction
To generate an informative multiple sequence alignment (MSA), the ‘same’ protein in different
species should be aligned. In this chapter, the ‘same’ protein is deﬁned as an orthologue that
performs an equivalent function or functions. Proteins that have diverged in function (either by
gaining or losing functionality) will show differences at key functional residues; aligning such
proteins will obscure patterns of functionally-relevant conservation. Two entities are homolo-
gous if they have a common evolutionary origin. An orthologous relationship denotes that this
common origin was a speciation event, whereas paralogues are related by a gene duplication
(Koonin, 2005).
Consider the HOX family of genes: a large family of transcription factor proteins containing
the well characterised homeobox motif. These proteins are well conserved across species and
are believed to be critical in embryogenesis, oncogenesis and differentiation processes such as
haematopoiesis (Yaron et al., 2001; Lill et al., 1995). HOX proteins are representative of large
protein families in that there are several paralogues within a species—thirteen in the case of the
human HOX family (Yaron et al., 2001)—and each paralogue can be involved in several distinct
aspects of the same biological process. A sequence alignment of such evolutionarily related, but
functionally different, proteins (i.e., paralogues) would contain signiﬁcant noise, and obscure
much of the genuine functional conservation between true FEPs.
Paralogues, having been derived via a mechanism for functional divergence, are likely to per-
form different functions (Fitch, 2000). While orthologues generally perform the same function,
it is possible for the function to diverge, particularly when orthologues are evolutionarily dis-
tant (Koonin, 2005). For example, Shibata et al. (2006) showed that although the general func-
tion of exportin-5 proteins (nuclear export of miRNAs and tRNAs) is conserved across different
species, substrate speciﬁcity varies. Further, the AGAMOUS gene in Arabidopsis is involved
in carpel and stamen development, but the two orthologues in maize have specialised: ZAG1
is highly expressed during carpel development and ZMM2 is expressed during stamen devel-
opment (Wagner, 2002). It is clear then that orthology need not imply functional equivalence
and it follows that sets of orthologues, deﬁned by methods such as Inparanoid (O’Brien et al.,
2005), C/KOG (Tatusov et al., 2001; Tatusov et al., 2003) and TOGA (Lee et al., 2002), are not
appropriate as lists of FEPs. Further, these methods are computationally intensive and as such
are often limited to small species sets.CHAPTER 3. FOSTA 94
While homology does not imply functional equivalence, it is also not possible to use func-
tional data alone to identify FEPs. Proteins can converge on similar functions without being
evolutionarily related. For example, subtilisin (EC 3.4.21.62) and trypsin (EC 3.4.21.4) have
evolved separately in bacteria and vertebrates respectively. They differ signiﬁcantly in protein
sequence, structure and fold, yet the same three amino acids form the catalytic triad in both
proteins (Akindahunsi and Chela-Flores, 2005). Aligning such functionally similar, but evo-
lutionarily unrelated, proteins is meaningless: only proteins which are both homologous and
functionally equivalent will generate an informative alignment.
The identiﬁcation of true FEPs requires consideration of features such as functional assays,
interaction networks, expression data and so forth. UniProtKB/Swiss-Prot is a carefully anno-
tated databank of protein sequences that includes functional annotations (The UniProt Consor-
tium, 2009). While many of these are transferred through orthology, where there is experimen-
tal evidence for function, it will be included. Thus, short of conclusive experimental studies, the
most reliable way of identifying families of FEPs is ﬁrst to identify families of homologues in
UniProtKB/Swiss-Prot and then to examine the annotations to ﬁnd a set of proteins that are an-
notated as performing the same function or functions. It is, of course, possible that annotations
in UniProtKB/Swiss-Prot will be incorrect, but as UniProtKB/Swiss-Prot is updated on a regu-
lar basis, it is expected that these annotations will represent the most up-to-date knowledge of
protein function and errors in annotations will be corrected with future releases.
While it is perfectly possible to perform this analysis on an individual basis by searching
UniProtKB/Swiss-Prot for homologues and comparing the annotations manually, there is
a pressing need for an automatically updated resource that simply lists families of FEPs in
UniProtKB/Swiss-Prot. Several methods exist that exploit database annotations to identify
related proteins (Artamonova et al., 2005; Kretschmann et al., 2001; Yu, 2004; Kunin and
Ouzounis, 2005), however there has been no resource that very simply provides sets of FEPs
annotated as having the same function in UniProtKB/Swiss-Prot in an easily-accessible
format, with extensive coverage of multiple proteomes.
FOSTA (Functional Orthologues from Swiss-Prot Text Analysis) has been developed to
automate the process that one would perform manually to extract a family of FEPs from
UniProtKB/Swiss-Prot. It considers UniProtKB/Swiss-Prot proteins for inclusion in groups
of FEPs (FOSTA families) rooted around human proteins. It reﬁnes an initial candidate list
of homologues on the basis of functional annotation similarity to distinguish FEPs fromCHAPTER 3. FOSTA 95
functionally diverged homologues (FDHs). To assess functional annotation similarity, FOSTA
employs simple text-mining techniques to compare UniProtKB/Swiss-Prot description ﬁelds.
3.2 Method
3.2.1 Obtaining the data
Figure 3.1 describes the ﬂow of data in the FOSTA system. FOSTA exploits data in
two UniProtKB/Swiss-Prot ﬁles in forming families of FEPs: the FASTA formatted
version of UniProtKB/Swiss-Prot sequences and the UniProtKB/Swiss-Prot .dat
ﬂatﬁle, from which the functional annotations are extracted. These ﬁles are auto-
matically mirrored from Expasy (ftp.expasy.org/databases/uniprot/ and
ftp.expasy.org/databases/swiss-prot/ speciﬁcally). The ﬁrst step in populating
FOSTA is to clone the most recent relevant UniProtKB/Swiss-Prot data and extract the desired
information from them. All FOSTA analyses (one for each human protein) are then distributed
across a local compute farm (using Sun GridEngine), with each individual process updating
the FOSTA database. All data required by the distributed processes are available in the FOSTA
database.
3.2.2 The FOSTA method
As input, FOSTA takes an entire UniProtKB/Swiss-Prot release; results presented in this chap-
ter are based on UniProtKB/Swiss-Prot v53.0. FOSTA roots families of FEPs (FOSTA families)
around human proteins of length 100 using the three stage ﬁltering processes shown in Figure
3.2. Candidates rejected at ﬁltering stages (2) and (3) are retained and recorded as functionally
diverged homologues (FDHs).CHAPTER 3. FOSTA 96
(2) Extract sequence data
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      of UniProtKB/Swiss−Prot
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UniProtKB/Swiss−Prot
uniprot_sprot.fasta
uniprot_sprot.dat
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uniprot_sprot.dat
      each human protein
(4) Form FOSTA family around
FOSTA
FOSTA Swiss−Prot clone
20−core grid
Figure 3.1: The workﬂow of FOSTA
STEP (1): the uniprot sprot.fasta and uniprot sprot.dat ﬁles from the most recent version of
UniProtKB/Swiss-Prot are cloned (this process is highlighted in red); STEP (2): sequence data are extracted from
uniprot sprot.fasta and stored in the FOSTA database; STEP (3): functional annotations are extracted from
uniprot sprot.dat and stored in the FOSTA database; STEP (4): FEPs for each human protein are identiﬁed (for
details, see Figure 3.2 and Sections 3.2.2.1-3.2.2.3). Solid black lines indicate the direction of data ﬂow, dashed blue
lines indicate where data are stored in the FOSTA database. A pre-exising mirror script ensures that the external
UniProtKB/Swiss-Prot data (separated from the cloned FOSTA data with a dashed grey line) are kept up to date. The
analysis for each human protein is distributed across the local 20-core grid (each core is represented above with a grey
rectangle). Note that FOSTA is updated by each inidividual process.CHAPTER 3. FOSTA 97
annotated similarly?
Is the protein
(2)
best functional match for
Is the protein the
this species?
(3)
MSVGFIGAGQLAFALAKGFTAAG
VLAAHKIMASSPDMDLATVSALR
KMGVKLTPHNKETVQHSDVLFLA
VSCAAGVTISSIEKKLSAFRPAP
VKPHIIPFILDEIGADIEDRHIV
A paralogue or a
functionally diverged
orthologue
A paralogue or a
functionally diverged
orthologue
An unrelated protein or
a distant paralogue
The functionally
equivalent protein
SwissProtv53.0
D
e
c
r
e
a
s
i
n
g
 
r
e
l
i
a
b
i
l
i
t
y
BLAST (e−2)
a homologue?
Is the candidate
(1)
Yes
Yes
Yes
No
No
No
Functionally diverged
homologues
(g) Collapsed match
(e) Containing 75% words
(c) Full containing
(b) Hyphen
(f) Containing 75% length
(d) Mixed containing
Tectonic 3 precursor & Tectonic−3 precursor
Kinesin light chain I & Kinesin light chain
Tubulin alpha chain & Tubulin alpha−1 chain
Myosin light chain alkali & Alkali myosin light chain I
Exportin−6 & Exportin 6−B
Hemoglobin subunit beta & Hemoglobin subunit beta−3
(a) Direct
Autoprothrombin IIA & Autoprothrombin IIA
of description
matches
(e.g., OTC_HUMAN / OTC_MOUSE)   (i) Protein prefix match
 (ii) Complete EC number match
(iii) The hierarchy
Protein of
interest
Figure 3.2: A schematic of the FOSTA method
The protein of interest is BLASTed against UniProtKB/Swiss-Prot (in the current version of FOSTA, this is
UniProtKB/Swiss-Prot v53.0). STEP (1) any BLAST matches (e 10 2) are retained, non matches are unrelated pro-
teins or distant paralogues; STEP (2) the annotations of each BLAST match are compared to those of the root protein
of interest, matches are retained, non-matches are described as paralogues or functionally diverged homologues; STEP
(3) the best match for each species is identiﬁed and described as the functionally equivalent protein, the rest are iden-
tiﬁed as paralogues or functionally diverged homologues. The inset box on the left hand side describes the functional
annotation match hierarchy. See Section 3.2.2.2 for detailed discussion.CHAPTER 3. FOSTA 98
3.2.2.1 The sequence ﬁlter
The ﬁrst stage identiﬁes sequence homologues using a BLAST (Altschul et al., 1990) e-value
threshold of 10 2. In stage (2) of Figure 3.2, this list of candidate FEPs is reﬁned using the ﬁlters
described in Sections 3.2.2.2 and 3.2.2.3.
3.2.2.2 The functional ﬁlter
This stage, shown in the functional match ‘pyramid’ in Figure 3.2, aims to ‘read’ the
UniProtKB/Swiss-Prot annotations. The homologues obtained in the previous stage are
ﬁltered on function using information from the UniProtKB/Swiss-Prot ‘Description’ (DE) ﬁeld
and the UniProtKB/Swiss-Prot ID itself. Each homologue identiﬁed by the BLAST search will
survive the functional ﬁlter if it matches the root protein in at least one of three levels (I-III);
the DE ﬁeld text matches compare synonyms at seven further levels of speciﬁcity (a-g):
(I) by the protein preﬁx element of the UniProtKB/Swiss-Prot ID
(II) by an EC number
(III) by matching synonyms at further multiple levels of speciﬁcity from the DE ﬁeld
(a) a ‘direct’ match, where the two proteins share an intact synonym (e.g., Autoprothrom-
bin IIa and Autoprothrombin IIa)
(b) a ‘hyphen’ match, where the proteins share a synonym after hyphen placement is
mirrored across both strings (e.g., Tectonic 3 precursor and Tectonic-3 precursor)
(c) a ‘full containing’ match, where one synonym is completely contained within an-
other (e.g., Kinesin light chain I and Kinesin light chain)
(d) a ‘mixed containing’ match, where one synonym is contained within another syn-
onym, but the words can be in a different order or they may be interrupted by addi-
tional annotation (e.g., Tubulin alpha chain and Tubulin alpha-1 chain)
(e) a ‘containing 75% words’ match, where 75% of the words of the shorter synonym
are also in the longer synonym (e.g., Myosin light chain alkali and Alkali myosin light
chain I)CHAPTER 3. FOSTA 99
(f) a ‘containing 75% length’ match, where 75% of the words in terms of length of the
shorter synonym are also in the longer synonym (e.g., Hemoglobin subunit beta and
Hemoglobic subunit beta-3)
(g) a ‘collapsed’ match, where one synonym is a substring of another, after spaces and
punctuation have been removed (e.g., Exportin-6 and Exportin 6-B)
When any two synonyms are compared, three common, functionally irrelevant words—
‘protein’, ‘fragment’ and ‘precursor’—are removed so as to avoid matches on functionally
irrelevant terms. All text comparisons are case insensitive.
The level (I) protein preﬁx match is considered the most reliable functional match (given that all
candidates have survived the homology screen and are therefore known to be evolutionarily
related) and the level (III) description match is considered to be the least reliable functional
match. Within the description ﬁeld match, reliability reduces from (a) the direct match to (g) the
collapsed match. Although the choice of the 75% threshold is somewhat arbitrary, it is unlikely
that false matches will be made, as all candidates have already been screened for homology. In
text comparison (g), the smaller synonym that is contained in the other must be at least four
characters long. The string ‘inhibit’ is treated as a special case: in synonym comparisons (c)-(g),
both or neither of the synonyms can contain the string ‘inhibit’ for a match to be possible; for
example, there is no match if one of the synonyms contains the word ‘inhibitor’ while the other
does not.
3.2.2.3 The FEP ﬁlter
Ifaprotein survivesboththesequenceand functionalﬁlteringstages, it iseithertheFEPforthat
species or a homologue that has undergone some (small) degree of functional divergence. To
eliminate the functionally diverged homologues (FDHs), only the best functional match from
each species (as deﬁned by the functional match reliability hierarchy described in Section 3.2.2.2
and in the match hierarchy pyramid shown in Figure 3.2) is assigned to the FOSTA family.
If two or more proteins cannot be discriminated functionally (i.e., they match the root human
protein at the same level of speciﬁcity), the protein with the highest sequence identity is chosen.
Note that sequence identity is used only as a last resort as highest sequence identity does not
guarantee functional equivalence even amongst close homologues (Notebaart et al., 2005; Koski
and Golding, 2001).CHAPTER 3. FOSTA 100
3.2.2.4 Unreliable proteins
UniProtKB/Swiss-Prot employs non-experimental qualiﬁers to describe proteins that have not
been characterised directly using experimental procedures1: ‘probable’ (there is some experi-
mental evidence, perhaps from a close homologue), ‘putative’ (there is some evidence, but not
enough to describe the function as ‘probable’) and ‘hypothetical’ (the sequence is automatically
translated from known genes). In addition, some proteins are not complete (fragments) and
others are described as ‘homologues’ or contain the ‘-like’ string. Further, as described in Sec-
tion 3.2.2.2, the FOSTA methodology uses sequence identity as the last resort match should two
candidate FEPs be indistinguishable with respect to function.
Such proteins and FEP assignments are less ‘reliable’ than others. FOSTA marks these assign-
ments as such, so that the user may choose to remove them from the FOSTA family.
3.3 Results and Discussion
3.3.1 An overview of FOSTA
Before presenting the evaluation of the method, it is helpful to present an overview of the
dataset. In this section, FOSTA is described with respect to proteome coverage and family size.
To appreciate the coverage of FOSTA, the UniProtKB/Swiss-Prot proteome coverage for each
species has been calculated as NF=NSP, where NSP is the number of proteins from that species
that are described in UniProtKB/Swiss-Prot (i.e., the size of the ‘UniProtKB/Swiss-Prot pro-
teome’) and NF is the number of proteins from that species described in FOSTA. Therefore,
a species that has all of its UniProtKB/Swiss-Prot proteins assigned to a FOSTA family will
have a UniProtKB/Swiss-Prot proteome coverage of 100%, while a species with none of its
UniProtKB/Swiss-Prot proteins represented in FOSTA would have a UniProtKB/Swiss-Prot
proteome coverage of 0%.
It is clear from Figure 3.3 that many species have 2% or less of their UniProtKB/Swiss-Prot pro-
1See http://www.uniprot.org/manual/non_experimental_qualifiers and http://www.uniprot.
org/docs/annbiochCHAPTER 3. FOSTA 101
teomes represented and a sizable number of species that have >98% of their UniProtKB/Swiss-
Prot proteome described in FOSTA. The high number of poorly represented species will reduce
over time as annotations are resolved across species.
Figure 3.3.1 shows the distribution of family sizes for all FOSTA families of 660 members or
less (only one human protein is assigned more than 660 FEPs: FOSTA identiﬁes 1787 FEPs for
human Cytochrome b [UniProtKB:P00156/CYB HUMAN]). FOSTA families with a member-
ship of <100 are shown in more detail in Figure 3.3.1. The most common family size is two,
which usually corresponds to an exclusively human/murine FOSTA family. These are not only
the most well represented species in UniProtKB/Swiss-Prot v53.0, they are also the most exten-
sively and similarly annotated.
There are increasingly fewer FOSTA families as family size increases beyond two. This is in part
due to annotations being less consistent across species, however it is also owing to genuine
functional divergence: as more species are added to a species set S, it is less likely that the
function F is common to every species in S.
With respect to how FEP relationships are formed, most FOSTA families are formed exclusively
usingthe proteinpreﬁx match, i.e., allmembers sharethe sameprotein preﬁx. However, 42.10%
(6 266/14 884) of FOSTA families contain at least two different protein preﬁxes. Furthermore, of
the 22 871 protein preﬁxes recorded in FOSTA, 5.42% are found to exist in more than one FOSTA
family. This indicates that, although UniProtKB/Swiss-Prot protein preﬁxes are very often re-
liable, incorporating additional information derived from the description ﬁeld is beneﬁcial in
identifying FEP relationships.
3.3.2 Difﬁculties in benchmarking
Evaluating FOSTA is difﬁcult because no gold-standard dataset exists. In addition, it is difﬁcult
to design an evaluation procedure to isolate the performance of the FOSTA method from the
quality of the UniProtKB/Swiss-Prot annotations that FOSTA interprets. To assess the FOSTA
method, it is necessary to assess whether FOSTA is clustering proteins correctly given the func-
tional annotations, rather than assessing whether the functional annotations are of sufﬁcient
detail to infer genuine functional equivalence. However, it is also very important to assess the
latter, as FOSTA is dependent on the UniProtKB/Swiss-Prot annotations.CHAPTER 3. FOSTA 102
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As such, FOSTA has been evaluated in three phases. The ﬁrst involves manual interpretation
of the results of several large protein families, some chosen at random and some chosen as
known problematic cases. This phase assesses how well FOSTA can interpret functional an-
notations and infer functional equivalence compared with manual interpretation. The second
phase benchmarks FOSTA against a fully manually annotated dataset and a larger partially an-
notated dataset. This phase not only indicates whether FOSTA performs well, but also assesses
whether the annotations are good enough to infer functional equivalence. The ﬁnal phase of
evaluation involves comparing FOSTA to Inparanoid, a popular method for identifying ortho-
logues. Note that the aim of FOSTA is not the same as that of the datasets used in the second
and third evaluation phases. Nevertheless, some interesting comparisons can be made.
3.3.3 HOX proteins
The family of homeobox (HOX) proteins was introduced in Section 3.1. In this section, the
performance of FOSTA is assessed when assigning the zebraﬁsh (Danio rerio) FEP to Homo Sapi-
ens homeobox protein Hox-B7. There is a body of literature on the problem of elucidating HOX
gene evolution, which is difﬁcult in zebraﬁsh given the extensive polyploidy in its evolutionary
history (Amores et al., 1998; Meyer, 1998; Stellwag, 1999).
The BLAST search identiﬁes 83 zebraﬁsh candidate FEPs and the ﬁltering process assigns
HXB7A DANRE to the FOSTA family of HXB7 HUMAN. There are 24 zebraﬁsh FDHs that
have higher sequence similarity to HXB7 HUMAN than the assigned FEP. These proteins, the
FEP and the root human protein are listed in Table 3.1, along with their UniProtKB/Swiss-Prot
annotations and their sequence identity to HXB7 HUMAN. It is clear that HXB7A DANRE is
the FEP given the similarity of its description and its protein preﬁx to that of HXB7 HUMAN;
this would be selected in a manual analysis of these candidates, despite its lower sequence
identity.
Several sites of functional relevance have been identiﬁed for HXB7 HUMAN (Table 3.2).
These functional sites have been extracted from UniProtKB/Swiss-Prot annotations and a
mutagenesis study by Yaron et al. (2001). Figure 3.6(a) shows the alignment of HXB7 HUMAN
and four conﬁdently assigned FEPs (i.e., those assigned to the FOSTA family on the basis
of protein preﬁx match) with HXB7A DANRE and the other 24 Danio rerio candidates
in the functionally relevant areas. Despite globally having the lowest sequence identityCHAPTER 3. FOSTA 106
Table 3.1: Zebraﬁsh candidates for the FOSTA family of HXB7 HUMAN
Protein: The UniProtKB/Swiss-Prot ID; ID: The sequence identity of the Protein to HXB7 HUMAN; Description: The
UniProtKB/Swiss-Prot description (DE) ﬁeld.
Protein ID Description
HXB7 HUMAN 100 Homeobox protein Hox-B7; Hox-2C; HHO.C1
HXB7A DANRE 54 Homeobox protein Hox-B7a; Hox-B7
HXA1A DANRE 63 Homeobox protein Hox-A1a; Hox-A1
HXA3A DANRE 68 Homeobox protein Hox-A3a
HXA4A DANRE 65 Homeobox protein Hox-A4a; Zf-26; Hoxx4
HXA5A DANRE 75 Homeobox protein Hox-A5a
HXA9B DANRE 62 Homeobox protein Hox-A9b
HXB1A DANRE 64 Homeobox protein Hox-B1a; Hox-B1
HXB1B DANRE 64 Homeobox protein Hox-B1b; Hox-A1
HXB2A DANRE 57 Homeobox protein Hox-B2a; Hox-B2
HXB3A DANRE 67 Homeobox protein Hox-B3a; Hox-B3
HXB4A DANRE 62 Homeobox protein Hox-B4a; Hox-B4; Zf-13
HXB5A DANRE 75 Homeobox protein Hox-B5a; Hox-B5; Zf-21
HXB5B DANRE 75 Homeobox protein Hox-B5b; Hox-B5-like; Zf-54
HXB6A DANRE 78 Homeobox protein Hox-B6a; Hox-B6; Zf-22
HXB6B DANRE 75 Homeobox protein Hox-B6b; Hox-A7
HXB8B DANRE 60 Homeobox protein Hox-B8b; Hox-A8
HXC1A DANRE 62 Homeobox protein Hox-C1a
HXC3A DANRE 61 Homeobox protein Hox-C3a; Hox-114; Zf-114
HXC5A DANRE 72 Homeobox protein Hox-C5a; Hox-C5; Hox-3.4; Zf-25
HXC6A DANRE 63 Homeobox protein Hox-C6a; Hox-C6; Zf-61
HXC6B DANRE 77 Homeobox protein Hox-C6b
HXC8A DANRE 73 Homeobox protein Hox-C8a
HXD4A DANRE 62 Homeobox protein Hox-D4a; Hox-D4
HXD9A DANRE 65 Homeobox protein Hox-D9a; Hox-D9
HXDAA DANRE 61 Homeobox protein Hox-D10a; Hox-D10; Hox-C10CHAPTER 3. FOSTA 107
Table 3.2: Functional sites in HXB7 HUMAN
Functional site: a description of the functional site; Location: the residue number in HXB7 HUMAN; Reference: The
source of the annotation.
Functional site Location Reference
DNA binding (homeobox) 137 - 197 UniProtKB/Swiss-Prot/FT DNA BIND
Crosslink (glycyl lysine isopeptide) 191 & 193 UniProtKB/Swiss-Prot/FT CROSSLNK
Motif (Antp-type hexapeptide) 126 - 131 UniProtKB/Swiss-Prot/FT MOTIF
Hypothesized binding to PBX 129 - 130 Yaron et al. (2001)
Putative CKII target 132 - 133 Yaron et al. (2001)
Putative CKII target 203 - 204 Yaron et al. (2001)
to HBX7 HUMAN of all the zebraﬁsh proteins shown in Figure 3.6(a), it is clear that
HXB7A DANRE has the highest conservation at functionally critical sites. Across residues
126 to 133, HXB7A DANRE only differs from HXB7 HUMAN at the position of a putative
PBX binding site, unlike all but one (HXB5A DANRE) of the other Danio rerio proteins which
differ in a known sequence motif (residues 126-131). The homeobox region (which also
includes crosslinking sites) is highly conserved across all of the zebraﬁsh proteins, and again,
conservation is highest in HXB7A DANRE. None of the zebraﬁsh proteins shows conservation
at residues 203 and 204, which describe a putative CKII target site (Yaron et al., 2001). It is
possible that this functional site has been wrongly predicted; however, this is unlikely as it is
absolutely conserved across the ﬁve mammalian species. It is more likely that this region is no
longer functional in the Danio rerio lineage or that this is a recently acquired functionality in
the mammalian clade.
Figure 3.6(b) shows an alternative approach to verifying the Danio rerio assignment of
HXB7A DANRE. Here, a phylogenetic tree has been constructed to characterise the
relationships between the same proteins that were aligned in Figure 3.6(a). Again, it is clear
that the protein selected by FOSTA (HXB7A DANRE) is most closely related to the human
protein and the four conﬁdently assigned FEPs than any of the other zebraﬁsh candidates,
despite being of lower sequence identity.
3.3.4 A solved annotation problem: PROC HUMAN
The UniProtKB/Swiss-Prot ID consists of a protein name followed by an underscore and
the species name. The initial assumption was that the protein name part of the ID was aCHAPTER 3. FOSTA 108
(a) Verifying the FOSTA assignment by way of annotated functional regions
Residues identical to that of HXB7 HUMAN are in bold capitals and highlighted yellow,
mismatching residues are non-captials and highlighted in light grey. The root human protein
(HXB7 HUMAN) is indicated in the red box and the FOSTA-assigned zebraﬁsh protein is
highlighted in the blue box. The position relative to HXB7 HUMAN is given on the top line. The
asterisks on the bottom line highlight fully conserved columns.
(b) Verifying the FOSTA assignment by way of phylogeny
Tree drawn using PHYLIP (ﬁtch/drawtree), the FEPs identiﬁed by FOSTA are highlighted in yellow;
HXB7 HUMAN, HXB7 BOVIN, HXB7 GORGO, HXB7 MOUSE and HXB7 RAT are shortened to H,
B, G, M and R respectively.
Figure 3.6: Verifying the zebraﬁsh assignment to the HXB7 HUMAN FOSTA familyCHAPTER 3. FOSTA 109
unique name used to label FEPs (Hulsen, 2004). However, while analysing human protein
C (PROC HUMAN) using the earlier UniProtKB/Swiss-Prot v50.62, it was evident that this
approach was unreliable. The ‘PROC’ preﬁx was used in forty different species to describe
three different proteins: Procalin in one species (PROC TRIPT), protein C in 11 species
(e.g., PROC HUMAN), and pyrroline-5-carboxylate reductase in the remaining 28 species
(e.g., PROC ECOLI). FOSTA was successful in correctly assigning only true examples of
protein C to the FEP group when analysing UniProtKB/Swiss-Prot v50.6, and analysis
of human pyrroline-5-carboxylate reductase results highlighted the inconsistencies in
UniProtKB/Swiss-Prot naming conventions.
Several of the FEPs in the FOSTA families of P5CR1 HUMAN (pyrroline-5-carboxylate reduc-
tase 1) and PROC HUMAN (protein C) have had multiple protein preﬁx changes. However,
after notifying UniProtKB/Swiss-Prot of the discrepancies, all the misnamed proteins were cor-
rected for the release of UniProtKB/Swiss-Prot v51.2: pyrroline-5-carboxylate reductase pro-
teins preﬁxed with PROC or PROH are now preﬁxed with P5CR or P5CR1 and PROC TRIPT
(procalin) is now called PRCLN TRIPT.
UniProtKB/Swiss-Prot makes no guarantee that the protein preﬁx is a unique identiﬁer, instead
describing it as a ‘mnemonic code’, but it is stressed that work is ongoing to standardize pro-
tein nomenclature: “Ambiguities regarding gene/protein names are a major problem in the literature
and it is even worse in the sequence databases which tend to propagate the confusion...UniProt is con-
stantly striving to further standardize the nomenclature for a given protein across related organisms”3.
Although this standardisation is discussed only with respect to protein names, and not the pro-
tein preﬁx elements of the UniProtKB/Swiss-Prot IDs, it is evident from the timings of preﬁx
updates for protein C and pyrroline-5-carboxylate reductase proteins since UniProtKB/Swiss-
Prot v50.6 that UniProtKB/Swiss-Prot does aim to standardize protein preﬁxes. If the protein
preﬁx ID was used consistently across all proteins in UniProtKB/Swiss-Prot there would be no
need for FOSTA.
2UniProtKB/Swiss-Prot v50.6 was released on 5th September 2006, UniProtKB/Swiss-Prot v53.0 was released on
29th May 2007; note that all results in this chapter are based on UniProtKB/Swiss-Prot v53.0, but older versions (in-
cluding UniProtKB/Swiss-Prot v50.6 and UniProtKB/Swiss-Prot v51.2) are discussed in the evalution
3http://www.expasy.org/cgi-bin/lists?nameprot.txtCHAPTER 3. FOSTA 110
3.3.5 Manual analysis of ﬁve protein families
To evaluate FOSTA, a manual analysis of ﬁve protein families was carried out. The focus was
the description ﬁelds and whether the description matches by FOSTA were appropriate. The
ﬁrst was trypsin-1, which was chosen because it belongs to the large serine protease family
of proteins. The remaining four—glucose-6-phosphate isomerase, aminopeptidase N, ATP-
dependent RNA helicase DDX51 and protoheme IX farnesyltransferase—were chosen at ran-
dom.
3.3.5.1 Trypsin-1
FOSTA identiﬁes eighteen FEPs for human trypsin-1 [UniProtKB:P07477/TRY1 HUMAN]. Of
these, ﬁfteen are clearly trypsin molecules. Some have additional non-functional qualiﬁcations
(cationic, anionic and alkaline) and demonstrate that FOSTA can make correct FEP assignments
despite extraneous information. There are ﬁve trypsin FEPs that are not described as trypsin-
1 in the second species: TRYB MANSE, TRYB DROME, TRYDG DROER, TRY5 AEDAE and
TRYA3 LUCCU. TRYB DROME and TRYDG DROER are assigned in favour of several other
trypsin proteins in Drosophila melanogaster and Drosophila erecta respectively. TRYB MANSE is
assigned in favour of TRYA MANSE and TRYC MANSE; in Manduca sexta (MANSE) it may be
that trypsin-B corresponds to human trypsin-1. It is not clear whether the annotations are mis-
leading or whether the FOSTA results are incorrect without speciﬁc information about how
and why these proteins were annotated by the respective species annotation communities.
There are only two trypsin proteins of adequate sequence similarity found in Aedes aegypti:
TRY5 AEDAE and TRY3 AEDAE. TRY3 AEDAE is equivalent to TRY3 HUMAN and there is
no human trypsin-5 protein in UniProtKB/Swiss-Prot v53.0, so the assignment here appears
sensible.
In Lucilia cuprina, two trypsin proteins are of sufﬁcient sequence similarity: TRYA3 LUCCU,
which has been identiﬁed as the FEP of TRY1 HUMAN, and TRYA4 LUCCU which has been
identiﬁed as the FEP of TRY3 HUMAN. This is a difﬁcult assignment to assess, particularly as
TRYA3 LUCCU is a fragmented protein. It is worth noting that these ﬁve questionable trypsin
proteins are derived from insect species: LUCCU, DROME and DROER are ﬂies, AEDAE is a
mosquito and MANSE is a moth. It may be that trypsin genes have duplicated and diverged in
insect species.CHAPTER 3. FOSTA 111
In addition to the trypsin molecules, FOSTA identifes GRAG MOUSE, VSP1 BOTJR,
VSP1M TRIST as FEPs because they are described as serine proteases, as is TRY1 HUMAN. All
mouse proteins explicitly described as trypsin belong to other FOSTA families, with protein
preﬁx matches. A manual text search of UniProtKB/Swiss-Prot v53.0 reveals that there are no
trypsin proteins for Bothrops jararacussu (BOTJR) or Trimeresurus stejnegeri (TRIST) described in
UniProtKB/Swiss-Prot v53.0, but again it is unclear whether the assignment is correct or not.
3.3.5.2 Aminopeptidase N
FOSTA identiﬁes 25 fully sequenced FEPs and two FEP fragments for aminopeptidase N
[UniProtKB:P15144/AMPN HUMAN]. There are seven assignments that do not match with
respect to protein preﬁx: AAP1 YEAST, AMP11 ENCCU, AMP1 PLAFQ, AMPM HELVI,
AMPN1 LACLA, APE1 SULSO, APE1 SULTO. AMPN1 LACLA is assigned over the one other
Lactococcus lactis subsp. lactis candidate (AMPN2 LACLA) as it is of higher sequence identity to
AMPN HUMAN. AMPN2 LACLA is assigned to the FOSTA family of PSA HUMAN, another
aminopeptidase. AMPN1 LACLA matches AMPN HUMAN with respect to EC number, and
contains the same synonym ‘Aminopeptidase N’. AMPM HELVI is the only protein Heliothis
virescens protein found by the BLAST search and has a good description ﬁeld match with
AMPN HUMAN; this appears to be the correct FEP for AMPN HUMAN in Heliothis virescens.
APE1 SULSO, APE1 SULTO, AAP1 YEAST, AMP11 ENCCU and AMP1 PLAFQ are the ﬁve
least reliable assignments, although they are clearly aminopeptidases. Four of the ﬁve are
ﬂagged as unreliable (see Section 3.2.2.4) by FOSTA.
3.3.5.3 ATP-dependent RNA helicase DDX51
The ATP-dependent RNA helicase DDX51 [UniProtKB:Q8N8A6/DDX51 HUMAN] is
assigned four full FEPs and four fragmented FEPs by FOSTA. The identiﬁcation of FEPs for
DDX51 HUMAN is a formidable task: DDX51 HUMAN belongs to a large family of ‘DEAD
box helicases’, described by UniProtKB/Swiss-Prot family classiﬁcations4. All four of the fully
sequenced proteins (DDX51 DANRE, DDX51 MOUSE, RH1 ARATH and RH1 ORYSJ) belong
to the same subfamily as DDX51 HUMAN (the DDX51/DBP6 subfamily). The fragments
IF413 TOBAC, DDX6 CAVPO, DDX1 DROVI and IF4A1 RABIT belong to the eIF4A,
2http://expasy.org/cgi-bin/get-similar?name=DEAD%20box%20helicase%20familyCHAPTER 3. FOSTA 112
DDX6/DHH1, DDX1 and eIF4A subfamilies respectively. All proteins assigned to a different
subfamily may be misassigned. The UniProtKB/Swiss-Prot family/domain classiﬁcations are
manually conﬁrmed, which suggests that in the case of DDX51 HUMAN, the candidate FEPs
are so similar that FOSTA ﬁnds it difﬁcult to discriminate between them. It should be stressed
that a manual analysis of UniProtKB/Swiss-Prot entries for this family is no more effective
than FOSTA, and that where FOSTA is incorrect in the DDX51 HUMAN assignments, the
proteins are fragments and ﬂagged as potentially unreliable.
3.3.5.4 Glucose-6-phosphate isomerase
The results for human glucose-6-phosphate isomerase [UniProtKB:P06744/G6PI HUMAN] ap-
pear very robust: 309 FEPs are identiﬁed, of which two are fragments. All of these proteins are
glucose-6-phosphate isomerases. Only eighteen of the 309 assignments are made on the basis
of sequence (where sequence matching is required to differentiate between G6PI1-4 or G6PIA-B
proteins) and 287 (92.88% of these are protein preﬁx matches). As already discussed, without
explanation of how these proteins were named, it is not clear whether FOSTA is generating the
correct pairs or whether the sequence matching is misleading.
3.3.5.5 Protoheme IX farnesyltransferase
FOSTA identiﬁes 34 FEPs for human protoheme IX farnesyltransferase [UniPro-
tKB:Q12887/COX10 HUMAN], all of which are fully sequenced proteins. These results
appear very reliable, with only one FEP chosen from all candidates on the basis of sequence
identity, where COXX BACSU is chosen over CTAO BACSU. Given that these two proteins
are annotated identically in UniProtKB/Swiss-Prot, it is reasonable to resort to sequence
similarity to discriminate between them. The results are particularly encouraging given that,
unlike most of the G6PI HUMAN FEPs for example, protoheme IX farnesyltransferases have
different UniProtKB/Swiss-Prot protein preﬁxes in different species.CHAPTER 3. FOSTA 113
3.3.6 Further benchmarking
In this section, FOSTA is benchmarked against two datasets: the large, partially manually an-
notated PIRSF dataset (Wu et al., 2004) and a reﬁnement of Hulsen et al.’s manually curated
dataset of six protein families that has been used previously to evaluate orthologue identiﬁca-
tion methods (Hulsen et al., 2006). Manual inspection of the Hulsen et al. dataset identiﬁed the
true one-to-one pairings in the one-to-many pairings.
FOSTA is designed to be conservative in the FEP assignments it makes: it is more important to
minimise the number of false positives than to minimise the number of false negatives. There-
fore, the most appropriate performance statistic with which to evaluate FOSTA is the positive
predictive value (PPV): the proportion of positive predictions that are correct, TP=(TP + FP).
However, where possible, all performance statistics have been calculated to assess FOSTA (the
performance statistics are described fully in Section 2.3.5). Within the context of FOSTA, sen-
sitivity assesses what proportion of the FEPs that should be identiﬁed are identiﬁed, while
speciﬁcity assesses what proportion of the FEPs that should be rejected are rejected.
3.3.6.1 Deﬁning the negative examples
A true negative (TN) is a result that is correctly identiﬁed as negative. In the context of FOSTA,
this is the number of non-FEPs that are correctly identiﬁed as non-FEPs. When benchmark-
ing FOSTA against other datasets, there are several ways to count the number of genuinely
negative examples. For example, all proteins identiﬁed by BLAST could be used regardless of
the species. However, this would artiﬁcally boost the performance of FOSTA as measured by
performance statistics that include true negatives (including speciﬁcity and MCC). A more ap-
propriate count of negative examples would only consider the proteins from the same species
identiﬁed by the BLAST search. For example, consider the assignment of a mouse FEP to the
FOSTA family of human protein A: if the BLAST search returned two mouse proteins, a rat
protein and a bovine protein, the count of negative examples could be two (the two mouse
proteins) or four (all proteins identiﬁed by the BLAST search). Choosing the less conservative
method (where the number of negative examples is 4), performance will be artiﬁcially boosted.
In this chapter, the number of negative examples is calculated as the number of FDH proteins
from that species.CHAPTER 3. FOSTA 114
Table 3.3: Benchmarking FOSTA against the PIRSF dataset
Set: the identiﬁer for each curation set [A=‘Full/Desc.’, B=‘Full’, C=‘Preliminary’, D=‘None’, N=aNnotated (A+B+C),
=All (N+D)]; Curation string: the string that deﬁnes the curation set; Families: the number of discrete protein families
in the curation set; Pairings: the number of discrete pairings across all families to be tested in FOSTA; Basic statistics:
the basic counts of true positives (TP), false positives (FP), true negatives (TN), false negatives (FN); Evaluation statis-
tics: the spec/speciﬁcity (TN=(FP +TN)), the sens/sensitivity (TP=(TP +FN)), the PPV (positive predictive value,
TP=(TP + FP)), and the MCC (Matthews Correlation Coefﬁcient), all rounded to 2dp.
Set Fams Pairs
Basic statistics Evaluation statistics
TP FP TN FN spec sens PPV MCC
A 122 2127 1744 2 3717 383 99.95 81.99 99.89 0.86
B 1095 18865 12967 23 34656 5898 99.93 68.74 99.82 0.77
C 474 11221 9146 62 11819 2075 99.48 81.51 99.33 0.83
D 339 5287 3674 16 4938 1613 99.68 69.49 99.57 0.72
N 1691 32213 23857 87 50192 8356 99.83 74.06 99.64 0.79
 2020 37500 27531 103 55130 9969 99.81 73.42 99.63 0.79
3.3.6.2 PIRSF evaluation
The Protein Information Resource (PIR) is a widely used, publicly available resource, and is
part of the UniProtKB consortium. With a view to the standardization of accurate propagation
of protein annotations, PIR has developed the PIRSF (PIR super family) classiﬁcation system
for UniProtKB proteins (Wu et al., 2004). However, unlike FOSTA, it does not identify FEPs as
it contains many-to-many orthologous pairings.
FOSTA was benchmarked against all one-to-one orthologous relationships between
UniProtKB/Swiss-Prot proteins that are listed in PIRSF families as ‘regular’ members
(‘associate’ members can be alternative splice variants, which should not be FEPs), at all four
levels of curation, where PIRSF families with a curation status of ‘Full/Desc’ have the highest
level of manual curation and families with a curation status of ‘None’ have not been manually
curated.
It is evident from Table 3.3 that FOSTA performs extremely well on the PIRSF protein families
according to the PPV and speciﬁcity metrics that are particularly important. However, it also
demonstrates reasonably high sensitivity and very high MCC scores.CHAPTER 3. FOSTA 115
Table 3.4: Benchmarking FOSTA against the reﬁned Hulsen et al. dataset
Family: the protein family being examined; TO pairings: the number of TO pairs in the Hulsen dataset (including
many-to-many orthologous pairings and non-UniProtKB/Swiss-Prot proteins); Reﬁned pairings: the number of one-
to-one TO pairings tested after reﬁnement of Hulsen TO dataset; Basic statistics: the basic counts of true positives (TP),
false positives (FP), true negatives (TN), false negatives (FN); Evaluation statistics: the spec/speciﬁcity (TN=(FP +
TN)), the sens/sensitivity (TP=(TP + FN)), the PPV (positive predictive value, TP=(TP + FP)), and the MCC
(Matthews Correlation Coefﬁcient), all rounded to 2dp.
Family Reﬁned (TO)
Basic statistics Evaluation statistics
TP FP TN FN spec sens PPV MCC
HBB 2 (9) 2 0 17 0 100.00 100.00 100.00 1.00
HOX 30 (41) 30 0 3853 0 100.00 100.00 100.00 1.00
SMm 12 (17) 12 0 22 0 100.00 100.00 100.00 1.00
SMc 6 (6) 6 0 5 0 100.00 100.00 100.00 1.00
NR 4 (29) 1 1 327 3 99.70 25.00 50.00 0.35
All 54 (102) 51 1 4224 3 99.98 94.44 98.08 0.96
3.3.6.3 Reﬁned Hulsen evaluation
Hulsen et al. (2006) recently evaluated the performance of several orthologue identiﬁcation
methods: BBH (bidirectional best hit), Inparanoid (O’Brien et al., 2005), KOG (Tatusov et al.,
2003), OrthoMCL (Chen et al., 2006), PhyloGeneticTree (van Noort et al., 2003) and Z 1 hundred
(estimating statistical signiﬁcance of alignment scores). The benchmarking included compari-
son with manually annotated ‘true-orthologue’ (TO) pairs of six protein families. For human-
mouse (Homo sapiens and Mus musculus) pairings, the protein families used were the homeobox
proteins (HOX), haemoglobins (HBB), and Sm and Sm-like proteins (SMm). For human and
worm (Caenorhabditis elegans) TO pairs, the families used were nuclear receptors (NR), toll-like
receptors (TLR), and Sm and Sm-like proteins (SMc).
These methods all aim to identify orthologues and do not consider functional equivalence.
Since they have different goals, it is not possible to compare FOSTA directly with the methods
evaluated by Hulsen et al., but FOSTA can be evaluated using a subset of the TO data.
The TO dataset supports many-to-many orthologous pairings where a human protein can map
to one or more proteins in another species and vice versa. To evaluate FOSTA, these data were
manually reﬁned to include only those TO pairings that can be conﬁdently identiﬁed as true
one-to-one orthologous pairings, where both proteins can be mapped to UniProtKB/Swiss-Prot
(compare the ‘Reﬁned’ and ‘TO’ counts in Table 3.4). This reﬁnement process removes the TLR
dataset from the analysis as no deﬁnitive one-to-one orthologous pairings could be identiﬁedCHAPTER 3. FOSTA 116
through manual inspection.
The results are summarised in Table 3.4. FOSTA demonstrates perfect performance in the HBB,
HOX, SMm and SMc families, identifying all reﬁned true-orthologue pairings.
However, FOSTA identiﬁed only one of the four reﬁned human/worm nuclear receptor (NR)
TO pairs (NHR67 CAEEL). On closer inspection, it is evident that these three failures of FOSTA
in the NR dataset are a result of widely varying formats of the UniProtKB/Swiss-Prot descrip-
tion ﬁeld across the two species. For example, the Homo sapiens proteins often have multiple
synonyms, which vary in format and content, whereas the Caenorhabditis elegans proteins are
more consistently named as ”Nuclear hormone receptor family member nhr-N” proteins (see
Table 3.5). These primary protein names or descriptions are deﬁned by the species-speciﬁc an-
notation communities (for example, Human Genome Nomenclature Committee, FlyBase and
Caenorhabditis Genetics Centre/Wormbase for Homo sapiens, Drosophila melanogaster and
Caenorhabditiselegansrespectively)withadditionalsynonymsobtainedbyUniProtKB/Swiss-
Prot from the literature. Therefore, it is not possible to attribute the lack of annotation consis-
tency to problems in UniProtKB/Swiss-Prot, as UniProtKB/Swiss-Prot is merely reﬂecting the
differing practices of the annotation communities and the content of the literature. Neverthe-
less, the lack of consistent description ﬁeld formatting within UniProtKB/Swiss-Prot limits the
extent to which text-mining methods such as FOSTA can exploit the data.
It is encouraging to note that FOSTA makes only one false positive assignment in the reﬁned
Hulsen dataset. Furthermore, FOSTA does not eliminate any of the one-to-one TO pairs: where
a FEP relationship is missed, the TO is retained as a FDH, indicating that the BLAST threshold
is not too conservative.
3.3.7 A comparison with Inparanoid
Inparanoid is a well-known method of constructing sets of orthologous proteins (O’Brien et al.,
2005). It uses BBH (best bidirectional hit) pairs in different species as a ‘seed’ around which a
cluster of orthologues can be formed. Other orthologues—or speciﬁcally other inparalogues—
can be added to this pairing if they are more similar to one of the seed orthologues than they
are to any other protein in another species.CHAPTER 3. FOSTA 117
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Inparanoid does not perform the same task as FOSTA: FOSTA is speciﬁcally interested in iden-
tifying functionally equivalent orthologous proteins, whereas Inparanoid is more interested in
identifying the correct phylogenetic relationships between proteins in different species. As
such, where Inparanoid detects one-to-one orthologous pairs, the results will be largely com-
plementary, but need not be identical. Therefore, FOSTA cannot be ‘benchmarked’ against In-
paranoid: it is not the gold standard dataset. However, by identifying one-to-one orthologous
pairings in the Inparanoid dataset that FOSTA rejects, a dataset of more difﬁcult test cases with
which FOSTA can be evaluated can be constructed.
The XML dataﬁles for Inparanoid v6.1 were obtained by FTP from http:
//inparanoid.sbc.su.se and parsed in Perl using XML::DOM. All human/X
one-to-one orthologues described by Inparanoid were extracted. For convenience, these
extracted human/X one-to-one Inparanoid orthologue pairs will be referred to as the
‘Inparanoid Pairs’ or IPs. There were ﬁfteen species in which no IPs were found (Aedes
aegypti, Anopheles gambiae, Arabidopsis thaliana, Caenorhabditis briggsae, Caenorhabditis elegans,
Caenorhabditis remanei, Candida glabrata, Cryptococcus neoformans, Debaryomyces hansenii,
Entamoeba histolytica, Escherichia coliK12, Kluyveromyces lactis, Schizosaccharomyces pombe,
Takifugu rubripes and Yarrowia lipolytica), leaving nineteen species with at least one IP to
compare with FOSTA.
As FOSTA groups UniProtKB/Swiss-Prot pairings, all extracted IPs must be mapped to
UniProtKB/Swiss-Prot. Inparanoid proteins are described using various database IDs,
including Ensembl5 (Flicek et al., 2008) (Apis mellifera, Bos taurus, Canis familiaris, Ciona
intestinalis, Gallus gallus, Gasterosteus aculeatus, Macaca mulatta, Monodelphis domestica, Pan
troglodytes, Rattus norvegicus, Tetraodon nigroviridis, Xenopus tropicalis), TAIR6 (Swarbreck et al.,
2008) (Arabidopsis thaliana), Zﬁn7 (Sprague et al., 2006) (Danio rerio), Dictybase8 (Chisholm et
al., 2006) (Dictyostelium discoideum), Flybase9 (Drysdale and The Flybase Consortium, 2008)
(Drosophila melanogaster and Drosophila pseudoobscura), MGI10 (Bult et al., 2008) (Mus musculus),
Gramene11 (Liang et al., 2008) (Oryza sativa) and SGD12 (Cherry et al., 1997) (Saccharomyces
cerevisiae). All relevant cross-references were extracted from UniProtKB/Swiss-Prot v53.0; any
conﬂicting or multiple cross-references (e.g., X!Y, X!Z) were not used.
5http://www.ensembl.org
6http://www.arabidopsis.org/
7http://zfin.org
8http://dictybase.org/
9http://flybase.org/
10http://www.informatics.jax.org/
11http://www.gramene.org/
12http://www.yeastgenome.org/CHAPTER 3. FOSTA 119
Using the UniProtKB/Swiss-Prot cross-references to map from the Inparanoid Ensembl protein
IDs to UniProtKB/Swiss-Prot sequences does result in a biased dataset: the UniProtKB/Swiss-
Prot sequences with explicit cross-references are likely to be well-annotated. Nevertheless,
it is reassuring that where the Inparanoid dataset does identify one-to-one pairings between
UniProtKB/Swiss-Prot proteins, FOSTA conﬁrms 96.23% of these pairings in a large dataset
(27 069 protein pairs) with signiﬁcant protein coverage (Apis mellifera, Bos taurus, Conis famil-
iaris, Ciona intestinalis, Danio rerio, Dictyostelium discoideum, Drosophila melanogaster, Drosophila
pseudoobscura, Gallus gallus, Gasterosteus aculeatus, Macaca mulatta, Monodelphis domestica, Mus
musulus, Oryza sativa, Pan troglodytes, Rattus norvegicus, Saccharomyces cerevisiae, Tetraodon ni-
groviridis and Xenopus tropicalis).
Columns 1-3 in Table 3.6 describe how many IPs from each species were successfully mapped
to UniProtKB/Swiss-Prot IDs, and therefore how many IPs from each species can be compared
with FOSTA. As described above, 27 069 IPs are extracted from Inparanoid v6.1, of which 26 073
(96.32%) are veriﬁed by FOSTA. Of the 996 IPs that are not found in FOSTA, 125 are rejected in
favour of another UniProtKB/Swiss-Prot protein from the non-human species (these IPs will
be described as ‘contested’ IPs). In the remaining 871 IPs, FOSTA fails to assign any FEP from
the non-human species to the human protein (these IPs will be described as ‘uncontested’ IPs).
These datasets can be further ‘cleaned’ to remove those IPs that either (i) cannot be found by
FOSTA or (ii) are clearly correct in FOSTA. Tables 3.7 and 3.8 describe this further reﬁnement
process. 43 of the contested Inparanoid pairs (IPs) appear to be wrong, since the FEP that
FOSTA assigns matches the human protein conﬁdently using the protein preﬁx match.
For example, Inparanoid identiﬁes SFH1 YEAST as the Saccharomyces cerevisiae partner to
SNF5 HUMAN, while FOSTA identiﬁes the more plausible FEP SNF5 YEAST. A further
ﬁve appear to be wrong, as the non-human protein is assigned as a FEP using a protein
preﬁx match elsewhere in FOSTA. For example, Inparanoid partners CAN9 HUMAN with
CAN3 BOVIN, while FOSTA identiﬁes the FEP CAN2 BOVIN; although it is not clear
which result is correct, FOSTA identiﬁes the Inparanoid partner CAN3 BOVIN as the FEP of
CAN3 HUMAN. It is therefore unlikely that CAN3 BOVIN is the true equivalent protein of
CAN9 HUMAN. Eliminating these examples, 77 IPs remain as test cases for FOSTA.
36.74% (320) of the 871 uncontested IPs cannot be identiﬁed by FOSTA: 26.98% are not found
using a BLAST threshold of 10 2 and 1.15% involve short human proteins that FOSTA does not
analyse (see Section 3.2). This is not strictly a failure of the FOSTA method but an inevitableCHAPTER 3. FOSTA 120
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Table 3.7: Identifying a ‘clean’ dataset of contested IPs to consider in FOSTA
Contested IPs are pairs of human/X Inparanoid protein pairs where FOSTA assigns a different protein from the species
X as the FEP of the human protein. Here, ‘conﬁdent’ FEP assignments are deﬁned as those based on a protein preﬁx
match.
125 100.00% contested IPs
43 34.40% IPs are wrong: FOSTA assigns the non-human protein conﬁdently
5 4.00% IPS are wrong: FOSTA assigns the non-human protein conﬁdently elsewhere
77 contested IPs remain to be tested
Table 3.8: Identifying a ‘clean’ dataset of uncontested IPs to consider in FOSTA
Uncontested IPs are pairs of human/X Inparanoid protein pairs where FOSTA does not assign any protein from the
species X as the FEP of the human protein. Here, ‘conﬁdent’ FEP assignments are deﬁned as those based on a protein
preﬁx match. Some IPs will not be identiﬁed as a FEP by FOSTA because (i) the IP protein does not exceed the e-value
BLAST threshold or (ii) the human protein is too short (see Section 3.2).
871 100.00% uncontested IPs
10 1.15% IPs will not be FEPs because the human protein is too short
235 26.98% IPs will not be FEPs because they aren’t found by BLAST
75 8.61% IPs are wrong: FOSTA assigns the non-human protein conﬁdently elsewhere
551 uncontested IPs remain to be tested
result of implementing a conservative method. A further 75 (8.61%) are found to be wrong:
FOSTA assigns the non-human protein elsewhere on the basis of a protein preﬁx match. For
example, Inparanoid identiﬁes xxx yyyyy as the partner to zzz HUMAN, but FOSTA describes
xxx yyyyy as the FEP to xxx HUMAN. This leaves 551 IPs to test as potential errors in FOSTA.
This leaves a ‘clean’ dataset of 77 contested IPs and 551 uncontested IPs with which to test
FOSTA. In a random sample of ten of the contested IPs (see Table 3.9), three FOSTA assignments
and one Inparanoid assignment appear to be correct. There is not enough evidence in the six
remaining contested IPs to ascertain which assignment might be correct; however, four of the
six remaining IPs are ﬂagged as less reliable sequence matches by FOSTA and could therefore
be removed from the dataset.
A random sample of 28 IPs (approximately 5%) were selected from the uncontested dataset
(see Table 3.10). Note that the IPs described in this dataset are not necessarily correct; they can,
however, be used as examples of difﬁcult test cases. Most of the IPs are not assigned a FEP by
FOSTA owing to uninformative or sparsely annotated DE ﬁelds. A signiﬁcant number ariseCHAPTER 3. FOSTA 122
Table 3.9: A random sample of ten contested IPs (Inparanoid pairs)
These are contested by FOSTA (i.e., FOSTA assigns a different FEP from that species).
Human Inparanoid FOSTA
PLCH HUMAN PLCHB DANRE PLCHA DANRE
MOXD1 HUMAN MOX11 DROME PHM DROME
EPN4 HUMAN ENT3 YEAST ENT4 YEAST
WDR59 HUMAN YD128 YEAST YBK4 YEAST
CP2B6 HUMAN CP2BB CANFA CP2CL CANFA
IF4A3 HUMAN FAL1 YEAST IF4A YEAST
O5AP2 HUMAN O1020 MOUSE O1086 MOUSE
DDX6 HUMAN DHH1 YEAST DBP6 YEAST
MCM4 HUMAN CDC54 YEAST CDC47 YEAST
OR5J2 HUMAN O1052 MOUSE O1094 MOUSE
Table 3.10: A random sample of 28 uncontested IPs (Inparanoid pairs)
These are uncontested in FOSTA (i.e., FOSTA does not assign any FEP from that species).
Human Inparanoid
TIM HUMAN TOF1 YEAST
CC45L HUMAN CDC45 YEAST
SURF1 HUMAN SHY1 YEAST
TEX10 HUMAN IPI1 YEAST
FA2H HUMAN SCS7 YEAST
IPO9 HUMAN IMB5 YEAST
ISK5 HUMAN IOV7 CHICK
LETM1 HUMAN A60DA DROME
FRK HUMAN SRC42 DROME
NVL HUMAN RIX7 YEAST
MMS19 HUMAN MET18 YEAST
DYR1A HUMAN MNB DROME
ATBP3 HUMAN NCS6 YEAST
DCR1A HUMAN PSO2 YEAST
PDXK HUMAN BUD16 YEAST
PLAP HUMAN DOA1 YEAST
JAZF1 HUMAN SFP1 YEAST
EXTL3 HUMAN EXT3 DROME
ZUBR1 HUMAN POE DROME
IPO11 HUMAN KA120 YEAST
RBBP6 HUMAN MPE1 YEAST
TRIPC HUMAN UFD4 YEAST
PAP1L HUMAN EPAB XENTR
PINX1 HUMAN YG5W YEAST
CFDP1 HUMAN SWC5 YEAST
FGF17 HUMAN FG17B DANRE
XPOT HUMAN LOS1 YEAST
TM11A HUMAN DESC4 RATCHAPTER 3. FOSTA 123
Table 3.11: Insensitivities in the FOSTA functional match methodology
By benchmarking FOSTA against the popular (but fundamentally different) method Inparanoid, some insensitivies in
the FOSTA description ﬁeld matching (described in Section 3.2.2.2) have become apparent. Two of these are shown
below.
Mapping to/from acronyms and long forms
CC45L HUMAN CDC45-related protein; PORC-PI-1; Cdc45
CDC45 YEAST Cell division control protein 45
Allowing for slight variations in names and numbers
FGF17 HUMAN Fibroblast growth factor 17 precursor; FGF-17
FG17B DANRE Fibroblast growth factor 17b precursor; FGF-17b
from large, densely populated protein families in which functional relationships are hard to
elucidate.
Only two examples highlight where the FOSTA functional match methodology may lack sen-
sitivity; these are shown in Table 3.11. The ﬁrst example—CC45L HUMAN/CDC45 YEAST—
suggests that mapping from acronyms to long forms and vice versa may be valuable in a future
version of FOSTA. In the ﬁrst example shown in Table 3.11, CDC would be extended to ‘Cell
division control’. In the second FGF17 HUMAN/FG17B DANRE example, some ﬂexibility in
names and numbers used by the matching machinery would lead to these two proteins being
identiﬁed as FEPs. However, introducing such additional ﬂexibility without careful considera-
tion would increase the likelihood of false positives being introduced into the FOSTA dataset.
The priority in FOSTA has been to minimize the number of false positives in order to have a
reliable dataset.
3.4 Conclusions
FOSTA is a novel method that extracts functionally equivalent proteins (FEPs) from the
UniProtKB/Swiss-Prot database by ‘reading’ the UniProtKB/Swiss-Prot annotations. As such,
it is a grouping of UniProtKB/Swiss-Prot proteins that are annotated similarly. FOSTA takes
advantage of the fact that UniProtKB/Swiss-Prot annotations are the result of many hours of
manual annotation and should encapsulate all knowledge available to the annotator at the
time.CHAPTER 3. FOSTA 124
Since FOSTA simply assimilates existing annotations, it is difﬁcult to separate the
performance of the FOSTA method from the quality and consistency of annotation in
UniProtKB/Swiss-Prot. Manual analysis of eight FOSTA families (those rooted around
PROC HUMAN, P5CR1 HUMAN, AMPN HUMAN, COX10 HUMAN, TRY1 HUMAN,
DDX51 HUMAN, G6PI HUMAN and HXB7 HUMAN) and two benchmarking evaluations
were carried out which indicate that FOSTA performs well and that UniProtKB/Swiss-Prot
annotations are generally of high quality. In a comparison with the popular but conceptually
quite different Inparanoid method, the results were largely complementary. In addition
to providing researchers with genuine FEP families for tasks such as studying sequence
conservation, FOSTA could be used to provide datasets to evaluate function prediction
methods.
Given the methodology, FOSTA has a few limitations. Firstly, FOSTA is clearly dependent on
UniProtKB/Swiss-Prot annotations. Any method based on database annotations is potentially
problematic as it relies on possibly mistaken, incomplete, inconsistent, ambiguous or outdated
information. However, the UniProtKB/Swiss-Prot database is considered to be the gold stan-
dard for protein annotation (the benchmarking results reﬂect that the annotations are indeed
very reliable), and annotations are constantly revised (for example, 210 454 annotation revisions
were made between release UniProtKB/Swiss-Prot v52.0 and UniProtKB/Swiss-Prot v53.013).
The continuous revision of UniProtKB/Swiss-Prot with the regular update of FOSTA ensures
that FOSTA FEP assignments can only improve in parallel with UniProtKB/Swiss-Prot.
Secondly, only proteins described in UniProtKB/Swiss-Prot can be assigned to FOSTA families.
Given that UniProtKB/Swiss-Prot is growing at an exponential rate14 and that it is the aim to
include all proteins in UniProtKB/Swiss-Prot, this limitation is not considered signiﬁcant. A re-
lated problem is that for many species, UniProtKB/Swiss-Prot does not describe the entire pro-
teome. In a few cases, a gene duplication may have resulted in two or more similar sequences
of which only one appears in UniProtKB/Swiss-Prot with an annotation which should more
appropriately be applied to one of the other sequences. Thus the true FEP may be a protein not
yet present in UniProtKB/Swiss-Prot. However, it should be noted that FOSTA is simply try-
ing to assimilate the current, curated knowledge of protein function to identify evolutionarily
related proteins that have been described similarly; manual examination of UniProtKB/Swiss-
Prot entries would make the same errors.
13http://www.expasy.ch/txt/old-rel/relnotes.53.htm
14http://expasy.org/sprot/relnotes/relstat.htmlCHAPTER 3. FOSTA 125
If FOSTA cannot discriminate between two candidate FEPs on the basis of function, it will
choose the candidate with the higher sequence identity to the root; only 6 047 of FEP assign-
ments (5.00%) are made on this basis. Any sequence matching is undesirable, as high sequence
similarity does not necessarily imply precise functional equivalence (see Section 3.1). It may
be avoided if more sensitive information extraction methods could be implemented to improve
functional discrimination. UniProtKB/Swiss-Prot keywords and GO terms may have some
value, but these tend to be at a higher level of annotation and are unlikely to improve discrimi-
nation of very detailed functional information. More sophisticated natural language processing
methods (Rice et al., 2005) would not be expected to improve performance, as the text being ex-
amined is simply a list of nouns. Alternatively, a more sensitive sequence matching protocol
could be implemented where annotated functional residues, or a consensus proﬁle of FEPs al-
ready assigned with high conﬁdence could be used, rather than the whole sequence (which
may be misleading). Furthermore, a vocabularly mapping acronyms to their long forms and
vice versa, and/or mapping between known synonyms may improve the functional compari-
son step.
FOSTA’s insistence on one-to-one FEP relationships may also be viewed as a limitation, but is
considered to be justiﬁed. Consider the protein X in species A that has two homologues Y1
and Y2 in species B. If Y1 and Y2 are both homologous to X, one must have been derived via
a gene duplication event. Gene duplication is a mechanism for functional divergence and one
can therefore argue that either Y1 or Y2, most likely (though not necessarily) the one with the
poorer sequence identity to X, has acquired novel, or lost existing, functionality (or is in the
process of doing so), and should not be selected as a FEP.
Currently, FOSTA roots families around human proteins because the priority is to identify FEPs
to human proteins, with a view to examining human disease. 58.36% (169 523 of 290 484)
of UniProtKB/Swiss-Prot proteins are not assigned to a FOSTA family in UniProtKB/Swiss-
Prot v53.0. Using the median size of a FOSTA family (87), one can estimate that another 1949
families will be formed if FOSTA were to cluster around non-human proteins. It is proposed
that a future version of FOSTA will root FOSTA families around decreasingly well deﬁned (in
terms of proteome coverage and functional annotation in UniProtKB/Swiss-Prot) species, until
all proteins are assigned to a FOSTA family. While it is hoped that this will be addressed in
future versions, it must be noted that human proteins are the most thoroughly annotated, and
it is unclear whether proteins from other organisms will be annotated well enough to identify
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Where there are annotation problems and inconsistencies across species, these are often not
strictly attributable to UniProtKB/Swiss-Prot, as the description ﬁelds are generated from an-
notations provided by the species-speciﬁc annotation communities, who may differ in their
annotation practices. However, as a widely used and trusted resource, UniProtKB/Swiss-Prot
is in a unique position to rectify such problems, and could implement a second layer of de-
scription above that of the separate annotation communities, which would aim to provide a
standardised nomenclature across all species. It is hoped that the FOSTA results may con-
tribute to any such effort. It has already done so with the recent correction of ‘PROC’ preﬁxes
as described in Section 3.3.4.
More generally, a controlled vocabulary for UniProtKB/Swiss-Prot description ﬁelds which
would allow description of all proteins across all species, would facilitate text mining and
result in more reliable hypotheses. This might be implemented as a second, computer-friendly
description ﬁeld, keeping the existing descriptions for human inspection. In addition, it
would be desirable to move some information from the description ﬁeld into separate tags in
the UniProtKB/Swiss-Prot ﬂatﬁle format; for example, ﬂags for fragmented or hypothetical
sequences. Given the size of UniProtKB/Swiss-Prot (UniProtKB/Swiss-Prot v53.0 contains
290 484 proteins), the resource must expect to be interrogated computationally, more so
with every new release. Any effort from UniProtKB/Swiss-Prot to make its contents more
computationally accessible would be valuable. Note that recent UniProtKB/Swiss-Prot
releases have split the description ﬁeld into an easier-to-parse, structured form, although
this was done in such a way that old parsers are not longer able to extract information from
UniProtKB/Swiss-Prot.
As stated above, a guarantee of unique UniProtKB/Swiss-Prot protein ID preﬁxes for equiv-
alent proteins in different species would preclude the need for hypotheses to be drawn by
software such as FOSTA. It is clear that the UniProtKB/Swiss-Prot team are making efforts
to standardise such annotations across species15; however it is also clear that some efforts are
not yet propagated fully across all relevant proteins and species. As stated above, the protein
C/pyrroline-5-carboxylate reductase case described in Section 3.3.4 has since been rectiﬁed by
the UniProtKB/Swiss-Prot annotators.
It is clear that not only is the automatic extraction of FEPs a surprisingly difﬁcult problem, but
that it is also very difﬁcult to evaluate these methods. The evaluation that was performed
15http://www.expasy.ch/txt/old-rel/relnotes.53.htmCHAPTER 3. FOSTA 127
not only demonstrated that FOSTA performs well, but also that the vast majority of
UniProtKB/Swiss-Prot annotations used by FOSTA are of high quality. This provides further
justiﬁcation of an annotation-based methods such as FOSTA and indicates that any concern
about FOSTA’s dependence on annotations need not be over-emphasized. In addition, it is
expected that FOSTA will improve with every revision of UniProtKB/Swiss-Prot.Chapter 4
Generating an Improved Protein
Alignment Conservation Threshold
Chapter 3 described FOSTA, a method for extracting functionally equivalent proteins (FEPs)
fromUniProtKB/Swiss-Prot. Inthischapter, aconservationscoringmethodisdescribed, which
analyses alignments of FEPs (or any other MSA) to generate an Improved Protein Alignment
Conservation Threshold, or ImPACT score, for any given protein alignment.
4.1 Introduction
When structural analyses fail to ‘explain’ a disease-causing mutation, it may be possible to infer
functional relevance from sequence conservation: if a residue is conserved across many differ-
ent branches of evolution, it is likely that that residue is functionally signiﬁcant. This motivates
the inclusion of a sequence anlaysis in SAAPdb as a form of ‘catch-all’ analysis. Should a func-
tionally important residue not be identiﬁed due to lack of coverage in the suite of structural
analyses, it may be identiﬁed using an analysis based on sequence conservation.
It is common to describe residues as being ‘highly conserved’, without explicitly deﬁning
‘highly conserved’. The extent of conservation is often described using some system of scoring
which assigns values between 0 and 1 to positions in an MSA, such as that used by the score-
128CHAPTER 4. IMPACT 129
cons server (Valdar, 2002). But what threshold should be applied to identify ‘highly conserved’
residues?
Conservation scores are a function of genuine functional equivalence across species. However,
theyarealsoafunctionofthespeciessetrepresentedandafunctionofpropertiesoftheproteins
they contain. As the species set represented by a multiple sequence alignment (MSA) widens, it
becomeslesslikelythatresidueswillbeconservedbychance, becausetheevolutionarydistance
between the species represented in the MSA is greater. As such, lower conservation scores will
become more signiﬁcant as markers of functional relevance.
In addition, some proteins are highly conserved throughout the MSA, due to a high number
of functional residues or a highly conserved network of stabilising interactions, for example.
An alignment of proteins highly conserved for functional or structural reasons might therefore
appear to represent a more closely related set of sequences than they actually do. On the other
hand, other proteins will be generally not well conserved, having diverged between species,
and will appear to represent a set of more distant species. Once again, lower conservation scores
will become signiﬁcant as markers of functional relevance when considering residue conserva-
tion in the context of a globally poorly conserved protein. Thus the deﬁnition of ‘highly con-
served’ will depend on the diversity of the species from which the sequences being aligned are
derived.
To elucidate genuine trends of conservation, it is necessary to (a) take into account the inﬂuence
of the species set represented by the MSA and (b) consider how well the protein is conserved
at the ‘global’ level. In the context of SAAPdb, any method developed must be automatic. As
such, it is necessary to factor out the inﬂuence of the species set and global conservation by
taking a statistical approach to deﬁning high conservation.
The other, currently implemented analyses (see Chapter 5) in SAAPdb are binary; that is, a
mutation is either explained by an analysis or it is not. The intention, ultimately, is to com-
bine these binary analyses to predict whether the mutation will be deleterious. With a view to
maintaining a homogeneous, binary vector for the prediction stage, the conservation analysis
described here must generate binary data: for each mutation, it must be able to describe it as
‘conserved’ or ‘not conserved’.CHAPTER 4. IMPACT 130
4.1.1 What is conservation?
Conservation describes whether a residue is seen at the equivalent position, in an equivalent
protein, in different species. Alignment methods identify which residues are equivalent. If a
residue is maintained across species, it has been subject to evolutionary pressure and therefore
is likely to be critical to the protein, in terms of function, stability or fold. Mutations affecting
such residues could therefore disrupt protein function, potentially causing disease. Where a
mutation cannot be explained using structural analyses, the functional information implicit in
alignments of FEPs may offer an explanation.
4.1.2 Scoring conservation
Conservation could simply be calculated as the fraction of sequences in the MSA that have the
residue of interest at an equivalent position. However, protein function can be maintained if a
residue with similar characteristics replaces the original. To take this into account, conservation
scoring methods use amino acid substitution matrices to calculate conservation (see Section
2.3.4). A typical calculation for residue x is shown below in Equation 4.1:
C(x) = 
N X
i
N X
j>i
M(si(x);sj(x)) (4.1)
where the MSA contains N sequences, sa(x) is the residue at position x in sequence a, M(p;q)
is the amino acid substitution value between residues p and q, and  scales C(x) between 0 and
1, that is,  = 1
N. In this chapter, M is always the PET91 matrix (Jones et al., 1992), an update of
the Dayhoff matrix, which has been normalised such that all scores on the diagonal are equal
(see Section 2.3.4.3).
An alternative approach uses the concept of ‘entropy’ and is borrowed from information the-
ory. The most commonly used entropy-based method is Shannon’s entropy (Shannon, 1948),
summarised in Equation 4.2:CHAPTER 4. IMPACT 131
H(X) =  
K X
i=1
pi log2 pi (4.2)
where H(X) is the Shannon’s entropy of a set of residues X; i denotes an amino acid; K is
the number of amino acids (therefore, K = 20), and pi is the fractional frequency of residue i
(that is, ni=jXj where ni is the number of i residues in X and jXj is the length of X). A column
containing one of each of the twenty amino acids (X20) would score H(X20) = 4:32, while
a column containing twenty of the same amino acid (X1) would score H(X1) = 0, reﬂecting
that there is less information contained in the X1 residue set than in the X20. This can be used
to measure conservation, where low entropy indicates high conservation and high entropy
indicates low conservation. Such methods, however, are unable to account for the similarity
between amino acids and are therefore inappropriate for use here.
In 2002, Valdar published a comprehensive review of conservation scoring methods, which de-
scribes many methods including weighted scores and Shannon’s entropy. One scoring system
that Valdar describes is that of Sander and Schneider (1991). This system is assessed later in
Section 4.2.1.
4.1.3 Identifying highly conserved residues
Althoughvariousmethodsexisttoscoreconservation, fewexistthatidentify‘highlyconserved’
residues. Two well known methods that are used to calculate conservation from MSAs, and aim
to identify highly conserved residues (and therefore functional residues) are Rate4Site and SIFT.
Rate4Site estimates the maximum likelihood rate at each position in the alignment, based on
a hypothesized phylogeny (Pupko et al., 2002). SIFT (which ‘Sorts Intolerant From Tolerant
mutations’) is a popular sequence-based method for identifying deleterious mutations (Ng and
Henikoff, 2001). It calculates a probability that an amino acid would be tolerated in the align-
ment, based on the observed variability and the estimated variability in a theoretical, complete
alignment. Neither of these methods explicitly considers the alignment with respect to species
coverage or with respect to global patterns of conservation, and further, neither method gener-
ates a threshold with which highly conserved residues can be identiﬁed.CHAPTER 4. IMPACT 132
4.1.4 Generating an improved protein alignment conservation threshold
As yet, no conservation identiﬁcation method exists that accounts for (i) species coverage and
(ii) background conservation levels in the alignment, that is also amenable to automated, dis-
tributed processing as required for SAAPdb. In this chapter, a method is described for gener-
ating an Improved Protein Alignment Conservation Threshold (ImPACT), that explicitly ‘nor-
malises’ the effects of species coverage and models the distribution of conservation scores to al-
low a threshold for high conservation to be generated. With such a threshold deﬁned, residues
in the context of an alignment can be described a conserved or not conserved, as required by
SAAPdb.
4.2 Methods
4.2.1 Accommodating the species set bias
Where species are very similar, some proportion of the conservation will be due to the small
evolutionary distance between the species. To ‘normalise’ for the species set, it is necessary to
reduce the inﬂuence of pairwise sequence comparisons between similar species. This can be
achieved by adding a weighted component to the conservation score.
In their paper, Sander and Schneider (1991) (hereafter referred to as SS) present a method that
deals with high levels of sequence similarity in protein alignments. When the conservation
score is calculated, pairwise scores are moderated by the similarity (or, strictly, dissimilarity) of
the two sequences. The calculation for column x of the MSA is shown in Equation 4.3.
CSS(x) = 
N X
i=1
N X
j=i+1
d(si;sj)m(si(x);sj(x)) (4.3)
 =
0
@
N X
i=1
N X
j=i+1
d(si;sj)
1
A
 1
(4.4)CHAPTER 4. IMPACT 133
d(si;sj) = 100  
1
L
L X
k=1
(Rki;Rkj) (4.5)
where m(si(x);sj(x)) is the score from the Dayhoff substitution matrix (Dayhoff et al., 1978)
for the residues in column x in sequences si and sj; (Rki;Rkj) is the identity f1,0g of Rki and
Rkj (the kth residue in the alignment of sequences i and j respectively); N is the number of
sequences in the MSA; and L is the length of the alignment.
This goes some way to accommodating the species bias inherent in MSAs. However, it uses the
similarity of sequences in the MSA to approximate species similarity. This will be misleading if
sequences are highly conserved for functional reasons. Should two similar sequences between
two very different species be compared as described by Equations 4.3-4.5, their contribution
to the overall alignment will be downweighted rather than correctly upweighted. As such, a
more rational and direct weighting system, which weights pairwise comparisons by the species
similarity, has been developed here.
Thus, species similarity is calculated directly: the FEPs identiﬁed by FOSTA (see Chapter 3) are
used to calculate how similar two species are, on average. The system of equations becomes:
Cspecsim(x) = 0
N X
i=1
N X
j=i+1
d0(si;sj)m0(si(x);sj(x)) (4.6)
0 =
0
@
N X
i=1
N X
j=i+1
d0(Q(si);Q(sj))
1
A
 1
(4.7)
d0(A;B) = 100  
1
F
F X
i
nw(Ai;Bi) (4.8)
where m0(si(x);sj(x)) is the score from the normalised PET91 matrix (Jones et al., 1992); A and
B are two species for the residues in column x in sequences si and sj; Q(a) is the species from
which sequence a is derived; F is the number of FEPs that are identiﬁed between A and B; Ai
and Bi are the ith FEPs; and nw(X;Y ) is the NW aligment score calculated across the aligned
regions of the protein sequences of X and Y (using a gap initialisation penalty of 11 and aCHAPTER 4. IMPACT 134
gap extension penalty of 2, see Section 2.3.3 for a description of NW). d0(A;B) is therefore a
dissimilarity coefﬁcient for A and B, scaled between 0 and 100.
The choice of the normalised form of the PET91 matrix follows its use as the default scoring
matrix by the scorecons server, a popular conservation scoring server established following
rigourous investigation by Valdar (2002). The normalisation precludes any bias that would re-
sult from high numbers of unusual (or, indeed, common) amino acids in a sequence: it ensures
that the maximum substitution value is the same for each residue, and that the range of sub-
stitution scores for all twenty residues is more similar than observed in, for example, the PAM
and BLOSUM matrices.
Using Equations 4.6-4.8, conservation scores are normalised with respect to species diversity.
Hereafter, the resulting species similarity matrix will be referred to as specsim (species
similarity).
To generate the matrix d0, all observed species pairings from FOSTA (i.e., all species pairs which
share membership of a FOSTA family) are extracted from the database. In the current imple-
mentation of FOSTA (November 2008), there are 6 801 254 protein pairs from 1 147 685 possible
species pairings, requiring that 6 801 254 pairwise alignments are run; this is not feasible on a
single machine. Further, each species pairing can be processed in parallel. As such, the code is
ideal for distribution across processors and has been developed for execution across the local
116-core grid. The pseudocode for each species comparison (i.e., each distributed job) is shown
in Figure 4.1.
4.2.2 Accommodating protein-speciﬁc patterns of conservation
Using the specsim scoring method described in Section 4.2.1 (Equations 4.6-4.8), conservation
scores are normalised with respect to the species set represented. The next step is to isolate
conservation patterns that are independent of the properties of the proteins.
To deﬁne an alignment-speciﬁc ‘high conservation’ threshold, it is necessary to characterise
the distribution of conservation scores appropriately. As the distribution of conservation scores
cannot be expected to conform to a single Gaussian distribution, standard parametric, statistical
approaches are not suitable. Non-parametric ranking methods (e.g., identifying the top 5% ofCHAPTER 4. IMPACT 135
(a) specsim inputs
 species1 : the ﬁrst species
 species2 : the second species
(b) specsim processing
(I) identify all good pairs of FEPs for species1 and species2
(II) for each protein pair:
(a) extract the sequences from the database
(b) align the sequences using NW, calculate and record the identity score
(III) calculate and record the mean of the identity scores
Figure 4.1: Calculating a similarity score for a pair of species
NW: Needleman & Wunsch (1970) using a gap initialisation penalty of 11 and gap extension penalty of 2. species1
and species2 are UniProtKB species sufﬁces. Good FEPs are those that are (a) not fragments (b) not unreliable and (c)
not assigned using the ‘last-resort’ sequence matching (see Section 3.2.2.3).
conservation scores) are also inappropriate as MSAs will vary with respect to the proportion of
columns that are highly conserved.
MixturemodelsallowdistributionstobedescribedusingmultipleGaussiancomponents(Aitkin
and Wilson, 1980). For the purposes of the current analysis, the distribution is characterised
as having three components, G0, G1 and G2: G0 will characterise the unconserved residues,
G1 will capture the distribution of moderately conserved residues, and G2 will describe the
distribution of the highly conserved residues. It is expected that these three classes have some
functional relevance: G0 describes freely mutating residues, G1 describes residues with some
minor structural role, while G2 describes residues that are critical to structure and/or function.
Thus, residues deﬁned by G2 are the ones that should be identiﬁed as ‘highly conserved’.
Figure 4.2 shows the mixture modelling of some example data. These data were randomly gen-
erated using the rnorm() function in R: 3000 points were drawn evenly from three Gaussian
distributions at  = f 5;0;5g; = f2;5;4g. Although the Gaussians overlap considerably,
the data are appropriately captured by the three Gaussians: the means of the ﬁtted Gaussians
(shown by the dashed blue lines) correspond closely to the true values f 5;0;5g; compare the
raw data, plotted in black, with the cumulative model in red to evaluate how well the model
ﬁts the data.
To ease discrimination at the extremeties of the distribution, the data are logit transformed (see
Figure 4.3). The formula is given in Equation 4.9 below.CHAPTER 4. IMPACT 136
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Figure 4.2: Using multiple Gaussians to model data
The data modelled above has been generated randomly using rnorm() in R. 3000 numbers were drawn evenly from
three Gaussian distributions: distribution A ( =  5; = 2), distribution B ( = 0; = 5), distribution C ( =
5; = 4). The black line represents the raw data. A 3-component mixture model is ﬁtted to these data and is shown
in blue. Fitted components are numbered from 0 to 2, from left to right; the means of these components are indicated
with dashed blue lines. The cumulative modelled distribution is shown in red. For details on the optimisation method
(BFGS), see Section 4.2.2.CHAPTER 4. IMPACT 137
xlogit = log

x
1   x

(4.9)
The three Gaussian components G0, G1 and G2 are ﬁtted to the logit transformed data and
two constraints are applied to the resulting model to deﬁne high conservation in the MSA. The
mixture model is ﬁtted using the optim() command in R, using the BFGS method (Broyden-
Fletcher-Goldfarb-Shanno) (Fletcher, 1970). ImPACT has been implemented to run ﬁfty rounds
of optimisation and to draw priors from the uniform Dirichlet conjugate prior ( = 1). The
Dirichlet distribution is used to represent any prior belief with regards to the values of the
parameters of the mixture model. Using a uniform prior where  = 1 in the context of the
ImPACT mixture model means that no prior belief as to the densities of the three component
Gaussians exists in the modelling system.
4.2.2.1 Constraint one: applying a basic concept of conservation
The method must ﬁrst ascertain whether the MSA contains any signiﬁcant conservation at
all. In the context of the modelled distribution described above, this translates to consider-
ing whether G2 is high enough. If G2 exists at, for example, ' 0:60, it may be high relative to
the other residues in the protein, but it is not high enough to infer functional signiﬁcance. To
deﬁne a basic concept of conservation, the lower bound of ‘high conservation’ must be deﬁned.
This value will be described as constraint one, or C1.
To establish a suitable value for C1, the conservation scores for combinations of eight residue
duples or triples were considered. That is, sets of two or three residues were combined to
represent alignment columns, with residues being chosen based on an existing expectation of
what would constitute conservation and what would not. By considering the conservation for
each combination and considering which sets of columns should be classiﬁed as conserved,
the value for C1 can be deﬁned. For example, the combination of residues CCCCCCWWWW
would not be considered conserved, as cysteine and tryptophan are very different, but the
combination of residues FFFFFFYYYY would be, as phenylalanine and tyrosine are much more
similar physicochemically.
Of the set of eight residue pairs, two residue tuples were included as examples of very differ-CHAPTER 4. IMPACT 138
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(c) Logit transformed data
Figure 4.3: The logit function and logit transformationCHAPTER 4. IMPACT 139
ent residues—fEWg and fCWg—with the remaining six—fILVg, fSTg, fDEg, fRKg, fFYg and
fNQg—representative of sets of more similar residues. The intention here is to set the value
for C1 such that appropriate mixtures of the similar residues are included, while excluding
appropriate mixtures of the dissimilar residues.
In this section, the term ‘X:Z ratio’ will be used to describe the composition of the combinations
of residues (X and Z are used so as to avoid confusion with amino acids). A high X:Z ra-
tio indicates that the combination predominantly comprises one residue (e.g., ‘FFFFFFFFFFFY’
has an X:Z ratio of 11:1 where X represents F and Z represents Y), whereas an X:Z ratio close
to 1:1 indicates that there are equal numbers of each/all residues in the combination (e.g.,
‘SSSSSSTTTTTT’ has an X:Z ratio of 1:1 where X represents S and Z represents T). For each
residue combination, all possible combinations of 12 residues were generated. 12 was used be-
cause (a) it allows a 1:1 residue composition in a residue duple and a 1:1:1 residue composition
in a residue triple (b) it allows a reasonable range of X:Z ratios, from 11:1 to 1:1 for duples and
10:1:1 to 1:1:1 for triples, and (c) it provides enough residues from which a reliable conservation
score can be calculated.
Conservation scores were generated as described in Equation 4.1 using amino acid substitution
scores from the normalised PET91 matrix (Jones et al., 1992) (see Section 4.2.1). The conservation
scores for fILVg, fSTg, fDEg, fRKg, fNQg, fFYg, fEWg and fCWg are shown in Tables 4.1-4.8.
A threshold of 0.80 identiﬁes any combination of twelve tyrosine and phenylalanine residues
as being conserved (Table 4.6); increasing the threshold to 0.85 only identiﬁes columns with an
X:Z ratio of 3:1 or higher. Unless the hydroxyl group of tyrosine is critical, tyrosine and phenyl-
alanine can generally replace each other without compromising protein function, suggesting
that a threshold of 0.80 is appropriate for this pair of amino acids. The threshold of 0.80 also
seems appropriate for the fDEg and fRKg combinations: both pairs of residues generate the
same conservation scores, and applying a threshold of 0.80 allows columns with an X:Z ratio of
2:1 or better to be identiﬁed as highly conserved.
The remaining sets of similar residues—fILVg (Table 4.1), fSTg (Table 4.2) and fNQg (Table
4.5)—maysuggestthatalowerthresholdof0.75ismoreappropriate, allowingforcolumnssuch
as ‘IILLLLLLLLLV’, ‘SSSSSSSSSTTT’ and ‘NNNNNNNNNNQQ’ to be identiﬁed as highly con-
served. However, dropping the threshold to 0.75 would compromise performance where very
different residues are being compared. For example, a threshold of 0.75 would identify anCHAPTER 4. IMPACT 140
Table 4.1: The conservation scores for all combinations of twelve fILVg residues
Column residues: the combination of residues; Conservation: the conservation score for the column residues. Thresh-
oldsof0.75, 0.80, 0.85, 0.90and0.95aremarkedontherighthandside. Columnsareorderedbydecreasingconservation
score. fILVg are a set of similar residues.
Column residues Conservation Threshold
LLLLLLLLLLLL 1.000000
IIIIIIIIIIII 1.000000
VVVVVVVVVVVV 1.000000 0.95
IVVVVVVVVVVV 0.933333
IIIIIIIIIIIV 0.933333
LLLLLLLLLLLV 0.911111
ILLLLLLLLLLL 0.911111
IIIIIIIIIIIL 0.911111
LVVVVVVVVVVV 0.911111 0.90
IIVVVVVVVVVV 0.878788
IIIIIIIIIIVV 0.878788
IIIIIIIIIILV 0.850505
ILVVVVVVVVVV 0.850505 0.85
IILLLLLLLLLL 0.838384
LLLLLLLLLLVV 0.838384
LLVVVVVVVVVV 0.838384
IIIIIIIIIILL 0.838384
IIIIIIIIIVVV 0.836364
IIIVVVVVVVVV 0.836364
ILLLLLLLLLLV 0.832323
IIIIVVVVVVVV 0.806061
IIIIIIIIVVVV 0.806061
IILVVVVVVVVV 0.802020
IIIIIIIIILVV 0.802020 0.80
IIIIIIIVVVVV 0.787879
IIIIIVVVVVVV 0.787879
IIIIIIIIILLV 0.783838
ILLVVVVVVVVV 0.783838
IIILLLLLLLLL 0.781818
LLLVVVVVVVVV 0.781818
LLLLLLLLLVVV 0.781818
IIIIIIIIILLL 0.781818
IIIIIIVVVVVV 0.781818
IILLLLLLLLLV 0.769697
ILLLLLLLLLVV 0.769697
IIILVVVVVVVV 0.765657
IIIIIIIILVVV 0.765657 0.75
IIIIIIIILLVV 0.741414
IIIIIIILVVVV 0.741414
IIIILLLLLLLL 0.741414
LLLLLLLLVVVV 0.741414
IIIIIIIILLLL 0.741414
IILLVVVVVVVV 0.741414
IIIILVVVVVVV 0.741414
LLLLVVVVVVVV 0.741414
continues next column...
...continues here
ILLLVVVVVVVV 0.733333
IIIIIIIILLLV 0.733333
IIIIILVVVVVV 0.729293
IIIIIILVVVVV 0.729293
ILLLLLLLLVVV 0.723232
IIILLLLLLLLV 0.723232
IIIIIIILLLLL 0.717172
LLLLLLLVVVVV 0.717172
IILLLLLLLLVV 0.717172
IIIIILLLLLLL 0.717172
LLLLLVVVVVVV 0.717172
IIIIIIILLVVV 0.711111
IIILLVVVVVVV 0.711111
LLLLLLVVVVVV 0.709091
IIIIIILLLLLL 0.709091
ILLLLVVVVVVV 0.698990
IIIIIIILLLLV 0.698990
IIIIIIILLLVV 0.696970
IILLLVVVVVVV 0.696970
ILLLLLLLVVVV 0.692929
IIIIIILLVVVV 0.692929
IIIILLLLLLLV 0.692929
IIIILLVVVVVV 0.692929
IIIIILLVVVVV 0.686869
IIIIIILLLLLV 0.680808
IIILLLLLLLVV 0.680808
ILLLLLVVVVVV 0.680808
IILLLLLLLVVV 0.680808
IIIIILLLLLLV 0.678788
ILLLLLLVVVVV 0.678788
IIILLLVVVVVV 0.672727
IIIIIILLLVVV 0.672727
IILLLLVVVVVV 0.668687
IIIIIILLLLVV 0.668687
IILLLLLLVVVV 0.660606
IIIIILLLVVVV 0.660606
IIIILLLVVVVV 0.660606
IIIILLLLLLVV 0.660606
IILLLLLVVVVV 0.656566
IIIIILLLLLVV 0.656566
IIILLLLLLVVV 0.654545
IIIIILLLLVVV 0.650505
IIILLLLVVVVV 0.650505
IIILLLLLVVVV 0.644444
IIIILLLLVVVV 0.644444
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Table 4.2: The conservation scores for combinations of twelve fSTg residues
Column residues: the combination of residues; Conservation: the conservation score for the column residues. Thresh-
oldsof0.75, 0.80, 0.85, 0.90and0.95aremarkedontherighthandside. Columnsareorderedbydecreasingconservation
score. fSTg are a set of similar residues.
Column residues Conservation Threshold
SSSSSSSSSSSS 1.000000
TTTTTTTTTTTT 1.000000 0.95
STTTTTTTTTTT 0.900000
SSSSSSSSSSST 0.900000 0.85/0.90
SSSSSSSSSSTT 0.818182
SSTTTTTTTTTT 0.818182 0.80
SSSSSSSSSTTT 0.754545
SSSTTTTTTTTT 0.754545 0.75
SSSSSSSSTTTT 0.709091
SSSSTTTTTTTT 0.709091
SSSSSSSTTTTT 0.681818
SSSSSTTTTTTT 0.681818
SSSSSSTTTTTT 0.672727
Table 4.3: The conservation scores for combinations of twelve fDEg residues
Column residues: the combination of residues; Conservation: the conservation score for the column residues. Thresh-
oldsof0.75, 0.80, 0.85, 0.90and0.95aremarkedontherighthandside. Volumnsareorderedbydecreasingconservation
score. fDEg are a set of similar residues.
Column residues Conservation Threshold
DDDDDDDDDDDD 1.000000
EEEEEEEEEEEE 1.000000 0.95
DEEEEEEEEEEE 0.933333
DDDDDDDDDDDE 0.933333 0.90
DDEEEEEEEEEE 0.878788
DDDDDDDDDDEE 0.878788 0.85
DDDDDDDDDEEE 0.836364
DDDEEEEEEEEE 0.836364
DDDDEEEEEEEE 0.806061
DDDDDDDDEEEE 0.806061 0.80
DDDDDEEEEEEE 0.787879
DDDDDDDEEEEE 0.787879
DDDDDDEEEEEE 0.781818 0.75CHAPTER 4. IMPACT 142
Table 4.4: The conservation scores for combinations of twelve fRKg residues
Column residues: the combination of residues; Conservation: the conservation score for the column residues. Thresh-
oldsof0.75, 0.80, 0.85, 0.90and0.95aremarkedontherighthandside. Columnsareorderedbydecreasingconservation
score. fRKg are a set of similar residues.
Column residues Conservation Threshold
RRRRRRRRRRRR 1.000000
KKKKKKKKKKKK 1.000000 0.95
KRRRRRRRRRRR 0.933333
KKKKKKKKKKKR 0.933333 0.90
KKRRRRRRRRRR 0.878788
KKKKKKKKKKRR 0.878788 0.85
KKKKKKKKKRRR 0.836364
KKKRRRRRRRRR 0.836364
KKKKKKKKRRRR 0.806061
KKKKRRRRRRRR 0.806061 0.80
KKKKKKKRRRRR 0.787879
KKKKKRRRRRRR 0.787879
KKKKKKRRRRRR 0.781818 0.75
Table 4.5: The conservation scores for combinations of twelve fNQg residues
Column residues: the combination of residues; Conservation: the conservation score for the column residues. Thresh-
oldsof0.75, 0.80, 0.85, 0.90and0.95aremarkedontherighthandside. Columnsareorderedbydecreasingconservation
score. fNQg are a set of similar residues.
Column residues Conservation Threshold
QQQQQQQQQQQQ 1.000000
NNNNNNNNNNNN 1.000000 0.90/0.95
NNNNNNNNNNNQ 0.888889
NQQQQQQQQQQQ 0.888889 0.80/0.85
NNQQQQQQQQQQ 0.797980
NNNNNNNNNNQQ 0.797980 0.75
NNNQQQQQQQQQ 0.727273
NNNNNNNNNQQQ 0.727273
NNNNQQQQQQQQ 0.676768
NNNNNNNNQQQQ 0.676768
NNNNNNNQQQQQ 0.646465
NNNNNQQQQQQQ 0.646465
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Table 4.6: The conservation scores for combinations of twelve fFYg residues
Column residues: the combination of residues; Conservation: the conservation score for the column residues. Thresh-
oldsof0.75, 0.80, 0.85, 0.90and0.95aremarkedontherighthandside. Columnsareorderedbydecreasingconservation
score. fFYg are a set of similar residues.
Column residues Conservation Threshold
YYYYYYYYYYYY 1.000000
FFFFFFFFFFFF 1.000000 0.95
FFFFFFFFFFFY 0.944444
FYYYYYYYYYYY 0.944444 0.90
FFFFFFFFFFYY 0.898990
FFYYYYYYYYYY 0.898990
FFFYYYYYYYYY 0.863636
FFFFFFFFFYYY 0.863636 0.85
FFFFYYYYYYYY 0.838384
FFFFFFFFYYYY 0.838384
FFFFFYYYYYYY 0.823232
FFFFFFFYYYYY 0.823232
FFFFFFYYYYYY 0.818182 0.75/0.80
Table 4.7: The conservation scores for combinations of twelve fEWg residues
Column residues: the combination of residues; Conservation: the conservation score for the column residues. Thresh-
oldsof0.75, 0.80, 0.85, 0.90and0.95aremarkedontherighthandside. Columnsareorderedbydecreasingconservation
score. fEWg are a set of very different residues.
Column residues Conservation Threshold
EEEEEEEEEEEE 1.000000
WWWWWWWWWWWW 1.000000 0.85/0.90/0.95
EEEEEEEEEEEW 0.833333
EWWWWWWWWWWW 0.833333 0.75/0.80
EEWWWWWWWWWW 0.696970
EEEEEEEEEEWW 0.696970
EEEWWWWWWWWW 0.590909
EEEEEEEEEWWW 0.590909
EEEEEEEEWWWW 0.515152
EEEEWWWWWWWW 0.515152
EEEEEEEWWWWW 0.469697
EEEEEWWWWWWW 0.469697
EEEEEEWWWWWW 0.454545CHAPTER 4. IMPACT 144
Table 4.8: The conservation scores for combinations of twelve fCWg residues
Column residues: the combination of residues; Conservation: the conservation score for the column residues. Thresh-
oldsof0.75, 0.80, 0.85, 0.90and0.95aremarkedontherighthandside. Columnsareorderedbydecreasingconservation
score. fCWg are a set of very different residues.
Column residues Conservation Threshold
CCCCCCCCCCCC 1.000000
WWWWWWWWWWWW 1.000000 0.95
CCCCCCCCCCCW 0.900000
CWWWWWWWWWWW 0.900000 0.85/0.90
CCCCCCCCCCWW 0.818182
CCWWWWWWWWWW 0.818182 0.80
CCCWWWWWWWWW 0.754545
CCCCCCCCCWWW 0.754545 0.75
CCCCWWWWWWWW 0.709091
CCCCCCCCWWWW 0.709091
CCCCCCCWWWWW 0.681818
CCCCCWWWWWWW 0.681818
CCCCCCWWWWWW 0.672727
alignment column comprising of ‘CCCCCCCCCWWW’ or ‘CCCWWWWWWWWW’ as highly
conserved.
With a view to applying a conservative threshold, an initial criteria that G2  logit(0:80) is
deﬁned.
4.2.2.2 Constraint two: generating the threshold
If C1 is not violated (i.e., the predeﬁned, basic model of conservation exists in the data), the
method then assesses whether the density at the high end of the distribution is sufﬁciently dis-
crete from that of the middle of the distribution. To do this, it must assess how separate G1
and G2 are (e.g., in Figure 4.2, the distance between the second and third vertical dashed lines
would be used to assess whether the highest distribution (distribution 2) is distant from the
middle distribution (distribution 1)). Using the parameters of G1, which models the distribu-
tion of moderately conserved residues, it is possible to identify those residues that exist at the
upper extreme of what constitutes ‘moderately conserved’: by moving two standard deviations
in the positive direction, the top 2.5% of the moderately conserved data is identiﬁed. If G2
(the Gaussian which represents highly conserved residues) exists at this point or higher, the two
Gaussians (G1 and G2) are considered to be separate; that is, if G2 >= G1 +C2G1;C2 = 2,CHAPTER 4. IMPACT 145
there is adequate distance between G1 and G2, and G1 +C2G1;C2 = 2 becomes the thresh-
old for high conservation. Otherwise, the basic concept of conservation is applied (i.e., C1
becomes the threshold).
Constraint two (C2) deﬁnes how far from G2 (in standard deviations) the threshold should be
set. The ImPACT threshold (IT) is therefore calculated as follows:
IT =
8
> <
> :
G1 + C2  G1 if G2 >= G1 + C2  G1;
C1 otherwise:
(4.10)
By default, C1 = 0:80 and C2 = 2. Note that the threshold for conservation can be < 0:80. C1
assesses whether the mean of G2 (the Gaussian representing the conserved residues) is greater
than 0.80. If this constraint is met, the threshold is calculated from the mean and standard
deviation of G1 (the Gaussian representing the moderately conserved residues). As such, the
threshold generated by the calculation G1 + 2G1 could be less than 0.80.
4.3 Results and Discussion
It is difﬁcult to assess how successful conservation scoring methods are. In his comprehen-
sive summary of protein conservation scoring methods, Valdar (2002) states that “there is no
rigourous mathematical test for judging a conservation measure...rather than accuracy then, a conser-
vation score may be judged on its verisimilitude: its ability to depict realism and its concordance with
biochemical notation”. However, further to scoring conservation, ImPACT generates a threshold,
the application of which aims to classify residues in an MSA as highly conserved or not highly
conserved. As such, should an appropriate dataset of conserved residues exist against which
ImPACT can be benchmarked, it is possible to use standard binary classiﬁcation performance
statistics (see Section 2.3.5) to evaluate the performance of ImPACT.
To perform a multi-faceted evaluation of ImPACT, it has been assessed using three
datasets. The ﬁrst is a dataset of four representative human proteins: glucose-6-
phosphate 1-dehydrogenase (G6PD) [UniProtKB:P11413/G6PD HUMAN]; ornithine
carbamoyltransferase (OTC) [UniProtKB:P00480/OTC HUMAN]; cellular tumor antigenCHAPTER 4. IMPACT 146
P53 [UniProtKB:P04637/P53 HUMAN] and haemoglobin subunit beta (HBB) [UniPro-
tKB:P68871/HBB HUMAN]. Secondly, the sequence motif database PROSITE (Hulo et al.,
2006) is parsed to extract residues that should be conserved in an alignment of functionally
equivalent proteins. Finally, artiﬁcial conservation data, for which the global conservation
patterns can be controlled, are used to evaluate the scoring method.
First, however, the specsim weighted scoring system is evaluated.
4.3.1 Normalising conservation using the specsim matrix
Figure 4.4 shows an unrooted phylogenetic tree (constructed using the fitch method from the
PHYLIP1 package of phylogenetic software) generated from a subset of ﬁfty species’ pairwise
dissimilarity scores calculated from the specsim matrix. It is clear that the dissimilarity scores
are representative of species diversity: the two main branches of the tree represent the eukary-
otes and prokaryotes. There is appropriate subdivision of eukaryotic species into mammal, ﬂy,
yeast, fungi and plant groups, and appropriate prokaryotic subdivisions including cynobateria
(including the Nostocales subfamily), mycobacteria, E-coli subspecies, helicobacteria and so on.
Figure 4.5 compares the unweighted, species-similarity-weighted and sequence-similarity-
weighted conservation scores for the four representative proteins introduced above. HBB and
P53 are the two most heavily adjusted proteins in terms of weighted conservation scores, while
G6PD and OTC are less affected. This indicates that the species similarity, as measured by
specsim , and the sequence similarity are both high within the P53 and HBB alignments. The
results for G6PD and OTC are clustered more closely around the identity line, demonstrating
that the proteins are more different from each other, with respect to species and sequence.
For all four proteins, the sequence and species weighting do correspond closely to each other,
indicating that sequence similarity is a reasonable approximation of the species similarity. In
general, however, it does appear that weighting by species similarity has a greater effect on
the score than sequence similarity, with blue points closer to the x axis than red points. The
exception is OTC, the conservation scores for which appear to be more heavily corrected when
weighting by sequence similarity than when weighting by species similarity.
1http://evolution.genetics.washington.edu/phylip.htmlCHAPTER 4. IMPACT 147
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Figure 4.4: Evaluating the specsim matrix using phylogeny
Dissimilarity scores between 50 species were taken from the specsim matrix (see Section 4.2.1) and used as distance
metricswithwhichtoconstructaphylogenetictree(usingfitchfromthePhylippackage). Speciesrepresentedusing
their UniProtKB/Swiss-Prot species sufﬁx. The ﬁrst branch of the tree divides the species into eukaryotes (highlighted
in blue) and prokaryotes (highlighted in yellow). Further subdivisions are highlighted in grey.CHAPTER 4. IMPACT 148
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Figure 4.5: Comparing specsim , SS and unweighted conservation scoring methods
The four representative proteins (OTC, G6PD, P53 and HBB) are used to evaluate the sequence similarity weighted
(SS, see Equations 4.3-4.5), species similarity weighted (specsim , see Equations 4.6-4.8) and unweighted conservation
scoring methods. The unweighted score is along the x axis and the weighted scores are plotted along the y axis, with
scores weighted by species plotted as blue +s and scores weighted by sequence plotted as red s. The identity line
(where the weighted and unweighted scores are equal) is marked by a dashed grey line.CHAPTER 4. IMPACT 149
Table 4.9: Conservation patterns vary across proteins
nres: the number of residues/columns in the alignment; nseq: the number of sequences/rows in the alignment; max:
the maximum conservation score; min: the minimum conservation score; c: the average conservation score; c: the
standard deviation of the conservation scores; percx: the percentage of columns that have a conservation score of x.
All numbers rounded to 2dp.
Protein nres nseq max min c c perc1:00 perc0:95 perc0:90
OTC 354 178 1.00 0.28 0.59 0.20 3.39 10.17 12.43
G6PD 515 49 1.00 0.27 0.58 0.22 5.05 9.32 13.59
P53 393 31 1.00 0.33 0.69 0.23 21.63 24.68 30.79
HBB 147 239 1.00 0.38 0.74 0.17 6.12 14.29 27.21
4.3.2 Using four representative proteins to assess ImPACT
Four representative human proteins have been chosen to evaluate ImPACT (see Table 4.9).
G6PD (515 residues long, 49 proteins in alignment) is representative of a protein that is gener-
ally not highly conserved. It has a low mean conservation score of 0.58 and a relatively large
standard deviation of 0.22. Only 5.05% of the residues are 100% conserved in an alignment
with 515 columns. OTC (354 residues long, with 178 proteins in the alignment) has a very
similar conservation proﬁle to that of G6PD, with a mean conservation score of 0.59, a stan-
dard deviation of 0.20 and 3.39% of the 354 residues 100% conserved. The mean conservation
score of the tumour suppressor protein P53 is 0.68; P53 displays the most amount of variation
around the mean, with a standard deviation of 0.24 and 21.63% of residues 100% conserved.
HBB has the highest mean score (0.74) and with less variation ( = 0:18) about the mean and
6.12% of residues 100% conserved. P53 and HBB are examples of highly conserved proteins.
HBB has higher mean conservation value (0.74 compared to 0.69), but far fewer residues that
are 100% conserved (6.12% compared to 21.63%). As such, it is possible to describe HBB as the
globally more conserved protein although P53 has more 100% conserved residues. The aim of
ImPACT is to identify high or low global conservation and generate appropriately higher or
lower scores. All proteins have at least one residue that is 100% conserved.
The graphs in Figure 4.6 plot the distribution of specsim -weighted (Section 4.2.1) conserva-
tion scores for each protein and its FEPs (as deﬁned by FOSTA, see Chapter 3) as a proportion
of the total number of residues (i.e., the data are normalised for the sequence length, nseq in
Table 4.9). It is clear that the four proteins vary with respect to conservation score distribution
and as such are appropriate datasets with which ImPACT can be assessed.CHAPTER 4. IMPACT 150
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Figure 4.6: Varying conservation patterns in the four representative proteins
The specsim -weighted conservation scores for the four representative proteins (OTC, G6PD, P53 and HBB). See Table
4.9 for more more details.CHAPTER 4. IMPACT 151
Table 4.10: ImPACT results for the four representative proteins
nres: the number of residues/columns in the alignment; nseq: the number of sequences/rows in the alignment; IT:
the threshold generated using ImPACT; percIT : the percentage of residues identiﬁed as highly conserved, according
to IT. IT rounded to 4dp, all other ﬁgures rounded to 2dp.
Protein nres nseq IT percIT
OTC 354 178 0.8672 13.27
G6PD 515 49 0.9612 8.54
P53 393 31 0.9636 23.66
HBB 147 239 0.9763 10.20
Figure 4.7 shows the logit transformed distributions as modelled by ImPACT and the results of
the ImPACT analysis. Visual inspection of the ﬁtted mixture models shows that the distribution
of raw, specsim -weighted conservation scores (shown in Figure 4.7 in black) is successfully
captured using the three Gaussians in all four proteins (compare the black and magenta traces).
The corresponding alignment representation on the right of each graph in Figure 4.7 depicts the
global conservation patters for each protein, where conservation increases from green (where
the conservation score is 0) to red (where the conservation score is 1) via blue and purple.
The width of the colour band indicates how many columns in the alignment are scored in that
range. Therefore, an alignment representation that is predominantly red is more highly con-
served than an alignment representation containing large blue bands. Using these alignment
representations to sort the four proteins according to increasing global conservation—taking
into account both the prevalence of high conservation and the lack of very low conservation—
would order the proteins as follows: OTC, G6PD, P53, HBB. Appropriately, ImPACT assigns
these proteins increasing ImPACT scores: 0.8672, 0.9612, 0.9636 and 0.9763 for OTC, G6PD, P53
and HBB respectively. As discussed at the beginning of this section, although P53 has a higher
proportion of 100% conserved residues, HBB has a higher mean conservation score and as such
is the more globally conserved protein. HBB should therefore have a higher conservation thresh-
old. ImPACT successfully captures these trends and generates a higher threshold for HBB than
for P53.CHAPTER 4. IMPACT 152
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Figure 4.7: Assessing ImPACT using four representative proteins
ImPACT analysis for (from top to bottom) OTC, G6PD, P53, and HBB, the four representative proteins. Distribution of
logit transformed raw data is shown in black, the three ﬁtted Gaussians are shown in blue and the cumulative model
is shown in magenta. The values for the ﬁrst and second constraints (see Section 4.2.2) are depicted as vertical orange
and red lines respectively. The resulting threshold is given in the grey box in the top-left corner of the graph. In
addition to the ﬁtted Gaussian components, to aid comparison of each protein’s global conservation trends, a depiction
of conservation trends for each protein’s MSA is shown to the right of the graph, where high conservation scores are
shown in red, more moderate scores are shown in blue and low scores are shown in green.CHAPTER 4. IMPACT 153
4.3.3 A large scale analysis of ImPACT: PROSITE
PROSITE is a databank of biologically relevant protein motifs (Hulo et al., 2006). Motifs are
identiﬁed using structural alignments of proteins and several levels of proﬁle extraction, re-
ﬁnement and scaling methods (for full details, see Gribskov et al. (1990), L¨ uthy et al. (1994),
Thompson et al. (1994b)). Motifs in PROSITE can be both functional (e.g., an N-linked glycoso-
lation site) and indicative of homologous protein families (e.g., an apple domain).
4.3.3.1 Deﬁning the data
PROSITE (version 20.36, 02/09/08) data were obtained from Expasy2. This version of PROSITE
contains 1315 PROSITE motifs. The motifs are described using a PROSITE-speciﬁc format:
where each element is separated by a ‘-’; standard single-letter symbols are used to represent
amino acids; ‘x’ indicates any residue; ‘[]’s indicate an inclusive choice (i.e., any residue in the
‘[]’ brackets); ‘fg’s indicate an exclusive choice (i.e., any residue except those in the ‘fg’ brack-
ets); < and > indicate the start and end of the sequence respectively; and numbers or ranges
in ‘()’s are quantiﬁers. For example, the AP endonuclease family 1 signature 1 (PROSITE fam-
ily PS00726) describes the sequence motif [APF]-D-[LIVMF](2)-fTg-[LIVM]-Q-E-fGg-K,
which translates as “ala or pro or phe / asp / leu or ile or val or met or phe / leu or ile or val
or met or phe / any residue except thr / leu or ile or val or met / gln / glu / anything but gly
/ lys”.
In this chapter, PROSITE is being used to deﬁne ‘conserved’ residues in human proteins; this
requires that ‘conservation’ must be deﬁned within PROSITE patterns. This is a question of
leniency: how many different residues can exist in equivalent positions before the position
becomes unconserved? For the results described in this chapter, the leniency has been set at
two; that is, those elements in the PROSITE sequence motifs that describe a set of at most two
amino acids are considered to be conserved. Although this may be viewed as a rather strict
deﬁnition of conservation, ImPACT has been designed to be conservative in its approach and
it is therefore undesirable to extend the leniency any further. These are the data against which
ImPACT has been benchmarked.
Figure 4.8 describes how PROSITE is parsed to identify conserved residues in human proteins.
2ftp://ftp.expasy.org/databases/prosite/prosite.datCHAPTER 4. IMPACT 154
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Figure 4.8: Extracting conserved residues from PROSITE
For each PROSITE record, a Perl regular expression is generated from the PROSITE motif string (see Figure 4.9(a) for an
example). All instances of the motif are identiﬁed in each true positive (TP) human protein (see text) using the regular
expression. Using a predeﬁned leniency value (throughout this chapter, a value of 2 is used), the conserved elements
of the motif are identiﬁed. The human sequence is annotated with the conserved PROSITE residues and these data are
recorded.CHAPTER 4. IMPACT 155
PROSITE PA S - Q - [STK] - [TA] - I - [SC] - R - [FH] - [ET] - x - [LSQ] - x(0,1) - [LIR] - [ST] .
Perl REGEX / S Q [STK] [TA] I [SC] R [FH] [ET] . [LSQ] .f0,1g [LIR] [ST] /g
Leniency  1    
Leniency  2         
Leniency  3            
(a) The POU-speciﬁc (POUs) domain signature 2 (PROSITE family PS00465)
Converting the POU domain signature 2 from the PROSITE PA format into a Perl regular expression
(REGEX). The consequence of applying different conservation leniencies (1, 2 and 3) are shown
beneath the PA/REGEX using s. Throughout this chapter, a leniency of 2 is used to identify
conserved elements of PROSITE motifs (shown in red).
(b) Identifying the POU-2 motif in the human proteins
Each TP human protein in the POU-2 PROSITE family (PS00465) is searched for the occurence
of the motif, using the regular expression given in Figure 4.9(a); The motif is highlighted here
in pale yellow and the conserved elements are marked with an ; positions for the preceeding
and following residue are shown in grey.
Figure 4.9: Extracting data from the POU-speciﬁc (POUs) domain signature 2 PROSITE family
(PS00465)CHAPTER 4. IMPACT 156
Each PROSITE pattern (PA) record is extracted and the PROSITE formatted motif is translated
into a Perl regular expression (REGEX). An example is shown in Figure 4.9(a). As described
above, a leniency of two has been set to identify conserved residues, which results in the fourth,
sixth, eighth, ninth and fourteenth elements in the example being described as conserved as
well as the ﬁrst, second, ﬁfth and seventh single residue elements. To illustrate the use of
leniency, the conserved elements using leniencies f1,2,3g are indicated with an asterisk beneath
the aligned PA and REGEX in Figure 4.9(a).
Then, each TP (true positive) human protein3 named in the PROSITE record is searched using
the Perl regular expression to identify where the motif occurs (the sequence is searched for
exhaustively, returning all occurrences of the motif). Figure 4.9(b) shows the motif described
in Figure 4.9(a) being identiﬁed in all the PROSITE-TP human proteins. Again, the conserved
residues, as deﬁned by the sequence motif and the leniency, are marked with an asterisk.
Once the PROSITE records are parsed to identify the conserved residues, the conserved
residues for each human protein are aggregated across PROSITE families into one set of
residues. For example, ACES HUMAN contains conserved residues at positions 221, 222,
223, 232, 234 and 236 according to the Carboxylesterase B1 motif (PROSITE family PS00122)
and contains further conserved residues at positions 126, 127 and 128 according to the
Carboxylesterase B2 motif (PROSITE family PS00941). ACES HUMAN is therefore annotated
as being conserved at positions 126, 127, 128, 221, 222, 223, 232, 234 and 236.
MUSCLEalignments(seeSection2.3.2foradescriptionoftheMUSCLEmethod)offunctionally
equivalent proteins or FEPs (as identiﬁed by FOSTA, see Chapter 3), are extracted from the
FOSTA database. Only the most reliable FEPs are used: those non-fragmented proteins that
have matched on protein preﬁx or share a synonym with the root human protein (see Section
3.2.2.2). In this chapter, these FEPs will be described as ‘strict’. The alignments are further
constrained in that they must contain twenty or more proteins, to ensure that the alignment is
adequately informative and will therefore generate reliable data for the modelling process. This
results in 231 proteins containing PROSITE conserved residues against which ImPACT can be
benchmarked.
Figure 4.10(a) shows a section of the alignment of RS27 HUMAN with the 28 strict FEPs that
are extracted from the FOSTA database. RS27 HUMAN contains the ribosomal S27E motif
3These are proteins that contain the motif as expected by PROSITE (Hulo et al., 2006), not to be confused with the
later use of ‘TP’ to indicate a true positive in the ImPACT/PROSITE benchmarkingCHAPTER 4. IMPACT 157
(PROSITE family PS01168). This sequence motif is highlighted along the bottom of the align-
ment in yellow or red. Using a leniency of two, seven of these elements are considered ‘con-
served’; these are marked in red in Figure 4.10(a). These will be the positive examples in the
PROSITE benchmarking of ImPACT, all non-annotated residues will be used as negative exam-
ples. Any positive example not identiﬁed by ImPACT is a ‘false negative’ (FN) and any nega-
tive example identiﬁed as conserved by ImPACT is a ‘false positive’ (FP); correct assignments
of positive and negative examples are true positives (TPs) and true negatives (TNs) respec-
tively (see Section 2.3.5 for an introduction to TPs, TNs, FPs and FNs and binary classiﬁcation
performance statistics).
There are two characteristics of this dataset that constrain how far the results can be interpreted.
Firstly, the number of negative examples will, in the vast majority of sequences, far outnumber
the number of positive examples. As such, it is inappropriate to use performance statistics such
as accuracy ((TP + TN)=(TP + TN + FP + FN)), as a high accuracy can be achieved simply
by classifying everything as not conserved.
More importantly, there will be residues that are conserved in the alignment, but will not be an-
notated by PROSITE. PROSITE is a database of sequence motifs. Residues involved at catalytic
sites, ligand binding and those important for structural conservation need not be described by
PROSITE. Indeed, a phenylalanine at position 11 in Figure 4.10(a) is 100% conserved but not
included in the PROSITE motif. In terms of the present dataset, this translates to uncertainty
in the set of TNs; in terms of performance statistics, this suggests that statistics that use the
number of FPs (including the postive predictive value or PPV; the false discovery rate, or FDR;
and the false positive rate or FPR) will be misleading, and will underestimate the performance
of ImPACT.
In the remainder of this chapter, the benchmarking of ImPACT against PROSITE will be de-
scribed. The ImPACT threshold generated will be compared with thresholds varying from
0 to 1, at increments of 0.01; these thresholds will be referred to as the ‘standard’ thresholds.
Residues deﬁned as conserved by PROSITE will be described as PC residues; all other PROSITE
residues will be described as !PC residues and residues that are deﬁned as conserved by Im-
PACT will be described as IC residues.
Bearing in mind the caveats described above, the performance statistics have been limited to
Receiver Operator Characteristic (ROC) plots and Matthews Correlation Coefﬁcient (MCC)CHAPTER 4. IMPACT 158
(again, for a description of these terms, see Section 2.3.5). When considering the ROC plots
in the context of the caveats described above, it is more imporant that ImPACT maximises the
TPR, however, small FPRs are also desirable. A good ImPACT result will be maximally distant
from the TPR/FPR identity line (the line that describes performance no better than random).
4.3.3.2 Examples of good results
There are many proteins for which ImPACT is successful in identifying the PROSITE conserved
(PC) residues. Figure 4.11 shows the ROC and MCC results for four such proteins: 40S ri-
bosomal protein S27 [UniProtKB:P42677/RS27 HUMAN], triosephosphate isomerase [UniPro-
tKB:P60174/TPIS HUMAN], transthyretin [UniProtKB:P02766/TTHY HUMAN] and calcium-
dependent phospholipase A2 [UniProtKB:P39877/PA2G5 HUMAN].
ImPACT generates a threshold of 0.9404 for high conservation in the RS27 HUMAN align-
ment, which gives an MCC of 0.93. The alignment for these data is shown in Figure 4.10(a).
It is clear that this is the optimal value with respect to MCC (Figure 4.11(b)). In addition, the
ImPACT ROC result is maximally distant from the TPR/FPR identity line as compared to the
other thresholds (Figure 4.11(a)). The reason that ImPACT doesn’t attain a perfect MCC score
of 1.00 is that one !PC residue is identiﬁed as an IC residue: the phenylalanine at position 11
is identiﬁed by ImPACT. In other words, ImPACT identiﬁes an additional highly conserved
residue which is not included in the PROSITE pattern.
The patterns of conservation in the TPIS HUMAN alignment (containing 318 proteins includ-
ing TPIS HUMAN, see Figure 4.12) result in an ImPACT threshold of 0.9786 which has an MCC
of 0.5047. This is clearly better than any of the standard thresholds (Figure 4.13(b)). Again, the
ImPACT result is maximally distant from the TPR/FPR identity line (Figure 4.13(a)). In addi-
tion to demonstrating that ImPACT performs well, this result shows that very precise thresh-
olds (in the case of ImPACT, precision to the fourth decimal place) can enhance detection of
highly conserved residues compared with thresholds of lower precision (in the case of the stan-
dard thresholds, precision to the second decimal place): the ImPACT result does not fall on the
line drawn by the standard thresholds.
Although the MCC result for the PROSITE benchmarking of TTHY HUMAN and its 20 FEPs
(see Figure 4.10(b)) is not as high as the previous two examples—the ImPACT threshold ofCHAPTER 4. IMPACT 159
0.9544 has an MCC of 0.3649, see Figure 4.14(b)—it is the best result, surpassing the small
peak of the standard thresholds (concentrated at  0:95) and achieving maximal distance from
TPR/FPR identity. Again, this demonstrates the increased discriminative power of higher pre-
cision thresholds; without a data modelling process such as that described in Section 4.2.2, it is
difﬁcult to generate such high precision thresholds. The relatively poorer performance in this
dataset is owing to high numbers of FPs: compare the number of IC residues and the number
of PC residues in Figure 4.10(b).
The ﬁnal example is for the protein PA2G5 HUMAN (see Figures 4.10(c), 4.15(a) and 4.15(b)).
ImPACT generates a high conservation threshold of 0.9623 for the MUSCLE alignment of
PA2G5 HUMAN and its 21 FEPs. Unlike in the previous examples, the best result is achieved
by several of the standard thresholds, clear by the performance ‘plateau’ at an MCC of 0.6850
from the standard threshold 0.97 onwards. The ImPACT threshold of 0.9623 achieves the same
MCC value as the best standard thresholds.
4.3.3.3 Examples of average results
In the previous section, four examples of very successful results were described. Given the
caveats regarding the dataset (see Section 4.3.3.1), it is expected that most results will underes-
timate the performance of ImPACT; this is indeed the case. In this section, three ‘typical’ results
are described.
Approximately 25% of PROSITE benchmarking results are similar to that of FSHB HUMAN.
That is, all standard thresholds and the ImPACT threshold result in a 100% TPR (Figure 4.17(a))
(i.e., all of the residues that should be identiﬁed as conserved are identiﬁed as conserved, or
all PC residues are identiﬁed as IC residues), and the ImPACT threshold yields a near-optimal
MCC score (Figure 4.17(b)). Given that all thresholds return a 100% TPR, all of the PC residues
must be 100% conserved. Further, the FPR is always 30% or greater regardless of the threshold
chosen. This indicates that for all thresholds, at least 30% of !PCs are 100% conserved and,
according to the PROSITE annotations, wrongly identiﬁed by ImPACT as highly conserved.
It is clear from Figure 4.16(a) that there are many residues in FSHB HUMAN that are 100%
conserved and not included as part of a motif in the PROSITE dataset.
The MCC and ROC results for RIR1 HUMAN are conﬂicting: the ImPACT threshold is near-CHAPTER 4. IMPACT 160
(a) RS27 HUMAN alignment, ImPACT threshold is 0.9408
(b) TTHY HUMAN alignment, ImPACT threshold is 0.9544
(c) PA2G5 HUMAN alignment, ImPACT threshold is 0.9623
Figure 4.10: Example annotated alignments analysed by ImPACT: RS27 HUMAN,
TTHY HUMAN, PA2G5 HUMAN
PROSITEandImPACTannotationsareshownbelowtheMSA:PROSITEmotifsareindicatedusingorange, PCresidues
(conserved PROSITE residues, as deﬁned using a leniency of 2) are indicated using red, residues classiﬁed as IC (highly
conserved after application of the ImPACT threshold) are indicated using blue. Amino acid colours as shown in Ap-
pendix [B.i].CHAPTER 4. IMPACT 161
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(a) RS27 HUMAN+28 FEPs, ROC
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(b) RS27 HUMAN+28 FEPs, MCC
Figure 4.11: Benchmarking ImPACT against PROSITE: RS27 HUMAN
The ‘standard’ thresholds (values from 0 to 1, at increments of 0.01) are shown in blue. The ImPACT threshold is shown
as a red asterisk. To give some idea of the composition of the datasets, the numbers of PROSITE-conserved (PC) and
non PROSITE-conserved (!PC) residues are given in the graph titles, along with the total number of residues considered
(i.e., PC+!PC ).CHAPTER 4. IMPACT 162
Figure 4.12: Example annotated alignments analysed by ImPACT TPIS HUMAN
PROSITEandImPACTannotationsareshownbelowtheMSA:PROSITEmotifsareindicatedusingorange, PCresidues
(conserved PROSITE residues, as deﬁned using a leniency of 2) are indicated using red, residues classiﬁed as IC (highly
conserved after application of the ImPACT threshold) are indicated using blue. Amino acid colours as shown in Ap-
pendix [B.i].CHAPTER 4. IMPACT 163
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(a) TPIS HUMAN+318 FEPs, ROC
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(b) TPIS HUMAN+318 FEPs, MCC
Figure 4.13: Benchmarking ImPACT against PROSITE: TPIS HUMAN
The ‘standard’ thresholds (values from 0 to 1, at increments of 0.01) are shown in blue. The ImPACT threshold is shown
as a red asterisk. To give some idea of the composition of the datasets, the numbers of PROSITE-conserved (PC) and
non PROSITE-conserved (!PC) residues are given in the graph titles, along with the total number of residues considered
(i.e., PC+!PC ).CHAPTER 4. IMPACT 164
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(a) TTHY HUMAN+20 FEPs, ROC
MCC for protein TTHY_HUMAN (PC=13, !PC=134, total=147)
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(b) TTHY HUMAN+20 FEPs, MCC
Figure 4.14: Benchmarking ImPACT against PROSITE: TTHY HUMAN
The ‘standard’ thresholds (values from 0 to 1, at increments of 0.01) are shown in blue. The ImPACT threshold is shown
as a red asterisk. To give some idea of the composition of the datasets, the numbers of PROSITE-conserved (PC) and
non PROSITE-conserved (!PC) residues are given in the graph titles, along with the total number of residues considered
(i.e., PC+!PC ).CHAPTER 4. IMPACT 165
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(a) PA2G5 HUMAN+21 FEPs, ROC
MCC for protein PA2G5_HUMAN (PC=8, !PC=130, total=138)
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(b) PA2G5 HUMAN+21 FEPs, MCC
Figure 4.15: Benchmarking ImPACT against PROSITE: PA2G5 HUMAN
The ‘standard’ thresholds (values from 0 to 1, at increments of 0.01) are shown in blue. The ImPACT threshold is shown
as a red asterisk. To give some idea of the composition of the datasets, the numbers of PROSITE-conserved (PC) and
non PROSITE-conserved (!PC) residues are given in the graph titles, along with the total number of residues considered
(i.e., PC+!PC ).CHAPTER 4. IMPACT 166
optimal with respect to the ROC plot (see Figure 4.18(a)), but the MCC results are rather poor
(Figure 4.18(b)). The ImPACT threshold has been set to 0.7639, which yields a much lower
MCC than many of the standard thresholds (performance peaks at 0.94). The alignment for
RIR1 HUMAN and its strict FEPs is shown in Figure 4.16(b). It is clear that many !PC residues
are identiﬁed as IC. It is also clear that there are regions of signiﬁcant insertions, despite all FEPs
sharing the ‘RIR1’ protein preﬁx. This suggests that there is considerable diversity between the
species and perhaps the lower threshold of 0.7639 generated by ImPACT is appropriate.
The ﬁnal typical example is of the analysis of THIL HUMAN. Again, it is evident that approx-
imately 10% of !PC residues in this dataset are 100% conserved, given that the FPR does not
fall below 0.10 (Figure 4.19(a)). Unlike the FSHB HUMAN example discussed above, ImPACT
does not achieve 100% TPR, however it is near-optimally distant from the TPR/FPR line, as
compared with the standard thresholds. Again, however, the MCC is less than optimal (Figure
4.19(b)). Figure 4.16(c) shows that there are many highly conserved residues outwith the motif
regions in the alignment of THIL HUMAN and its 19 FEPs.
4.3.3.4 Examples where sequence conservation fails to identify PROSITE motif residues
For ﬁve proteins (2.16%) in the PROSITE dataset, more than half of the standard thresholds are
found on the ‘wrong-side’ of the TPR/FPR identity line. That is, the FPR is greater than the
TPR. For one protein in the dataset, the general level of conservation is so low that the ﬁrst
criteria (see Section 4.2.2.1) is not met. In this section, these results are discussed.
Human glycyl-tRNA synthetase [UniProtKB:P41250/SYG HUMAN] is assigned 61 strict FEPs;
the MUSCLE alignment of this protein and its FEPs is shown in Figure 4.20(a). The WHEP-
TRS domain signature motif (PS00762) is identiﬁed at positions 74-102 in SYG HUMAN. As
the alignment clearly shows these residues (highlighted in yellow and red) occur in a very
sparse section of the alignment, where only ﬁve (including SYG HUMAN) of the proteins are
represented.
Not only do all these proteins share their protein preﬁx ‘SYG’ with the human protein, but they
all (but one) share the same four synonyms:
 Glycyl-tRNA synthetaseCHAPTER 4. IMPACT 167
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Figure 4.17: Benchmarking ImPACT against PROSITE: FSHB HUMAN
The ‘standard’ thresholds (values from 0 to 1, at increments of 0.01) are shown in blue. The ImPACT threshold is shown
as a red asterisk. To give some idea of the composition of the datasets, the numbers of PROSITE-conserved (PC) and
non PROSITE-conserved (!PC) residues are given in the graph titles, along with the total number of residues considered
(i.e., PC+!PC ).CHAPTER 4. IMPACT 169
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(a) RIR1 HUMAN+54 FEPs, ROC
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Figure 4.18: Benchmarking ImPACT against PROSITE: RIR1 HUMAN
The ‘standard’ thresholds (values from 0 to 1, at increments of 0.01) are shown in blue. The ImPACT threshold is shown
as a red asterisk. To give some idea of the composition of the datasets, the numbers of PROSITE-conserved (PC) and
non PROSITE-conserved (!PC) residues are given in the graph titles, along with the total number of residues considered
(i.e., PC+!PC ).CHAPTER 4. IMPACT 170
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(a) THIL HUMAN+19 FEPs, ROC
MCC for protein THIL_HUMAN (PC=16, !PC=411, total=427)
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Figure 4.19: Benchmarking ImPACT against PROSITE: THIL HUMAN
The ‘standard’ thresholds (values from 0 to 1, at increments of 0.01) are shown in blue. The ImPACT threshold is shown
as a red asterisk. To give some idea of the composition of the datasets, the numbers of PROSITE-conserved (PC) and
non PROSITE-conserved (!PC) residues are given in the graph titles, along with the total number of residues considered
(i.e., PC+!PC ).CHAPTER 4. IMPACT 171
 Glycine–tRNA ligase
 GlyRS
 EC 6.1.1.14
The one exception is SYG YEAST, which is annotated with the synonyms:
 Glycyl-tRNA synthetase 1
 Glycine–tRNA ligase 1
 GlyRS 1
 GlyRS1
 EC 6.1.1.14
Given these annotations, this set of proteins appears to be functionally coherent; the annota-
tions do not suggest that the alignment is inappropriate. Rather, the motif is only found in a
speciﬁcsubsetofproteinsandthissubfunctionalityisnotreﬂectedintheUniProtKB/Swiss-Prot
annotations.
Some species have gained (or lost) the WHEP-TRS domain without affecting the overall func-
tion of the protein, suggesting that the presence (or absence) of the motif has little impact on
functionality. On closer inspection, it appears that the WHEP-TRS domain is a eukaryotic em-
bellishment: only the eukaryotic species—Homo sapiens, Mus musculus, Bombyx mori, Pongo pyg-
maeus and Caenorhabditis elegans—contain the domain, with Saccharomyces cerevisiae being the
only eukaryotic exception. Indeed, the WHEP-TRS domain has been shown to exist in sev-
eral higher eukaryotic aminoacyl-transfer RNA synthetases and that the same functionality in
Prokaryotes is encoded by distinct genes (Cerini et al., 1991), explaining the absence of the do-
main in the non-eukaryotic species.
TheﬁttedmixturemodelforRNC HUMAN(ribonucleaseIII)andits219strictFEPsviolatesthe
ﬁrst constraint of the ImPACT analysis, suggesting that the minimal model of conservation as
deﬁned in Section 4.2.2.1 does not exist in the alignment. Figure 4.20(b) shows the entire align-
ment for RNC HUMAN and its 219 strict FEPs. It is immediately apparent that this alignment
is very sparse: a small number of ribonuclease III proteins (including RNC HUMAN) haveCHAPTER 4. IMPACT 172
acquired extensive insertions. The paucity of amino acid representation in these regions will
result in many very low scoring columns that will dominate the distribution of conservation
scores, forcing the mixture modelling to be biased towards accounting for the low conservation
scores.
Figure 4.22 shows a column-wise subsection of the full RNC HUMAN alignment. Two ribonu-
clease III family signatures (PROSITE family PS00517) are identiﬁed in RNC HUMAN, at po-
sitions 966-974 and 1144-1152; of these positions, 969, 971, 972 and 973 in the ﬁrst occurence of
the motif are PC, and 1147, 1149, 1150 and 1151 in the second occurence of the motif are PC. The
ﬁrst set of PC residues is very well-conserved across all FEPs, with specsim corrected conser-
vation scores of 1.00, 0.96, 1.00 and 1.00 (to 2dp) respectively. However the second occurence
of the motif is present only in the human protein, and as such the conservation scores for these
values are very low (0.40 to 2dp).
All 219 FEPs share the following synonyms:
 Ribonuclease 3
 Ribonuclease III
 RNase III
 EC 3.1.26.3
Further, all but one share the “RNC” protein preﬁx, the only exception being RNT1 YEAST. As
in the SYG HUMAN results, the proteins aligned here are clearly all ribonuclease III proteins.
Ribonuclease III is expressed in most eukaryotic and prokaryotic cells (Wu et al., 2000; Con-
rad and Rauhut, 2002) and therefore, although the function of the protein has been maintained
throughout evolution, it is likely that signiﬁcant changes have occurred between species. Fig-
ure 4.20(b) shows that this is indeed the case, with large inserts in several proteins between
smaller, reasonably well conserved regions.
Unlike SYG HUMAN however, the vast majority of the proteins in the alignment do contain
the PROSITE motif. Therefore, it is not the case that the UniProtKB/Swiss-Prot annotations fail
to represent some subfunctionality within the ribonuclease III proteins, at least not at the level
of this particular PROSITE motif. More disruptive to the successful performance of ImPACT inCHAPTER 4. IMPACT 173
this case are the extensive insertion regions evident in the alignment and, with respect to the
PROSITE benchmarking, the acquisition of a second ribonuclease III family signature only in
the human protein.
The strict FEPs used to create the alignment are all prokaryotic or archaeal, excepting Homo
Sapiens, two worm species (Caenorhabditis briggsae and Caenorhabditis elegans) and two yeast
species (Schizosaccharomyces pombe and Saccharomyces cerevisiae). Figure 4.21 (taken and modi-
ﬁed from Conrad and Rauhut (2002)) shows the domain structure of ribonuclease III proteins
across different species and demonstrates that there have indeed been several extensive embel-
lishments in eukaryotic species. Even within the eukaryotic domain, signiﬁcant additions have
been aquired (compare the structure of the yeast species, S. pombe and S. cerevisiae in Figure
4.21, with that of the human species, H. sapiens in Figure 4.21). If other eukaryotic species closer
to Homo sapiens were to be included in the alignment, the second occurrence of the PS00517
PROSITE motif might be represented.
In addition, as seen previously for SYG HUMAN, the extensive insertion regions will result in
a distribution of conservation scores saturated with very low values, which will dominate the
mixture model optimisation, and limit the extent to which ImPACT can accurately model the
distribution.
4.3.3.5 The representative proteins in PROSITE
Three of the four proteins discussed in Section 4.3.2 contain PROSITE motifs: G6PD HUMAN,
P53 HUMAN and OTC HUMAN. Their alignments are shown in Figures 4.23(a), 4.23(b) and
4.23(c) respectively. In contrast to the alignments shown in Figures 4.16 and 4.20, a higher pro-
portion of the motif residues (those highlighted in yellow or red in Figure 4.23) are classiﬁed as
PC (those coloured in red in Figure 4.23). That is, the motifs are more strict than seen previously.
The results for G6PD HUMAN (Figures 4.23(a), 4.24(a), 4.24(b)) and P53 HUMAN (Figures
4.23(b), 4.25(a), 4.25(b)) are similar to those of FSHB HUMAN described in Section 4.3.3.3. That
is, 100% TPR rate is achieved by all thresholds, indicating that all PC residues are 100% con-
served, and the FPR is never 0%, indicating that there are !PC residues that are 100% conserved.
The MCC values for G6PD HUMAN and P53 HUMAN approach optimal performance.CHAPTER 4. IMPACT 174
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Figure 4.21: Domain structures of eukaryotic and prokaryotic ribonuclease IIIs
Asterisks indicate sequence signatures. (1) N-terminal extension in eukaryotic ribonuclease IIIs (except yeasts); (2/3)
duplicated bacterial N-terminus; (4) double strand RNA-binding domain. P, S and SR indicate proline, serine and
serine-arginine rich regions respectively. Figure taken and adapted from Conrad and Rauhut (2002), ﬁgure 1.
The variation in TPR in Figure 4.26(a) demonstrates that there are some PC residues that are not
100% conserved in OTC HUMAN. However, ImPACT still achieves 100% TPR with a compara-
tively low threshold of 0.8672 and is close to optimal performance with respect to the FPR. Like
the previous results for G6PD HUMAN and P53 HUMAN, ImPACT approaches the maximal
MCC. Here however, it is signiﬁcant that ImPACT does not apply too rigourous a threshold for
the patterns of conservation in the OTC HUMAN alignment. If the ImPACT threshold gener-
ated for the P53 HUMAN alignment (0.9636) were applied to the OTC HUMAN data, the TPR
would drop signiﬁcantly from 100% to 66.67%.
4.3.4 Using artiﬁcial alignments to assess ImPACT
As discussed in Section 4.3, no gold standard dataset exists against which ImPACT can be
benchmarked. Thus far, ImPACT has been evaluated by considering four representative pro-
teins (OTC, G6PD, P53 and haemoglobin (HBB)) and by using PROSITE data. To evaluate
ImPACT further, a battery of artiﬁcial alignment data have been generated. Three Gaussian
components—being assumed to underlie the real data—have been used to generate artiﬁcial
distributions of conservation scores that might be derived from protein MSAs. By varying theCHAPTER 4. IMPACT 176
Figure 4.22: A subsection of the RNC HUMAN alignment
PROSITEandImPACTannotationsareshownbelowtheMSA:PROSITEmotifsareindicatedusingorange, PCresidues
(conserved PROSITE residues, as deﬁned using a leniency of 2) are indicated using red, residues classiﬁed as IC (highly
conserved after application of the ImPACT threshold) are indicated using blue. Amino acid colours as shown in Ap-
pendix [B.i].CHAPTER 4. IMPACT 177
(a) G6PD HUMAN alignment, ImPACT threshold is 0.9612
(b) P53 HUMAN alignment, ImPACT threshold is 0.9636
(c) OTC HUMAN alignment, ImPACT threshold is 0.8672
Figure 4.23: Example annotated alignments analysed by ImPACT, three representative proteins:
G6PD HUMAN, P53 HUMAN and OTC HUMAN
PROSITEandImPACTannotationsareshownbelowtheMSA:PROSITEmotifsareindicatedusingorange, PCresidues
(conserved PROSITE residues, as deﬁned using a leniency of 2) are indicated using red, residues classiﬁed as IC (highly
conserved after application of the ImPACT threshold) are indicated using blue. Amino acid colours as shown in Ap-
pendix [B.i].CHAPTER 4. IMPACT 178
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(a) G6PD HUMAN+48 FEPs, ROC
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Figure 4.24: Benchmarking ImPACT against PROSITE: G6PD HUMAN
The ‘standard’ thresholds (values from 0 to 1, at increments of 0.01) are shown in blue. The ImPACT threshold is shown
as a red asterisk. To give some idea of the composition of the datasets, the numbers of PROSITE-conserved (PC) and
non PROSITE-conserved (!PC) residues are given in the graph titles, along with the total number of residues considered
(i.e., PC+!PC ).CHAPTER 4. IMPACT 179
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ROC for protein P53_HUMAN (PC=13, !PC=380, total=393)
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(a) P53 HUMAN+30 FEPs, ROC
MCC for protein P53_HUMAN (PC=13, !PC=380, total=393)
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Figure 4.25: Benchmarking ImPACT against PROSITE: P53 HUMAN
The ‘standard’ thresholds (values from 0 to 1, at increments of 0.01) are shown in blue. The ImPACT threshold is shown
as a red asterisk. To give some idea of the composition of the datasets, the numbers of PROSITE-conserved (PC) and
non PROSITE-conserved (!PC) residues are given in the graph titles, along with the total number of residues considered
(i.e., PC+!PC ).CHAPTER 4. IMPACT 180
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(a) OTC HUMAN+176 FEPs, ROC
MCC for protein OTC_HUMAN (PC=6, !PC=348, total=354)
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Figure 4.26: Benchmarking ImPACT against PROSITE: OTC HUMAN
The ‘standard’ thresholds (values from 0 to 1, at increments of 0.01) are shown in blue. The ImPACT threshold is shown
as a red asterisk. To give some idea of the composition of the datasets, the numbers of PROSITE-conserved (PC) and
non PROSITE-conserved (!PC) residues are given in the graph titles, along with the total number of residues considered
(i.e., PC+!PC ).CHAPTER 4. IMPACT 181
Table 4.11: The densities of three Gaussian components for OTC, G6PD, P53 and HBB
Protein: the protein to which the mixture model has been ﬁtted (‘Chosen values’ indicates which values were chosen to
generate the artiﬁcial alignments); G0, G1, G2: the names of the Gaussian components (see Section 4.2.2). The ‘density’
of a component describes how much of the data the component accounts for, or models.
Protein G0 G1 G2
OTC 27.24 51.33 21.43
G6PD 52.58 45.41 2.10
P53 50.65 30.92 18.43
HBB 44.31 23.46 32.23
Chosen values 45.00 45.00 10.00
parameters of the data-generating Gaussians (called D0, D1 and D2 to correspond with the G0,
G1 and G2 components used to model the data, see Section 4.2.2), the distribution of conserva-
tion scores can be ﬁnely controlled.
When generating the artiﬁcial data, it is possible to vary the mean, standard deviation and rel-
ative densities of the three Gaussian components (the density of a component describes how
much of the data the component accounts for, or models). To ensure that the randomly gen-
erated data are representative of real conservation data, the ﬁtted mixture models for the four
representative proteins described in Section 4.3.2 were considered. The densities for the three
ﬁtted Gaussian components for OTC, G6PD, P53 and HBB are shown in Table 4.11. Using the
average of these values as a starting point, and taking into account the known conservation
patterns of the proteins, the relative densities of G0, G1 and G2 for the artiﬁcial alignments
were chosen as 45%, 45% and 10% (as shown in the ﬁnal line of Table 4.11). Experience of
many MSA-ﬁtted mixture models was used to determine the placement and spread of these
components as f = 0:40; = 0:10; = 0:65; = 0:10; = 0:95; = 0:025g for G0, G1 and G2
respectively.
4.3.4.1 Fitting increasingly homogeneous Gaussian components
The ﬁrst set of artiﬁcial alignments has been devised simply to demonstrate the mixture mod-
elling process; no ImPACT analysis has been carried out. Here, the three underlying Gaussian
components that generate the data become increasingly homogenous from example (1.1) to ex-
ample (1.4) (see Figure 4.27). However, it is clear throughout the examples that the mixtureCHAPTER 4. IMPACT 182
Table 4.12: The test sets of artiﬁcially generated conservation data
Set: the name of the test set; D0, D1, D2: the names of the Gaussians used to generate the data (the unconserved,
moderately conserved and highly conserved respectively). Values that are varied within an example set are italicised.
Set D0 D1 D2
1.1 0.35 0.65 0.95
1.2 0.40 0.65 0.90
1.3 0.45 0.65 0.85
1.4 0.50 0.65 0.80
2.1 0.40 0.65 0.70
2.2 0.40 0.65 0.80
2.3 0.40 0.65 0.90
2.4 0.40 0.65 0.95
3.1 0.40 0.90 0.95
3.2 0.40 0.85 0.95
3.3 0.40 0.80 0.95
3.4 0.40 0.70 0.95
model ﬁtting process accurately models the data: the peaks of the ﬁtted Gaussians correspond
closely with the means of the underlying Gaussians (compare with the non-logit transformed
axis across the top of the plots in Figure 4.27).
4.3.4.2 Generating thresholds as D2 increases
This second set of artiﬁcial conservation score data keeps the parameters D0 and D1 constant,
while increasing the mean of D2 from 0.7 to 0.95. This will speciﬁcially test the second con-
straint as the distance between the D1 and D2 will increase. It is expected that as D2   D1
increases—that is, as the distance between D2   D1 increases—the threshold will increase.
This is appropriate because, as D2  D1 increases, the highly conserved residues will become
distinct from that of the moderately conserved residues and the global patterns of conservation
will rise.
In examples (2.1) and (2.2), where D2 is placed at 0.7 and 0.8 respectively, the ﬁrst constraint is
violated; i.e., the mean of D2 does does not exceed 0.80. However, as the mean of D2 increases
to 0.9 and 0.95 in examples (2.3) and (2.4), constraint one is met and ImPACT thresholds of
0.7951 and 0.8405 are calculated. It appears that ImPACT is generating appropriate thresholds.CHAPTER 4. IMPACT 183
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Figure 4.27: Assessing ImPACT using artiﬁcially generated data: ﬁtting a mixture model
Parameters for the three underlying Gaussian components of test tests (1.1)-(1.4) are shown in Table 4.12. Distribution
of logit transformed raw data is shown in black, the three ﬁtted Gaussians are shown in blue and the cumulative
model is shown in magenta. In this set of examples, no threshold has been generated. In addition to the ﬁtted Gaussian
components, to aid comparison of each protein’s global conservation trends, a depiction of conservation trends for each
protein’s MSA is shown to the right of the graph, where high conservation scores are shown in red, more moderate
scores are shown in blue and low scores are shown in green.CHAPTER 4. IMPACT 184
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Figure 4.28: Assessing ImPACT using artiﬁcially generated data: increasing D2
Parameters for the three underlying Gaussian components of test tests (2.1)-(2.4) are shown in Table 4.12. Distribution
of logit transformed raw data is shown in black, the three ﬁtted Gaussians are shown in blue and the cumulative model
is shown in magenta. The values for the ﬁrst and second constraints (see Section 4.2.2) are depicted as vertical orange
and red lines respectively. The resulting threshold is given in the grey box in the top-left corner of the graph. In
addition to the ﬁtted Gaussian components, to aid comparison of each protein’s global conservation trends, a depiction
of conservation trends for each protein’s MSA is shown to the right of the graph, where high conservation scores are
shown in red, more moderate scores are shown in blue and low scores are shown in green.CHAPTER 4. IMPACT 185
4.3.4.3 Generating thresholds as D1 decreases
This set of artiﬁcial data is analogous to that of the second set in that the distance between
D1 and D2 is being varied. Here, however, the placement of D1 is being varied rather than
the placement of D2. Therefore, unlike in the previous set of examples, the ﬁrst constraint
should always be met; indeed, as Figure 4.29 shows, this is the case. As the distance between
the two underlying Gaussians increases, it is expected that the ImPACT threshold generated
will decrease to reﬂect the ease with which D1 and D2 can be distinguished and to reﬂect the
reduction of global conservation patterns.
As shown in Figure 4.29, as G1 decreases from 0.9 to 0.7 and D2  D1 increases, the ImPACT
threshold generated decreases appropriately.CHAPTER 4. IMPACT 186
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Figure 4.29: Assessing ImPACT using artiﬁcially generated data: decreasing D1
Parameters for the three underlying Gaussian components of test tests (3.1)-(3.4) are shown in Table 4.12. Distribution
of logit transformed raw data is shown in black, the three ﬁtted Gaussians are shown in blue and the cumulative model
is shown in magenta. The values for the ﬁrst and second constraints (see Section 4.2.2) are depicted as vertical orange
and red lines respectively. The resulting threshold is given in the grey box in the top-left corner of the graph. In
addition to the ﬁtted Gaussian components, to aid comparison of each protein’s global conservation trends, a depiction
of conservation trends for each protein’s MSA is shown to the right of the graph, where high conservation scores are
shown in red, more moderate scores are shown in blue and low scores are shown in green.CHAPTER 4. IMPACT 187
4.4 Conclusions
SAAPdb is primarily concerned with structural analysis of single amino acid polymorphisms,
with a view to explaining deleterious phenotypes. However, where structural information is
not available or not informative, functional relevance can be inferred from sequence conserva-
tion in multiple sequence alignments (MSAs). MSAs are products of the protein characteristics,
the species set represented and genuine functional traces. In this chapter, a method (ImPACT)
for isolating the genuine functional data to deﬁne high conservation within an MSA and its
multi-faceted evaluation have been described.
Given difﬁculties in evaluation of conservation scoring methods, two qualitative evaluations
of ImPACT were carried out. The ﬁrst considered four ‘representative’ proteins (P53, G6PD,
OTC and haemoglobin) and the second considered artiﬁcial conservation data. Both qualita-
tive analyses demonstrated that ImPACT is successful in selecting appropriate thresholds for
high conservation. A third more quantitative evaluation of ImPACT used PROSITE motifs to
deﬁne which residues, in an alignment of functionally equivalent proteins (FEPs, see Chapter
3), should be classiﬁed as highly conserved by the ImPACT threshold.
A concern over the deﬁnition of a negative example (i.e., those residues that should not be con-
sidered as highly conserved) limits the extent to which the PROSITE benchmarking may be
considered a fair evaluation of ImPACT. PROSITE records sequence motifs, but other residues
may also be conserved for structural (e.g., hydrogen-bonding) or functional (e.g., ligand bind-
ing) reasons. The observation that the analysis of many (approximately 25%) PROSITE proteins
generated a positive, non-zero FPR for all thresholds indicates that it is indeed common for a
residue not identiﬁed in a PROSITE motif to be 100% conserved.
Given the concerns regarding negative examples, the most accurate measure with which Im-
PACT can be evaluated using these data is the TPR (see Section 2.3.5). A TPR of 100% is
achieved in 99/231 (42.86%) of the proteins in the PROSITE dataset using the ImPACT thresh-
old. As maintained throughout this chapter (and, indeed, throughout this thesis), the aim is
to be conservative in the predictions that are made. For example, the ﬁrst constraint is set rea-
sonably high (0.80) and a strict leniency of 2 is set for the extraction of conserved residues in
PROSITE motifs, which, as a result of limiting over-prediction (i.e., limiting the number of FPs),
will increase under-predicting (i.e., increasing the number of FNs). This conservative approachCHAPTER 4. IMPACT 188
will, at least in part, explain why a 100% TPR is not found more often in the PROSITE datset.
Despite concerns with regards to the deﬁnition of negative examples, good performance with
respect to MCC and ROC plots was observed in many cases, with ImPACT often approaching
optimal performance. Most informative, however, is the close consideration of cases where se-
quence conservation data fails to identify PROSITE motif residues. For example, the alignment
of RNC HUMAN and its corresponding (strict) FEPs have large insertions (Figure 4.20(b)), but
the proteins are clearly functionally equivalent given their UniProtKB/Swiss-Prot annotations.
It is apparent that where genuinely functionally equivalent, but evolutionarily distant proteins,
are aligned, extensive inserts could dominate the distribution of conservation scores, in that
many columns will have very low conservation scores. A valuable addition to ImPACT would
be to consider only the conservation scores of columns that are adequately represented in all
proteins in the alignment (for example, SIFT (Ng and Henikoff, 2001) limits predictions to those
columns with at least 50% MSA coverage).
ImPACT performance may improve if the set of PROSITE motifs were reﬁned. PROSITE se-
quence motifs can be both functional (e.g., an N-linked glycosolation site) and indicative of ho-
mologous protein families (e.g., an apple domain). It may be more appropriate to benchmark
ImPACT against only those family motifs described by PROSITE, as the functional motifs may
only apply to the single protein. However, it is not straightforward to identify which PROSITE
motifs are functional and which describe protein families. A more straightfoward approach
would be to constrain the dataset to those residues within PROSITE motifs, with the negative
examples being those that do not make the leniency threshold, for example, those residues in
Figures 4.9(a)-4.9(b) that are not marked with an asterisk.
In summary, three-component Gaussian mixture modelling is sensitive to small but signiﬁcant
changes in the distribution of conservation scores and is able to model the changes accord-
ingly. The ImPACT threshold generation method provides appropriate thresholds as patterns
of global conservation vary, as observed in the artiﬁcial alignment dataset. Where some belief
is held as to what the threshold for high conservation should be, as in the case of the four rep-
resentative proteins, the ImPACT threshold is consistent with expectations. By analysing the
performance of ImPACT using sequence motif data, while being aware of caveats regarding the
dataset, it is evident that ImPACT often approaches near optimal performance, when compared
with static thresholds.Chapter 5
SAAPdb: The analysis pipeline
SAAPdb is a database of disease-causing and neutral mutations, which have been analysed
to assess what effect, if any, they may have on protein structure and therefore function. The
hypothesis is that disease mutations will more often affect protein structure, thus introducing a
deleterious phenotype. SAAPdb attempts to identify the structural effect and therefore explain
the mutation1. The development of a conservative, comprehensive structural analysis pipeline
with which to analyse SAAPs is one of the main aims of the SAAPdb project. In this chapter,
the suite of analyses with which SAAPdb assesses each mutation is described.
5.1 Introduction
The SAAPdb structural analysis pipeline aims to identify whether a mutation will affect the
native protein structure. Therefore, motivating the choice of structural analyses to include in
the pipeline are the known fundamentals of protein structure: hydrogen bonding, interactions
with ligands, characteristics of the protein core and so on (see Section 1.5 for an introduction to
protein structure).
Currently, the pipeline consists of ﬁfteen structural analysies, of which eight have been devel-
oped as part of this thesis. A ninth novel sequence-based analysis (ImPACT) was described in
1As stated in Chapter 1, the term ‘explain’ or ‘explanation’ is used to refer to predicted structural effects even for
neutral mutations where there is no phenotypic effect to be explained
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(a) Rotating the mutant residue (shown in magenta) about 1 in 30 increments
(b) Rotating the mutant residue (shown in magenta) about 2 in 30 increments
Figure 5.1: Using mutmodel to model a mutant residue into an existing structure: rotation
about the  angles.
Chapter 4. The pipeline is implemented in python as a series of ‘wrappers’, allowing informa-
tion to be passed to each analysis by the main driver program. The analyses themselves are
implemented in various languages, including C, Perl and SQL queries and functions.
This chapter will ﬁrst describe the method by which mutant structures are generated where
necessary (Section 5.2) and then describe the seven analyses that were developed previously
for SAAPdb in Andrew Martin’s group (Section 5.3). It will then describe the implementation
and incorporation of the nine new analyses that have been developed (Sections 5.4-5.12).
Some of the work presented in this chapter has been published elsewhere (Martin et al., 2002;
Kwok et al., 2002; Cuff and Martin, 2004; Cuff et al., 2006; Hurst et al., 2009).
5.2 Generating mutant structures
For two of the analyses described in this chapter—the void and clash analyses—it is necessary
to generate a mutant structure. A minimum pertubation protocol (MPP) (Shih et al., 1985; SnowCHAPTER 5. SAAPDB: THE ANALYSIS PIPELINE 191
and Amzel, 1986) has been used to model the mutant residue into the native structure.
The method is as follows:
(I) Use maximum overlap protocol (MOP) (Snow and Amzel, 1986) to replace the sidechain,
inheriting torsion angles from the native residue where possible
(II) Identify neighbouring residues within 8 ˚ A of the residue
(III) Rotate the sidechain around 1 (Figure 5.1(a)) and 2 (Figure 5.1(b)) and record whether
a bad contact is made or not (a bad contact is deﬁned as two atom centres within 2.50 ˚ A of
each other)
(IV) If the MOP conformation makes  1 bad contacts the conformation is accepted; otherwise
a choice is made from the set of conformations generated in step III
(V) If no rotamer exists that makes  1 bad contacts, the one with the least number of bad
contacts is chosen
With a view to being conservative in ‘explaining’ mutations, sidechain replacements that clash
with two or fewer other residues are considered acceptable. As described above, a clash is
deﬁned as two atom centres that are within 2.50 ˚ A of each other.
5.3 Existing analyses
The analyses described in this section have been previously published in Martin et al. (2002),
Cuff and Martin (2004) and Cuff et al. (2006). They have been used elsewhere to explain disease
mutations in disease-speciﬁc example datasets, including P53 (Martin et al., 2002) and G6PD
(Kwok et al., 2002). They will be described brieﬂy in this section, together with information
about how they are integrated into the analysis pipeline.CHAPTER 5. SAAPDB: THE ANALYSIS PIPELINE 192
5.3.1 Disrupting native hydrogen bonding
Hydrogen bonding is critical to maintaining the native protein fold. Using a grid-based ap-
proach, Cuff et al. (2006) analysed the occurrence and geometry of hydrogen bonds in the PDB
for each hydrogen bonding donor and acceptor residue pair. Hypothetical mutant structures
can then be compared with the observed hydrogen bonding residue proﬁles to assess whether
a hydrogen bond is possible or not using the program checkhbond, which is available for use
over the web at http://www.bioinf.org.uk/.
Each mutation must be analysed by checkhbond, but the algorithm is designed to be fast and
each mutant structure does not need to be modelled: only the native structure is required by
checkhbond. The ‘pseudo-energy’ score generated by checkhbond is extracted and stored in
the SAAPdb database. The pseudo-energy score uses data on the likelihood that a hydrogen
bond exists between two given residues for a given geometry and approximates the energy
for the interaction, where a score of 0 implies that it is very unlikely that a hydrogen bond is
formed. At present this processing is done sequentially on one machine although it is suitable
for distributed processing.
Mutations that break hydrogen bonds (i.e., those with a pseudo-energy score of 0) are identiﬁed
between backbone/sidechain and sidechain/sidechain donor and acceptor atoms.
5.3.2 Mutations at the interface
Residues at the interface between PDB chains, or between chains and ligands, will be critical in
forming the biologically relevant multimer. Mutating such residues may disrupt native struc-
ture and may be deleterious. Interface residues are identiﬁed by a > 10% ASA (accessible
surface area) in the monomer state as compared with the multimer state. ASA is calculated us-
ing a local implementation of the Lee and Richards algorithm (Lee and Richards, 1971). These
data are obtained from XMAS ﬁles, an existing local resource of XML/ASN.1-like formatted
PDB ﬁles (see Section 2.2.3).CHAPTER 5. SAAPDB: THE ANALYSIS PIPELINE 193
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Figure 5.2: Allowed regions for proline and glycine
The pink areas mark the restricted comformation for proline residues, the hatched grey area marks the regions for
non-proline, non-glycine residues, and the pale yellow colour marks the rest of the conformational space, primarily
occupied by glycine residues.
5.3.3 Mutations to binding residues
Many PDB structures describe proteins in complex with ligands and other proteins; mutations
to protein-ligand or protein-protein binding residues will hinder native protein function. Mu-
tations to residues that form hydrogen bonds, as described by Baker and Hubbard (1984), and
‘non-bonds’ are identiﬁed by parsing the XMAS formatted PDB ﬁles (see Section 2.2.3). Non-
bonds are formed between non-consecutive, inter-residue atoms that do not meet the criteria
of Baker and Hubbard (1984) and whose centres are within 2.7-3.35 ˚ A of each other; this will
include Van der Waals contacts and electrostatic interactions. Residues meeting these criteria
will be a subset of the interface residues described in Section 5.3.2.CHAPTER 5. SAAPDB: THE ANALYSIS PIPELINE 194
5.3.4 Mutations to proline
The cyclic nature of the proline sidechain limits the conformations which the residue can adopt.
It is therefore likely that introducing a proline where the torsion angles are unfavourable will
distort the protein structure or inhibit folding entirely. X!P mutations are identiﬁed outwith
the region:  70     50 and ( 70      50 or 110     130). In Figure 5.2, this
area is marked in pink.
5.3.5 Mutations from glycine
Glycine has no sidechain and so can adopt backbone conformations that other amino acids can-
not. Replacing a glycine with another amino acid, where the torsion angles are unfavourable,
will affect protein structure. G!X mutations that occur outwith the region ( 180     30,
60      180) or ( 155     15,  90     60) or ( 180     45,
 180      120) or (30    90,  20     105) are identiﬁed. In Figure 5.2,
this area is coloured yellow.
5.3.6 Mutations that cause steric clashes
It may not be possible to accommodate a larger mutant residue in the native structure with-
out disrupting the fold, and therefore the function. MutModel calculates the number of steric
clashes caused by introducing a mutant residue in a protein structure (Section 5.2). Mutations
that can be modelled into the native structure without clashing with three or more other atoms
are identiﬁed. As discussed in Section 5.2, two residues clash if any atom centres are within
2.50 ˚ A of each other.
5.3.7 Introducing a void in the core
Where the previous section considered small to large residue mutations, here, large to small
residue mutations are considered. Replacing a large amino acid with a smaller one could affect
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or crevice with a protein structure that is not accessible to bulk solvent. The software AVP is
used to identify and measure the size of internal voids in protein structures (Cuff and Martin,
2004). AVP allows independent probe sizes for deﬁnition of solvent and voids with probe radii
of 1.4 ˚ A and 0.5 ˚ A respectively being used.
Obtaining these data requires signiﬁcant preprocessing: all mutant structures must be gener-
ated using MutModel (see Section 5.2) before AVP is run on each individual structure. The
compute time for each structure is dependent on the size of the protein chain being analysed,
and can vary from a few seconds to several minutes.
5.4 Improving the analysis of disruption of quaternary struc-
ture
5.4.1 Background
The assembly of multiple tertiary protein structures into biologically relevant multimers is de-
scribed as the quaternary structure (see Section 1.5). Residues at the quaternary interface will be
critical to the native protein fold. The ‘interface’ and ‘binding’ analyses (Sections 5.3.2 and 5.3.3
respectively) attempt to identify mutations at the quaternary interface. However, this analysis
is based on crystallographic unit cells from PDB ﬁles. These can have artiﬁcial crystal contacts
or missing biologically relevant contacts (Janin, 1997).
The Protein Quaternary Structure (PQS) database describes hypothetical quaternary structures
for PDB structures (Henrick and Thornton, 1998). All interatomic contacts 3.7 ˚ A for all space-
group symmetry operations of the unit cell are calculated. Potential quaternary structures are
assembled by the addition of monomeric chains; chains are selected based on the number of
interchain contacts and the number of residues in the chain. Figure 5.3(b) shows the com-
plete hypothetical quaternary structure of the Human poliovirus capsid protein 2plv with the
original PDB structure shown in Figure 5.3(a). Although some of the binding contacts will be
recognised by the binding and interface analyses, many will be lost (compare Figures 5.3(a) and
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(a) The PDB structure of Human poliovirus capsid protein
(b) The hypothetical PQS assembly of Human poliovirus
capsid proteins
Figure 5.3: Quaternary structure information from PQS
Figure 5.3(a) shows the PDB representation (2plv) of the Human poliovirus capsid protein which has four chains. The
biologically relevant structure, as assembled by PQS is shown in Figure 5.3(b) (2plv.mmol).CHAPTER 5. SAAPDB: THE ANALYSIS PIPELINE 197
Further to identifying residues at the quaternary interface, the PQS database removes non-
biological interactions that arise from the crystallisation process. The structure of the homo-
dimer quinone reductase (PDB record 1qrd) is shown in Figure 5.4(a); the interface between the
two chains is minimal. A more plausible homo-dimer is calculated by PQS and is shown in Fig-
ure 5.4(b) (in fact, PQS provides two similar alternative assemblies: 1qrd 1.mmol (shown below)
and 1qrd 2.mmol). Several factors (ASA, interface size, interchain crosslinks and change in
solvation energy) contribute to the discrimination between true macromolecular contacts and
crystal packing artefacts. The analysis of PQS structures has been used elsewhere to identify
biologically relevant contacts (Salama et al., 2001).
Interchain contacts derived from the analysis of PQS structures are more likely to be genuine,
biologically relevant interactions than those derived from an analysis of PDB structures.
5.4.2 Incorporating PQS information into the pipeline
The PQS database is mirrored locally. For each mutation identiﬁed in a structure, all corre-
sponding PQS ﬁles are identiﬁed (for example, for PDB record 1qki, there are two correspond-
ing PQS ﬁles: 1qki 1.mmol and 1qki 2.mmol). Each PQS ﬁle containing the relevant chain is
retained for analysis.
PQS ﬁles are generated from PDB structures and maintain the PDB numbering. It is therefore
straightforward to map PDB residues to PQS residues. To identify interface residues in the PQS
structure, the following method was used:
(I) For each PQS record:
(a) Strip the waters from the structure
(b) Convert the PDB-formatted PQS data into XMAS format (see Section 2.2.3)
(c) Parse the generated XMAS ﬁle to identify residues with > 10% increase in relative
accessibility as a monomer as compared with the multimer structure
This process is identical to that of the interface analysis described in Section 5.3.2, but PQS
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(a) PDB structure (1qrd)
(b) Suggested PSQ structure: 1qrd 1.mmol
Figure 5.4: Artiﬁcial X-ray contacts in PDB unit cells
PDB describes quinone reductase as a homo-dimer in the PDB structure 1qrd (Figure 5.4(a)). A more plausible homo-
dimer is calculated by PQS (1qrd 1.mmol) and is shown above in Figure 5.4(b).CHAPTER 5. SAAPDB: THE ANALYSIS PIPELINE 199
As each PQS structure can be processed independently, these analyses were distributed across
the local 20-core grid. A Perl script was written to analyse the PQS data and to distribute it
cleanly across the grid using the Sun GridEngine.
388 452 PQS interface residues were identiﬁed in 7 487 PDB chains.
5.5 Mutations to binding residues (MMDBBIND)
5.5.1 Background
MMDBBIND (Salama et al., 2001) is an assimilation of the three-dimensional structure informa-
tion described by Entrez’s MMDB database (Wang et al., 2007b) and the mmCIF PDB chemical
component dictionary2 (Feng et al., 2003), and is part of the larger BIND database (Bader et al.,
2003; Bader et al., 2001). MMDB itself is a reﬁned and extended representation of the PDB: the
data are represented in ASN.1 format; multiple conformations for atoms are removed; all non-
standard or modiﬁed residues are explicitly annotated, and binding and secondary structure
data are explicitly recorded3.
To identify binding residues in MMDB structures, all inter-molecule residue pairs (a) within a
10 ˚ A radius, and (b) with a van der Waals interatomic distance of  0:5 ˚ A are identiﬁed. Redun-
dant interaction records are removed and the PQS database (see Section 5.4) is used to remove
nonbiological interaction artefacts that arise from the crystallography process.
This analysis identiﬁes all small-to-medium range interaction types between proteins, DNA
(excluding complementary DNA interactions, i.e., DNA base pairing), RNA and small
molecules in the PDB. Mutations to residues that form intermolecular contacts are likely to
disrupt native protein function and therefore cause disease. In effect, MMDBBIND provides a
reﬁned version of the ‘binding’ analysis described in Section 5.3.3.
2formerly the HET group dictionary
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>65310|1BOM|383|B|A|809234|809233
xqpqavhTYCGrhLarTLadLCweagvd
gIVdeCClrpcsVdvLLsYC
Figure 5.5: An example of an MMDBBIND record
In the header line, 65310 is the BIND identiﬁer; 1BOM is the PDB ID; 383 is the MMDB ID; B names the ﬁrst sequence
— given on the second line — as chain B of 1BOM; A names the second sequence — given on the third line — as chain
A of 1BOM; 809234 is the GI (Genbank ID) of molecule A and 809233 is the GI of molecule B. GIs are taken from the
MMDB database. Binding residues are highlighted in the sequences, using capital letters.
5.5.2 Incorporating MMDBBIND data into the pipeline
To include the MMDBBIND data in SAAPdb, the content of the MMDBBIND ﬂat ﬁle4 is parsed
for intermolecular contacts involving at least one protein sequence. The annotation in this
ﬁle does not deﬁne binding partners or describe the nature of the bond, it simply annotates a
residue as binding or non-binding.
Figure 5.5 gives an example of an MMDBBIND record. The record consists of a header line
(preceeded by the > symbol) and two annotated sequences. The header describes which chains
in which PDB structure are being annotated and the sequences provide the annotation, where
binding residues are identiﬁed using capital letters. The sequences provided are derived from
the SEQRES records of the PDB ﬁles, which do not necessarily correspond directly with the
sequence derived from the amino acids in the structure. To include MMDBBIND annotations
in the pipeline, the numbering must be resolved with respect to the residues described by the
structure.
First, the method ensures that the sequences described in the MMDBBIND record are identical
to the SEQRES records in the named PDB structure. If this is the case, the numbering is resolved
as follows:
(I) For each record containing at least one protein sequence:
(a) Record seqseqres : the sequence as described by the SEQRES record
(b) Record seqstr : the sequence as described by the ATOM records
(c) Record firstseqres : the number describing the ﬁrst residue in seqseqres
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(d) Record lastseqres : the number describing the last residue in seqseqres
(e) Identify ﬂanking regions (flankpre and flankpost) described in seqseqres, but not in
seqstr
(f) Calculate the offset as:
offset = (numfirst   flankpre)   1
(g) To ensure correct numbering, check whether the numlast is as expected using the
offset value. The value should be:
numfirst + length(seqseqres)   (flankpre + flankpost)   1
If the value of numlast is not as expected, then the sequence of residues given by the ATOM
records is different to that of the SEQRES records (most commonly, residues in ﬂexible loop
structures are missing). Only those MMDBBIND data that satisfy both criteria are recorded, for
structures to which a SAAP has been mapped in SAAPdb. Any interactions described in the
MMDBBIND record are numbered using the offset value as calculated above.
This method does result in more MMDB data being rejected than is necessary and there is deﬁ-
nite scope for improvement using alignments of the SEQRES and ATOM records. One approach
for improving the verifation of this numbering is included in the discussion (Section 5.13).
A set of Perl methods was developed to handle the MMDBBIND data. First, the MMDBBIND
ﬂatﬁle4 is parsed, and all relevant, veriﬁed data are recorded in a second tab-delimited ﬁle. A
second set of methods generate SQL statements for these data and record them in the database.
94 277 interacting residues are identiﬁed in 3 731 PDB chains.
5.6 Disrupting disulphide bonding
5.6.1 Background
Disulphide bonds (see Section 1.5.2) are crosslinks that form between cysteine residues in
polypeptides and stabilise protein structure (Figure 5.6). Mutations to disulphide bonding
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Figure 5.6: A disulphide bond between CYS6 and CYS127 of lysozyme (7lyz), showing SSd,
SSa1 and SSa2
5.6.2 Incorporating disulphide data into the pipeline
APerlscriptwaswrittentoidentifypotentialdisulphidebondingcysteineresiduesinPDBﬁles.
First, all cysteine residues are identiﬁed. Secondly, each pair of cysteine residues is assessed as
to whether it forms a disulphide bond. The residues must satisfy the following criteria (Hazes
and Dijkstra, 1988):
 S1–S2 bond length should be 2.50 ˚ A
 C1–S1–S2 and C2–S2–S1 bond angles should be 104  10%
Standard trigonometry calculations and methods from the Perl Math::Trig module were
used to calculate distances and angles from PDB coordinates.
Each protein structure described in SAAPdb is analysed to identify potential disulphide bond-
ing cysteine residues. Isolated PDB chains are used, as interchain disulphide bonding will be
identiﬁed by the PQS analysis. All candidate sulphur atoms from cysteine residues are ex-
tracted from the PDB ﬁle. All possible pairs of the cysteine-sulphur atoms are considered and
those that meet the criteria described by Hazes and Djikstra (1988) are recorded as disulphide
bond partners.
The computational pre-processing for this analysis is comparatively light: PDB ﬁles are parsed
and simple calculations are carried out to calculate potential bond angles and distances. The
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is processed sequentially. The script analyses the PDB structures, extracts potential disulphide
bonding partners and generates the corresponding SQL to record disulphide bonding cysteine
residues in SAAPdb. Multiple occupancy cysteines are processed as any other cysteine; that is,
the atoms for each alternative conformation are grouped together and each alternative confor-
mation is considered as a disulphide bonding cysteine.
15 963 potential disulphide bonds are identiﬁed in 9 223 PDB structures.
5.7 Mutations to cisprolines
5.7.1 Background
The peptide bond forms a partial double-bond between the carboxylate C and amide N atoms
of amino acids. Energetically, this favours two conformations where the C, O, C, N’, H’, C’
atoms form a planar unit (i.e., those atoms exist in the same plane): the trans conformation
where ! ' 180 (Figure 5.7(a)) and the cis conformation where ! ' 0 (Figure 5.7(b)). The vast
majority of peptide bonds are found in the trans conformation: the proximity of C and C’
makes the cis conformation less stable.
However, peptide bonds between any residue and proline (Xaa-Pro) more readily adopt the
cis conformation than other peptide bonds (Xaa-nonPro). The cis conformation is more than
1000 times less stable than the trans conformation in Xaa-nonPro peptide bonds, while the cis
conformation is only four times less stable than the alternative trans conformation in Xaa-Pro
peptide bonds (Branden and Tooze, 1999). It has been shown that approximately 5-6.5% of Xaa-
Pro bonds are cis, and 0.03-0.05% of Xaa-nonPro are cis (Jabs et al., 1999; Stewart et al., 1990).
Figure 5.7(c) shows a histogram of cispeptide frequency for each amino acid in a representative
set of CATH v3.0.0 HReps (Pearl et al., 2003). Although the Xaa-nonPro peptide bond can adopt
the cis conformation, it is clear that cis peptide bonds are predominantly between a non-proline
and a proline residue.
Thus, a mutation from a cis-proline to another amino acid, forcing an Xaa-nonPro peptide bond
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(a) The cis conformation of the peptide bond (b) The trans conformation of the peptide bond
(c) cis peptide prevalence in CATH v3.0.0 HReps
The raw frequencies of cis-peptide bonds in CATH v3.0.0 HReps was calculated. The Amino acid deﬁnes
the second residue in the peptide-bond. Most cis-peptide bonds are between Xaa-Pro residues.
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5.7.2 Incorporating these data into the pipeline
The ! torsion angle measurements are calculated using the torsions program (Martin, un-
published) and are calculated when populating the structural analysis table (see Section
6.2.7). The analysis can therefore be implemented as a simple SQL query which identiﬁes mu-
tations from proline to non-proline where  90 < ! < 90.
4.40% (6 584/14 9642) of Xaa-Pro and 0.15% (4 342/2 946 025) of Xaa-nonPro peptide bonds
described by SAAPdb adopt the cis-conformation. This is in agreement with existing data
(MacArthur and Thornton, 1991; Weiss et al., 1998).
5.8 Introducing a charge shift in the core
subsectionBackground
Charged residues are often functional in protein structures (Torshin and Harrison, 2001). Argi-
nine and lysine, and histidine to a lesser extent, are positively charged and often form salt
bridges with negatively charged groups, while aspartic acid and glutamic acid are negatively
chargedandabletoformsaltbridgeswithpositivelychargedgroups. Theseaminoacidsalmost
invariably occur as satisﬁed pairs of oppositely charged residues in the protein core (Torshin
and Harrison, 2001). Removing or introducing a charged residue from or into the protein core
may disrupt the fold and cause a deleterious phenotype. Surface charged residues are solvated
and therefore do not need to occur as charge pairs.
It is of course possible for a charged residue on the surface to interact with other molecules and
therefore be critical to protein function. However, these residues should be identiﬁed by the
PQS, binding and/or MMDBBIND analysis which are described elsewhere (Sections 5.4, 5.3.3
and 5.5 respectively). Here, the focus is speciﬁcally on the effects of removing charge in the
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Table 5.1: Charge shift values for mutations between charged and neutral residues
Mutations between residues that are identically charged do not generate a charge shift, mutations between oppositely
charged residues generate a charge shift of 2, mutations between charged and neutral residues generate a charge shift
of 1. Negative scores indicate a movement towards a more negative charge, positive scores indicate a movement
towards a more positive charge.
Native charge Mutant charge Charge shift
positive negative -2
positive neutral -1
positive positive 0
neutral neutral 0
negative negative 0
negative neutral 1
negative positive 2
5.8.1 Incorporating these data into the pipeline
This analysis does not require any additional processing as all the required data are parsed from
the XMAS ﬁles (see Section 2.2.3). A PostgreSQL function was written to calculate the ‘charge
shift’ of a mutation (see Appendix [E.i] for the deﬁnition of this function). Table 5.1 shows
the charge shift values for mutations between all possible pairs of charged and neutral amino
acids. With this PostgreSQL function, it is possible to implement this analysis as a single SQL
query, where mutations with a non-zero charge shift occurring in the core (where the relative,
monomer accessibility statistic  5%) are easily identiﬁed as introducing a buried, unsatisﬁed
charge.
5.9 Introducing hydrophobic residues on the protein surface
5.9.1 Background
Hydrophobic residues are concentrated in the protein core (Branden and Tooze, 1999). Replac-
ing a hydrophilic residue with a hydrophobic residue on the surface of a protein could result in
protein aggregation or misfolding and therefore a deleterious phenotype (for example, the E6V
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5.9.2 Incorporation into the pipeline
Phenylalanine, isoleucine, leucine, methionine, valine and tryptophan are classiﬁed as hy-
drophobic and aspartate, glutamate, histidine, lysine, asparagine, glutamine, arginine, serine,
threonine and tyrosine are classiﬁed as hydrophilic.
All data required to identify the hydrophobic mutations on the surface—i.e., native/mutant
amino acids and accessibility statistics—are recorded when the XMAS format of each mapped
PDB structure is parsed to populate the structural analysis database table (see Section
6.2.7). The analysis can therefore be performed by a single SQL query. Mutations from a
hydrophilic residue to a hydrophobic residue where the relative surface accessibility in the
monomer state is > 5% are identiﬁed.
5.10 Introducing hydrophilic residues in the protein core
5.10.1 Background
Replacingahydrophobicresiduewithahydrophilicresiduecoulddestabilisethenativeprotein
fold based on the observation that the vast majority of hydrogen bonding capable sidechains
participate in hydrogen bonding (McDonald and Thornton, 1994). Without potentially stabilis-
ing native hydrogen bonding in the protein core, native protein folding may be compromised.
5.10.2 Incorporation into the pipeline
Again, phenylalanine, isoleucine, leucine, methionine, valine and tryptophan are classiﬁed as
hydrophobic and aspartate, glutamate, histidine, lysine, asparagine, glutamine, arginine, ser-
ine, threonine and tyrosine are classiﬁed as hydrophilic.
As described in the Section 5.9, the information required to identify the introduction of a hy-
drophilic residue in the protein core already exists in SAAPdb and no additional processing is
required. As such, the analysis can be implemented as a single SQL query identifying muta-CHAPTER 5. SAAPDB: THE ANALYSIS PIPELINE 208
tions from any hydrophobic residue to any hydrophilic residue where the relative accessibility
of the residue in the monomer is  5%.
5.11 UniProtKB/Swiss-Prot features
5.11.1 Background
UniProtKB/Swiss-Prot uses a controlled vocabulary and the FT tag to annotate regions of in-
terest in protein sequences5. A small number of these annotations are manual, however many
more are transferred ‘by similarity’ from another annotated protein.
Manyoftheseregionswillbecriticaltoproteinfunction(forexample, post-translationalmodiﬁ-
cations and binding sites) and others will be critical to protein stability (for example, disulphide
bonds and other crosslinks). Mutations to such residues could disrupt protein function.
5.11.2 Incorporating these data into the pipeline
The UniProtKB/Swiss-Prot DAT ﬂatﬁle is parsed and residues annotated with FT tags are iden-
tiﬁed. As the aim is to explain the effects of mutations, a subset of features which have the
potential to affect protein stability or function are relevant. These are described in Table 5.2.
In UniProtKB/Swiss-Prot, the FT tag annotations can describe the start and end of contiguous
regions of annotation, or they can describe two non-adjacent residues (see third ‘Numbering
scheme’ column of Table 5.2). If the start and end number are the same, it describes a sin-
gle residue. When parsing the UniProtKB/Swiss-Prot data, the two numbering schemes are
handled appropriately, annotating all residues between the start and end of contiguous feature
regions with the corresponding feature. FT tag numbering that includes the non-digit charac-
ters ?, < or > is unreliable and these data are not extracted. After extracting the annotations
from the UniProtKB/Swiss-Prot ﬂatﬁle, all feature residues that have been extracted are stored
in the database; 1 488 092 residues are annotated in 135 883 UniProtKB/Swiss-Prot records. The
PDBSWS mapping (Martin, 2005) that is imported to SAAPdb allows these annotations to be
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Table 5.2: UniProtKB/Swiss-Prot FT annotations used to identify functional residues in
SAAPdb
Feature tag: the UniProtKB/Swiss-Prot FT tag; Description: a description of the feature; Numbering scheme: what
the UniProtKB/Swiss-Prot FT numberings describe - a contiguous region or a pair of non-adjacent residues.
Feature tag Description Numbering scheme
ACT SITE Residues involved in enzymatic activity contiguous
BINDING A ligand or substrate binding site contiguous
CA BIND Residues involved in calcium binding contiguous
DNA BIND A DNA binding site contiguous
NP BIND A nucleotide phosphate-binding region contiguous
METAL A metal binding site contiguous
LIPID Residues binding to a lipid substrate contiguous
CARBOHYD A glycosylation site contiguous
MOD RES A site of PTM contiguous
MOTIF A short sequence motif of biological interest contiguous
DISULFID Location of a disulphide bond non-adjacent
CROSSLNK Crosslinks formed after PTMs non-adjacent
mapped to protein structure (see Section 2.1.5 for a description of PDBSWS and Section 6.2.2
for a description of how PDBSWS is imported into SAAPdb).
The mapping process used to populate SAAPdb requires that all mutations are mapped ini-
tially to a residue in a UniProtKB/Swiss-Prot record. With the relevant data extracted from
the UniProtKB/Swiss-Prot DAT ﬂatﬁle and stored in the database, this analysis can be imple-
mented by a simple PostgreSQL query.
Upon closer inspection, it appears that these data can be unreliable. Figure 5.8 shows the struc-
ture of human P53 (PDB record 1tsr) in complex with DNA (highlighted in red). Residues near
to the DNA (within 10 ˚ A) are shown in yellow. The corresponding protein record ([UniPro-
tKB:P04637/P53 HUMAN]) describes residues 102-292 as DNA BINDing. These residues are
shown in blue in Figure 5.8, having been mapped onto the protein structure using PDBSWS
(see Section 2.1.5), and comprise most of the protein chain. It is clear from this example that the
UniProtKB/Swiss-Prot functional annotation is too coarse-grained, with many residues remote
from the DNA (i.e., distant by > 10 ˚ A) being annotated as DNA BINDing.
Given this observation, the UniProtKB/Swiss-Prot FT data have not been included in the later
analysis stage (see Chapter 7). However, the data are retained in the hope that annotations will
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Figure 5.8: An example of coarse-grained UniProtKB/Swiss-Prot FT annotation
The ﬁgure shows the structure of human P53, PDB record 1tsr. The DNA to which P53 binds is shown in red with
the protein chains shown as cartoon ribbons. The yellow residues indicate those within 10 ˚ A of the DNA, the blue
residues are those annotated as DNA BINDing by UniProtKB/Swiss-Prot, all other residues are coloured grey. Even
using the very generous distance threshold of 10 ˚ A, the UniProtKB/Swiss-Prot DNA BINDing annotation appears to be
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5.12 Mutating conserved residues
5.12.1 Background
Where it is not possible to identify the structural effect of a disease mutation, sequence infor-
mation can be used to infer functionality. Comparing the same protein in different species will
highlight which residues are conserved and therefore likely to be critical to protein function
and/or stability.
This led to the development of a novel method for identifying highly conserved residues which
accounts for species diversity and protein-global conservation patterns. This method, called
ImPACT, is described in Chapter 4. Here, the method by which these data are incorporated
into the pipeline is described.
5.12.2 Incorporating ImPACT scores into the pipeline
In SAAPdb, each mutation must be mapped to a UniProtKB accession number to order to ex-
ploit the sequence-to-structure mapping in PDBSWS (see Section 2.1.5). Using these acces-
sion numbers, all functionally equivalent proteins (FEPs) for each protein (should it exist in
UniProtKB/Swiss-Prot) can be identiﬁed by querying the FOSTA database. FOSTA is a method
for identifying FEPs in UniProtKB/Swiss-Prot and is described in Chapter 3. The sequence
data used to populate FOSTA are cloned for populating the ImPACT database so that all se-
quences can be retrieved, including records that have been replaced, merged or deleted since
the last FOSTA run. A multiple sequence alignment (MSA) is generated by aligning the FEPs
using MUSCLE (Edgar, 2004a) (see Section 2.3.2 for a description of this method). To identify
a protein-speciﬁc threshold for high conservation, the distribution is modelled and analysed as
described in Chapter 4.
As each protein can be processed independently, the ImPACT analyses are distributed across
the local 20-core grid. For each MSA, the ImPACT threshold, target protein and size (i.e., num-
ber of sequences) are recorded, and for each residue in each MSA, the position (with respect to
the target protein), the species similarity conservation score (see Section 4.2.1) and whether or
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the sequence conservation analysis can be implemented as a single SQL query.
5.13 Discussion
The pipeline has been extended signiﬁcantly as part of this thesis and analysis shows that the
recent augmentation has been valuable with respect to explaining mutations (see Chapter 7).
However, there remains considerable scope for improvement of the current analyses and incor-
poration of new ones.
Currently, the void analysis is rather crude: a static threshold of 275 ˚ A3 is used to identify dele-
terious void creating mutations. This threshold was selected based on an analysis of PDB struc-
tures that showed that the largest void in 80% of protein structures is 275 ˚ A3 (Cuff and Martin,
2004). However, it is likely that the threshold for deleterious void creation is dependent on the
protein structure, its size and stability, its environment and its resistance to destabilising voids.
Similar to what has been done for the sequence analysis—where MSA-speciﬁc thresholds for
high conservation are calculated—it would be valuable to consider each protein structure indi-
vidually, and, based on its properties, estimate the maximum void size that may be tolerated.
The existing method for resolving residue numbering in MMDBBIND should also be improved
bydealingwithstructureswithmissingresidues. Currently, themethodcorrectsthenumbering
for leading and trailing ﬂanking regions, but rejects any MMDBBIND record which describes a
PDB structure with absent residues in the structure, i.e., where the SEQRES and ATOM records
differ. This method could be improved by using the SEQRES/ATOM alignment provided in the
XMAS ﬁles (see Section 2.2.3) to correctly map all MMDBBIND annotations to the PDB.
Further, the current deﬁnition of a clash—identifying atoms that are within 2.50 ˚ A of each other,
as measured from the centre of the atom—could be improved. Using a static threshold does
not differentiate between two residues that are slightly overlapping and two residues that are
largely occupying the same space. Using a more informative Van der Waals energy calculation
would reﬁne the clash analysis and may improve results.
More generally, the set of structures within which the SAAPs are analysed could be reﬁned.
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the best structure within which to analyse the mutations. In addition, replacing the binding
analysis with the corresponding PQS analysis would further reﬁne the structural dataset, as
PDB structures can contain apparent interaction artefacts that arise from the crystallography
process as well as missing biologically relevant contacts (see Section 5.4).
With a view to extending the pipeline, it would be possible to incorporate external datasources
such as the Catalytic Site Atlas (Porter et al., 2004), PROCOGNATE (Bashton et al., 2008) or
dbPTM (Lee et al., 2006) to identify functionally relevant sites in protein structures. In addition,
it may be beneﬁcial to consider the protein in a wider context, for example, its role in known
pathways (Kanehisa et al., 2008).Chapter 6
The SAAPdb machinery and
mechanics
In Chapters 4 and 5, the ﬁfteen structural analyses that comprise the current suite of analyses
in SAAPdb were described. This chapter will describe how SAAPdb is populated and how the
pipeline is implemented.
MuchoftheworkdescribedinthischapterwasdevelopedbyJacobHurst. Theworkcompleted
as part of this thesis included porting and updating software to work on a new system with
new versions of PostgreSQL and python; updating the pipeline to include the new analyses
(see Sections 5.4-5.12); cache-ing of data; and retrieving, parsing and using the dbSNP XML
data.
Some of the methods described in this chapter are described in Hurst et al. (2009).
6.1 Introduction
The raw data upon which SAAPdb is based describe two kinds of genomic variation, the ﬁrst of
which—the single nucleotide polymorphism or SNP—is assumed to have a negligible effect on
protein structure and therefore function, and the second of which—the pathogenic deviation or
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Table 6.1: Data overlap in SAAPdb
Numbers describe how many mutations are common to the two corresponding datasets. The emboldened identity
numbers (i.e., where a dataset is compared with itself) show how many mutations are described by that dataset. The
dbSNP and OMIM datasets are separated from the other LSMDB datasets using double ruled lines. Dataset names are
self-explanatory (apart from ‘P53-G’ which represents the Germline IARC p53 Database and ‘P53-S’ which represents
the ‘Somatic IARC p53 Database’). All datasets are further described in Section 2.1.2. Empty cells indicate that there is
no overlap between two datasets.
OMIM 7119
ADABase 19 38
G6PD 44 103
HAMSTeRS 135 526
P53-G 23 94
P53-S 27 89 1396
OTC 12 148
SOD1db 27 96
ZAP70 1 5
dbSNP 3 3 34081
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PD—has been associated with disease and, therefore, are thought to have a deleterious effect(s)
on protein structure and function. Here, the resources from which these data are taken are
reviewed (they were introduced in Chapter 2).
6.1.1 SNP data
Two SNP resources are described in Section 2.1.1: dbSNP (Sherry et al., 1999; Smigielski et al.,
2000) and HGVBase (Brookes et al., 2000). However, as of October 2008, only dbSNP data are
analysed by SAAPdb. The decision to eliminate HGVBase data was taken for two reasons, one
of which is the data themselves and the second of which is the processing of these data.
Firstly, HGVBase has not be consistently maintained, with only sporadic updates since 2003.
Secondly, HGVBase, unlike recent builds of dbSNP, does not provide reliable mappings to pro-
tein sequences. This requires that the genomic data be mapped to protein sequences via cod-
ing sequence assembly from genomic records, translation and ORF identiﬁcation, and ﬁnally
alignment and mapping with the referenced protein sequence or sequences. This is a computa-
tionally expensive process.
However, the analysis described in Chapter 7 was carried out before the HGVBase data were
removed from the system and when the in-house mapping system was used to map all SNPs to
protein sequence. As such, the method for importing these data is described below in Section
6.2.4.
Note that HGVBase has recently become HGVBaseG2P and it is expected that many of these
problems will soon be resolved. However, at the time of writing, no downloadable set of mu-
tations was available.
6.1.2 PD data
OMIM and LSMDBs (Locus Speciﬁc Mutation Databases) were discussed in Section 2.1.2. The
resources are obtained in varying formats. The major challenges in processing LSMDB data are
(i) to standardise the format of these data to allow them to be processed identically and (ii) to
verify the sequence numbering that is provided by each LSMDB community.CHAPTER 6. SAAPDB MACHINERY 217
6.1.3 SNP/PD overlap
Table 6.1 shows the size of the datasets currently used in SAAPdb and the overlap between
them. The central PD resource OMIM has, as would be expected, at least some overlap with
all of the other PD datasets. It is also by far the largest resource, being ﬁve times larger than
the next largest, the somatic P53 dataset. However, larger still is the dataset of neutral non-
synonymous SNPs, which is approximately ﬁve times larger than the OMIM resource. Within
the LSMDBs, the only overlap that exists is between the germline and somatic P53 datasets.
Encouragingly, very few mutations are described as disease-associated and neutral. Only six
mutations are described simultaneously as a PD and a SNP: three are common to the dbSNP
and OMIM datasets and three are common to the dbSNP and P53 somatic datasets. When
analysing the data in Chapter 7, these mutations are removed from the SNP dataset but re-
tained in the disease dataset, working on the assumption that the large-scale genomic scanning
technology by which the SNPs are identiﬁed happens to have sequenced the genome of an
individual carrying a disease mutation.
It is worth noting that the unique complexity of cancer (where many mutations are acquired
over a short period of time) means that there is less certainty as to the pathogenicity of those
mutations found in both the somatic P53 dataset and the dbSNP dataset. Apparently carcino-
genic mutations may simply be ‘passenger’ mutations that have little or no pathogenic effect,
having ‘hitchhiked’ into the cancer cell by virtue of being coincident with a deleterious mu-
tation (Greenman et al., 2006). However, none of these three SNPs are mapped onto protein
structures and are therefore not analysed in Chapter 7.
6.1.4 Additional resources
Several additional resources are required to processes these data: UniProtKB (Section 2.1.3) is
required to map gene names to proteins and identify annotated functional residues; EMBL and
Genbank (Section 2.1.6) are required to map genomic data to protein sequences where map-
pings are unreliable or absent; and PDBSWS (Section 2.1.5) is used to map protein sequences to
protein structures accurately.CHAPTER 6. SAAPDB MACHINERY 218
6.2 Materials and Methods
There are two main stages of data processing: (1) importing the SAAP data (PDs or SNPs) and
(2) pushing it through the structural analysis pipeline. This naturally leads to a three-part data
‘architecture’ division, both with respect to data storage and data processing: (a) SNP data; (b)
PD data and (c) pipeline data. These three sections are described below in Sections 6.2.3-6.2.4,
6.2.6 and 6.2.7 respectively, following a brief description of the database (Section 6.2.1) and
information regarding the import of additional ‘reference’ data (Section 6.2.2).
Several other people have contributed to the design, development and maintainence of
SAAPdb, including Jacob Hurst, James Allen, Craig Porter and Antonio Cavallo. Where
appropriate, the contribution of each individual has been indicated in italics and marked with
a . symbol under the section heading.
6.2.1 The database
. The database was designed and previously maintained by Jacob Hurst, James Allen, Craig Porter and
Antonio Cavallo. It has been extended to include additional analysis data by Lisa McMillan.
Figure 6.1 describes structure of the SAAPdb database. The database is divided into three
sections: (a) handling the SNPs, (b) handling the PDs and (c) pushing the SAAP data through
the pipeline. Within the SNP and PD sections, tables separate the storage of sequence and
structural data (using lsdb and lsdb saap for PD sequence and structural data respectively,
and snp2annotated and saap for SNP sequence and structural data respectively). In the
pipeline section, the storage of purely structural data (i.e., data pertaining to native structures,
prior to mutation analysis) is kept separate (in the structural analysis table) from the
storage of mutation analysis data. The mutanalysis table contains the results of the structural
analyses. In the pipeline section, summary tables are created to allow the fast retrieval of data
via a webserver.CHAPTER 6. SAAPDB MACHINERY 219
(a) HANDLING THE SNPs
(b) HANDLING THE PDs
(c) STRUCTURAL ANALYSIS
Additional pipeline data
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Figure 6.1: The structure of the SAAPdb database
Tables pertaining to data importation are enclosed by a blue box while tables containing pipeline data are enclosed by
a red box. Within the data importation section, the PD and SNP data are separated with a dotted blue line. Additional
data required are shown at the top of each section, delimited from the rest of the data by a solid blue or red line. Tables
containing cached data are shown in grey. Foreign keys are linked with solid black lines. Excepting the additional data
within each processing stage, data ﬂow is largely from left to right; that is, the tables on the left hand side of the ﬁgure
are populated ﬁrst.CHAPTER 6. SAAPDB MACHINERY 220
6.2.2 Populating reference tables
. These methods were developed by Jacob Hurst and Craig Porter.
Three tables in SAAPdb are populated by parsing UniProtKB: swprottrembl, genenamemap
and accessionmap. These tables contain sequence data, mappings between gene names and
proteins and a mapping between secondary and primary accession numbers respectively. An
existing local mirroring of UniProtKB is cached locally before processing begins to ensure that
the most recent version of UniProtKB is used in all relevant SAAPdb processes.
SAAPdb uses PDBSWS (Martin, 2005) to map those mutations identiﬁed in UniProtKB se-
quences to structures described by the PDB. The mappings are obtained from http://www.
bioinf.org.uk/pdbsws/pdbsws_res.txt. This ﬁle is parsed to populate the sprot2pdb
table.
6.2.3 Importing the dbSNP data: new method
. These methods were developed by Lisa McMillan.
This section describes how the SNP data are imported and mapped to protein sequences and
structures, represented in section (a) of Figure 6.1.
The Entrez Programming Utilities1 (or eUtils) are used to obtain the most recent dbSNP data
from the NCBI. XML records of valid, non-synonymous, human SNPs are retrieved. ‘Valid’
SNPs are deﬁned as those annotated with validation strings “by frequency”, “by 2hit 2allele”
or “by hapmap”. All records retrieved are combined into one XML ﬁle and parsed to populate
the snp and snp2annotated tables with dbSNP data.
It is expected that the new HGVBaseG2P2 (Thorisson et al., 2009) release will be available in the
near future which is likely to include protein sequence mappings. This will allow HGVBase
to be handled in much the same way as dbSNP currently is in SAAPdb and may render the
in-house mapping process redundant.
1http://www.ncbi.nlm.nih.gov/entrez/query/static/eutils_help.html
2http://www.hgvbaseg2p.orgCHAPTER 6. SAAPDB MACHINERY 221
Figure 6.2: SNP data processing in SAAPdb
The layers indicate dependencies in the data, i.e., data in layer (1) must be present before data in layer (2) can be
generated (the arrow indicates data ﬂow). Layer (1): data required to map SNPs to genes/proteins; Layer (2): the
raw dbSNP and HGVBase data (stored separately); Layer (3): the combined dbSNP and HGVBase data; Layer (4): the
mapped SNP data. Grey boxes indicate data required but described elsewhere (Section 6.2.2).
6.2.4 Importing the dbSNP/HGVBase data: old method
. These methods were developed by Jacob Hurst.
As described above (section 6.2.3), the method for obtaining and retrieving dbSNP data has
been changed to improve data integrity and accelerate processing: SAAPdb now uses protein
sequence mappings provided by dbSNP. However, all SNP data (both dbSNP and HGVBase)
that are analysed in Chapter 7 were mapped using the in-house mapping methodology. There-
fore, this section will summarise the in-house system by which the SNPs were mapped to pro-
tein sequence. This method is an extension to that described in Cavallo and Martin (2005) and
was deceloped by Jacob Hurst.
The mapping system consists of four layers of processing, each of which requires the previous
layer to be complete before it itself can be initiated. Processing within a layer may be completed
in any order. These layers of processing and their dependencies are shown in Figure 6.2, where
layer (n) must be complete before processing in layer (n+1) can commence. Each layer of data
processing is described below.CHAPTER 6. SAAPDB MACHINERY 222
6.2.4.1 First layer: fundamental genomic and proteomic data
Both dbSNP and HGVBase provide the upstream and downstream ﬂanking regions, and
an EMBL or Genbank record ID describing the SNP. As the intention is to map to protein
structures using PDBSWS, it is necessary to map the SNPs to UniProtKB records. The
EMBL/Genbank entries provide database cross-references to protein sequence databases
including UniProtKB. To map to UniProtKB/Swiss-Prot sequences, it is necessary to identify
the SNP in the EMBL/Genbank record and map forward onto the protein sequence.
The most recent version of EMBL and Genbank are obtained via ftp from the EBI and NCBI
respectively. To allow retrieval of individual records, all EMBL and Genbank ﬁles are parsed,
with each record ‘indexed’ in the tables embloffsets and genbankoffsets respectively.
The embl and embloffsets tables store data about EMBL entries and are populated by pars-
ingtheEMBL.datﬁles. ThegenbankoffsetstablestoresthesameinformationforGenbank
ﬁles and is populated by parsing the Genbank .seq ﬁles. These data are required to map the
SNPs to sequence and populate the snp2annotated table.
Also required at this stage are the tables swprottrembl, genenamemap, accessionmap and
sprot2pdb, previously described in Section 6.2.2.
The ss2genbank table links dbSNP SS IDs to their Genbank accession IDs; these data are
extracted from the ‘Sub*’ ﬁles included in the dbSNP release. These data are used later to
populate the dbsnp table.
6.2.4.2 The second layer: importing the raw data from dbSNP and HGVBase
Raw dbSNP data in XML format are obtained via FTP from the NCBI. These ﬁles are then
parsed to generate the appropriate SQL which is executed in SAAPdb.
The most recent version of HGVBase is mirrored. An HGVBase release takes the form of several
g-zipped ﬁles. Each of these is unzipped and parsed to identify the necessary data. These data
are then piped directly into SAAPdb.CHAPTER 6. SAAPDB MACHINERY 223
6.2.4.3 The third layer: combining the dbSNP and HGVBase data in the snp table
ThesnptablecomprisesthethirdlayerofSNPdatainSAAPdb. Thislayersimplycombinesthe
SNP data from dbSNP and HGVBase into a single table, ensuring that there is no redundancy
within each dataset (note that there may be redundancy between the datasets), so that both sets
of SNPs can be processed identically henceforth. The raw genomic data are now ready to be
mapped to protein sequence.
6.2.4.4 The fourth layer: mapping to UniProtKB sequence records
There are several signiﬁcant challenges in mapping these genomic data to protein sequence
records. Firstly, the EMBL/Genbank data contain introns and exons; to determine whether the
SNP occurs in a coding region, the coding sequence must be reconstructed from CDS records
in the EMBL/Genbank record. Secondly, it is not known (a) whether the ﬂanking regions and
alleles are derived from the forward or reverse complement sequence, and (b) whether the
EMBL/Genbank record itself is given in the forward or reverse direction. Thirdly, no infor-
mation is provided describing which reading frame should be used to translate the coding
sequence into the gene product. In addition to the challenge of deﬁning the mapping, the size
of the SNP repositories requires that distributed computing be used to process the data within
a reasonable time frame.
The process of batching the SNPs and submitting them to the local grid is described in Figure
6.3. The ﬁrst step is to extract the relevant data from SAAPdb and save it to a ﬁle. Next, the
SNPs are grouped according to the EMBL/Genbank ﬁle in which they occur. This is necessary
as these ﬁles will be cached locally on the individual processing nodes; by consolidating all
SNPs from one particular EMBL/Genbank ﬁle into one ﬁle, caching transactions will be min-
imised. Finally, these record-speciﬁc ﬁles are split into 2000 SNP batches which are processed
individually across the grid. Figure 6.4 describes the processing carried out by each job on the
compute nodes.
EMBL and Genbank are stored centrally on a single compute node (acrm3). To overcome
sporadic NFS ﬁle system errors when using these ﬁles from nodes on the grid, the relevant
EMBL/Genbank ﬁle must be cached locally. Once the relevant ﬁle has been cached locally, all
SNPs in the batch are analysed with findsnp5, the software central to this mapping process.CHAPTER 6. SAAPDB MACHINERY 224
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Figure 6.3: Submitting findsnp5 to the grid
First, all SNPs are extracted and grouped according to the EMBL/Genbank record to which they are mapped. These
EMBL/Genbank record-speciﬁc lists of SNPs are then divided into batches of 2000 to be distributed across the grid.
findsnp5 (developed by Jacob Hurst) is depicted in Figure 6.5 and described in pseudocode
in Figure 6.6.
findsnp5 initiates the search by constructing an appropriate search term, consisting of the
concatenation of the downstream sequence, the native allele and the upstream sequence.
findsnp5 determines the direction of the reading frame by searching for this assembled
search term in the genomic sequence as described by the record and in the reverse complement
sequence.
As findsnp5 relies on annotated coding regions, if the EMBL/Genbank record does not con-
tain any annotated coding regions no mappings can be made and findsnp5 reports a failed
mapping. Otherwise, findsnp5 assembles the full coding sequence from the exons described
by the EMBL/Genbank CDS records. The assembly can accommodate external CDS references
and reverse complement CDS records (reverse complement CDS records are explicitly anno-
tated in EMBL/Genbank). The position of the SNP is then identiﬁed in the new assembled
coding sequence (ACS) by scanning for the original search term; if this is not found, the SNP
exists in a non-coding region of the genome, no protein mapping is possible and processing is
terminated.
Next, the longest reading frame in the ACS is identiﬁed and the ACS is translated. At this stage
the codon; the position of the corresponding amino acid in the ACS; and the position of the SNPCHAPTER 6. SAAPDB MACHINERY 225
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Figure 6.4: The processing done by a batch of findsnp5 jobs
Each batch of jobs is submitted to a node on the local 20-core grid (shown in blue above). First, the oldest ﬁle in the
data directory is recursively deleted to accommodate the new EMBL/Genbank ﬁle (if space is not available already)
which is then retrieved from acrm3 (shown in grey). After the EMBL/Genback ﬁle has been cached successfully, each
SNP in the batch is analysed with findsnp5.CHAPTER 6. SAAPDB MACHINERY 226
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Figure 6.5: The findsnp5 mapping process
Process (1): look for the allele plus the ﬂanking regions and determine which direction the ORF will be; Process
(2): reconstruct coding sequence from CDS records (using both internal and external references; Process (3): ﬁnd the
longest RF and translate to obtain the protein sequence; Process (4): compare the correct translated ORF to the protein
sequence provided and identify the relevant residue. The mapping progress of the original allele is marked in yellow;
other colours are used to match regions of the genome or the proteome between mapping stages. See Figure 6.6 for
pseudocode describing findsnp5.CHAPTER 6. SAAPDB MACHINERY 227
(a) findsnp5 inputs
 snp id : the ID of the SNP in the source database
 record id : the record containing snp id
 searchterm : upstream + ’X’ + downstream
 fseekinfo : position of record id in ﬁle (format is ﬁle:start:end)
 alleles : the alleles (separated by ’,’)
(b) findsnp5 process
(I) Determine record type, construct appropriate parser
(II) Determine which direction to use (forward/reverse complement)
(III) if ( record id contains CDS records ):
(a) Assemble CDS into ACS
(b) Find SNP in ACS using searchterm (newsnp pos)
(c) Find longest RF in ACS (bestrf)
(d) Translate ACS using bestrf (bestRF seq)
(e) Identify codon affected (codon seq)
(f) Identify calculated position in bestRF seq (codon pos)
(g) Identify which allele of codon seq is affected (allele pos)
(h) Extract ”translation” ﬁeld from record id (record seq)
(i) if ( bestRF seq not in record seq ):
i. Mapping failed, exit
(j) Calculate offset value (offset) for bestRF seq in record seq
(k) Calculate offset codon pos as codon pos + offset
(l) Identify wildtype AA (record seq[offset codon pos])
(m) Determine mutation type (nonsense/missense/silent)
(n) Obtain dbxref and genename pairs from record id
(o) Write record for each dbxref
(IV) else:
(V) Mapping failed, exit
Figure 6.6: The findsnp5 mapping process in pseudocode
ACS = assembled coding sequence; RF = reading frame. Process at line (#1) identiﬁes whether record id is an EMBL
or Genbank record (all record id names are preceeded by ’embl:’ or ’genbank:’ to indicate which record type they
are). Process at line (#2) searches for the searchterm in the ”SQ” feature of the EMBL record. Process at line (#3a)
allows for reverse complement CDS records. Process at line (#3i) will check for the ﬁrst 5 residues if the entire sequence
fails to map. Process at line (#3m) compares the native allele with the mutant allele, as constructed by replacing the
allele at allele pos with the mutant base.CHAPTER 6. SAAPDB MACHINERY 228
in the codon are determined, and the protein sequence as provided by the EMBL/Genbank
record is extracted.
The protein sequence as derived from the ACS and the protein sequence as provided by the
EMBL/Genbank record can then be compared in order to map the SNP onto the protein se-
quence correctly. If findsnp5 cannot ﬁnd the entire translated ACS in the protein sequence
record, it tries to ﬁnd the ﬁrst ﬁve residues of the translated ACS in the protein sequence record.
If this also fails, no mappings can be made and findsnp5 reports a failed mapping. Otherwise,
findsnp5 can proceed in identifying the relevant residue in the protein sequence record and
determine whether the base change(s) described by the SNP will result in a silent, nonsense
or missense mutation by comparing the translated mutant codon with the translated native
codon. After further information is extracted from the EMBL/Genbank record (namely the
‘db xref’ and ‘gene’ name records), the successful mapping is reported.
The snp2annotated table is populated with the mappings as identiﬁed by findsnp5.
6.2.5 Mapping the SNPs to protein structure
. These methods were developed by Jacob Hurst.
The sprot2pdb table is used to map all UniProtKB records in the snp2annotated table to
protein structures. The resulting mappings are described in the saap table.
6.2.6 Importing the PDs
. These methods were developed by James Allen.
6.2.6.1 The PD data
In many ways, the task of mapping and processing the PD data is more straightforward: there
is less data, allowing processing to be sequential, and protein sequence mappings are usually
provided, avoiding computationally expensive mapping procedures. Instead, the challenges
are in accommodating the different ﬁle formats of the source databases. In this section, the
method by which the PD data (described in Section 2.1.2) are imported is described.CHAPTER 6. SAAPDB MACHINERY 229
6.2.6.2 The dataset-speciﬁc wrapper
As the PD data are coalesced from different sources, the primary data vary in format. To sepa-
rate the parsing, veriﬁcation and import phases, and to permit easy integration of all the data
into SAAPdb, it is necessary to represent all the data in the same format. An XML format has
been developed within the Martin group to represent mutation data and therefore process each
dataset identically. An extract from an example record is shown in Figure 6.7.
This approach requires that each dataset be accommodated by a dataset-speciﬁc ‘wrapper’
which converts the original data into the XML format. Along with the retrieval of the raw
dataﬁles themselves, these are the only manual steps required to import the PD data.
6.2.6.3 Verifying the protein sequence numbering
OMIM is a centrally maintained, curated resource for disease mutation data. However, given
that the described mutations are derived from multiple sources and from the literature, it is not
surprising that there are inconsistencies in the numbering of amino acids. It is important to
verify that the numbering provided by the primary datasets is correct.
A version of OMIM with corrected numbering is currently automatically maintained within the
Martin group. Figure 6.8 shows how the veriﬁed OMIM mapping is derived for each disease
dataset. First, a partial sequence is constructed from the native residues described in OMIM
(Figure 6.8(a)). This partial sequence is then compared with the protein sequence named by
OMIM, by sliding it along in increments of one residue and storing the number of residue
matches for each comparison (Figure 6.8(b)). The alignment that is the best match to the named
protein sequence is used to calculate an offset value describing how the OMIM numbering
should be corrected; in the example, the offset is -3 (Figure 6.8(c)). The offset is then applied
to these ‘matching’ residues to correct their numbering. If any mutations remain unmatched
that would match the sequence with an offset of 0 (e.g., the A20L mutation in the example,
highlighted in blue in Figure 6.8(c)), it is assumed that these were submitted to OMIM in a
separate batch where correct UniProtKB numbering was used and these data are added to theCHAPTER 6. SAAPDB MACHINERY 230
<lsdb name=’DatabaseABC’ url=’http://DatabaseABC.com’>
<mutation id=’001’ supplementary id=’456’ arbitrary id=’1’ number of records=’6’>
<dna data>
<gene>ABC</gene>
<dna base wildtype=’T’ mutant=’G’>1</dna base>
<codon wildtype=’ATT’ mutant=’AGT’>1</codon>
</dna data>
<protein data ac=’P00123’>
<amino acid aa label=’1’ wildtype=’I’ mutant=’S’ valid=’t’>1</amino acid>
</protein data>
<occurrence>
<prevalence text>High</prevalence text>
<prevalence count>1000</prevalence count>
<prevalence percentage>10</prevalence percentage>
</occurrence>
<patient data>
<age>12</age>
<sex>M</sex>
<race>UK</race>
<phenotype mendelian=’dominant’>
<disease name>ABC Deﬁciency</disease name>
<disease class>4</disease class>
<disease severity numeric=’2’>Moderate</disease severity>
<disease onset numeric=’2’ age=’10’>Childhood</disease onset>
<enzyme activity numeric=’3’ percentage=’6’>Severely-decreased </enzyme activity>
<delta delta gee>-0.95</delta delta gee>
<melting point>40</melting point>
<prognosis>10 years</prognosis>
</phenotype>
<external factors details=’1’>Radiation exposure</external factors>
</patient data>
<references>
<citation year=’2006’>Author, A. N. (2006)</citation>
</references>
</mutation>
...
</lsdb>
Figure 6.7: An example of the XML formatCHAPTER 6. SAAPDB MACHINERY 231
 −−−−− −−−−− −−− −−−−−−−  S     A         P       K             A            
(c)     5   10   15   20   25   30
    |    |    |    |    |    |
ADNASHPNTAASASVNYMYAPIRIEFLHKMAP
matches = 4/5
offset = −3
 −−−−− −−−−− −−− −−−−−−−  S     A     A   P       K
 −−−−− −−−−− −−− −−−−−−−  S     A         P       K             A            
S     A     A   P       K  −−−−− −−−−− −−− −−−−−−− 
S     A         P       K  −−−−− −−−−− −−− −−−−−−−              A            
      A                    S           A   P       K  −−−−− −−−−− −−− −−−−−−− 
(b) ADNASHPNTAASASVNYMYAPIRIEFLHKMAP
matches = 1/5
matches = 0/5
matches = 0/5
matches = 1/5
matches = 1/5
(a)
    S−−−−−A−−−−−A−−−P−−−−−−−K
S 8 −> T
A14 −> R
P24 −> L
K32 −> S
A20 −> L
S 5 −> T
A11 −> R
P21 −> L
K29 −> S
A20 −> L
(d)
Figure 6.8: Verifying the OMIM mapping
(a): a partial sequence is reconstructed from the mutations described in the OMIM record; (b): this partial sequence is
slid along the UniProtKB/Swiss-Prot sequence to which it is mapped in OMIM and the number of matches for each
position is recorded (matches are shown in green, mismatches are shown in red); (c): the best matching position is
used to calculate the offset (note that the A20 record (shown in blue) could be correct with an offset of 0 (i.e., the OMIM
annotationiscorrect)asanalaninedoesexistatposition20); (d): theoffsetisappliedtothe‘matched’originalmutations
(i.e., the residues found to match in (c)) to generate a corrected numbering and all ‘probably correct’ mutations (those
matched using an offset of 0) are also included in the dataset (again, the ‘probably correct’ A20 example is highlighted
in blue).CHAPTER 6. SAAPDB MACHINERY 232
corrected dataset, ﬂagged as ‘probably correct’. Some mutations may remain unmapped after
these stages. The completed corrected dataset is shown in Figure 6.8(d).
To provide some idea of the extent to which the OMIM data are corrected, 2318 of OMIM
mutations (31.0% of all OMIM mutations) from 182 OMIM entries (14.6% of all crosslinked-to
from UniProtKB/Swiss-Prot OMIM entries) available in August 2008 required an offset to be
applied to correct the sequence numbering. These corrected OMIM data are publicly available
at http://www.bioinf.org.uk/omim.
An identical scheme is applied to each of the LSMDB datasets in an attempt to maximise the
amount of correct data extracted from the LSMDBs (see Section 6.2.6.4).
6.2.6.4 Pushing the data into the database
Figure 6.9 shows the complete workﬂow by which the PD data are entered into SAAPdb, in-
cluding the manual ‘Write wrapper function’ step (highlighted in red). Clearly, this is only
written once for each dataset, though it is not uncommon for updates to break the wrappers.
The ﬁrst stage of processing is to convert the raw data into XML. Before a new dataset can be
accommodated by SAAPdb, an appropriate wrapper function must be written which deﬁnes
which data are where in the raw dataﬁle. The pseudocode for the wrapper scripts is shown in
Figure 6.10.
The system will attempt to identify the correct AC should the mutations not be mapped to
a UniProtKB/Swiss-Prot sequence. It does this by constructing a partial native sequence by
combining the wildtype residues from the data and representing all other residues with an ‘X’.
This partial sequence is then searched for in the most recent version of UniProtKB/Swiss-Prot
using ssearch34 (Pearson and Lipman, 1988). The raw data are updated accordingly so that
the time consuming sequence search need not be repeated. This step is highlighted in green in
Figure 6.9.
The corresponding wrapper function is run on each raw data ﬁle to generate XML representa-
tions of the PD data. Each XML ﬁle is then converted to SQL statements via an XSLT speciﬁ-CHAPTER 6. SAAPDB MACHINERY 233
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Figure 6.9: Importing an LSMDB dataset
A wrapper script converts the raw data into valid XML and this XML is translated to appropriate SQL using XSLT; the
single manual intervention step, where the data wrapper is written, is highlighted in red. Should no AC be provided
for the dataset, the AC number is determined using ssearch (highlighted in green, for details see text). This diagram
describes the PD data ﬂow for a single LSMDB dataset, from original data format to XML (via wrapper), to SQL (via
XSL). In reality, all datasets are processed simultaneously; that is, all raw data-XML processing is done, then all XML-
SQL processing. XML and SQL processing stages are separated by a dotted blue line.CHAPTER 6. SAAPDB MACHINERY 234
(a) wrapper inputs
 data folder : the folder containing the raw data
 xml folder : the foler containing the xml
If these are not provided, the default values of ‘../data’ and ‘../xml’ respectively are used.
(b) wrapper process
(I) parse the lsdb info.txt ﬁle to ﬁnd the dbname, dburl, sprotac, rawdatafile
(II) open rawdatafile using cvs.reader() and the appropriate delimiter
(III) check whether a corresponding XML ﬁle already exists (if so, exit cleanly without doing any-
thing)
(IV) identify the sprotac using lsdb utils.get ac number() unless sprotac has been ex-
tracted from lsdb info.txt
(V) for each entry in rawdatafile:
(a) if no mutation id exists:
i. increment an arbitrary mutation ID counter
(b) deﬁne an appropriate UI
(c) extract all the relevant information
(d) increment the count for this particular mutation using the UI
(e) record the basic mutation data using the UI
(f) record the numbering (res num, aa wildtype) using the UI
(VI) verify the numbering using lsdb utils.validate numbering():
(a) retrieve the sequence of sprotac from the UniProtKB website
(b) identify all possible offsets for each unveriﬁed res num/aa wildtype pair
(c) identify the most commonly found offset (most common offset)
(d) if all res num/aa wildtype pairs are offset by most common offset:
i. correct all values of res num by most common offset
ii. mark all res num/aa wildtype pairs as fully validated (‘t’)
(e) else:
i. if  50% of the res num/aa wildtype pairs have an offset of 0:
A. Mark these res num/aa wildtype pairs as fully validated (‘t’)
ii. else if  2 of the res num/aa wildtype pairs have an offset of 0:
A. Mark these res num/aa wildtype pairs as probable (‘?’)
(f) if there are more res num/aa wildtype pairs to validate:
i. repeatedly calculate offsets as described above until everything is probable or
fully validated, or there are only a small number left
(VII) write the XML ﬁle using the validated data
Figure 6.10: The PD data wrapper: pseudocode
UI = unique identiﬁer; the thresholds that deﬁne what is fully, probably or not validated (in processes #(6(e)i)-#(6(f)i))
can be changed; process at line #6a retrieves the sequence from http://us.expasy.org/uniprot/.CHAPTER 6. SAAPDB MACHINERY 235
cation (see Section 2.2.2) and all SQL is executed in the database. This populates the database
tables lsdb, lsdb references, lsdb info and lsdb info ref link (see Figure 6.1) with
the appropriate data.
The ﬁnal step is to map the imported and veriﬁed PDs to protein structures and populate the
appropriate database table (lsdb saap) with the mappings (this step requires that the data
described in Section 6.2.2 be present in the database). First, the UniProtKB/Swiss-Prot acces-
sion numbers to which the disease mutations are mapped are updated to their corresponding
primary accession number which will be present in PDBSWS. Then, the lsdb saap table is
populated with the appropriate sequence and structural data. These steps are implemented as
SQL statements.
Figure 6.9 describes the complete data ﬂow for a single dataset. In reality, processing progresses
through the data representations, rather than through each dataset. That is, all raw data to XML
processing is executed, all SQL is generated by applying the XSLT schema to each XML ﬁle in
turn and ﬁnally all SQL is executed. Once the sequence data are in the database, the SQL
statements updating the AC numbers and the structural mappings are executed.
6.2.7 The pipeline
. These methods were originally developed by Jacob Hurst and have been extended by Craig Porter and
Lisa McMillan.
Once the SNP and PD data are mapped to protein structures (i.e., once the saap and
lsdb saap tables have been populated), the SAAP data can be processed by the pipeline.
Eight of the analyses require additional data to be present in the database: the hydrogen
bonding (Section 5.3.1), clash (Section 5.3.6), void (Section 5.3.7), MMDB (Section 5.5),
UniProtKB/Swiss-Prot features (Section 5.11), sequence conservation (Section 5.12), PQS
(Section 5.4) and disulphide geometry (Section 5.6) analyses. Detailed information regarding
these analyses, what data are required and how they are derived is available in the Sections
given above in parentheses.
Figure 6.11 shows how the pipeline is run and how the data are coordinated. There are four
phases of processing, which are delineated in Figure 6.11 using dashed lines. In phase (A), theCHAPTER 6. SAAPDB MACHINERY 236
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[3] Check linking
[12] Glycine analysis
[13] Proline analysis
[14] Interface analysis
[15] Functional analysis
[16] Hbond analysis
[17] Void analysis
[18] Surface/phobic analysis
[19] Core/philic analysis
[20] Cisproline analysis
[21] Buried charge analysis
[22] Uniprot/FT analysis
[23] MMDBBIND analysis
[24] PQS analysis
[25] SSGEOM analysis
[26] ImPACT analysis
Table containing the
results of the structural
analysis of the SAAPs
[1] Import SAAPs
Update each SAAP:
is it explained?
Create summaries
for each SAAP
Fill summary tables
with 0 values for
unexplained SAAPs
[27]
[28]
[29]
PDB files
MMDBBIND
PDB
PQS
UniprotKB
FOSTA
[4] Hbond preprocessing
[11] SSGEOM preprocessing
[10] Uniprot/FT preprocessing
[9] MMDBBIND preprocessing
[2]
[5] Clash preprocessing
(includes clash analysis)
[7] PQS preprocessing
[8] ImPACT preprocessing
[6] Void preprocessing **
Table containing
structural data about
the residues in the
PDB structures
Table summarising the results
for the SNP SAAPs
Table summarising the results
for the disease−causing SAAPs
Specialised tables:
(ii) MMDBBIND
(iii) PQS
(iv) Uniprot/FT
(v) ImPACT scores
(vi) SSGEOM
(i) voids
Table linking the
SAAPs to the results
of their structural
analysis
Extract structural
information **
Figure 6.11: Pushing the SAAPs through the structural analysis pipeline
Square boxes indicate data processing, boxes with rounded corners represent database tables and arrows indicate
information ﬂow. In processing stage (A), steps [1-3] populate the database with all disease-associated SAAPs and
structural information about all PDB structures. In processing stage (B), steps [4-11] generate mutant structures and
carry out essential pre-processing for the hydrogen bonding, clash, void, MMDBBIND, Swiss-Prot/FT, PQS, ImPACT
and SSGEOM analyses. In processing stage (C), steps [12-26] carry out the structural analyses. In the ﬁnal processing
stage (D), steps [27-29] generate summary information for each SAAP. Cached data are highlighted with  and all
distributed grid processing is highlighted with a grey background.CHAPTER 6. SAAPDB MACHINERY 237
data from the saap and lsdb saap tables are imported into the mutanalysis table (step [1])
and the structural analysis table is populated with data extracted and calculated from
the relevant PDB ﬁles (including torsion angle data; accessibility statistics; secondary structure,
and interface and functional ﬂags; step [2]). In step [3], the link between the mutanalysis and
structural analysis tables is created.
In phase (B), all the necessary preprocessing is carried out for the hydrogen bonding (step
[4]), clash (step [5]), void (step [6]), PQS (step [7]), sequence conservation/ImPACT (step [8]),
MMDB (step [9]), UniProtKB features (step [10]) and disulphide geometry analyses (step [11]).
Four of the analyses—clash, void, PQS and ImPACT (steps [5-8])—require considerable pre-
processing and as such are distributed across the local 20-core grid. Results are written to the
specialist tables (impact alignment/impact residue, disulphide geometry, voids,
pqs, mmdb and swissprot features, see Figure 6.1); the clash preprocessing also updates
the mutanalysis table with the clash result and therefore carries out the clash analysis. In
Figure 6.11, all distributed processing is highlighted in grey.
The two most time consuming processing steps are step [2] in phase (A)—extracting informa-
tion from the PDB structures—and step [6] in phase (B)—calculating the void data. To avoid
unnecessary and time-consuming repeated processing, these data are cached (in a ‘cloned’ ta-
ble) before each run of SAAPdb. In the current implementation of SAAPdb, this creates the
tables voids cache and structural analysis cache (these are shown in grey in Figure
6.1). The original table is then dropped and recreated and the original data from the cached
table are imported if requested. Processing can then proceed as normal.
With all of the additional data imported into SAAPdb, the remaining analyses can be imple-
mented as SQL queries. These are carried out in phase (C) (steps [12-26]) and update the ap-
propriate columns in the mutanalysis table.
The results are summarised in phase (D). First, each mutation described in the mutanalysis
table is annotated as predicted to have a structural effect or not, based on the results of steps
[5,12-26]. In step [28], the disease mutation summary and saap mutation summary ta-
bles are populated. These tables summarise the structural analysis results for each sequence mu-
tation, as described in either saap or lsdb saap, by summing over all mapped structures. Fi-
nally, any blank entries in the disease mutation summary and saap mutation summary
tables are replaced by zeros (step [29]).CHAPTER 6. SAAPDB MACHINERY 238
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Figure 6.12: The SAAPdb Makeﬁle
All targets are shown in square-edged boxes, with the ﬁve top-level targets (init, init nohgv, pipeline, publish
and backup) at the top of the diagram, highlighted in thick-lined boxes. The thick green line follows processing, from
START to FINISH (indicated by round-edged green boxes); alternative processing steps are shown by a split in the
green line. init: processes all SAAPs (dbSNP, HGVBase and LSMDBs); init nohgv: processes only dbSNP and
LSMDB SAAPs; pipeline: runs the pipeline on the SAAP data in SAAPdb; backup: creates a backup of SAAPdb,
and publish: creates a web-live version of SAAPdb and creates an SQL download of the most recent backup of
SAAPdb. Boxes highlighted in gold are ‘executing’ targets (i.e., they execute the scripts) whereas white boxes are
‘abstract’ targets, pointing to other targets. The blue lines trace the targets of the top-level init and the red lines trace
the targets of init nohgv. Dashed black lines link two uses of the same target.
6.2.8 Putting it all together: the Makeﬁle
. The Makeﬁle was originally written by Craig Porter, with small additions (including the ability to
backup and make the data web-live) by Lisa McMillan.
The SAAPdb system is controlled via a Makeﬁle. The targets for the Makeﬁle are described in
this section and illustrated in Figure 6.12.
The init target imports and processes dbSNP and HGVBase SNPs, and all LSMDB PDs. The
SNP importing requires several layers of data processing as described in Section 6.2.3. The
init nohgv targets initiates processing of the dbSNP and LSMDB PD data only (i.e., HGVBase
is not imported or processed). The pipeline target runs the pipeline on all SAAPdb data.
The backup target runs a ‘VACUUM FULL ANALYSE;’ on SAAPdb and creates a gzipped-tar
backup of the data. publish can be used to make a web-live version of the database and to
construct an SQL download of the relevant tables for remote reconstruction of SAAPdb.Chapter 7
SAAPdb : data overview
In Chapters 4 and 5 the current suite of structural analyses in SAAPdb was described. In Chap-
ter 6 the mechanics and machinery of SAAPdb were described, including the import of PD and
SNP data; the mapping of SAAPs to protein structures; the integration of data necessary for
the structural analyses and the implementation of the structural analyses themselves. In this
chapter, the resulting data are analysed. The aim of this analysis is to characterise pathogenic
deviations (PDs) and single nucleotide polymorphisms (SNPs), with a view to building models
that predict whether a novel SAAP (single amino acid polymorphism) will cause disease.
Note that this analysis includes SNP data from HGVBase and that all SNPs have been mapped
to sequence using the mapping procedure described in Section 6.2.4. Some of the work in this
chapter has been published in Hurst et al. (2009).
7.1 Introduction
It is the intention that the data compiled in SAAPdb will eventually be used to train machine
learning methods to predict whether a novel SAAP will disrupt the native protein structure,
thus inducing a disease phenotype. In this context, it is important to characterise both datasets
as fully as possible for several reasons.
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Firstly, the analysis will suggest whether it is possible to train a prediction algorithm at all: the
data analysis may conclude that there is no discriminatory power in the data and therefore no
potential for successful prediction. Such a result would motivate the collection of more data,
and, in particular, more varied data in the form of additional structural analyses.
Secondly, characterising the datasets would inform the choice of data representation and ma-
chine learning method. By drawing on existing literature and the results described in this chap-
ter, it will be possible to maximise the discriminative power inherent in the feature vector with
which the training data are represented. Further, should the analysis reveal characterstics of
the dataset as a whole (e.g., whether the data are particularly sparse), this will inform the most
appropriate choice of algorithm.
Finally, a maturing body of literature exists in this ﬁeld (see Section 1.9). To date, SAAPdb is the
most extensive collation of SAAPs, both deleterious and neutral, and their structural effects. A
systematic analysis of the contents of SAAPdb will contribute signiﬁcantly to the understand-
ing of disease polymorphisms, and ultimately the treatment of the deleterious phenotype.
To recap the SAAPdb system, Figure 7.1 shows a simpliﬁed workﬂow for the population of
SAAPdb. PD processing is highlighted in yellow and SNP processing is highlighted in grey.
This colour scheme will be used throughout this chapter to denote each dataset. As described
in detail in Chapter 6, SNPs are mapped to protein structure by assembling the genomic cod-
ing sequence from EMBL and Genbank records, and aligning the translated sequence with
UniProtKB/Swiss-Prot sequences (step (1) in Figure 7.1, see Section 6.2.4). PDs, being derived
from multiple sources (OMIM and several LSMDBs, see Section 2.1.2), are imported by ﬁrst
representing the data in the same XML format and then processing and verifying these data
(step (2) in Figure 7.1, see Section 6.2.6 for details). At this point, both PDs and SNPs—together
described as SAAPs—are mapped to protein sequences. The SAAPs are then mapped to pro-
tein structures using PDBSWS (step (4), see Section 6.2.2 for details) and the native structures
are analysed to extract basic information, such as binding sites, relative accessibilities and sec-
ondary structure classiﬁcations (step (4)). Finally, each SAAP is processed by the structural
analysis pipeline (step (5), see Chapter 5 for details) to ascertain whether it is expected to have
a structural effect.
Table7.1summarizesthecontentofSAAPdb. AfterimportingtherawdatafromtheSNPrepos-
itories and the various LSMDBs (i.e., after step (2) in Figure 7.1), there are approximately tenCHAPTER 7. SAAPDB : DATA OVERVIEW 241
Genbank dbSNP HGVBase EMBL LSMDBs UniProtKB OMIM
(3) Map SAAP to protein structure PDBSWS
(4) Analyse native structure
(5) Identify possible structural effects
PDB
 SAAPdb
PQS
FOSTA
(1) Identify coding SNPs (2) Identify missense PDs and
verify their mapping to
protein sequence records
and map them to protein
sequence records
MMDBBIND
Figure 7.1: The SAAPdb workﬂow
STEP(1)SNPsaremappedtoproteinsequencebytranslatingthegenomiccodingsequenceintoaproteinsequenceand
aligning this with named UniProtKB/Swiss-Prot sequences (see Section 6.2.4); STEP (2) PDs are imported from OMIM
and various LSMDBs and the protein sequence mappings provided are veriﬁed (see Section 6.2.6); STEP (3) From
now on, both PDs and SNPs (together, described as SAAPs) are processed identically, in step (3), they are mapped to
protein structures using PDBSWS (see Section 2.1.5); STEP (4) The native structure is analysed to extract basic data
like accessibility and binding sites; STEP (5) Each SAAP is analysed by the structural analysis pipeline (see Chapters
5-6) which requires some additional data, external to SAAPdb, including FOSTA (Chapter 3), PQS (Section 5.4) and
MMDBBIND (Section 5.5. Resources and processes speciﬁc to the PD dataset are highlighted in yellow, resources and
processes speciﬁc to the SNP dataset are highlighted in grey, resources and processes common to both datasets are not
coloured. SAAPdb is highlighted in blue. Solid black arrows indicate the direction of data ﬂow; dashed blue lines
indicate where data are stored in SAAPdb.CHAPTER 7. SAAPDB : DATA OVERVIEW 242
Table 7.1: A summary of the data in SAAPdb
PDs SNPs
Raw number described in database 9997 16227751
Raw number of SAAPs mapped to sequence 9617 24492
Unique sequence polymorphisms 8972 14015
Raw number mapped to at least one structure 4319 2022
thousand pathogenic deviations (PDs) and over 16 million neutral mutations described. 9 617
PDs (8 972 of which are unique) and 24 492 SNPs (of which 14 015 are unique) are successfully
mapped to amino acid changes in a UniprotKB sequence. Using PDBSWS (Martin, 2005), the
SAAPs are then mapped onto PDB structures (step (3) in Figure 7.1). Of the 9 617 mapped and
coding PDs, 44.91% are mapped to at least one PDB structure, but only 8.26% of the neutral
mutations are identiﬁed in a protein structure.
Despite having over one thousand times more ‘raw’ mutations in the SNP dataset as compared
with the PD dataset, the two mapping stages (gene to protein sequence and protein sequence
to protein structure) eliminate much of the SNP data to leave a more balanced dataset (many
SNPs will have been lost when mapping to protein sequence as they will occur in non-coding
areas of the genome).
It is possible that the SNP repositories (in particular dbSNP) describe polymorphisms as neu-
tral that should be described as disease-causing. In SAAPdb, only six (see Section 6.1) poly-
morphisms are described in both datasets. For the analyses presented in this chapter, these
polymorphisms are removed from the SNP dataset, but remain in the PD dataset. This is based
on the assumption that the large-scale genomic scanning technology by which the SNPs are
identiﬁed happens to have sequenced the genome of an individual carrying a disease muta-
tion.
ThischapterwillreportananalysisofthedataobtainedbytheprocessesdescribedinFigure7.1.CHAPTER 7. SAAPDB : DATA OVERVIEW 243
7.2 Methods
7.2.1 Averaging across multiple structures
PDBSWS (Martin, 2005) is used to map mutations in UniProtKB/Swiss-Prot sequences to PDB
structures (see Section 2.1.5). The redundancy in the PDB allows multiple SAAP/structure
mappings to be identiﬁed by PDBSWS.
ThereisdisparityinthenumberofstructurestowhichSAAPsaremappedinthedatasets: some
are mapped to a single structure (e.g., mutations to the UniProtKB/Swiss-Prot record P02766,
human transthyretin), while others are mapped to over three hundred (e.g., mutations to the
UniProtKB/Swiss-Prot record P68871, human haemoglobin subunit ). This is primarily due
to research bias: some proteins are more heavily researched than others. To illustrate this, the
distributions of the number of structures to which PDs and SNPs map are shown in Figures
7.2(a) and 7.2(b) respectively. These graphs conﬁrm the expectation that proteins implicated
in disease are more heavily researched and more often structurally characterised than proteins
not implicated in disease. Furthermore, there may be some structures that are of poorer quality
andmaygivespuriousASA(accessiblesurfacearea), torsionanglemeasurementsorhydrogen-
bonding assignments.
ToaccommodatemultiplemappingsfairlyandtolimittheeffectofpoorqualityPDBstructures,
it is necessary to average over all structures to which a SAAP has been mapped when analysing
the data. The median of measurements over all mapped structures is used to average numeric
data. Where the measurement is nominal (for example, secondary structure DSSP code (Kabsch
and Sander, 1983)), the mode of the data is used.
7.2.2 Statistics
The statistics used in this chapter were introduced in Section 2.3.6. In this section, any addi-
tional information speciﬁc to the analyses used in this chapter is given.CHAPTER 7. SAAPDB : DATA OVERVIEW 244
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(a) The number of structures to which PDs are mapped
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(b) The number of structures to which SNPs are mapped
Figure 7.2: Proﬁling SAAPs by the number of structures to which they are mapped
SAAPs are mapped to structures using PDBSWS (Martin, 2005). PDs are more often mapped to multiple structures due
to research bias. PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 245
7.2.2.1 2 tests
2 tests are used to assess whether there is a signiﬁcant difference between the PD and the SNP
datasets with respect to the occurrence of a particular feature. All 2 tests with one degree of
freedom (i.e., a 2x2 contingency table) are carried out using the Yates correction (which prevents
underestimating the p-value, see Section 2.3.6.3). Note that, where results are reported with
percentages, raw counts have been used in the 2 test.
Where possible, 2 statistics have been calculated using separately calculated expected values.
In the case of individual native and mutant residues, standard amino acid frequencies (Robin-
son and Robinson, 1991) were used to estimate the numbers to be expected in the dataset. To
analyse each polymorphism (i.e., each native/mutant residue pair), the PAM30 (Dayhoff et al.,
1978) matrix was normalised (i) to include only positive values, and (ii) to sum to 100. To reﬂect
the SAAP data more accurately, only native/mutant residue pairs (a;b) that can be generated
by a single base change were considered when normalising the matrix. The formula for this
transformation is shown below:
P0
sbc(a;b) = 100 
Psbc(a;b)   min(Psbc)
P
Psbc
(7.1)
where n is the number of different amino acids (therefore n = 20); Psbc is the submatrix of
the PAM30 matrix which describes only those mutations that can be derived from a single base
change; P0
sbc is the normalised PAM30 single base change submatrix; Psbc(a;b) is the amino acid
substitution matrix Psbc score for replacing residue a with residue b; min(Psbc) is the minimum
value in the matrix Psbc, and
P
Psbc is the sum of all the scores in the matrix Psbc.
These normalised cell values were then used to approximate relative frequencies of mutations
and therefore estimate the expected frequencies in the given dataset. The PAM30 substitu-
tion matrix was used because it is the most widely used amino acid substitution matrix that is
derived from closely related sequences. This is appropriate because, in this dataset, human pro-
teins are effectively being compared with themselves. Finally, expected values for secondary
structure element occurrence were derived from a dataset of high resolution (2.0 ˚ A) PDB struc-
tures.CHAPTER 7. SAAPDB : DATA OVERVIEW 246
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Figure 7.3: Interpreting a cumulative distribution function (CDF) plot
The two sets randomly generated data are shown above: the dataset A (shown in blue) has a mean of -1 and a standard
deviation of 1, the dataset B (shown in red) has a mean of 1 and a standard deviation of 1. It becomes immediately
apparent which dataset contains higher values in the CDF plot (far right): the CDF for dataset A is consistently higher
than that of B, indicating that a higher proportion of datapoints in A are found at lower values.
2 testsareunreliableifthedatasufferlowcounts, speciﬁcallywherethecontingencytablecon-
tains one or more cell values  5. Fisher-exact tests have been carried out on low-count datasets
to verify 2 results. Low-count datasets are deﬁned as datasets with at least one contingency
table cell with a value  10.
7.2.2.2 Kolmogorov-Smirnov tests
The Kolomogorov-Smirnov (KS) test has been used to compare the distribution of numerical
data in the SAAP datasets. All KS tests have been run in R using the ks.boot method (see
Section 2.3.6.2).
Cumulative distribution function (CDF) plots are used extensively in this chapter. Often, when
comparing large datasets, histograms are difﬁcult to interpret; differences become more appar-
ent by comparing CDFs. In Figure 7.3, two datasets are compared using their CDF functions.
Although it is clear from the histograms that these datasets are different, the CDF plot makes it
immediately apparent that the values in dataset A are lower than the values in dataset B.CHAPTER 7. SAAPDB : DATA OVERVIEW 247
7.2.2.3 Log ratios
Log ratios demonstrate clearly where features in the dataset are seen more or less often than
expected when compared to some reference values. Where such reference values are available
or can be reliably estimated, the corresponding log ratios have been calculated. As described in
Section 7.2.2.1, expected values for the individual mutant and native residues were taken from
Robinson and Robinson (1991), and expected values for each native/mutant residue pair were
estimated by transforming the PAM30 matrix to (i) eliminate negative values and (ii) to sum to
100.
All log ratios are log2.
7.2.3 Discriminative features
With a view to distinguishing between PDs and SNPs, and potentially training machine learn-
ing methods to predict whether a novel SAAP is deleterious or not, it is most important to
identify those features that are ‘discriminative’. In the context of the current dataset, a dis-
criminative feature must meet two criteria. Firstly, it must be found at signiﬁcantly different
frequencies in the PD dataset and the SNP dataset, by 2 tests or otherwise. Secondly, where
reliable expected frequencies are available, the feature must be over-represented in one dataset,
while being under-represented in the other.
7.3 Results and Discussion
7.3.1 Illustrative examples
Before describing the analysis of the SAAPdb data, this section illustrates some of the results of
the analysis pipeline.
Figure 7.4 shows the structure of human super-oxide dismutase [UniPro-
tKB:P00441/SODC HUMAN], as described by the PDB structure 2c9s. Mutations toCHAPTER 7. SAAPDB : DATA OVERVIEW 248
Figure 7.4: PDs identiﬁed at the interface
PDB structure 2c9s, chains A (in blue and light blue, on the left) and F (in red and pink, on the right). Ligands are
shown in spaceﬁll using the CPK colour scheme. Mutated residues identiﬁed by the interface (see Section 5.3.2) and
PQS (see Section 5.4) analyses are shown in darker blue and red, with Van der Waals volumes indicated. Note that
these analyses also identify residues near ligand binding sites, as well as residues at the chain interface.
super-oxide dismutase have been associated with amyotrophic lateral sclerosis or motor
neurone disease (Aguirre et al., 1999). Chain A is shown in blue, chain F is shown in
red. Residues identiﬁed by the interface or PQS analyses are shown in darker blue and
red respectively, with their Van der Waals suface indicated with dots. This illustrates that
PQS/interface residues occur both at the inter-chain interface and at ligand binding sites.
Figure 7.5 shows three orientations of the human transthyretin protein [UniPro-
tKB:P02766/TTHY HUMAN] as described by the PQS record 1soq 1.mmol. Mutations to
transthyretin are associated with several amyloid diseases, including cardiomyopathy (Ranløv
et al., 1992) and polyneuropathology (Ferlini et al., 2000). 48 transthyretin disease mutations
(derived from OMIM, MIM:176300) are mapped to structure in SAAPdb.
The transthyretin PDs identiﬁed at the interchain protein interface are shown in orange or red
in Figure 7.5 (the residues highlighted in red introduce a hydrophobic residue on the surface
of the protein chain in addition to occurring at the interface). To demonstrate the value of
using the ‘corrected’ PQS structures (see Section 5.4) rather than the basic PDB structures (seeCHAPTER 7. SAAPDB : DATA OVERVIEW 249
(a) Native 1soq:B,D (b) Native 1soq:A,B,C,D (c) Native 1soq:A,C
Figure 7.5: PDs identiﬁed at the PQS interface
PQS structure 1soq 1.mmol, chains A, B, C and D. Residues identiﬁed by the PQS analysis (see Section 5.4) but not
the interface analysis (see Section 5.3.2) are highlighted in orange and red above (red residues are also identiﬁed by
the surface-phobic analysis, see Section 5.9). Figure 7.5(b) shows all four chains (ABCD) together; Figure 7.5(a) shows
chains B and D rotated +90on the horizontal axis; Figure 7.5(c) shows chains A and C rotated -90on the horizontal
axis.
Section 5.3.2-5.3.3), only those PDs explained by the PQS analysis but not explained by the PDB
interface analysis are highlighted. The BD and AC dimers are separated and rotated to display
the interface in Figures 7.5(a) and 7.5(c) respectively. It is clear that the mutations cluster at the
interface of the AC and BD dimers (no ligands are described by the 1soq structure).
The tumour suppressor protein P53 [UniProtKB:P04637/P53 HUMAN] is mutated in roughly
half of human cancers (Greenblatt et al., 1994; Sidransky and Hollstein, 1996; Lane and Fischer,
2004). Chain B of the solved P53 structure 1tsr is shown in complex with DNA in Figure 7.6;
residues identiﬁed as ‘functional’ by the binding, PQS and UniProtKB/Swiss-Prot FT analyses
(i.e., residues identiﬁed by all of these analyses) are highlighted in blue (these residues are also
identiﬁed as highly conserved by ImPACT). These functional residues are clustered around the
DNA-binding site.
Another P53 mutant is shown in Figure 7.7. Here, the native glycine residue at position 279 is
mutated to tryptophan, the largest amino acid. When modelling the mutant residue into the
native structure (using MutModel, see Section 5.2), the best orientation of the mutant sidechain
clashes with 27 other native atoms. Figure 7.7(a) shows that the native glycine ﬁts neatly in-
side the structure, while the tryptophan residue in Figure 7.7(b) protrudes out of the structure,
clashing with other atoms, inhibiting formation of the native fold and inducing the diseaseCHAPTER 7. SAAPDB : DATA OVERVIEW 250
Figure 7.6: Binding PDs in P53
PDB structure 1tsr, chain B (in grey and blue) in complex with DNA. PDs that disrupt binding, as deﬁned by the
binding (see Section 5.3.3), PQS (see Section 5.4), ImPACT (high conservation, see Chapter 4) and UniProtKB/Swiss-
Prot FT analyses (see Section 5.11) are highlighted in blue.
phenotype.
The native tyrosine residue at position 236 of human P53 forms a hydrogen bond with the
threonine residue at position 253; these residues are highlighted in blue in Figure 7.8(a). This
hydrogen bond is broken in the Y236D mutant structure in Figure 7.8(b), as the introduced
aspartic acid sidechain is too distant to accept the hydrogen donor atom from T253. Note also
that this hydrogen bond is buried, and therefore could be critical to the scaffold of interactions
that stabilise the protein structure. In addition to breaking the hydrogen bond, this mutation
will introduce an unpaired buried charge and is found to cause a de-stabilising internal void.
Many mutations to the structure of human haemoglobin have been reported: SAAPdbCHAPTER 7. SAAPDB : DATA OVERVIEW 251
(a) Native 2ata:A (b) Mutant G279W 2ata:A
Figure 7.7: PDs found to clash with other existing residues
PDB structure 2ata, chain A (shown in grey). The mutation G279W is described in the P53 somatic mutation dataset.
The native and mutant structures are shown above, on the left and right respectively. The modelled tryptophan mutant
residue clashes with 27 other atoms, and cannot be accommodated in the native structure.
(a) Native 2j1w:B (b) Mutant Y236D 2j1w:B
Figure 7.8: PDs that break hydrogen bonds
PDB structure 2j1w, chain B. The hydrogen bond that exists between the Y236 and T253 is not maintained in the mutant
Y236D structure shown on the right (see Section 5.3.1). Residues 236 and 253 are highlighted in blue in both structures.CHAPTER 7. SAAPDB : DATA OVERVIEW 252
contains over six hundred. The mutation F42S in human haemoglobin [UniPro-
tKB:P68871/HBB HUMAN] is reported to be associated with cyanosis, moderate
reticulocytosis and mild anaemia (Stabler et al., 1994). SAAPdb ‘explains’ this mutation as
introducing a void on the surface of the protein (compare the native structure in Figure 7.9(a)
with the mutant form in Figure 7.9(b)). Note also that this void is close to the binding site of
the haem ligand and therefore may affect the function of haemoglobin directly in addition to
destabilising the structure. SAAPdb explains mutations at residue 42 with the interface, PQS
and binding analyses.
Figure 7.10 shows the 1r1y crystal structure of human haemoglobin. Here, the mutation
V54D introduces a buried, unsatisﬁed charge by replacing a neutral valine residue with the
negatively charged aspartic acid (see Section 5.8). In addition, this mutation introduces an
unfavourable hydrophilic residue in the protein core. An example of the complementary
analysis—introducing a hydrophobic residue on the surface of the protein—is shown in Figure
7.11. The mutation seen here is the E6V mutation described in Chapter 1 that causes sickle cell
anaemia, where the ‘sticky’ hydrophobic patch owing to the mutant valine residue causes
aggregation and subsequent deformation of erythrocytes.
The example in Figure 7.12 shows a broken disulphide bond in super-oxide dismutase, iden-
tiﬁed both by the UniProtKB/Swiss-Prot FT analysis and the geometric disulphide analysis of
the PDB ﬁles.
Figures 7.13 and 7.14 show the Ramachandran plots (Ramachandran et al., 1963) obtained from
a RAMPAGE (Lovell et al., 2003) analysis of two mutant protein structures. RAMPAGE is a
webserver that identiﬁes unfavourable torsion angles for non-pro, non-gly, pro, gly and pre-
pro residues in protein structures. Favoured conformations are plotted in black, less favoured
conformations are plotted in orange and disallowed conformations are shown in red. Figure
7.13(a) shows the RAMPAGE analysis of human haemoglobin (PDB record 1ch4, chain A) and
Figure 7.13(b) shows the same analysis for a multiple to-pro mutant (prolines are introduced
at positions 2, 32, 38, 48, 76, 86, 88, 96, 97, 117, 138, 142, 143 and 146) of the same structure.
Comparison of the two ﬁgures demonstrates that the torsion angle conformations in the mutant
structure are generally less favoured, with some conformations disallowed.
Figures 7.14(a) and 7.14(b) show the same comparison for the native and a multiple from-gly
(speciﬁcally G!D mutations at positions 105, 154, 226, 245 and 262) mutant of chain A of theCHAPTER 7. SAAPDB : DATA OVERVIEW 253
(a) Native 1qsh:D (b) Mutant F42S 1qsh:D
Figure 7.9: PDs that create a void or crevice
PDB structure 1qsh, chain D. Replacing the native phenylalanine residue at position 42 with a serine residue (as shown
on the right) creates a void or surface crevice which may destabilise the protein. Residue 42 is highlighted in magenta
and the haem ligand is highlighted in blue. This mutation is also explained by affecting the PQS interface (i.e., affecting
binding to the haem ligand).CHAPTER 7. SAAPDB : DATA OVERVIEW 254
(a) Native 1r1y:D (b) Mutant V54D 1r1y:D
Figure 7.10: PDs that introduce a buried, unsatisﬁed charge
PDB structure 1r1y, chain D. The buried charge analysis (see Section 5.8) identiﬁes the V54D mutation in 1r1y as replac-
ing a neutral valine residue (Figure 7.10(a)) with a negatively charged aspartic acid (Figure 7.10(b)), thus introducing
a buried unsatisﬁed charge. Residue 54 is highlighted in magenta and the haem ligand is highlighted in blue. The
mutation also introduces a hydrophilic residue in the core (see Section 5.10).CHAPTER 7. SAAPDB : DATA OVERVIEW 255
(a) Native 1hbb:D (b) Mutant E6V 1hbb:D
Figure 7.11: PDs that introduce hydrophobic residues on the surface
PDB structure 1hbb, chain D. A mutation from glutamic acid to valine at residue 6 introduces a ‘sticky’ hydrophobic
residue on the surface of 1hbb (see Section 5.9). Residue 6 is highlighted in magenta and the haem ligand is highlighted
in red. This is the mutation that causes sickle cell anaemia.
(a) Native 1hl5:I (b) Mutant C146R 1hl5:I
Figure 7.12: PDs that disrupt disulphide bonding
PDB structure 1hl5, chain I. A disulphide bond exists between C57 and C146 in chain I of 1hl5 (see native structure
on the left). A mutation replacing C146 with an arginine (see mutant structure on the right, with the mutant arginine
highlighted in red) is ‘explained’ both by the SSGEOM and UniProtKB/Swiss-Prot FT analyses (see Sections 5.6 and
5.11) as breaking a disulphide bond. The same mutation is also identiﬁed by ImPACT (see Chapter 4) and the clash
analysis (see Section 5.3.6).CHAPTER 7. SAAPDB : DATA OVERVIEW 256
PDB structure 2bin (human P53). Again, there are a larger number of less well favoured and
disallowed torsion angle conformations in the mutant structure.
Figure 7.15 shows the structure of glucosylceramidase [UniProtKB:P04062/GLCM HUMAN]
as described by the PDB record 2nt0. Many genomic aberrations have been identiﬁed in the
corresponding GBA gene which are associated with Gaucher’s disease, a disorder of lysoso-
mal storage that results in a spectrum of neuropathologies (Jmoudiak and Futerman, 2005).
39 disease-associated glucosylceramidase mutations have been mapped to 2nt0, chain A and
subsequently analysed by SAAPdb. In addition, a smaller number (10) of glucosylceramidase
mutations described by dbSNP have been mapped to 2nt0, chain A and subsequently analysed
by SAAPdb.
The 39 PDs (shown in yellow in Figures 7.15(a) and 7.15(b)) and 10 SNPs (shown in grey in
Figures 7.15(c) and 7.15(d)) are mapped to chain A of 2nt0. In the left hand column (Figures
7.15(a) and 7.15(c)) all mutations mapped to the structure are shown, while only the explained
mutationsareshown intheﬁguresintheright handcolumn(Figures7.15(b)and7.15(d)). Other
protein chains in the structure are shown in grey with their Van der Waals volume suggested
by a dotted surface.
It appears that the SNPs are more likely to be found near the surface of the protein chain,
while the PDs are clustered more internally. Furthermore, SNPs appear to be more distant from
ligands than PDs, although two SNPs are found very close to the interface with other protein
chains.
Figure 7.15 suggests that there are some differences between PDs and SNPs with respect to
structure, at least in this example. The remainder of this chapter will discuss the large scale
sequence, structural and structural effect analysis of disease-associated and neutral polymor-
phisms collated in SAAPdb, from which it is hoped statistically signiﬁcant differences will be
found.
7.3.2 PD residues are more often ‘unique’
It is expected that neutral SNPs will more often be between ‘replaceable’ residues; that is,
residues that can more easily replace each other without affecting protein structure and/orCHAPTER 7. SAAPDB : DATA OVERVIEW 257
(a) Native 1ch4:A
(b) Multiple mutant 1ch4:A
Figure 7.13: PDs that introduce proline where /  are not favourable
Fourteen conformationally unacceptable mutations to proline (at positions 2, 32, 38, 48, 76, 86, 88, 96, 97, 117, 138, 142,
143 and 146) are identiﬁed in PDB structure 1ch4, chain A [UniProtKB:P68871/HBB HUMAN]. The RAMPAGE (Lovell
et al., 2003) analysis for the native and mutant structures are shown above in Figures 7.13(a) and 7.13(b) respectively.
Each Figure shows the results for all residues (blue shading, top left), glycine residues (orange shading, top right),
proline residues (green shading, bottom right) and pre-proline residues (blue shading, bottom left). Disallowed con-
formations are shown in red and less favourable conformations are plotted in orange. Note that there are many more
unfavourable /  conformations in Figure 7.13(b).CHAPTER 7. SAAPDB : DATA OVERVIEW 258
(a) Native 2bin:A
(b) Multiple mutant 2bin:A
Figure 7.14: PDs that replace glycine where /  are not favourable
Five conformationally unacceptable mutations from glycine to aspartic acid (at residues 105, 154, 226, 245 and 262)
are identiﬁed in PDB structure 2bin, chain A [UniProtKB:P04637/P53 HUMAN]. The RAMPAGE (Lovell et al., 2003)
analysis for the native and mutant structures are shown above in Figures 7.14(a) and 7.14(b) respectively. Each Figure
shows the results for all residues (blue shading, top left), glycine residues (orange shading, top right), proline residues
(green shading, bottom right) and pre-proline residues (blue shading, bottom left). Disallowed conformations are
shown in red and less favourable conformations are shown in orange. Note that there are many more unfavourable
/  conformations in Figure 7.14(b).CHAPTER 7. SAAPDB : DATA OVERVIEW 259
(a) PDs mapped to 2nt0, chain A (b) Explained PDs in 2nt0:A
(c) SNPs mapped to 2nt0, chain A (d) Explained SNPs in 2nt0:A
Figure 7.15: The distribution of PDs and SNPs in glucosylceramidase
PDB structure 2nt0, chain A. Here, both the disease (shown in yellow in Figure 7.15(a)) and the neutral mutations
(shown in grey in Figure 7.15(c)) are shown in spaceﬁll in the diagrams in the left hand column. The explained PDs
and SNPs are shown in yellow and grey spaceﬁll in the diagrams in the right hand column (Figures 7.15(b) and 7.15(d)
respectively). Residues from other chains are shown in grey, with their Van der Waals radii indicated by a dotted
surface. Ligands are coloured using the CPK colour scheme.CHAPTER 7. SAAPDB : DATA OVERVIEW 260
Table 7.2: Characterising the twenty amino acids with respect to their ‘replaceability’
Residue: the amino acid; : the average dissimilarity score (see text); Residues are sorted in ascending  (i.e., from most
‘unusual’ residues to more ‘replacable’ residues). All data are rounded to 2dp.
Residue 
Tryptophan -3.32
Cysteine -3.21
Glycine -3.16
Proline -3.05
Aspartic acid -2.68
Phenylalanine -2.58
Isoleucine -2.58
Leucine -2.32
Valine -2.16
Arginine -2.05
Asparagine -1.95
Tyrosine -1.95
Histidine -1.89
Glutamic acid -1.79
Lysine -1.68
Methionine -1.53
Alanine -1.42
Threonine -1.37
Glutamine -1.32
Serine -1.16
function. To quantify how ‘replaceable’ or, conversely, how ‘unusual’ a residue is, an average
dissimilarity value for each residue has been calculated by averaging the BLOSUM62 matrix
values (see Section 2.3.4.2) of all mutations to/from the residue. The average dissimilarity
value for a residue has been denoted with . The calculation is shown in Equation 7.2 below:
X =
1
n   1
n X
A6=X
s(A;X) (7.2)
where n is the number of amino acids (therefore, n = 20); X is the residue of interest; A denotes
all other residues, and s(A;X) denotes the BLOSUM62 amino acid substitution matrix score.
The  values for all twenty amino acids are shown in the second column of Table 7.2.
2 tests show that there are signiﬁcant differences between PDs and SNPs in terms of the native
and mutant amino acids (Table 7.3). These results are discussed in detail in Sections 7.3.2.1-
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Table 7.3: Mutant and native residues in the SAAP datasets
2: the 2 statistic from a 2x2 Yates-corrected 2 test, testing for a difference in occurrence of the residue in the two
datasets; p: the p-value (?? denotes p  0:01, ? denotes p  0:05); set: the SAAP set which has a higher occurrence of
the corresponding amino acid. All numbers are rounded to 2dp.
Native residue 2 p set
Cysteine ?? 27:70 1:42  10 7 PD
Glycine ?? 44:58 2:44  10 11 PD
Arginine ?? 56:01 7:21  10 14 PD
Tryptophan ? 4:28 3:86  10 2 PD
Tyrosine ? 4:24 3:95  10 2 PD
Alanine ?? 8:05 4:56  10 3 SNP
Glutamic acid ? 4:07 4:37  10 2 SNP
Isoleucine ?? 32:62 1:12  10 8 SNP
Lysine ?? 36:39 1:61  10 9 SNP
Glutamine ?? 8:38 3:80  10 3 SNP
Threonine ?? 15:32 9:06  10 5 SNP
Valine ?? 19:20 1:18  10 5 SNP
Mutant residue 2 p set
Cysteine ?? 29:66 5:16  10 8 PD
Aspartic acid ? 4:15 4:16  10 2 PD
Proline ?? 46:38 9:74  10 12 PD
Arginine ?? 22:62 1:98  10 6 PD
Tryptophan ?? 8:76 3:07  10 3 PD
Tyrosine ?? 8:58 3:39  10 3 PD
Alanine ?? 9:74 1:80  10 3 SNP
Phenylalanine ?? 19:43 1:04  10 5 SNP
Isoleucine ?? 68:60 1:11  10 16 SNP
Leucine ?? 9:23 2:38  10 3 SNP
Asparagine ?? 7:11 7:66  10 3 SNP
Valine ?? 17:59 2:74  10 5 SNPCHAPTER 7. SAAPDB : DATA OVERVIEW 262
7.3.2.1 Native residues
Cysteine, arginine, glycine, tryptophan and tyrosine are more often native residues in the dis-
ease dataset; alanine, glutamic acid, isoleucine, lysine, glutamine, threonine and valine are mu-
tated more often in the neutral dataset. The native residues associated with the SNP dataset are
more ‘replacable’ than those associated with the PD dataset; that is, there is at least one other
residue that behaves similarly and can often replace it without affecting function (for example,
glutamic acid/aspartic acid, isoleucine/valine and lysine/arginine). The PD-associated native
residues, which are more unusual in character, are less likely to be replaced without affecting
function.
7.3.2.2 Replacement residues
In terms of the residues introduced, there are signiﬁcantly more deleterious cysteine, aspartic
acid, proline, arginine, tryptophan and tyrosine mutant residues, and signiﬁcantly more ala-
nine, phenylalanine, isoleucine, leucine, asparagine and valine mutant residues in the neutral
dataset. Once again, those residues common in the SNP dataset are more often replaceable,
while the PD-associated residues are more unusual in character.
7.3.2.3 Discriminating residues
Figure 7.16(a) expresses each native amino acid as the log ratio of observed percentages over
the expected percentages and Figure 7.16(b) shows the same data for the mutant residues (see
Section 7.2.2.3 for a description of the log ratio calculation). The results described as signiﬁcant
in Table 7.3 are denoted with stars in Figure 7.16 (two where p  0:01 and one where p  0:05).
Positive values in Figure 7.16 indicate that the amino acid is over-represented compared with
the standard amino acid frequencies and negative values indicate under-representation.
With a view to discriminating between the two types of SAAP, the most interesting results are
those that are signiﬁcantly different from what is expected and over-represented in one dataset
and under-represented in the other (see Section 7.2.3).
For native residues, cysteine and tryptophan were identiﬁed as ‘discriminating’ residues thatCHAPTER 7. SAAPDB : DATA OVERVIEW 263
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(b) Proﬁling SAAPs by mutant residue, normalising by standard amino acid frequencies
Figure 7.16: Proﬁling SAAPs by native and mutant residues
Data are normalised using standard amino acid frequencies (see Section 7.2.2.1). Statistically signiﬁcant 2 results are
denoted with red stars (two stars denote p  0:01, one star denotes p  0:05). Residues are ordered as suggested by
Vitkup et al. (2003).PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 264
are enriched in the PD dataset, and glutamic acid, lysine, isoleucine and valine as ‘discrimi-
nating’ native residues that are enriched in the SNP dataset. For mutant residues, asparagine,
isoleucine, phenylalanine and valine are favoured as mutant residues in the SNP dataset, while
proline is the only mutant residue favoured in the PD dataset.
The discriminating residues associated with the PD dataset have unique roles in protein struc-
ture, while those associated with the SNP dataset have characteristics that are shared with other
amino acids and so may more readily be replaced, without resulting in a disease phenotype.
These results are supported by earlier work in which glycine, cysteine and tryptophan have
been characterised as targets of deleterious polymorphisms (Vitkup et al., 2003; Dobson et al.,
2006).
In Table 7.4, the  dissimilarity score for the twenty amino acids is given; again, these data
are ordered from the least to the most replaceable residue, as measured by . Those residues
that have been described as discriminatory above (either as a native or mutant residue) are
annotated with z symbols; statistically signiﬁcant results that were not found to be discrimi-
natory are denoted with a y. The PD+ve column is used for residues associated with or over-
represented in the PD dataset, while the SNP+ve column is used for residues associated with or
over-represented in the neutral SNP dataset.
The top ﬁve residues, and therefore the ﬁve most unusual residues (as measured by ) are more
frequently found in the deleterious dataset. Of these ﬁve, three are discriminatory; that is, they
are over-represented in the PD dataset while being under-represented in the SNP dataset. The
SNP-associated residues have lower  values, suggesting that they are more ‘replaceable’.
7.3.3 PDs are more often between residues with different characteristics
In Section 7.3.2, the native or mutant residues were considered independent of their mutation
partner. In this section, the native/mutant residue pairs are analysed.
Table 7.5 lists the discriminating mutations that (i) occur at signiﬁcantly different rates com-
pared with what is expected, and (ii) are found to be over-represented in one dataset and
under-represented in the other (see Section 7.2.3). Ten of the eleven discriminating SAAPs
that are associated with the deleterious dataset include at least one of glycine, cysteine or pro-CHAPTER 7. SAAPDB : DATA OVERVIEW 265
Table 7.4: Characterising the native/mutant amino acids observed in SAAPdb with respect to
their ‘replaceability’
Residue: the amino acid; : the average dissimilarity score (see text); PD+ve: residues more often seen as mutant or
native residues in the PD dataset are annotated with a y in the PD+ve column, discriminating residues (see text) are
annotated with a z. SNP+ve: residues more often seen as mutant or native residues in the SNP dataset are annotated
with a y in the SNP+ve column, discriminating residues (see text) are annotated with a z. Residues are sorted in
ascending  (i.e., from most ‘unusual’ residues to more ‘replacable’ residues). All data are rounded to 2dp.
Residue  PD +ve SNP +ve
Tryptophan -3.32 z
Cysteine -3.21 z
Glycine -3.16 y
Proline -3.05 z
Aspartic acid -2.68 y
Phenylalanine -2.58 z
Isoleucine -2.58 z
Leucine -2.32 y
Valine -2.16 z
Arginine -2.05 y
Asparagine -1.95 z
Tyrosine -1.95 y
Histidine -1.89
Glutamic acid -1.79 z
Lysine -1.68 z
Methionine -1.53
Alanine -1.42 y
Threonine -1.37 y
Glutamine -1.32 y
Serine -1.16CHAPTER 7. SAAPDB : DATA OVERVIEW 266
Table 7.5: Mutations found to be signiﬁcantly over-represented in one dataset and under-
represented in the other
2: the 2 statistic from a 2x2 Yates-corrected 2 test; p: the p-value (?? denotes where p < 0:01, ? denotes where
p < 0:05); LR: the log2 ratio; Blo62: the BLOSUM62 score for this mutation. Results are ordered by the absolute
difference between the two L2R scores. All numbers are rounded to 2dp.
PD mutations 2 p PD LR SNP LR Blo62
Cys!Tyr ?? 14:72 1:25  10 4 0.68 -3.53 -2
Tyr!Cys ?? 16:78 4:21  10 5 1.09 -1.94 -2
Phe!Cys ? 4:30 3:82  10 2 0.86 -2.04 -2
Leu!Pro ?? 29:45 5:74  10 8 2.32 -0.37 -3
Arg!Pro ?? 10:98 9:22  10 4 0.80 -1.53 -2
Gly!Asp ?? 16:21 5:66  10 5 1.40 -0.63 -1
Leu!Arg ?? 8:50 3:55  10 3 1.21 -0.72 -2
Ser!Pro ? 5:14 2:34  10 2 0.19 -1.40 -1
Gly!Ser ?? 9:69 1:86  10 3 1.18 -0.26 -1
Cys!Arg ? 5:79 1:61  10 2 1.19 -0.23 -3
Gly!Glu ? 6:19 1:29  10 2 0.95 -0.36 -2
SNP mutations 2 p PD LR SNP LR Blo62
Asp!Glu ?? 36:05 1:92  10 9 -1.21 0.77 2
Arg!Lys ?? 17:13 3:49  10 5 -1.88 0.02 2
Ile!Phe ?? 16:13 5:91  10 5 -1.65 0.19 0
Lys!Arg ?? 29:26 6:34  10 8 -1.02 0.81 2
Val!Ile ?? 36:47 1:55  10 9 -0.79 1.00 3
Ile!Val ?? 21:51 3:51  10 6 -1.28 0.42 3
Leu!Val ?? 31:98 1:55  10 8 -0.42 1.28 1
Gln!His ?? 21:51 3:51  10 6 -1.21 0.49 0
Ala!Ser ?? 23:04 1:59  10 6 -0.88 0.75 1
Glu!Asp ?? 31:86 1:65  10 8 -0.45 1.13 2
Ile!Met ?? 10:58 1:14  10 3 -1.35 0.10 1
Ser!Ile ?? 8:99 2:72  10 3 -0.93 0.52 -2
Lys!Asn ?? 17:80 2:45  10 5 -0.03 1.19 0
Glu!Gln ?? 8:34 3:88  10 3 -1.06 0.12 2
His!Gln ?? 8:34 3:88  10 3 -1.06 0.12 0
Met!Ile ?? 16:05 6:16  10 5 -0.03 1.15 1
Val!Phe ? 5:97 1:46  10 2 -0.07 0.96 -1
Val!Ala ?? 9:24 2:37  10 3 -0.15 0.87 0
Ser!Cys ? 4:66 3:09  10 2 -0.41 0.46 -1CHAPTER 7. SAAPDB : DATA OVERVIEW 267
line, the residues identiﬁed in Section 7.3.2 as a PD-favoured native or mutant discriminating
residue. Interestingly, no from-tryptophan mutations are identiﬁed, despite Trp!X being iden-
tiﬁed as PD+ve discriminating residue in Section 7.3.2. It is possible that the deleterious effect
of from-tryptophan mutations is predominantly due to losing the characteristics of tryptophan
and that the introduced residue is irrelevant; thus the counts for each Trp!X mutation are too
low to be signiﬁcant. It is also interesting to note that both Cys!Tyr and Tyr!Cys are the mu-
tations that generate the two most disparate log ratio results in the two datasets (c.f. columns 4
and 5 in Table 7.5).
There are nineteen SNP-associated discriminating mutations, which include ﬁve pairs of
‘commutative’ mutations (i.e., X!Y and Y!X). The discriminating SNP-associated residues
identiﬁed from Figure 7.16 commonly occur in this dataset (lysine, glutamic acid, isoleucine,
valine, phenylalanine and asparagine). Once again, many of these mutations are between
interchangable amino acids (for example, aspartic acid/glutamic acid, lysine/arginine,
isoleucine/valine, leucine/valine and glutamine/glutamic acid).
The ﬁnal column of Table 7.5 describes the discriminating mutations in terms of their BLO-
SUM62 score (Henikoff and Henikoff, 1992). It is striking that all eleven of the discriminating
mutations enriched in the PD dataset have a negative score, while eleven of the nineteen dis-
criminating mutations enriched in the neutral dataset have a positive score (ﬁve further mu-
tations have a BLOSUM62 score of 0). This indicates that the mutations characteristic of the
SNP dataset tend to be between similar residues, which more commonly replace one another
in evolution, whereas PD mutations are more likely to be between amino acids which rarely
replace one another in evolution.
The distribution of BLOSUM62 scores for the deleterious and neutral mutations are shown in
Figures 7.17(a)-7.17(c), and the distribution of their PAM30 scores are shown in Figures 7.18(a)-
7.18(c). It is useful to compare PDs and SNPs using both amino acid substitution matrices be-
cause they are derived from different data: the BLOSUM62 matrix is derived from sequence
alignments of more distantly related species than are used to derive the PAM30 matrix. Al-
though the distributions are not continuous, the CDF plots in Figures 7.17(c) and 7.18(c) serve
to show that PDs have lower BLOSUM62 and PAM30 scores than SNPs. A 2 test shows that
these differences are statistically sigiﬁcant (2
df=15 = 533:55;p ' 0 and 2
df=33 = 315:34;p ' 0
for BLOSUM62 and PAM30 scores respectively).CHAPTER 7. SAAPDB : DATA OVERVIEW 268
Blosum scores (PDs)
Blosum score
F
r
e
q
u
e
n
c
y
−4 −3 −2 −1 0 1 2 3
0
5
0
0
1
0
0
0
1
5
0
0
2
0
0
0
2
5
0
0
(a) Distribution of BLOSUM62 scores for PDs
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(c) CDF plot of PD/SNP BLOSUM62 scores
Figure 7.17: Proﬁling SAAPs by their BLOSUM62 AA substitution matrix scores
PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 269
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(c) CDF plot of PD/SNP PAM30 scores
Figure 7.18: Proﬁling SAAPs by their PAM30 AA substitution matrix scores
PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 270
To return to the concept of average dissimilarity as described in Section 7.3.2, Figure 7.19 shows
a matrix, describing all possible mutations. The rows describe the native residues and the
columns describe the mutant residues. Both the colums and rows are ordered by increasing .
The matrix is partitioned into a pale yellow PD-associated area and a pale grey SNP-associated
area. This is done by identifying the residue with the highest  score that is identiﬁed as a
PD+ve discriminatory residue (proline, see Table 7.4) and using this residue as the inclusive
PD+ve threshold. Using this method, W, C, G and P cells are deﬁned as the PD-associated area
and all others are deﬁned as the SNP-associated area.
PD+ve discriminatory mutations (as described in Table 7.5) are then indicated by colouring the
corresponding cell with a brighter yellow and SNP+ve discriminatory mutations are indicated
by colouring the corresponding cell with a darker grey. It is clear that the partitioning of the
mutation matrix in this way is very successful in capturing the classiﬁcation of the discrim-
inatory mutations: only two discriminatory mutations are found in the ‘wrong’ region: the
Leu!Arg mutation and the Ser!Cys mutation.
It is impossible at this stage to comment with any conﬁdence as to whether the proﬁle of residue
substitutions will change if the site of the mutation is, for example, on the surface, in the core or
at a functional site. However, there is a clear and signiﬁcant tendency for PDs to be mutations
to and from amino acids known to have a unique role in protein structure, and for SNPs to be
mutations between physicochemically similar residues.
7.3.4 PDs affect sites of higher conservation
Residues that are highly conserved across diverse species have been consistently selected for
across different branches of evolution. It is therefore likely that they are critical to protein
function.
The histograms in Figures 7.20(a) and 7.20(b) describe the distribution of conservation scores
for SNPs and PDs. These conservation scores are generated by the species-similarity weighted
method (described in Section 4.2.1) used by ImPACT (see Chapter 4). Only data for those
SAAPs that are mapped to alignments of 10 or more reliable, fully sequenced, functionally
equivalent proteins as identiﬁed by FOSTA (see Chapter 3) are included here.CHAPTER 7. SAAPDB : DATA OVERVIEW 271
Figure 7.19: Characterising the SAAPs with respect to the ‘replaceability’ of the native and
mutant residues
The rows describe the native amino acid, the columns describe the mutant amino acid in the polymorphism pair. Amino
acids are ordered by increasing ; that is, from most unique to more replaceable. The PD-associated mutation region
(as deﬁned by the dicriminatory mutations, see text) is coloured in pale yellow, while the SNP-associated mutation
region is coloured in pale grey. Yellow and grey boxes denote discriminatory mutations (see text): yellow mutations
are over-represented in the PD dataset and under-represented in the SNP dataset, grey mutations are over-represented
in the SNP dataset and under-represented in the PD dataset. It is clear that PDs cluster in the top left hand half of the
matrix, where mutations between the most unique residues are described.CHAPTER 7. SAAPDB : DATA OVERVIEW 272
It is clear from the CDF in Figure 7.20(c) that PDs more often occur at sites of high conservation.
This trend is statistically signiﬁcant (D = 0:12;p ' 0).
Despite the tendency for PDs to occur at sites of higher conservation, there is also a surprisingly
large proportion of SNPs that are found at sites that are fully conserved. Such SNPs may be at
more ﬂexible or accommodating sites of protein structure (and the 100% conservation may
therefore be a chance event) or there may be some tandem compensatory mutation nearby that
stiﬂes the effect of the polymorphism. Regardless of the mechanism by which the effects of
SNPs at highly conserved sites are neutralised, it is clear that methods that rely exclusively on
sequence data—in particular, sequence conservation—to discriminate between PDs and SNPs
are limited in their potential.
7.3.5 PDs and SNPs have the same torsion angle proﬁles
 and   angles describe the dihedral angles involving the C-N’-C’-C’ and N-C-C-N’ respec-
tively. Together they describe allowed conformational regions for amino acid backbones in the
form of a Ramachandran plot (Ramachandran et al., 1963). The ! torsion angle strictly adheres
to a  0 (cis),  180 (trans) proﬁle and deﬁnes the dihedral angle of the peptide bond (C-C-
N’-C’) which is delocalised. Beyond deﬁning whether the peptide bond is cis or trans, the !
angle has little relevance to protein structure, at least in the context of the current analysis, and
only  and   angles are considered here.
Figures 7.21(a)-7.21(c) and 7.22(a)-7.22(c) proﬁle deleterious and neutral SAAPs in terms of the
=  torsion angles at the site of mutation. There is no statistical difference between PDs and
SNPs with respect to =  torsion angles (D = 0:02;p = 0:54 and D = 0:02;p = 0:71 respec-
tively).
7.3.6 PDs and SNPs have the same secondary structure proﬁles
In Section 7.3.5, it was found that there is no difference between PDs and SNPs with respect to
the /  torsion angles. In this section, a related analysis assesses whether there is a correlation
between secondary structure and deleterious mutations.CHAPTER 7. SAAPDB : DATA OVERVIEW 273
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(c) CDF plot of PD/SNP conservation scores
Figure 7.20: Proﬁling SAAPs by their specsim -weighted conservation scores
PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 274
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(a) Distribution of  angles for PDs
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 angles for SNPs
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(c) CDF plot of PD/SNP  angles
Figure 7.21: Proﬁling SAAPs by their  torsion angles
PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 275
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(c) CDF plot of PD/SNP   angles
Figure 7.22: Proﬁling SAAPs by their   torsion angles
PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 276
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Figure 7.23: Proﬁling SAAPs by secondary structure
The proprotion of all represented secondary structures (represented by the corresponding DSSP code) in SAAPdb. PDs
are shown in yellow, SNPs are shown in grey. E represents -ladders; B represents -sheets; G represents 310 helices;
H represents -helices; C represents coils; S represents bends; T represents turns. E and B describe  structures; G and
H describe helical structures; C, S and T describe loop structures. PDs are shown in yellow; SNPs are shown in grey.
DSSP (Kabsch and Sander, 1983) deﬁnes eight classes of secondary structure. The 310,  and 
helical structures are denoted by G, H and I respectively and the -strand and extended -sheet
are denoted by B and E. The third category describes all other ‘loop’ structures: C for coil, T for
turn and S for bend.
Where a mutation is mapped to multiple structures, the mode secondary structure code has
been recorded (see Section 7.2.1). No mutation is found to exist in the I (-helix) conformation
following this averaging process and no further data for this class are given.
Figure7.23showshowoftenPDsandSNPsarefoundinparticulartypesofsecondarystructure.
There does not appear to be any difference between PDs and SNPs with respect to secondary
structure. This is conﬁrmed by multiple 2 tests (which use pre-calculated expected values, see
Section 7.2.2.1), the results of which are shown in Table 7.6.CHAPTER 7. SAAPDB : DATA OVERVIEW 277
Table 7.6: 2 tests comparing secondary structure in PDs and SAAPs
Comparison of PDs and SNPs with respect to their occurence in secondary structure elements. Results are for 2x2
(Yates corrected) 2 tests using real expected values, as calculated from CATH v3.0.0 HReps structures. E represents
-ladders; B represents -sheets; G represents 310 helices; H represents -helices; C represents coils; S represents
bends; T represents turns. E and B describe  structures; G and H describe helical structures; C, S and T describe loop
structures.
DSSP code 2 p set
 structures 1:03 0:31 -
B 0:36 0:55 -
E 0:88 0:35 -
Helical structures 0:09 0:77 -
G 0:14 0:71 -
H 0:31 0:58 -
Loop structures 1:61 0:20 -
C 1:64 0:20 -
S 0:74 0:39 -
T 0:00 0:95 -
7.3.7 PDs are more commonly found in the protein core
Relative accessibility measures the accessibile surface area (ASA) in ˚ A2 as a proportion of the
standard ASA observed for that amino acid in an extended Ala-X-Ala peptide. This is calcu-
lated using a local implementation of the Lee and Richards algorithm (Lee and Richards, 1971).
Residues with a high relative accessibility will be found on the surface, while buried residues
will have values of zero.
Figure 7.24(a) shows the distribution of monomer accessibility scores for PDs and Figure 7.24(b)
shows the distribution of monomer accessibility scores for SNPs. Both sets of SAAPs appear to
consist of two components: a concentration at 10% ASA (corresponding to buried residues)
and another at 40-60% (corresponding to residues on the surface). The CDFs of both distribu-
tions (Figure 7.24(c)) show that there are proportionally more buried residues in the PD dataset
than the SNP dataset. This difference is found to be signﬁcant (D = 0:076;p ' 0).
A greater proportion of PDs are buried than SNPs. Residues in the core of the protein are gener-
ally critical to the stability of the structure and it follows that mutations in the core of the protein
could critically affect protein stability and be deleterious. It is also likely that surface residues,CHAPTER 7. SAAPDB : DATA OVERVIEW 278
unless at critical functional sites or at tertiary or quaternary interfaces, can change more readily
without disrupting protein structure and/or function. This trend has been identiﬁed elsewhere
(Ferrer-Costa et al., 2002; Chasman and Adams, 2001; Saunders and Baker, 2002; Krishnan and
Westhead, 2003; Yue et al., 2005).
7.3.8 PD residues are in contact with more other residues
It is expected that mutating residues that are deeply embedded in the protein structure are
more likely to cause disease. Indeed, in Section 7.3.7 it was shown that PDs are found to have
lower relative ASA (i.e., are more buried) than SNPs. A complementary analysis considers the
number of residue contacts. It is expected that mutations to residues that are in contact with
many other residues will have a greater effect on structure than mutations to residues that have
a low number of residue contacts.
An existing, locally-developed algorithm has been used to calculate the relative number of
residue contacts (excepting primary-sequence-adjacent residues) for each residue in a protein
structure. The raw number of residue contacts is normalised by the number of atoms in the
target residue to generate the relative number of residue contacts, as described in Equation 7.3.
Ci
n =
R
j
d<3:5
Ni
(7.3)
where Ci
n is the normalised contact number for a residue i; R is the number of residues, j,
which make a contact at an atom centre distance of < d and where j 6= i, and Ni is the number
of atoms in residue i.
The graphs in Figure 7.25 describe the distribution of relative residue contacts in both datasets;
the CDF in Figure 7.25(c) shows that PDs are in contact with a higher number of other residues
than SNPs. This difference is found to be statistically signiﬁcant (D = 0:12;p = 3:05  10 14).CHAPTER 7. SAAPDB : DATA OVERVIEW 279
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(c) CDF plot of PD/SNP ASA
Figure 7.24: Proﬁling SAAPs by their relative accessible surface area (ASA)
PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 280
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(c) CDF plot of PD/SNP residue contacts
Figure 7.25: Proﬁling SAAPs by number of residue contacts
PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 281
7.3.9 PDs are more often explained
Sections 7.3.2-7.3.8 described PDs and SNPs with respect to basic sequence and structural char-
acteristics. In this section, the SAAPs are proﬁled with respect to their structural ‘explanations’.
One of the aims of SAAPdb is to ‘explain’ the effect of deleterious mutations by identifying
their effect on local protein structure. It is hypothesized that mutations having an identiﬁable
effect on protein structure will cause disease, whereas mutations that have little or no effect on
protein structure will not cause disease. As such, it is expected that PDs will more often be
explained by at least one of the analyses described in Chapter 5.
Figure 7.26 shows the results of the analyses, for each unique sequence mutation which has at
least one mapped structure that generates a positive result for the corresponding explanation.
The results of multiple 2 tests are compiled in Table 7.7. Disease mutations are more often
explainedbyatleastoneoftheanalysesthanneutralmutations(seebarsmarked‘EXPLAINED’
in Figure 7.26): 87.17% of disease mutations are explained by at least one analysis compared
with 58.68% of neutral mutations. This difference is highly statistically signiﬁcant (2
df=1 =
552:99;p ' 0).
7.3.10 PDs most often affect protein stability
Alleffectsofmutationscanbedividedintothreegroups: (1)thosewhichdirectlyaffectfunction
(be it binding, catalysis, allosteries, etc.); (2) those which prevent correct folding; and (3) those
which affect protein stability–i.e., they don’t prevent correct folding, but destabilise the correct
fold with respect to unfolded or misfolded states.
Much research has suggested that the deleterious effects of disease mutations are predom-
inantly due to their effect on protein stability (Ferrer-Costa et al., 2002; Ferrer-Costa et al.,
2004; Wang and Moult, 2001; Yue et al., 2005). This is the most interesting category of muta-
tions as these mutations have the potential to be ‘rescued’ by drugs which bind the correctly
folded state (Boeckler et al., 2008). In the current suite of structural analyses (see Chapter 5),
there are six analyses that assess whether a mutation will make the protein structure unstable.
Figure 7.26 shows that PDs are often explained by at least one of these analyses. In this section,CHAPTER 7. SAAPDB : DATA OVERVIEW 282
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Figure 7.26: Proﬁling SAAPs with respect to explanations
pqs: the mutation disrupts an inter-chain interface as described by PQS; bind: the mutation disrupts a binding site
as described by PDB; mmdb: the mutation disrupts a binding site as described by MMDBBIND; ANY BINDING: the
mutation is positive for bind and/or mmdb; pro: the mutation introduces a proline where torsions are unfavourable;
gly: the mutation replaces a glycine where torsions are unfavourable; clash: the mutation causes a steric clash in the
hypothesised mutant structure; cispro: the mutation replaces a cisproline; ANY FOLDING: the mutation is positive
for pro, gly, clash and/or cispro; hbond: the mutation breaks an existing hydrogen bond; void: the mutation creates
a void in the protein core; corephilic: the mutation introduces a hydrophilic residue in the core; surfacephobic: the
mutation introduces a hydrophobic residue on the surface; buriedcharge: the mutation introduces a buried unsatisﬁed
charge; ssgeom: the mutation disrupts a disulphide bond as calculated from PDB coordinates; ANY INSTABILITY: the
mutation is positive for hbond, void, corephilic, surfacephobic, buriedcharge and/or ssgeom; highcons: the mutation
affects a highly conserved residue; EXPLAINED: the mutation is explained by at least one of the above analyses.
Different ‘classes’ of explanation (i.e., interface, functional, folding, instability and conservation) are separated by pale
grey vertical lines. Precise percentages are given above the corresponding bar. Statistically signiﬁcant results are
denoted with red stars (two where p < 0:01 and one where p < 0:05). For more information on these analyses, see
Chapter 5. Yellow bars denote results for PDs, grey bars denote results for SNPs.CHAPTER 7. SAAPDB : DATA OVERVIEW 283
Table 7.7: Structural analysis of the SAAP datasets: individual explanations
Explanation the explanation (see Materials and Methods); 2: the 2 statistic from a 2x2 Yates-corrected 2 test; p: the
p-value (?? denotes p < 0:01, ? denotes p < 0:05); set: the SAAP set which has a signiﬁcantly higher occurrence of the
corresponding explanation. a denotes a result with cell counts  10 but conﬁrmed with Fisher-exact test. All numbers
are rounded to 2dp.
Explanation 2 p set
PQS interface ?? 119:47 0 PD
PDB binding ?? 82:85 0 PD
MMDB binding ?? 54:31 1:71  10 13 PD
Any binding ?? 173:85 0 PD
To-Proline ?? 38:63 5:13  10 10 PD
From-glycine ?? 16:65 4:49  10 5 PD
Clash causing ?? 113:52 0 PD
From-cisprolinea 0:04 8:33  10 1 -
Any folding ?? 136:44 0 PD
Hydrogen bond break ?? 84:86 0 PD
Void creation ?? 401:84 0 PD
Hydrophilic in core ?? 32:91 9:67  10 9 PD
Hydrophobic on surface ? 4:13 4:22  10 2 SNP
Buried unsatisﬁed charge ?? 86:69 0 PD
Disulphide (geometric)a ? 4:07 4:37  10 2 PD
Any instability ?? 956:01 0 PD
High conservation ?? 239:39 0 PD
Explained ?? 552:99 0 PD
2 tests are presented with percentages; note that where this is the case, the 2 tests have been
carried out on the raw counts.
PDs more often break native hydrogen bonds (28.33% of PDs, 16.07% of
SNPs/2
df=1 = 84:86;p ' 0); more often create voids in the core of the protein (40.19% of PDs,
11.98% of SNPs/2
df=1 = 401:84;p ' 0); more often introduce hydrophilic residues in the core
of the protein (5.54% of PDs, 1.84% of SNPs/2
df=1 = 32:91;p = 9:67  10 9); more often create
a buried, unsatisﬁed charge (12.13% of PDs, 3.61% of SNPs/2
df=1 = 86:69;p ' 0) and more
often break disulphide bonds (1.25% of PDs, 0.54% of SNPs/2
df=1 = 4:07;p = 4:37  10 2,
p = 0:033 two-tailed Fisher exact test) than SNPs. Unexpectedly, it is found that SNPs more
often introduce a hydrophobic residue on the surface of a protein (9.39% of PDs, 11.30% of
SNPs/2
df=1 = 4:13;p = 4:22  10 2); Saunders and Baker (2002) also found that this is a
poor predictor of pathogenicity. This will in part be due to SNPs occurring more often on the
protein surface than PDs (see Section 7.3.7).
Cumulatively, the instability analyses explain most of the PDs (65.48%), while only explainingCHAPTER 7. SAAPDB : DATA OVERVIEW 284
35.06% of SNPs, which is a signiﬁcant result (2
df=1 = 956:01;p ' 0). It appears that PDs are
more often associated with destabilising changes in the core of the protein. This is consistent
with the ﬁnding described in Section 7.3.7 that PDs are more often buried than SNPs.
7.3.11 Sequence conservation discriminates most successfully between PDs
and SNPs
Figure 7.26 shows that 22.82% of disease mutations occur at a site of high conservation—as
deﬁned by ImPACT (Chapter 4)—whereas less than 5% of neutral polymorphisms affect highly
conserved residues. This difference is highly statistically signiﬁcant (2
df=1 = 239:39;p ' 0) and
is consistent with the hypothesis that mutating residues that are highly conserved is likely to
be disease-causing.
7.3.12 PDs are more diverse in their structural explanations
It is useful to characterise the PD and SNP datasets in terms of their homogeneity. It may
be that SNPs are very similar to each other while PDs have a more diverse structural effect
proﬁle. Differences in explanation diversity as well as differences in the occurrence of particular
explanations (as discussed in Section 7.3.10) are encouraging for future prediction work.
The explanation proﬁles can be represented as a binary vector, where 1 indicates a postive result
for an analyses (i.e., an explanation), and 0 indicates a negative result (i.e., the absense of an
explanation). A convenient metric for which to compare the explanation proﬁles, or calculate
the distance between them, is the Hamming distance (here, denoted by DH). The Hamming
distance between two binary vectors is the number of corresponding elements in which they
differ. For example, the Hamming distance between the binary vectors 01001 and 01100 is
2 (they differ at the third and ﬁfth element). Explanation proﬁles that are very different will
have a large Hamming distance (the maximum possible Hamming distance is the length of the
vector, where all elements are different), while two identical proﬁles will have DH = 0.
The Hamming distance between each pairwise comparison within each dataset was recorded.
The graphs in Figure 7.27 characterise the PD and SNP dataset with respect to the diversityCHAPTER 7. SAAPDB : DATA OVERVIEW 285
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Figure 7.27: Proﬁling SAAPs by pairwise hamming distances within each dataset
PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 286
of the explanation proﬁles, as measured by the Hamming distance. Figure 7.27(b) shows that
for the vast majority of SNP proﬁle comparisons, DH  1. That is, most SNPs are identical in
their explanation vectors, or differ by one explanation result. Note that the unexplained vector
is included, and that the high frequency of DH = 0 for the SNP data may be due to a high
frequency of SNPs being unexplained and therefore identical. PDs, however, are more diverse:
Figure 7.27(a) shows that the distribution of DH is shifted to the right as compared to SNPs,
indicating that for the majority of PD proﬁle comparisons, DH  2.
However, it is possible that this effect is due to the PDs being explained more often by multiple
analyses: if PDs are explained by multiple, simultaneous analyses more often than SNPs are
(see Section 7.3.13), the Hamming distances will always be larger in an all-against-all pairwise
comparison of PDs than in the same comparison within the SNP dataset. To account for poten-
tial bias in the number of simultaneous explanations, it is necessary to have some estimate of the
‘background’ or expected Hamming distance with which to normalised the data. This would
require an, as yet unformed, comprehensive understanding of the co-occurrence of structural
explanations in these datasets. Therefore, the Hamming distance distributions will not be com-
pared and will only be used to characterise each dataset individually.
7.3.13 PDs are more often explained by multiple analyses
The analyses described in Section 7.3.9 showed that PDs are more often explained by at least
one analysis. Here, the number of simultaneous explanations for PDs and SNPs are considered.
In this section, the term ‘simultaneous’ will be used to describe two or more analyses that
explain one SAAP. Given the hypothesis that PDs bring about signiﬁcant structural disruption
(potentially in more than one way) while SNPs do not, it is expected that PDs will be associated
with multiple structural explanations while SNPs will be associated with very few.
Figures 7.28(a)-7.28(c) describe and compare the distribution of simultaneous explanations for
PDs and SNPs and Table 7.8 describes the results of multiple 2 tests that compare PDs and
SNPs with respect to the number of simultaneous explanations. SNPs are more likely than PDs
to be explained by zero or one analyses (2
df=1 = 464:79;p ' 0 and 2
df=1 = 9:93;p = 1:6310 3
respectively). Cumulatively, these categories account for 71.46% of SNPs, but only 38.97% of
PDs. PDs are more often explained by between two and seven explanations: 60.93% of PDs are
explained by two to seven explanations, while only 28.40% of SNPs are explained by two toCHAPTER 7. SAAPDB : DATA OVERVIEW 287
Table 7.8: Structural analysis of the SAAP datasets: the simultaneous explanations
# EXP: the number of simultaneous analyses that are positive, and so explain the SAAP; 2: the 2 statistic from
a 2x2 Yates-corrected 2 test; p: the p-value (?? denotes p < 0:01, ? denotes p < 0:05); set: the SAAP set which
has a signiﬁcantly higher occurrence of the corresponding explanation; a denotes a result with cell counts  10 but
conﬁrmed with Fisher-exact test. All numbers are rounded to 2dp.
# EXP %PDs %SNPs 2 p set
0 ?? 16.74 45.15 464:79 0 SNP
1 ?? 22.23 26.31 9:93 1:63  10 3 SNP
2 ?? 21.84 15.59 25:90 3:59  10 7 PD
3 ?? 17.65 8.14 75:65 0 PD
4 ?? 11.18 3.66 72:90 0 PD
5 ?? 6.80 0.81 78:45 0 PD
6a ?? 2.66 0.20 33:25 8:11  10 9 PD
7a ?? 0.80 0.00 11:90 5:61  10 4 PD
8a 0.10 0.14 0:10 0:75 -
seven simultaneous explanations.
These results conﬁrm that it is not possible to compare the distributions of Hamming distances
(see Section 7.3.12) in the PD and the SNP datasets: as the PDs are more often explained by
multiple analysis, the Hamming distances will be consistently greater than those derived from
the SNP dataset. However, the Hamming distance analysis can contribute to the understanding
of the structural effects of SAAPs as a measure of diversity within each dataset.
7.3.14 The most common explanation proﬁles are different for PDs and
SNPs
It has been shown that PDs are more likely to be explained simultaneously by two or more
analyses (see Section 7.3.13). Here, the most common explanation proﬁles for PDs and SNPs
are identiﬁed.
Not all the explanation proﬁle combinations are shown here: to identify those explanation pro-
ﬁles that occur more often than expected, a rough estimate of the ‘expected’ frequency of each
proﬁle was calculated as N=E, where N is the size of the dataset (i.e., the number of SAAPs, or
the number of observed explanation proﬁles) and E is the number of unique explanation pro-
ﬁles observed in that dataset. For example, consider a dataset of 100 SAAPs where ﬁve uniqueCHAPTER 7. SAAPDB : DATA OVERVIEW 288
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Figure 7.28: Proﬁling SAAPs by the number of simultaneous explanations
PDs are shown in yellow; SNPs are shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 289
explanation proﬁles are observed; here, N = 100 and E = 5. The rough estimate of ‘expected’
frequency for each proﬁle would be 100=5 = 20. This estimation results in the same expected
occurrence for each proﬁle which is clearly not representative. Due to dependencies between
analyses, the severity of the analyses themselves and aspects of protein structure, some ex-
planations will occur together more often than others. For example, it may be expected that
mutations identiﬁed as disrupting MMDBBIND sites (Section 5.5) will often also be identiﬁed
as disrupting binding sites as extracted from the PDB (Section 5.3.3). However, as discussed
in Section 7.3.12, it is difﬁcult to estimate the expected frequencies of explanation proﬁles at
present. Any proﬁle that exceeds the rough estimate of the expected frequency will be de-
scribed as ‘enriched’.
Figures 7.29(a) and 7.29(b) show those explanation proﬁles that are enriched in the PD and
SNP datasets respectively. The term ‘positive proﬁle’ will be used to describe any explanation
proﬁle that contains at least one explanation, i.e., all observed explanation proﬁles excepting
the ‘unexplained’ proﬁle.
Firstly, far more positive explanation proﬁles are enriched in the PD dataset than in the SNP
dataset. This suggests a stronger association between PDs and their positive explanation pro-
ﬁles than exists between SNPs and their positive explanation proﬁles. In Section 7.3.12 it was
shown that SNPs are more similar to each other with respect to their explanation proﬁles than
PDs, most often differing from each other in zero or one analyses. Taking this ﬁnding together
with the trends shown in this Figure 7.29, SNPs can be characterised as primarily unexplained
with the occasional explanation (which may be due to insensitivies in the analyses) while PDs
can be characterised as primarily explained by at least two analyses.
Of the fourteen positive proﬁles that are enriched in the SNP dataset, half are single analysis
explanations; similarly, a high proportion of the explanation proﬁles enriched in the PD dataset
are multiple analysis explanation proﬁles. These observations support the ﬁndings of Section
7.3.13, where it was shown that SNPs are more likely to be associated with zero or one analyses
and PDs are more likely to be associated with two to seven simultaneous explanations.
It is interesting to note that the three highest ranking positive proﬁles in both datasets are the
void, hydrogen bonding and quaternary structure interface analyses. This indicates that—for
these analyses more than any other single analyses—there is a differential in the extent to which
the mutation affects protein structure. As discussed previously in Section 7.3.4 with respect toCHAPTER 7. SAAPDB : DATA OVERVIEW 290
(a) Frequency of explanation combinations for PDs
(b) Frequency of explanation combinations for SNPs
Figure 7.29: Proﬁling SAAPs by the explanation ‘proﬁle’
The explanation ‘proﬁle’ of a SAAP is the set of analyses that ‘explain’ that SAAP. PDs are shown in yellow; SNPs are
shown in grey.CHAPTER 7. SAAPDB : DATA OVERVIEW 291
the high number of SNPs found at sites of high conservation, it is possible that void-causing,
hydrogen-bond-breaking and quaternary-structure-affecting mutations can more readily be ac-
commodated by (i) adjustments in the existing structure or (ii) compensatory mutations. In
an investigation into the phenomenon of compensatory mutations in SAAPdb, it was indeed
found that PDs with identiﬁable compensatory mutations in other species are most commonly
found to disrupt the quaternary interface, disrupt hydrogen bonding or introduce a void in
the protein structure (Bareˇ si´ c et al., 2009). Irrespective of the mechanism by which they are ac-
commodated in SNPs, it is clear that these analyses in particular could be more sensitive and
perhaps should score mutations rather than being binary classiﬁers.
Concentrating on those positive proﬁles common in the PD dataset, it is striking that neither
the binding nor MMDBBIND analyses, both found to be signiﬁcantly associated with PDs pre-
viously (see Figure 7.26 and Table 7.7), occur as single analyses or as a two-explanation pair.
However, they are often found, both separately and together, in several  3 analysis explana-
tion proﬁles. This suggests that for a mutation to occur at a binding site is often not enough to
induce a deleterious phenotype. As suggested in Section 7.3.10, where it was found that PDs
are more strongly associated with destabilising protein structure than affecting binding sites,
perhaps the mechanics of protein-ligand binding are more ﬂexible than might be expected.
7.4 Conclusions
This chapter described an analysis of the data in SAAPdb. PDs have most frequently been
characterised as mutations between very different residues, where the introduced or replaced
residue has a unique role in protein structure. They are found embedded in the protein struc-
ture, both in terms of accessibility and in terms of contacts with other residues, and they more
often affect residues that have been conserved across different branches of evolution and there-
fore likely to have been subject to selection pressure. This characterisation is consistent with
ﬁndingselsewhere(WangandMoult, 2001;Ferrer-Costaetal., 2002;Ferrer-Costaetal., 2004;Yue
et al., 2005; Chasman and Adams, 2001; Saunders and Baker, 2002; Krishnan and Westhead,
2003; Dobson et al., 2006; Vitkup et al., 2003).
As described in Chapters 5 and 6, SAAPdb analyses all SAAPs with a view to identifying any
local structural effect owing to the change in amino acid. PDs more often have a discernableCHAPTER 7. SAAPDB : DATA OVERVIEW 292
effect on protein structure than SNPs, and more often affect the structure in more than one way.
Further, PDs have been found to affect protein structure in more diverse ways than SNPs.
It is perhaps surprising that PDs are not more often found at binding sites: disruption of ligand
binding would directly affect protein function. More than double the number of PDs introduce
instability in the protein structure than do affect binding sites (65.48% of PDs as opposed to
30.10%). There are several possible explanations for this trend: (i) protein-ligand binding is
more ﬂexible than is commonly believed; (ii) mutations at binding sites are fatal to the cell,
therefore never observed in a patient, and therefore never reported as disease-associated, or
(iii) given the mechanics of protein structure, a higher proportion of residues are involved in
maintaining protein stability than are involved in binding sites. The similar ratio of instabil-
ity explanations to binding explanations for SNPs (17.10% as compared to 35.05%) is roughly
equivalent to the ratio of instability explanations to binding explanations for PDs (17.10% :
35.05% ' 30.10% : 65.48% ' 2), which lends some weight to the third theory. Further, Steward
et al. (2003) demonstrated that the proportion of disease mutations identiﬁed as disrupting var-
ious types of interface (protein-ligand, protein-protein and so on) corresponds to the proportion
of residues occuring at those interfaces. By estimating frequencies of each kind of ‘explanation’
in native protein structures, the results described in Section 7.3.9 could be corrected. However,
without further investigation it is not possible to discount any of the proposed explanations.
In Sections 7.3.2 and 7.3.3, an average dissimilarity statistic  was used to rank the amino acids
from the most unique residue (tryptophan) to the most replaceable residue (serine). Although
the calculation of this statistic is very simple (see Equation 7.2), it appears to be an effective
statistic with which to describe amino acids when comparing disease-causing and neutral mu-
tations and should be included in the feature vector when training machine learning algo-
rithms. More work should be done to investigate such an average dissimilarity score.Chapter 8
Conclusions
This thesis has described the SAAPdb database, a resource that collates information on sin-
gle amino acid polymorphisms or SAAPs. SAAPdb attempts to identify the effects of disease
mutations by providing hypotheses as to how they might disrupt structure and/or function.
In Chapter 3, a novel method of identifying functionally equivalent proteins (FEPs) was de-
scribed, called FOSTA (Functional Orthologues from Swiss-Prot Text Analysis). In Chapter 4,
a novel method of identifying high conservation within a multiple sequence alignment was
described, called ImPACT (Improved Protein Alignment Conservation Threshold). Together,
these chapters describe the one sequence analysis that has been incorporated into SAAPdb.
Chapters 5 and 6 described the structural analysis pipeline with which SAAPdb analyses mu-
tations and Chapter 7 described an analysis of the resulting SAAPdb data.
Here, the conclusions that can be drawn from the work presented in this thesis are collated.
The discussion begins with a review of SAAPdb’s contribution to the ﬁeld and how it can be
used by the research community.
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8.1 SAAPdb and its contribution to the ﬁeld
As discussed in Section 1.9, SAAPdb is a unique resource. Several other resources collate
SAAPs and some calculate SAAP explanations. However, there is no resource that (1) takes
a predominantly structural perspective of protein structure perturbation (that is, it attempts
to explain mutations primarily with respect to their effect on protein structure); (2) is built to
allow the easy integration of new data and the regular reprocessing of all data; (3) provides
a straightforward but powerful graphical interface with which PDs and/or SAAPs within the
protein structures; or (4) that takes as careful, as conservative and as sophisticated an approach
to explaining SAAPs as SAAPdb.
The original motivation for the SAAPdb project was the collation of SAAP structural explana-
tions for use in predicting previously unseen SAAPs. Indeed, work will continue in this direc-
tion within the Martin group. However, there are numerous other ways that the resource could
be used and the data exploited. These potential applications fall into three general categories:
protein structure, disease research and protein evolution.
8.1.1 Protein structure
Wet lab scientists requiring to design a stable mutant protein structure for use in an experi-
ment will be able to consult SAAPdb to assess whether any mutation has been analysed and
not explained by any of the structural analyses; such mutations are unlikely to disrupt the na-
tive protein structure. Candidate mutant structures could be ﬁltered using the annotations in
SAAPdb, reducing the time taken to devise an appropriate experiment. On a wider and more
theoretical scale the structural integrity of all the structures in SAAPdb could aid in the under-
standing of protein structure in general: currently, the precise mechanisms that are responsible
for structural stability are not well understood. These mechanisms could be examined by con-
sidering deleterious mutations as ‘perturbations’ of the usual structural ‘system’, much in the
same way that experimental assays are designed.CHAPTER 8. CONCLUSIONS 295
8.1.2 Disease research
SAAPdb describes thousands of disease-associated mutations, both with respect to sequence
and structure. These data could be exploited to examine pharmacogenomic variation within
populations, speciﬁcally, the precise mechanistic reasons for variation in pharmacological re-
sponse in different populations. In addition, the SAAPdb data could aid in the understanding
of a disease process: should a disease-associated mutation introduce a hydrophobic residue on
the surface of a protein, for example, this may indicate that the disease is caused by protein
aggregation, as is the case in sickle-cell anaemia (see Section 1.6). It may also be possible to
characterise gain of function and loss of function PDs differently with respect to their analyses,
and as such devise different strategies for their treatment. And ﬁnally, as a consequence of
mapping thousands of PDs to structure using PDBSWS (see Section 2.1.5), currently uncharac-
terised disease protein structures can be identiﬁed as targets for crystallographers and NMR
scientists.
8.1.3 Protein evolution
There is a signiﬁcant number of disease-associated PDs described in SAAPdb that are observed
as native residues in other species. The deleterious effect of these mutations must be com-
pensated for in the non-human protein. Identifying such compensated PDs in the SAAPdb
dataset and examining their structural explanation proﬁles will elucidate mechanisms of pro-
tein evolution. Indeed, the Martin group are and have been actively considering this particular
application of the SAAPdb data (Bareˇ si´ c et al., 2009).
8.2 Incorporating sequence data: FOSTA and ImPACT
8.2.1 FOSTA
The benchmarking of FOSTA demonstrated that not only are UniProtKB/Swiss-Prot
annotations informative enough to capture the functionality of proteins, but that the simple
string comparison methods employed by FOSTA are successful in identifying functionalCHAPTER 8. CONCLUSIONS 296
ID PROC HORSE Reviewed; 157 AA.
AC Q28380;
DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT 01-NOV-1996, sequence version 1.
DT 12-JUN-2007, entry version 45.
DE Vitamin K-dependent protein C (EC 3.4.21.69) (Autoprothrombin IIA)
DE (Anticoagulant protein C) (Blood coagulation factor XIV) (Fragment).
d
. . .
ID PROC HORSE Reviewed; 157 AA.
AC Q28380;
DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT 01-NOV-1996, sequence version 1.
DT 02-SEP-2008, entry version 49.
DE RecName: Full=Vitamin K-dependent protein C;
DE RecName: EC=3.4.21.69;
DE AltName: Full=Autoprothrombin IIA;
DE AltName: Full=Anticoagulant protein C;
DE AltName: Full=Blood coagulation factor XIV;
DE Flags: Fragment;
d
. . .
Figure 8.1: Recent changes to the UniProtKB/Swiss-Prot ﬂatﬁle format
Above is an extract from the record describing PROC HORSE in UniProtKB/Swiss-Prot v53.0, below is the correspond-
ing extract updated with the new formatting (as of UniProtKB/Swiss-Prot v56.0). The corresponding EC, synonym and
fragment ﬂag data are shown in red, blue and green respectively. The improvements facilitate fast extraction of the rel-
evant information using regular expressions, for example.
equivalence between proteins. Some inconsistencies identiﬁed by the FOSTA analysis of
certain proteins (e.g., human protein C [UniProtKB:P04070/PROC HUMAN]) have since been
rectiﬁed by UniProtKB.
UniProtKB has recently changed the format of the description line from which FOSTA extracts
the functional annotations1. Although the change is inconvenient, as existing parsers must be
updated, the update has vastly improved the ease with which the desired data can be extracted.
Furthermore, useful ﬂags have been added to indicate whether the protein record describes, for
example, a fragment. Figure 8.1 shows the change to the format of the horse protein C record,
an example of a record of a protein fragment.
However, the comparison of FOSTA with Inparanoid did highlight some insensitivies in
1http://www.expasy.ch/sprot/relnotes/spwrnew.html#rel56.0CHAPTER 8. CONCLUSIONS 297
the methods with which FOSTA identiﬁes functional equivalence. For example, mapping
acronyms or short forms to long forms and vice versa would increase the functional
match sensitivity of FOSTA. More generally, more ‘fuzzy’ matching should be employed to
accommodate slight variations in names and numbers. See Table 3.11 for speciﬁc examples
where these changes would lead to additional FEP assignments in FOSTA.
As pointed out in Chapter 3, annotation conventions in UniProtKB/Swiss-Prot are largely
inherited from the source databases and organism-speciﬁc annotation communities.
UniProtKB/Swiss-Prot is in a unique position to unify these annotations, thus avoiding any
requirement for fuzzy matching, or for matching long forms of names with acronyms or
abbreviations.
8.2.2 ImPACT
ImPACT was benchmarked against four representative proteins and against a dataset of se-
quence motifs extracted from PROSITE. In addition, a battery of artiﬁcial conservation data
was designed to test the response of ImPACT to controlled variations in the distribution of
conservation scores.
The more qualitative evaluations (using four representative proteins and the artiﬁcial conser-
vation data) demonstrated that ImPACT generates sensible thresholds for many different con-
servation score datasets. The more quantitative PROSITE analysis, despite concerns regarding
the deﬁnition of negative examples, was possibly more informative in that it drew attention to
the fact that ImPACT can perform poorly in sparse alignments. Extensive gaps will generate
very low conservation scores which could dominate the distribution of conservation scores to
be modelled. A valuable addition to the ImPACT method would be to disregard data from
columns that are not adequately represented across the aligned proteins.
A further valuable addition to ImPACT would be some measure of conﬁdence that would ac-
company each generated threshold. This could be a combination of (i) how well the mixture
model has ﬁtted the data; (ii) some measure of the deviation from the threshold that would be
generated from random data; and (iii) some measure of the diversity and number of species in-
cluded in the alignment. It is possible to calculate the former—all modelling methods provide
a measurement of error—but it is more difﬁcult to deﬁne how the latter conﬁdence componentsCHAPTER 8. CONCLUSIONS 298
might be calculated. An alternative to using a background distribution of random data (which
is likely to deviate from characteristics of multiple sequence alignments) is to use permuted
data, or to use alignments of known functionally deviant proteins to construct a background
distribution of conservation scores. This might be possible by considering the functionally di-
verged homologues (FDHs) generated by FOSTA.
Included in the set of representative proteins with which ImPACT is assessed are P53 and
haemoglobin (HBB), two proteins for which a large number of disease mutations (1 712 and
423 respectively) are analysed in SAAPdb. Although a higher proportion of P53 residues are
100% conserved, the HBB alignment has a higher mean conservation score and is the more
globally conserved protein. To accommodate the higher global conservation, ImPACT correctly
generates a higher ImPACT threshold of 0.9763 for HBB than it does for P53 (0.9636). However,
mutations to HBB are rarely fatal and more often lead to mild anaemia, whereas mutations to
P53 are found in approximately 50% of human cancers (Greenblatt et al., 1994; Sidransky and
Hollstein, 1996). As such, a higher threshold for HBB appears to depart from what might be
expected: because the phenotypic effect of HBB mutations is less severe than that of P53, it
might be expected that the threshold for high conservation would be lower in HBB than P53.
This apparent incongruity could be due to any number of differences between the two proteins,
including their differential roles; their involvement in multiple pathways; the differential ﬂexi-
bility of the structures and so on. Regardless of the mechanisms by which HBB can withstand
mutations, it is clear that sequence information alone cannot capture the differential phenotypic
effects of these two proteins.
8.3 The analysis of disease mutations
Chapter 7 described a broad analysis of the data in SAAPdb. The existing characterisation of
deleterious PDs (pathogenic deviations) and neutral SNPs (single nucleotide polymorphisms)
was summarised in Table 1.9. This summary is updated in Table 8.3 to include the ﬁndings
of Chapter 7 (which are highlighted in yellow) and to compare them to the characterisation
that exists in the literature. Where the results described in this thesis overlap with previ-
ous work, they largely agree with the existing characterisation of disease and neutral SAAPs;
where SAAPdb has used novel analyses (e.g., identiﬁcation of unsatisﬁed buried charges, un-
favourable voids and broken hydrogen bonds), the results complement the existing characteri-CHAPTER 8. CONCLUSIONS 299
sation of disease mutations. Several signiﬁcant differences—with respect to sequence, structure
and structural effects—have been identiﬁed when comparing disease-associated PDs with phe-
notypically neutral SNPs. These ﬁndings have implications for future predictive methods and
may facilitate the identiﬁcation of drug targets.
8.3.1 Understanding the data
PDs are characterised as mutations involving the more ‘unusual’ amino acids, speciﬁcally tryp-
tophan, cysteine and proline. The PDs have lower BLOSUM62 and PAM30 amino acid substi-
tution matrix scores than SNPs, indicating that PDs tend to describe mutations between more
different residues. PDs are found more often in the protein core, in contact with a larger number
of other residues and most often disrupt the stability of the protein structure; they most often
introduce a void or crevice in the protein structure. Further, PDs are more likely than SNPs to
disrupt sites of high conservation.
It appears that the simple average dissimilarity score used to rank amino acids in terms of their
‘replaceability’ (described by Equation 7.2) is a powerful measurement with which to represent
the amino acids. More work is required to realise fully the potential of such a statistic in the
context of disease mutations.
It is perhaps surprising that PDs are not more often found at binding sites: disrupting ligand
binding would directly affect protein function. More than double the proportion of PDs intro-
duce instability in the protein structure than do affect binding sites (65.48% of PDs as opposed
to 30.10%, see Figure 7.26). This may indicate that interactions at binding sites are more ﬂexible
than previously thought. Alternatively, it may simply reﬂect the proportion of residues that are
involved in instability compared with binding (as suggested in Steward et al. (2003)); or it may
draw attention to the spectrum of disease mutations that can be observed: many mutations at
the binding site may be fatal to the cell and therefore will never be observed in a living patient;
should this be the case, the only observed mutations at binding sites will not be deleterious.
More investigations are required before any conﬁdent statement can be made; a useful ﬁrst
step would be to quantify the number of binding-associated and instability-associated residues
in protein structures in general: is it more likely that an instability-associated residue would be
chosen at random than a binding-associated residue? With ‘expected’ frequencies of features
known, the data represented in Figure 7.26 could be represented as log ratios (as in FiguresCHAPTER 8. CONCLUSIONS 300
Table 8.1: Comparing SAAPdb ﬁndings with the existing characterisations of PDs and SNPs
: PDs were associated with this feature; : SNPs were associated with this feature. ‘-’: no relationship was found.
?: the paper includes some prediction work. y: the paper considered only deleterious data. A blank cell denotes that
the feature was not considered. Datasets: A = LacI repressor (Suckow et al., 1996); B = T4 lysozyme (Rennell et al.,
1991); C = HIV protease (Loeb et al., 1989); D = dbSNP (Smigielski et al., 2000); J = uses natural residue variation across
species to represent ‘neutral’ SAAPs; M = HMGD (Stenson et al., 2003); N = HGVBase (Fredman et al., 2002); O = OMIM
(McKusick, 1998; Amberger et al., 2009); S = UniProtKB/Swiss-Prot VARIANT (The UniProt Consortium, 2009); X =
other LSMDB (various references). Structural data used: Y = where PDB structures were unavailable, models were
used; Yi = structural features were inferred from sequence. AA: amino acid. SAAPdb ﬁndings (see Chapter 7) are
highlighted in yellow.
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Bao & Cui (2005) ? S Y Y     
Cai et al. (2004) ? AB Y Y  
Chasman & Adams (2001) ? AB Y Y    
Clifford et al. (2004) ? DX Y Y 
Dobson et al. (2006) ? S Y Y  
Ferrer-Costa et al. (2002) S Y Y      
Ferrer-Costa et al. (2004) ? AS Y Yi 
Khan & Vihinen (2007) y MX n Y  - 
Krishnan & Westhead (2003) ? AB Y Yi    
Needham et al. (2006) ? AB Y Y  -  
Ng & Henikoff et al. (2001) ? ABC Y n 
Saunders & Baker et al. (2002) ? AC Y Y -    
Stitziel et al. (2003) DO Y Y  -  
Steward et al. (2003) O Y Y   
Sunyaev et al. (2001) ?a DNS Y Y      
Torkamani & Schork (2007) X Y Y   
Verzilli et al. (2005) ? AB Y Y     
Vitkup et al. (2003) S Y Y    
Wang & Moult (2001) b DM n Y 
Yue et al. (2005) ? JM n Y   
SAAPdb c DOX Y Y      -     
a http://genetics.bwh.harvard.edu/pph/
b http://www.snps3d.org/
c http://www.bioinf.org.uk/saap/db/CHAPTER 8. CONCLUSIONS 301
7.16(a) and 7.16(b)).
Indeed, there are many similar questions that have arisen from these investigations that, to be
considered fully, require a more comprehensive understanding of the background or expected
frequencies to be deﬁned. For example, consider the frequency-of-explanation proﬁle data de-
scribed in Figures 7.29(a) and 7.29(b). It is not possible that the same mutation will be explained
on the basis of introducing a hydrophobic residue on the surface and introducing a hydrophilic
residue in the core; it is however likely that some mutations will be explained simultaneously
by breaking a hydrogen bond and creating an internal void (see an example in Figure 7.8). Such
inter-dependencies will not only allow the normalisation of data, but may also reveal important
and interesting relationships that are fundamental to protein structure. For example, perhaps
most hydrophobic residues that are introduced on the protein surface occur at the interface,
which may improve inter-chain binding and therefore explain why the surfacephobic analysis
is the only structural analysis to be associated with SNPs (see Figure 7.26).
A recent collaboration concentrated on the analysis of mutations in the kinase domain
(Izarzugaza et al., 2009), comparing the explanation proﬁles of kinase PDs with all other PDs
(non-kinase PDs) in SAAPdb, and comparing kinase PDs with kinase SNPs. This found that,
unlike the vast majority of PDs analysed by SAAPdb previously (see Section 2.1.2), kinase
PDs were signiﬁcantly less likely to be attributable to some structural effect according to the
SAAPdb analysis pipeline than non-kinase PDs, and that kinase PDs were no more likely to be
attributable to some structural effect than kinase SNPs. It would seem that the current suite
of structural analyses—the formation of which was motivated by a general understanding
of protein structure—is failing to capture some important aspects of kinase structure, most
importantly what differentiates kinase PDs from kinase SNPs. However, when using a set
of kinase-speciﬁc features, and using a distance based analysis where proximity to features
was measured rather than only considering the feature sites themselves, there was a clearer
difference between kinase PDs and kinase SNPs.
It is possible that several of the kinase domain mutations interfere with the movement from
the inactive to the active state and vice versa. Indeed, in a comprehensive study of oncogenic
mutations in B-RAF by Wan et al. (Wan et al., 2004), it was proposed that several oncogenic
mutations destabilise the inactive state by disrupting the hydrophobic interactions between the
P-loop and the DFG motif in the kinase domain, promoting the active conformation and thus
mimicking the phosphorylated state.CHAPTER 8. CONCLUSIONS 302
8.3.2 Applying the ﬁndings to protein structure in general
Most (at the time of writing, November 2008, 85.50%) protein structures described by the PDB
werederivedviaX-raycrystallography(seeSection1.5); assuch, mostofthestructuresanalysed
by SAAPdb will also be X-ray structures. It is important to appreciate that protein crystals are
merely ‘snapshots’ of protein structure. The manner in which PDB structures are derived—by
enforced crystallisation—cannot capture the ﬂexibility of protein structures. However, by con-
sidering the data and trends described in Chapter 7 as indirect measurements of the response
to structural ‘lesions’, some comment on protein ﬂexibility is possible: the extent to which pro-
tein structures can accommodate mutant residues, and what kinds (with respect to structural
explanations) of mutant residues can be accommodated, will convey information regarding the
ﬂexibility of the structures. For example, the analysis described in Chapter 7 demonstrated that
PDs are more often found to affect protein stability than ligand binding sites. This may suggest
that protein-ligand binding is more ﬂexible, or can more easily accommodate mutations, than
the network of scaffolding interactions that stabilise protein structure. Further, this trend may
be owing to differences between obligate and transient interactions: perhaps transient binding
is more ﬂexible than obligate binding, which may be as constrained as the buried interior of a
protein.
As discussed in Sections 7.4 and 8.3.1, such trends must be investigated further before attribut-
ing effects to variations in protein ﬂexibility. Should the trends be veriﬁed, they could inform
an alternative representation of protein structure to include hypothesised sites of ﬂexibility,
providing a more realistic model of protein structure with which to work.
8.3.3 Extending the pipeline
TherearemanypotentialstructuraleffectsofSAAPsthatarecurrentlynotassessedbySAAPdb,
as highlighted by the analysis of the kinase domain (see Section 8.3.1) where oncogenic muta-
tions are known not only to destabilise the inactive form of B-RAF, but mimic the phosphory-
lated, active form of the protein (Wan et al., 2004) thus disrupting native protein function. Data
derived from other external resources (including the Catalytic Site Atlas (Porter et al., 2004),
PROCOGNATE (Bashton et al., 2008) or dbPTM (Lee et al., 2006)) could be incorporated to
widen the focus of SAAPdb with respect to explaining mutations. It may also be beneﬁcial toCHAPTER 8. CONCLUSIONS 303
consider the protein in a wider context, for example its role in known pathways (Kanehisa et
al., 2008).
What is entirely missing from SAAPdb currently is the consideration of genomic data. The
focus of SAAPdb is the manifestation and effects of genomic mutations at the protein level,
primarily with respect to structure; however, there is undoubtedly more information implicit
in the raw genomic data (Cargill et al., 1999). For example, are PDs more often transversions
(where a purine base (AG) is substituted with a pyrimidine base (CT) or vice versa) and there-
fore an alteration of the chemical nature of the base, and SNPs more often transitions (muta-
tions between purine bases or between pyrimidine bases), where the chemical nature of the
base does not change? Is there any bias in codons targeted by PDs or SNPs, or is there a bias
in the particular position in the codon that is mutated? At the very least, estimates of base
change substitution rates, calculated from a basic understanding of biochemistry and mutage-
nesis mechanisms, could allow protein level data to be ‘normalised’ such that genomic effects
are removed from analysis at the protein level (e.g., Care et al. (2007)). For example, argi-
nine has a high rate of mutability (due to deamination of 5’-CpG dinucleotides in the arginine
codon); such information could be used to normalise, for example, amino acid frequencies as
shown in Figure 7.16 (where, indeed, arginine is one of the most commonly mutated residues).
Further, mutations may have effects in controlling expression or splicing. Such effects have
been completely disregarded in this thesis.
8.3.4 Moving onto prediction
Despite the emergence of a biologically rational characterisation of disease mutations, consis-
tent with existing literature, none of the features is strongly predictive on its own. Further,
there appears to be a signiﬁcant ‘pathogenicity-differential’ in the results of some analyses;
that is, some analyses both commonly explain disease associated mutations and commonly
explain neutral mutations, indicating that there is a differential in the extent to which the muta-
tion affects protein structure. This is most true for the void-creating, hydrogen-bond-breaking,
quaternary-structure-affecting and conserved-residue-affecting mutations.
This suggests that careful and considered application of machine learning techniques could
exploit the weak predictive power of all of these individual features, resulting in a potentiallyCHAPTER 8. CONCLUSIONS 304
very sensitive and accurate method for classifying previously unseen mutations as disease-
causing or neutral. As mentioned in Section 8.3.1, inter-dependencies between features may
exist and the method should be designed to take advantage of informative inter-dependencies
while being able to factor out redundant data.
Furthermore, the investigations into kinase mutations described in Section 8.3.1 showed that
protein families vary in their explanation proﬁles. In addition to calling for more research into
the extent of such differences and how such protein families might be represented as train-
ing data to a predictive model, it is recommended that machine learning methods should at
least initially build classiﬁers for each protein family. One method to predict speciﬁcally ki-
nase mutations (Torkamani and Schork, 2008), achieves an MCC of 0.87, higher than any other
‘general-purpose’ prediction method. Further, several methods use the popular LacI (Suckow
et al., 1996), HIV protease (Loeb et al., 1989) and/or T4 lysozyme (Rennell et al., 1991) muta-
genesis datasets, often reporting widely varying performance between these datasets (Ng and
Henikoff, 2001;ChasmanandAdams, 2001), particularlywhenthetrainingandtestsetsarehet-
erogeneous, that is, they are drawn from different mutagenesis datasets (Chasman and Adams,
2001; Krishnan and Westhead, 2003; Needham et al., 2006).
Preliminary work using several unoptimised machine learning methods (both with respect to
the method parameters and with respect to the input vector) as provided by WEKA (Witten
and Frank, 2005)—including several methods used previously in the literature (e.g., decision
trees (Krishnan and Westhead, 2003), SVMs (Krishnan and Westhead, 2003; Tian et al., 2007),
1R (Dobson et al., 2006))—suggests that there is much potential in the current dataset for suc-
cessful discrimination: default parameterisations of KNN2, rule learner3 and decision tree4 al-
gorithms all exceed the current ‘gold-standard’ prediction performance of Tian et al. (2007) of
MCC=0.50. The results are summarised brieﬂy in Appendix [A]. Active collaborations with
Professor David Corne (Heriot-Watt University, Edinburgh), Professor Mark Girolami (Univer-
sity of Glasgow) and Professor Giuliano Armano (University of Cagliari) are pursuing further
work in this area.
2weka.classifiers.lazy.IBk
3weka.classifiers.rules.PART
4weka.classifiers.trees.J48CHAPTER 8. CONCLUSIONS 305
8.3.5 Implications for disease therapies
There is much potential for SAAPdb data to be used in the identiﬁcation of novel drug targets.
If one can characterise the speciﬁc reason that a mutated protein is not able to function properly,
a counteractive rescue mechanism could be developed.
Recently, Boeckler et al. (2008) reported the development of an in-silico screened drug that was
shown to rescue the function of a P53 mutant, Y220C. This mutant was known to destabilise
the protein by introducing a crevice in the protein structure (compare Figure 8.2(a) with Figure
8.2(b)); incidentally, SAAPdb does successfully identify this mutation as void-creating. Boeck-
ler et al., by way of in-silico screening and multiple NMR spectroscopy experiments, identiﬁed
a compound (PhiKan083) that bound to the destabilised mutant P53 structure, but not the na-
tive P53 structure, and is sufﬁciently distant from the DNA binding region not to interfere with
functionality (see Figure 8.2(c)). Friedler et al. (2002) have shown that alternative pharma-
ceuticals could bind to the functional native structure of P53, thus ‘chaperoning’ the correctly
folded structure. Such compounds may form the basis of future P53-deﬁcient cancer therapies,
or indeed therapy for any disease caused by structurally-destabilising mutations.
It is therefore encouraging to note that most disease-associated mutations in SAAPdb have
been shown to affect protein stability. There is potential for similar stabilising compounds to be
identiﬁed for other destabilising protein mutations, thus rescuing native protein function and
potentially treating disease.
8.4 Final thoughts
Large-scale automated analyses systems like SAAPdb are becoming more standard in bioin-
formatics: sequencing technologies are improving with respect to reliability, scale and speed,
and high performance computational resources are becoming more affordable. The frequency
with which disease mutation data are published is increasing (Ding et al., 2008; Sreedharan et
al., 2008; Wang et al., 2007a; Stevanin et al., 2007; Mao et al., 2007; The Wellcome Trust Case Con-
trol Consortium, 2007) are a few recent examples.
Such methods rely on external data sources maintaining the same data format; maintaining theCHAPTER 8. CONCLUSIONS 306
(a) P53 native structure (b) P53/Y220C mutant structure (c) PhiKan083 bound to P53/Y220C
Figure 8.2: Stabilising a P53 mutant: a potential cancer therapeutic
The Y220C P53 mutant is the ninth most frequent p53 mutant that is implicated in cancer. An in-silico/NMR screening
procedure identiﬁed the PhiKan083 compound that binds and stabilises the mutant form of P53 (Boeckler et al., 2008).
The relevant sections of the native and mutant P53 structures are shown in Figures 8.2(a) (1tsr, chain B) and 8.2(b)
(2vuk, chain B) respectively. The native Y220 residue is highlighted in Figure 8.2(a) in green; the mutant C220 residue
is highlighted in Figures 8.2(b) and 8.2(c) in red; the stabilising compound PhiKan083 is shown in Figure 8.2(c) in
magenta; voids are represented as blue spheres. Voids are identiﬁed by AVP as described in Section 5.3.7.
public interface with the data, and enforcing rigourous standards in how the data are repre-
sented. Unfortunately, it is the exception rather than the norm that data formats and interfaces
are maintained and that standards are enforced. To cope with such changes within a system
like SAAPdb, time that could be dedicated to analysing the data is instead required to correct
parsers and mirroring systems.
Bioinformatics is a young ﬁeld, but can beneﬁt from well-established conventions in com-
puter science. Ideally, data representation systems (including UniProtKB, the PDB and dbSNP)
should adhere to strict standards of formatting (e.g., valid XML or JSON) enabling fast and
reliable extraction of data from all records without having to deal with rare exceptions. They
should be backwards compatible; that is, parsers written for previous versions of the dataset
should also be able to parse newer versions. Should the addition of attributes and values be
absolutely necessary, extensible systems of data representation like XML and JSON allow new
data to be included without breaking existing parsers, provided existing schemas are not vi-
olated. Should the format change, old representations should be deprecated, but gradually
phased out rather than removed. Reformatting the UniProtKB description ﬁeld as described
above (see Figure 8.1) requires that every UniProtKB parser being used across the world be
individually updated: although the change clearly facilitates the extraction of data from the
description (DE) lines, any method that expects the data in the previous format will now fail
to extract the appropriate data. Ideally the maintainers of such resources would also provide aCHAPTER 8. CONCLUSIONS 307
parser and API to access the data. Should fundamental, deﬁning features of a record change,
some feature of the record identiﬁer should also change: currently, if UniProtKB/Swiss-Prot
changes the sequence of the protein, this is not expressed in the accession number; the user
would have to compare sequence version numbers.
The fact that data formats do change on a regular basis demonstrates that the problem of rep-
resenting these data is not conceptualised fully from the outset. More effort and discussion
with regards to which data are relevant, how these data are related and what standards should
be enforced is necessary before data are collected. Furthermore, biological resources must ex-
pect to be interrogated computationally and as such should facilitate data extraction. It is clear,
then, that the best representation of data, both with respect to the biology and the informat-
ics, can only be achieved by way of collaboration between biologists, computer scientists and
bioinformaticians.Bibliography
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[A] Preliminary predictive work
As described in Chapter 8, some very preliminary, exploratory predictive work has been
carried out on the SAAPdb data using several unoptimised methods in Weka (Witten and
Frank, 2005). Results are shown in the ﬁgure below. Default parameterisations of KNN
(weka.classifiers.lazy.IBk), rule learner (weka.classifiers.rules.PART)
and decision tree (weka.classifiers.trees.J48) algorithms all exceed the current
‘gold-standard’ prediction performance of Tian et al. (2007) of MCC=0.50.
Several issues with regards to the predictive methods are unresolved. Quite apart from the
optimial parameterisation of the individual methods, the issues of dataset sampling and feature
vector contents require to be considered.
Sampling methods (discussed in Dobson et al. (2006)) deﬁne how the datasets should be bal-
anced, if at all. In SAAPdb, there are many more PDs mapped to structure than SNPs; over-
sampling would repeat examples in the SNP dataset so as to balance the size of the datasets,
while undersampling would reduce the size of the PD datset to that of the SNP dataset. The
results shown in the graphs below suggest that oversampling is more successful than under-
sampled or unbalanced datasets; however, this requires more investigation and may simply be
due to biasing the datasets. Alternatively, some methods may not be sensitive to dataset size
and consideration of sampling may not be required.
The feature set used to generate these results was reasonably rudimentary, containing only a
binary vector with the results of fourteen analyses (the UniProtKB/Swiss-Prot feature analysis
was removed as it was found to be unreliable, see Section 5.11); the relative accessibility, and
the native and mutant amino acids, represented as strings. It does not include numerical repre-
sentation of the amino acids (for example, the BLOSUM/PAM amino acid substitution matrix
score, both of which were shown to be statistically signiﬁcant when comparing the PD and SNP
datasets, see Section 7.3.3), nor does it include the apparently powerful ‘average dissimilarity’
score (Section 7.3.2) for the native and mutant residues.
As seen in Section 7.2.1 some proteins are described by the PDB more than once. It follows that
some sequence mutations will be analysed more than once in the analysis pipeline. It is yet to
be decided how such multiple results are to be combined to represent the one mutation. It is329
undesirable to present each analysis to the predictive method at the training stage, as this will
bias the predictor. The results in the ﬁgure below describe ‘aggregated’ counts, where all struc-
tural analysis results were aggregated into one vector, where a positive result was assigned to
the sequence mutation if any of the mapped structures generated a positive result. Also con-
sidered was a ‘hybrid’ counting system, where the sequence mutation was assigned a positive
result for an analysis if at least half of the mapped structures generated a positive result. Re-
sults were very slightly better for the aggregated results. Most desirable would be to use a
machine learning method that can make use of this additional information, without biasing the
predictor towards those data that are mapped to multiple structures.
Although very rudimentary, it is clear that signiﬁcant predictive power lies in these data. With
the proper consideration of machine learning approaches and the appropriate choice of feature
vector, it should be possible to improve the current gold standard prediction performance.330
Results of some very preliminary predictive work Chapter 8 brieﬂy described some very preliminary predictive
carried out on the data from SAAPdb; these are the results. Empty symbols describe training errors, closed symbols
describe validation errors; paired training and validation errors are joined by a line. Different symbols indicate various
datasamplingapproaches: theunbalancedapproachisindicatedwithasquare; theoversamplingapproachisindicated
with a circle; the undersampling approach is indicated with a triangle. Each graph describes a different performance331
statistic (from top left to bottom right: Matthew’s Correlation Coefﬁcient (MCC); accuracy (ACC); speciﬁcity (SPEC);
sensitivity (SENS); positive predictive value (PPV); false positive rate (FPR); false negative rate (FNR); balanced error
rate (BER); root mean squared error (RMSE). All methods are plotted on the same graph (legend given above).332
[B] Biology
[B.i] Amino acid colours (taken from RASMOL ‘amino’ colour scheme)
These colours are used primarily in Chapter 4 to colour the multiple sequence alignments.
They are taken from the Rasmol (Sayle and Milner-White, 1995) ‘amino’ colour scheme, which
colours residues according to traditional amino acid properties (e.g., hydrophobicity and
charge).333
[C] Amino acid subsitution matrices
[C.i] PAM30
A R N D C Q E G H I L K M F P S T W Y V B J Z X *
A 6 -7 -4 -3 -6 -4 -2 -2 -7 -5 -6 -7 -5 -8 -2 0 -1 -13 -8 -2 -3 -6 -3 -1 -17
R -7 8 -6 -10 -8 -2 -9 -9 -2 -5 -8 0 -4 -9 -4 -3 -6 -2 -10 -8 -7 -7 -4 -1 -17
N -4 -6 8 2 -11 -3 -2 -3 0 -5 -7 -1 -9 -9 -6 0 -2 -8 -4 -8 6 -6 -3 -1 -17
D -3 -10 2 8 -14 -2 2 -3 -4 -7 -12 -4 -11 -15 -8 -4 -5 -15 -11 -8 6 -10 1 -1 -17
C -6 -8 -11 -14 10 -14 -14 -9 -7 -6 -15 -14 -13 -13 -8 -3 -8 -15 -4 -6 -12 -9 -14 -1 -17
Q -4 -2 -3 -2 -14 8 1 -7 1 -8 -5 -3 -4 -13 -3 -5 -5 -13 -12 -7 -3 -5 6 -1 -17
E -2 -9 -2 2 -14 1 8 -4 -5 -5 -9 -4 -7 -14 -5 -4 -6 -17 -8 -6 1 -7 6 -1 -17
G -2 -9 -3 -3 -9 -7 -4 6 -9 -11 -10 -7 -8 -9 -6 -2 -6 -15 -14 -5 -3 -10 -5 -1 -17
H -7 -2 0 -4 -7 1 -5 -9 9 -9 -6 -6 -10 -6 -4 -6 -7 -7 -3 -6 -1 -7 -1 -1 -17
I -5 -5 -5 -7 -6 -8 -5 -11 -9 8 -1 -6 -1 -2 -8 -7 -2 -14 -6 2 -6 5 -6 -1 -17
L -6 -8 -7 -12 -15 -5 -9 -10 -6 -1 7 -8 1 -3 -7 -8 -7 -6 -7 -2 -9 6 -7 -1 -17
K -7 0 -1 -4 -14 -3 -4 -7 -6 -6 -8 7 -2 -14 -6 -4 -3 -12 -9 -9 -2 -7 -4 -1 -17
M -5 -4 -9 -11 -13 -4 -7 -8 -10 -1 1 -2 11 -4 -8 -5 -4 -13 -11 -1 -10 0 -5 -1 -17
F -8 -9 -9 -15 -13 -13 -14 -9 -6 -2 -3 -14 -4 9 -10 -6 -9 -4 2 -8 -10 -2 -13 -1 -17
P -2 -4 -6 -8 -8 -3 -5 -6 -4 -8 -7 -6 -8 -10 8 -2 -4 -14 -13 -6 -7 -7 -4 -1 -17
S 0 -3 0 -4 -3 -5 -4 -2 -6 -7 -8 -4 -5 -6 -2 6 0 -5 -7 -6 -1 -8 -5 -1 -17
T -1 -6 -2 -5 -8 -5 -6 -6 -7 -2 -7 -3 -4 -9 -4 0 7 -13 -6 -3 -3 -5 -6 -1 -17
W -13 -2 -8 -15 -15 -13 -17 -15 -7 -14 -6 -12 -13 -4 -14 -5 -13 13 -5 -15 -10 -7 -14 -1 -17
Y -8 -10 -4 -11 -4 -12 -8 -14 -3 -6 -7 -9 -11 2 -13 -7 -6 -5 10 -7 -6 -7 -9 -1 -17
V -2 -8 -8 -8 -6 -7 -6 -5 -6 2 -2 -9 -1 -8 -6 -6 -3 -15 -7 7 -8 0 -6 -1 -17
B -3 -7 6 6 -12 -3 1 -3 -1 -6 -9 -2 -10 -10 -7 -1 -3 -10 -6 -8 6 -8 0 -1 -17
J -6 -7 -6 -10 -9 -5 -7 -10 -7 5 6 -7 0 -2 -7 -8 -5 -7 -7 0 -8 6 -6 -1 -17
Z -3 -4 -3 1 -14 6 6 -5 -1 -6 -7 -4 -5 -13 -4 -5 -6 -14 -9 -6 0 -6 6 -1 -17
X -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -17
* -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 -17 1
[C.ii] PET91
A R N D C Q E G H I L K M F P S T W Y V B Z X *
A 10 -1 0 -1 -1 -1 -1 1 -2 0 -1 -1 -1 -3 1 1 2 -4 -3 1 0 -1 0 0
R -1 10 0 -1 -1 2 0 0 2 -3 -3 4 -2 -4 -1 -1 -1 0 -2 -3 0 1 0 0
N 0 0 10 2 -1 0 1 0 1 -2 -3 1 -2 -3 -1 1 1 -4 -1 -2 2 0 0 0
D -1 -1 2 10 -3 0 4 1 0 -3 -4 0 -3 -5 -2 0 -1 -5 -2 -3 3 2 0 0
C -1 -1 -1 -3 10 -3 -4 -1 0 -2 -3 -3 -2 0 -2 1 -1 1 2 -2 -2 -3 0 0
Q -1 2 0 0 -3 10 2 -1 3 -3 -2 2 -2 -4 0 -1 -1 -3 -1 -3 0 3 0 0
E -1 0 1 4 -4 2 10 1 0 -3 -4 1 -3 -5 -2 -1 -1 -5 -4 -2 2 3 0 0
G 1 0 0 1 -1 -1 1 10 -2 -3 -4 -1 -3 -5 -1 1 0 -2 -4 -2 0 0 0 0
H -2 2 1 0 0 3 0 -2 10 -3 -2 1 -2 0 0 -1 -1 -3 4 -3 0 1 0 0
J 0 -3 -2 -3 -2 -3 -3 -3 -3 10 2 -3 3 0 -2 -1 1 -4 -2 4 -2 -3 0 0
L -1 -3 -3 -4 -3 -2 -4 -4 -2 2 10 -3 3 2 0 -2 -1 -2 -1 2 -3 -3 0 0
K -1 4 1 0 -3 2 1 -1 1 -3 -3 10 -2 -5 -2 -1 -1 -3 -3 -3 0 1 0 0334
M -1 -2 -2 -3 -2 -2 -3 -3 -2 3 3 -2 10 0 -2 -1 0 -3 -3 2 -2 -2 0 0
F -3 -4 -3 -5 0 -4 -5 -5 0 0 2 -5 0 10 -2 -2 -2 -1 5 0 -4 -4 0 0
P 1 -1 -1 -2 -2 0 -2 -1 0 -2 0 -2 -2 -2 10 1 1 -5 -3 -1 -1 -1 0 0
S 1 -1 1 0 1 -1 -1 1 -1 -1 -2 -1 -1 -2 1 10 1 -3 -1 -1 0 -1 0 0
T 2 -1 1 -1 -1 -1 -1 0 -1 1 -1 -1 0 -2 1 1 10 -4 -3 0 0 -1 0 0
W -4 0 -4 -5 1 -3 -5 -2 -3 -4 -2 -3 -3 -1 -5 -3 -4 10 0 -4 -4 -4 0 0
Y -3 -2 -1 -2 2 -1 -4 -4 4 -2 -1 -3 -3 5 -3 -1 -3 0 10 -3 -1 -2 0 0
V 1 -3 -2 -3 -2 -3 -2 -2 -3 4 2 -3 2 0 -1 -1 0 -4 -3 10 -2 -2 0 0
B 0 0 2 3 -2 0 2 0 0 -2 -3 0 -2 -4 -1 0 0 -4 -1 -2 10 1 0 0
Z -1 1 0 2 -3 3 3 0 1 -3 -3 1 -2 -4 -1 -1 -1 -4 -2 -2 1 10 0 0
X 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
[C.iii] BLOSUM62
A R N D C Q E G H I L K M F P S T W Y V B Z X *
A 6 -2 -2 -3 -1 -1 -1 0 -2 -2 -2 -1 -1 -3 -1 2 0 -4 -3 0 -2 -1 -1 -6
R -2 8 -1 -2 -5 1 0 -3 0 -4 -3 3 -2 -4 -3 -1 -2 -4 -3 -4 -2 0 -2 -6
N -2 -1 8 2 -4 0 0 -1 1 -5 -5 0 -3 -4 -3 1 0 -6 -3 -4 5 0 -2 -6
D -3 -2 2 9 -5 0 2 -2 -2 -5 -5 -1 -5 -5 -2 0 -2 -6 -5 -5 6 1 -2 -6
C -1 -5 -4 -5 13 -4 -5 -4 -4 -2 -2 -5 -2 -4 -4 -1 -1 -3 -4 -1 -5 -5 -3 -6
Q -1 1 0 0 -4 8 3 -3 1 -4 -3 2 -1 -5 -2 0 -1 -3 -2 -3 0 5 -1 -6
E -1 0 0 2 -5 3 7 -3 0 -5 -4 1 -3 -5 -2 0 -1 -4 -3 -4 1 6 -1 -6
G 0 -3 -1 -2 -4 -3 -3 8 -3 -6 -5 -2 -4 -5 -3 0 -2 -4 -5 -5 -1 -3 -2 -6
H -2 0 1 -2 -4 1 0 -3 11 -5 -4 -1 -2 -2 -3 -1 -3 -4 3 -5 -1 0 -2 -6
I -2 -4 -5 -5 -2 -4 -5 -6 -5 6 2 -4 2 0 -4 -4 -1 -4 -2 4 -5 -5 -2 -6
L -2 -3 -5 -5 -2 -3 -4 -5 -4 2 6 -4 3 1 -4 -4 -2 -2 -2 1 -5 -4 -2 -6
K -1 3 0 -1 -5 2 1 -2 -1 -4 -4 7 -2 -5 -2 0 -1 -4 -3 -3 -1 1 -1 -6
M -1 -2 -3 -5 -2 -1 -3 -4 -2 2 3 -2 8 0 -4 -2 -1 -2 -1 1 -4 -2 -1 -6
F -3 -4 -4 -5 -4 -5 -5 -5 -2 0 1 -5 0 9 -5 -4 -3 1 4 -1 -5 -5 -2 -6
P -1 -3 -3 -2 -4 -2 -2 -3 -3 -4 -4 -2 -4 -5 11 -1 -2 -5 -4 -4 -3 -2 -2 -6
S 2 -1 1 0 -1 0 0 0 -1 -4 -4 0 -2 -4 -1 6 2 -4 -3 -2 0 0 -1 -6
T 0 -2 0 -2 -1 -1 -1 -2 -3 -1 -2 -1 -1 -3 -2 2 7 -4 -2 0 -1 -1 -1 -6
W -4 -4 -6 -6 -3 -3 -4 -4 -4 -4 -2 -4 -2 1 -5 -4 -4 16 3 -4 -6 -4 -3 -6
Y -3 -3 -3 -5 -4 -2 -3 -5 3 -2 -2 -3 -1 4 -4 -3 -2 3 10 -2 -4 -3 -2 -6
V 0 -4 -4 -5 -1 -3 -4 -5 -5 4 1 -3 1 -1 -4 -2 0 -4 -2 6 -5 -4 -1 -6
B -2 -2 5 6 -5 0 1 -1 -1 -5 -5 -1 -4 -5 -3 0 -1 -6 -4 -5 5 0 -2 -6
Z -1 0 0 1 -5 5 6 -3 0 -5 -4 1 -2 -5 -2 0 -1 -4 -3 -4 0 5 -1 -6
X -1 -2 -2 -2 -3 -1 -1 -2 -2 -2 -2 -1 -1 -2 -2 -1 -1 -3 -2 -1 -2 -1 -2 -6
* -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 1335
[D] Database queries
[D.i] Generating a list of species pairings from FOSTA
SELECT f1.species, f2.species
FROM feps f1, f2
WHERE f1.fosta_family = f2.fosta_family
AND f1.runid = 1
AND f2.runid = 1
AND f1.species != f2.species;
[D.ii] Finding the number of proteins in FOSTA for each species
SELECT f.species, count(f.*)
FROM feps f
GROUP BY f.species;
[D.iii] Finding the FEPs common to both $speciesA and $speciesB
SELECT f1.id, f2.id
FROM feps f1, feps f2
WHERE f1.id != f2.id
AND f1.fosta_family = f2.fosta_family
AND f1.species = ’$speciesA’
AND f2.species = ’$speciesB’
AND f1.runid = 1
AND f2.runid = 1;336
[E] SQL functions
[E.i] Calculating the ‘charge shift’ of a mutation
CREATE OR REPLACE FUNCTION charge_shift(integer) RETURNS int AS ’
DECLARE
mutanalysisRowID ALIAS FOR $1;
nativeRes varchar;
nativeCharge int;
nativeStatus varchar;
mutantRes varchar;
mutantCharge int;
mutantStatus varchar;
BEGIN
SELECT INTO nativeRes,mutantRes m.aa_wildtype,m.aa_mutant
FROM mutanalysis m
WHERE m.mutanalysis_row_id=mutanalysisRowID;
SELECT INTO nativeStatus a.charged
FROM amino_acids a
WHERE a.threelettercode=nativeRes;
nativeCharge := 0;
IF nativeStatus = ’’positive’’ THEN nativeCharge := 1 ;
ELSIF nativeStatus = ’’negative’’ THEN nativeCharge := -1 ;
END IF;
SELECT INTO mutantStatus a.charged
FROM amino_acids a
WHERE a.singlelettercode=lower(mutantRes);
mutantCharge := 0;
IF mutantStatus = ’’positive’’ THEN mutantCharge := 1 ;
ELSIF mutantStatus = ’’negative’’ THEN mutantCharge := -1 ;
END IF;
RETURN ( mutantCharge - nativeCharge );
END
’ LANGUAGE plpgsql;